

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 June 2001 (14.06.2001)

PCT

(10) International Publication Number  
WO 01/42288 A2

(51) International Patent Classification<sup>7</sup>: C07K 14/00

(21) International Application Number: PCT/US00/33382

(22) International Filing Date: 7 December 2000 (07.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/172,852	10 December 1999 (10.12.1999)	US
60/171,732	22 December 1999 (22.12.1999)	US
60/176,148	14 January 2000 (14.01.2000)	US
60/177,331	21 January 2000 (21.01.2000)	US

(71) Applicant (for all designated States except US): INCYTE GENOMICS, INC. [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): BURFORD, Neil [GB/US]; 105 Wildwood Circle, Durham, CT 06422 (US).

BAUGHN, Mariah, R. [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). AU-YOUNG, Janice [US/US]; 233 Golden Eagle Lane, Brisbane, CA 94005 (US). YANG, Junming [CN/US]; 7125 Bark Lane, San Jose, CA 95129 (US). LU, Dyung, Aina, M. [US/US]; 233 Coy Drive, San Jose, CA 95123 (US). REDDY, Roopa [IN/US]; 1233 W. McKinley Avenue #3, Sunnyvale, CA 94086 (US).


(74) Agents: HAMLET-COX, Diana et al.; Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian

[Continued on next page]

(54) Title: G-PROTEIN COUPLED RECEPTORS



(57) Abstract: The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

WO 01/42288 A2



patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

**Published:**

— *Without international search report and to be republished upon receipt of that report.*

## G-PROTEIN COUPLED RECEPTORS

### TECHNICAL FIELD

This invention relates to nucleic acid and amino acid sequences of G-protein coupled receptors and to the use of these sequences in the diagnosis, treatment, and prevention of cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections, and in the assessment of the effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of G-protein coupled receptors.

### BACKGROUND OF THE INVENTION

Signal transduction is the general process by which cells respond to extracellular signals. Signal transduction across the plasma membrane begins with the binding of a signal molecule, e.g., a hormone, neurotransmitter, or growth factor, to a cell membrane receptor. The receptor, thus activated, triggers an intracellular biochemical cascade that ends with the activation of an intracellular target molecule, such as a transcription factor. This process of signal transduction regulates all types of cell functions including cell proliferation, differentiation, and gene transcription. The G-protein coupled receptors (GPCRs), encoded by one of the largest families of genes yet identified, play a central role in the transduction of extracellular signals across the plasma membrane. GPCRs have a proven history of being successful therapeutic targets.

GPCRs are integral membrane proteins characterized by the presence of seven hydrophobic transmembrane domains which together form a bundle of antiparallel alpha ( $\alpha$ ) helices. GPCRs range in size from under 400 to over 1000 amino acids (Strosberg, A.D. (1991) *Eur. J. Biochem.* 196:1-10; Coughlin, S.R. (1994) *Curr. Opin. Cell Biol.* 6:191-197). The amino-terminus of a GPCR is extracellular, is of variable length, and is often glycosylated. The carboxy-terminus is cytoplasmic and generally phosphorylated. Extracellular loops alternate with intracellular loops and link the transmembrane domains. Cysteine disulfide bridges linking the second and third extracellular loops may interact with agonists and antagonists. The most conserved domains of GPCRs are the transmembrane domains and the first two cytoplasmic loops. The transmembrane domains account, in part, for structural and functional features of the receptor. In most cases, the bundle of  $\alpha$  helices forms a ligand-binding pocket. The extracellular N-terminal segment, or one or more of the three extracellular loops, may also participate in ligand binding. Ligand binding activates the receptor by inducing a conformational change in intracellular portions of the receptor. In turn, the large, third intracellular loop of the activated receptor interacts with a heterotrimeric guanine nucleotide binding (G) protein complex which mediates further intracellular signaling activities, including the activation of second

messengers such as cyclic AMP (cAMP), phospholipase C, and inositol triphosphate, and the interaction of the activated GPCR with ion channel proteins. (See, e.g., Watson, S. and S. Arkininstall (1994) The G-protein Linked Receptor Facts Book, Academic Press, San Diego CA, pp. 2-6; Bolander, F.F. (1994) Molecular Endocrinology, Academic Press, San Diego CA, pp. 162-176; Baldwin, J.M. (1994) *Curr. Opin. Cell Biol.* 6:180-190.)

GPCRs include receptors for sensory signal mediators (e.g., light and olfactory stimulatory molecules); adenosine,  $\gamma$ -aminobutyric acid (GABA), hepatocyte growth factor, melanocortins, neuropeptide Y, opioid peptides, opsins, somatostatin, tachykinins, vasoactive intestinal polypeptide family, and vasopressin; biogenic amines (e.g., dopamine, epinephrine and norepinephrine, histamine, glutamate (metabotropic effect), acetylcholine (muscarinic effect), and serotonin); chemokines; lipid mediators of inflammation (e.g., prostaglandins and prostanoids, platelet activating factor, and leukotrienes); and peptide hormones (e.g., bombesin, bradykinin, calcitonin, C5a anaphylatoxin, endothelin, follicle-stimulating hormone (FSH), gonadotropic-releasing hormone (GnRH), neurokinin, and thyrotropin-releasing hormone (TRH), and oxytocin). GPCRs which act as receptors for stimuli that have yet to be identified are known as orphan receptors.

The diversity of the GPCR family is further increased by alternative splicing. Many GPCR genes contain introns, and there are currently over 30 such receptors for which splice variants have been identified. The largest number of variations are at the protein C-terminus. N-terminal and cytoplasmic loop variants are also frequent, while variants in the extracellular loops or transmembrane domains are less common. Some receptors have more than one site at which variance can occur. The splicing variants appear to be functionally distinct, based upon observed differences in distribution, signaling, coupling, regulation, and ligand binding profiles (Kilpatrick, G.J. et al. (1999) *Trends Pharmacol. Sci.* 20:294-301).

GPCRs can be divided into three major subfamilies: the rhodopsin-like, secretin-like, and metabotropic glutamate receptor subfamilies. Members of these GPCR subfamilies share similar functions and the characteristic seven transmembrane structure, but have divergent amino acid sequences. The largest family consists of the rhodopsin-like GPCRs, which transmit diverse extracellular signals including hormones, neurotransmitters, and light. Rhodopsin is a photosensitive GPCR found in animal retinas. In vertebrates, rhodopsin molecules are embedded in membranous stacks found in photoreceptor (rod) cells. Each rhodopsin molecule responds to a photon of light by triggering a decrease in cGMP levels which leads to the closure of plasma membrane sodium channels. In this manner, a visual signal is converted to a neural impulse. Other rhodopsin-like GPCRs are directly involved in responding to neurotransmitters. These GPCRs include the receptors for adrenaline (adrenergic receptors), acetylcholine (muscarinic receptors), adenosine, galanin, and glutamate (N-



methyl-D-aspartate/NMDA receptors). (Reviewed in Watson, S. and S. Arkinstall (1994) The G-Protein Linked Receptor Facts Book, Academic Press, San Diego CA, pp. 7-9, 19-22, 32-35, 130-131, 214-216, 221-222; Habert-Ortoli, E. et al. (1994) Proc. Natl. Acad. Sci. USA 91:9780-9783.)

The galanin receptors mediate the activity of the neuroendocrine peptide galanin, which  
5 inhibits secretion of insulin, acetylcholine, serotonin and noradrenaline, and stimulates prolactin and growth hormone release. Galanin receptors are involved in feeding disorders, pain, depression, and Alzheimer's disease (Kask, K. et al. (1997) Life Sci. 60:1523-1533). Other nervous system rhodopsin-like GPCRs include a growing family of receptors for lysophosphatidic acid and other  
10 lysophospholipids, which appear to have roles in development and neuropathology (Chun, J. et al. (1999) Cell Biochem. Biophys. 30:213-242).

The largest subfamily of GPCRs, the olfactory receptors, are also members of the rhodopsin-like GPCR family. These receptors function by transducing odorant signals. Numerous distinct olfactory receptors are required to distinguish different odors. Each olfactory sensory neuron expresses only one type of olfactory receptor, and distinct spatial zones of neurons expressing distinct receptors  
15 are found in nasal passages. For example, the RA1c receptor which was isolated from a rat brain library, has been shown to be limited in expression to very distinct regions of the brain and a defined zone of the olfactory epithelium (Raming, K. et al. (1998) Receptors Channels 6:141-151). However, the expression of olfactory-like receptors is not confined to olfactory tissues. For example, three rat genes encoding olfactory-like receptors having typical GPCR characteristics showed expression  
20 patterns not only in taste and olfactory tissue, but also in male reproductive tissue (Thomas, M.B. et al. (1996) Gene 178:1-5).

Members of the secretin-like GPCR subfamily have as their ligands peptide hormones such as secretin, calcitonin, glucagon, growth hormone-releasing hormone, parathyroid hormone, and vasoactive intestinal peptide. For example, the secretin receptor responds to secretin, a peptide  
25 hormone that stimulates the secretion of enzymes and ions in the pancreas and small intestine (Watson, supra, pp. 278-283). Secretin receptors are about 450 amino acids in length and are found in the plasma membrane of gastrointestinal cells. Binding of secretin to its receptor stimulates the production of cAMP.

Examples of secretin-like GPCRs implicated in inflammation and the immune response  
30 include the EGF module-containing, mucin-like hormone receptor (Emr1) and CD97 receptor proteins. These GPCRs are members of the recently characterized EGF-TM7 receptors subfamily. These seven transmembrane hormone receptors exist as heterodimers in vivo and contain between three and seven potential calcium-binding EGF-like motifs. CD97 is predominantly expressed in leukocytes and is markedly upregulated on activated B and T cells (McKnight, A.J. and S. Gordon  
35 (1998) J. Leukoc. Biol. 63:271-280).

The third GPCR subfamily is the metabotropic glutamate receptor family. Glutamate is the major excitatory neurotransmitter in the central nervous system. The metabotropic glutamate receptors modulate the activity of intracellular effectors, and are involved in long-term potentiation (Watson, supra, p.130). The  $\text{Ca}^{2+}$ -sensing receptor, which senses changes in the extracellular concentration of calcium ions, has a large extracellular domain including clusters of acidic amino acids which may be involved in calcium binding. The metabotropic glutamate receptor family also includes pheromone receptors, the  $\text{GABA}_B$  receptors, and the taste receptors.

Other subfamilies of GPCRs include two groups of chemoreceptor genes found in the nematodes Caenorhabditis elegans and Caenorhabditis briggsae, which are distantly related to the mammalian olfactory receptor genes. The yeast pheromone receptors STE2 and STE3, involved in the response to mating factors on the cell membrane, have their own seven-transmembrane signature, as do the cAMP receptors from the slime mold Dictyostelium discoideum, which are thought to regulate the aggregation of individual cells and control the expression of numerous developmentally-regulated genes.

GPCR mutations, which may cause loss of function or constitutive activation, have been associated with numerous human diseases (Coughlin, supra). For instance, retinitis pigmentosa may arise from mutations in the rhodopsin gene. Furthermore, somatic activating mutations in the thyrotropin receptor have been reported to cause hyperfunctioning thyroid adenomas, suggesting that certain GPCRs susceptible to constitutive activation may behave as protooncogenes (Parma, J. et al. (1993) Nature 365:649-651). GPCR receptors for the following ligands also contain mutations associated with human disease: luteinizing hormone (precocious puberty); vasopressin  $\text{V}_2$  (X-linked nephrogenic diabetes); glucagon (diabetes and hypertension); calcium (hyperparathyroidism, hypocalcemia, hypercalcemia); parathyroid hormone (short limbed dwarfism);  $\beta_3$ -adrenoceptor (obesity, non-insulin-dependent diabetes mellitus); growth hormone releasing hormone (dwarfism); and adrenocorticotropin (glucocorticoid deficiency) (Wilson, S. et al. (1998) Br. J. Pharmacol. 125:1387-1392; Stadel, J.M. et al. (1997) Trends Pharmacol. Sci. 18:430-437). GPCRs are also involved in depression, schizophrenia, sleeplessness, hypertension, anxiety, stress, renal failure, and several cardiovascular disorders (Horn, F. and G. Vriend (1998) J. Mol. Med. 76:464-468).

In addition, within the past 20 years several hundred new drugs have been recognized that are directed towards activating or inhibiting GPCRs. The therapeutic targets of these drugs span a wide range of diseases and disorders, including cardiovascular, gastrointestinal, and central nervous system disorders as well as cancer, osteoporosis and endometriosis (Wilson, supra; Stadel, supra). For example, the dopamine agonist L-dopa is used to treat Parkinson's disease, while a dopamine antagonist is used to treat schizophrenia and the early stages of Huntington's disease. Agonists and antagonists of adrenoceptors have been used for the treatment of asthma, high blood pressure, other cardiovascular

disorders, and anxiety; muscarinic agonists are used in the treatment of glaucoma and tachycardia; serotonin 5HT1D antagonists are used against migraine; and histamine H1 antagonists are used against allergic and anaphylactic reactions, hay fever, itching, and motion sickness (Horn, *supra*).

Recent research suggests potential future therapeutic uses for GPCRs in the treatment of  
5 metabolic disorders including diabetes, obesity, and osteoporosis. For example, mutant V2 vasopressin receptors causing nephrogenic diabetes could be functionally rescued *in vitro* by co-expression of a C-terminal V2 receptor peptide spanning the region containing the mutations. This result suggests a possible novel strategy for disease treatment (Schöneberg, T. et al. (1996) EMBO J. 15:1283-1291). Mutations in melanocortin-4 receptor (MC4R) are implicated in human weight regulation and obesity.  
10 As with the vasopressin V2 receptor mutants, these MC4R mutants are defective in trafficking to the plasma membrane (Ho, G. and R.G. MacKenzie (1999) J. Biol. Chem. 274:35816-35822), and thus might be treated with a similar strategy. The type 1 receptor for parathyroid hormone (PTH) is a GPCR that mediates the PTH-dependent regulation of calcium homeostasis in the bloodstream. Study of PTH/receptor interactions may enable the development of novel PTH receptor ligands for the  
15 treatment of osteoporosis (Mannstadt, M. et al. (1999) Am. J. Physiol. 277:F665-F675).

The chemokine receptor group of GPCRs have potential therapeutic utility in inflammation and infectious disease. (For review, see Locati, M. and P.M. Murphy (1999) Annu. Rev. Med. 50:425-440.) Chemokines are small polypeptides that act as intracellular signals in the regulation of leukocyte trafficking, hematopoiesis, and angiogenesis. Targeted disruption of various chemokine receptors in  
20 mice indicates that these receptors play roles in pathologic inflammation and in autoimmune disorders such as multiple sclerosis. Chemokine receptors are also exploited by infectious agents, including herpesviruses and the human immunodeficiency virus (HIV-1) to facilitate infection. A truncated version of chemokine receptor CCR5, which acts as a coreceptor for infection of T-cells by HIV-1, results in resistance to AIDS, suggesting that CCR5 antagonists could be useful in preventing the  
25 development of AIDS.

The discovery of new G-protein coupled receptors and the polynucleotides encoding them satisfies a need in the art by providing new compositions which are useful in the diagnosis, prevention, and treatment of cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections, and in the assessment of the  
30 effects of exogenous compounds on the expression of nucleic acid and amino acid sequences of G-protein coupled receptors.

#### SUMMARY OF THE INVENTION

The invention features purified polypeptides, G-protein coupled receptors, referred to

collectively as "GCREC" and individually as "GCREC-1," "GCREC-2," "GCREC-3," "GCREC-4," "GCREC-5," "GCREC-6," "GCREC-7," "GCREC-8," "GCREC-9," "GCREC-10," "GCREC-11," "GCREC-12," "GCREC-13," "GCREC-14," "GCREC-15," "GCREC-16," "GCREC-17," "GCREC-18," "GCREC-19," "GCREC-20," "GCREC-21," "GCREC-22," "GCREC-23," "GCREC-24," "GCREC-25," "GCREC-26," "GCREC-27," "GCREC-28," "GCREC-29," "GCREC-30," "GCREC-31," "GCREC-32," "GCREC-33," "GCREC-34," "GCREC-35," "GCREC-36," "GCREC-37," "GCREC-38," and "GCREC-39." In one aspect, the invention provides an isolated polypeptide

comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-39. In one alternative, the invention provides an isolated polypeptide comprising the amino acid sequence of SEQ ID NO:1-39.

The invention further provides an isolated polynucleotide encoding a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-39. In one alternative, the polynucleotide encodes a polypeptide selected from the group consisting of SEQ ID NO:1-39. In another alternative, the polynucleotide is selected from the group consisting of SEQ ID NO:40-78.

Additionally, the invention provides a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-39. In one alternative, the invention provides a cell transformed with the recombinant polynucleotide. In another alternative, the invention provides a transgenic organism comprising the recombinant polynucleotide.

The invention also provides a method for producing a polypeptide comprising an amino acid

sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-39. The method comprises a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide, and b) recovering the polypeptide so expressed.

10 Additionally, the invention provides an isolated antibody which specifically binds to a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-39.

The invention further provides an isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:40-78, b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:40-78, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a)-d). In one alternative, the polynucleotide comprises at least 60 contiguous nucleotides.

25 Additionally, the invention provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:40-78, b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:40-78, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a)-d). The method comprises a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization complex is formed between said probe and said target polynucleotide or fragments thereof, and b) detecting the presence or absence of said hybridization complex, and

optionally, if present, the amount thereof. In one alternative, the probe comprises at least 60 contiguous nucleotides.

The invention further provides a method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide comprising a polynucleotide sequence  
5 selected from the group consisting of a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:40-78, b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:40-78, c) a polynucleotide sequence complementary to a), d) a polynucleotide sequence complementary to b), and e) an RNA equivalent of a)-d). The method comprises a) amplifying said target polynucleotide or  
10 fragment thereof using polymerase chain reaction amplification, and b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

The invention further provides a composition comprising an effective amount of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence  
15 selected from the group consisting of SEQ ID NO:1-39, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, and a pharmaceutically acceptable excipient. In one  
20 embodiment, the composition comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-39. The invention additionally provides a method of treating a disease or condition associated with decreased expression of functional GCREC, comprising administering to a patient in need of such treatment the composition.

The invention also provides a method for screening a compound for effectiveness as an  
25 agonist of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, and d) an immunogenic fragment of an amino  
30 acid sequence selected from the group consisting of SEQ ID NO:1-39. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting agonist activity in the sample. In one alternative, the invention provides a composition comprising an agonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with decreased expression of  
35 functional GCREC, comprising administering to a patient in need of such treatment the composition.

Additionally, the invention provides a method for screening a compound for effectiveness as an antagonist of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence  
5 selected from the group consisting of SEQ ID NO:1-39, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, and d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-39. The method comprises a) exposing a sample comprising the polypeptide to a compound, and b) detecting antagonist activity in the sample. In one alternative, the invention provides a composition comprising  
10 an antagonist compound identified by the method and a pharmaceutically acceptable excipient. In another alternative, the invention provides a method of treating a disease or condition associated with overexpression of functional GCRC, comprising administering to a patient in need of such treatment the composition.

The invention further provides a method of screening for a compound that specifically binds  
15 to a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, and d) an immunogenic fragment of an amino acid  
20 sequence selected from the group consisting of SEQ ID NO:1-39. The method comprises a) combining the polypeptide with at least one test compound under suitable conditions, and b) detecting binding of the polypeptide to the test compound, thereby identifying a compound that specifically binds to the polypeptide.

The invention further provides a method of screening for a compound that modulates the  
25 activity of a polypeptide comprising an amino acid sequence selected from the group consisting of a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, and d) an immunogenic fragment of an amino  
30 acid sequence selected from the group consisting of SEQ ID NO:1-39. The method comprises a) combining the polypeptide with at least one test compound under conditions permissive for the activity of the polypeptide, b) assessing the activity of the polypeptide in the presence of the test compound, and c) comparing the activity of the polypeptide in the presence of the test compound with the activity of the polypeptide in the absence of the test compound, wherein a change in the activity of  
35 the polypeptide in the presence of the test compound is indicative of a compound that modulates the

activity of the polypeptide.

The invention further provides a method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence selected from the group consisting of SEQ ID NO:40-78, the method comprising a) exposing a sample comprising the target polynucleotide to a compound, and b) detecting altered expression of the target polynucleotide.

The invention further provides a method for assessing toxicity of a test compound, said method comprising a) treating a biological sample containing nucleic acids with the test compound; b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at least 20 contiguous nucleotides of a polynucleotide comprising a polynucleotide sequence selected from the group consisting of i) a polynucleotide sequence selected from the group consisting of SEQ ID NO:40-78, ii) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:40-78, iii) a polynucleotide sequence complementary to i), iv) a polynucleotide sequence complementary to ii), and v) an RNA equivalent of i)-iv). Hybridization occurs under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence selected from the group consisting of i) a polynucleotide sequence selected from the group consisting of SEQ ID NO:40-78, ii) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:40-78, iii) a polynucleotide sequence complementary to i), iv) a polynucleotide sequence complementary to ii), and v) an RNA equivalent of i)-iv). Alternatively, the target polynucleotide comprises a fragment of a polynucleotide sequence selected from the group consisting of i)-v) above; c) quantifying the amount of hybridization complex; and d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.

#### BRIEF DESCRIPTION OF THE FIGURES AND TABLES

Figure 1 shows the hydrophobicity plot for GCREC-1 (SEQ ID NO:1; Incyte ID number 104941CD1). The hydrophobicity plot was generated using the MacDNASIS Pro software. The positive X axis reflects amino acid position, and the negative Y axis, hydrophobicity. The numbers indicate the positions of predicted transmembrane domains.

Figure 2 shows the hydrophobicity plot for GCREC-3 (SEQ ID NO:3; Incyte ID number 3168839CD1).



Figure 3 shows the hydrophobicity plot for GCREC-4 (SEQ ID NO:4; Incyte ID number 3291235CD1).

Figure 4 shows the hydrophobicity plot for GCREC-5 (SEQ ID NO:5; Incyte ID number 7472001CD1).

5 Figure 5 shows the hydrophobicity plot for GCREC-6 (SEQ ID NO:6; Incyte ID number 7472003CD1).

Figure 6 shows the hydrophobicity plot for GCREC-7 (SEQ ID NO:7; Incyte ID number 7472004CD1).

10 Figure 7 shows the hydrophobicity plot for GCREC-19 (SEQ ID NO:19; Incyte ID number 3068234CD1).

Figure 8 shows the hydrophobicity plot for GCREC-20 (SEQ ID NO:20; Incyte ID number 5029478CD1).

Figure 9 shows the hydrophobicity plot for GCREC-21 (SEQ ID NO:21; Incyte ID number 5102576CD1).

15 Table 1 summarizes the nomenclature for the polynucleotide and polypeptide sequences of the present invention.

Table 2 shows the GenBank identification number and annotation of the nearest GenBank homolog for each polypeptide of the invention. The probability score for the match between each polypeptide and its GenBank homolog is also shown.

20 Table 3 shows structural features of each polypeptide sequence, including predicted motifs and domains, along with the methods, algorithms, and searchable databases used for analysis of each polypeptide.

Table 4 lists the cDNA and genomic DNA fragments which were used to assemble each polynucleotide sequence, along with selected fragments of the polynucleotide sequences.

25 Table 5 shows the representative cDNA library for each polynucleotide of the invention.

Table 6 provides an appendix which describes the tissues and vectors used for construction of the cDNA libraries shown in Table 5.

Table 7 shows the tools, programs, and algorithms used to analyze the polynucleotides and polypeptides of the invention, along with applicable descriptions, references, and threshold parameters.

30

## DESCRIPTION OF THE INVENTION

Before the present proteins, nucleotide sequences, and methods are described, it is understood that this invention is not limited to the particular machines, materials and methods described, as these may vary. It is also to be understood that the terminology used herein is for the purpose of describing

particular embodiments only, and is not intended to limit the scope of the present invention which will be limited only by the appended claims.

It must be noted that as used herein and in the appended claims, the singular forms "a," "an," and "the" include plural reference unless the context clearly dictates otherwise. Thus, for example, a reference to "a host cell" includes a plurality of such host cells, and a reference to "an antibody" is a reference to one or more antibodies and equivalents thereof known to those skilled in the art, and so forth.

Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this invention belongs. Although any machines, materials, and methods similar or equivalent to those described herein can be used to practice or test the present invention, the preferred machines, materials and methods are now described. All publications mentioned herein are cited for the purpose of describing and disclosing the cell lines, protocols, reagents and vectors which are reported in the publications and which might be used in connection with the invention. Nothing herein is to be construed as an admission that the invention is not entitled to antedate such disclosure by virtue of prior invention.

#### DEFINITIONS

"GCREC" refers to the amino acid sequences of substantially purified GCREC obtained from any species, particularly a mammalian species, including bovine, ovine, porcine, murine, equine, and human, and from any source, whether natural, synthetic, semi-synthetic, or recombinant.

The term "agonist" refers to a molecule which intensifies or mimics the biological activity of GCREC. Agonists may include proteins, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of GCREC either by directly interacting with GCREC or by acting on components of the biological pathway in which GCREC participates.

An "allelic variant" is an alternative form of the gene encoding GCREC. Allelic variants may result from at least one mutation in the nucleic acid sequence and may result in altered mRNAs or in polypeptides whose structure or function may or may not be altered. A gene may have none, one, or many allelic variants of its naturally occurring form. Common mutational changes which give rise to allelic variants are generally ascribed to natural deletions, additions, or substitutions of nucleotides. Each of these types of changes may occur alone, or in combination with the others, one or more times in a given sequence.

"Altered" nucleic acid sequences encoding GCREC include those sequences with deletions, insertions, or substitutions of different nucleotides, resulting in a polypeptide the same as GCREC or a polypeptide with at least one functional characteristic of GCREC. Included within this definition are polymorphisms which may or may not be readily detectable using a particular oligonucleotide probe of

the polynucleotide encoding GCREC, and improper or unexpected hybridization to allelic variants, with a locus other than the normal chromosomal locus for the polynucleotide sequence encoding GCREC. The encoded protein may also be "altered," and may contain deletions, insertions, or substitutions of amino acid residues which produce a silent change and result in a functionally equivalent GCREC.

- 5 Deliberate amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues, as long as the biological or immunological activity of GCREC is retained. For example, negatively charged amino acids may include aspartic acid and glutamic acid, and positively charged amino acids may include lysine and arginine. Amino acids with uncharged polar side chains having similar hydrophilicity
- 10 values may include: asparagine and glutamine; and serine and threonine. Amino acids with uncharged side chains having similar hydrophilicity values may include: leucine, isoleucine, and valine; glycine and alanine; and phenylalanine and tyrosine.

The terms "amino acid" and "amino acid sequence" refer to an oligopeptide, peptide, polypeptide, or protein sequence, or a fragment of any of these, and to naturally occurring or synthetic

15 molecules. Where "amino acid sequence" is recited to refer to a sequence of a naturally occurring protein molecule, "amino acid sequence" and like terms are not meant to limit the amino acid sequence to the complete native amino acid sequence associated with the recited protein molecule.

"Amplification" relates to the production of additional copies of a nucleic acid sequence. Amplification is generally carried out using polymerase chain reaction (PCR) technologies well known

20 in the art.

The term "antagonist" refers to a molecule which inhibits or attenuates the biological activity of GCREC. Antagonists may include proteins such as antibodies, nucleic acids, carbohydrates, small molecules, or any other compound or composition which modulates the activity of GCREC either by directly interacting with GCREC or by acting on components of the biological pathway in which

25 GCREC participates.

The term "antibody" refers to intact immunoglobulin molecules as well as to fragments thereof, such as Fab, F(ab')<sub>2</sub>, and Fv fragments, which are capable of binding an epitopic determinant. Antibodies that bind GCREC polypeptides can be prepared using intact polypeptides or using fragments containing small peptides of interest as the immunizing antigen. The polypeptide or

30 oligopeptide used to immunize an animal (e.g., a mouse, a rat, or a rabbit) can be derived from the translation of RNA, or synthesized chemically, and can be conjugated to a carrier protein if desired. Commonly used carriers that are chemically coupled to peptides include bovine serum albumin, thyroglobulin, and keyhole limpet hemocyanin (KLH). The coupled peptide is then used to immunize the animal.

35 The term "antigenic determinant" refers to that region of a molecule (i.e., an epitope) that

makes contact with a particular antibody. When a protein or a fragment of a protein is used to immunize a host animal, numerous regions of the protein may induce the production of antibodies which bind specifically to antigenic determinants (particular regions or three-dimensional structures on the protein). An antigenic determinant may compete with the intact antigen (i.e., the immunogen used to elicit the immune response) for binding to an antibody.

The term "antisense" refers to any composition capable of base-pairing with the "sense" (coding) strand of a specific nucleic acid sequence. Antisense compositions may include DNA; RNA; peptide nucleic acid (PNA); oligonucleotides having modified backbone linkages such as phosphorothioates, methylphosphonates, or benzylphosphonates; oligonucleotides having modified sugar groups such as 2'-methoxyethyl sugars or 2'-methoxyethoxy sugars; or oligonucleotides having modified bases such as 5-methyl cytosine, 2'-deoxyuracil, or 7-deaza-2'-deoxyguanosine. Antisense molecules may be produced by any method including chemical synthesis or transcription. Once introduced into a cell, the complementary antisense molecule base-pairs with a naturally occurring nucleic acid sequence produced by the cell to form duplexes which block either transcription or translation. The designation "negative" or "minus" can refer to the antisense strand, and the designation "positive" or "plus" can refer to the sense strand of a reference DNA molecule.

The term "biologically active" refers to a protein having structural, regulatory, or biochemical functions of a naturally occurring molecule. Likewise, "immunologically active" or "immunogenic" refers to the capability of the natural, recombinant, or synthetic GCREC, or of any oligopeptide thereof, to induce a specific immune response in appropriate animals or cells and to bind with specific antibodies.

"Complementary" describes the relationship between two single-stranded nucleic acid sequences that anneal by base-pairing. For example, 5'-AGT-3' pairs with its complement, 3'-TCA-5'.

A "composition comprising a given polynucleotide sequence" and a "composition comprising a given amino acid sequence" refer broadly to any composition containing the given polynucleotide or amino acid sequence. The composition may comprise a dry formulation or an aqueous solution. Compositions comprising polynucleotide sequences encoding GCREC or fragments of GCREC may be employed as hybridization probes. The probes may be stored in freeze-dried form and may be associated with a stabilizing agent such as a carbohydrate. In hybridizations, the probe may be deployed in an aqueous solution containing salts (e.g., NaCl), detergents (e.g., sodium dodecyl sulfate; SDS), and other components (e.g., Denhardt's solution, dry milk, salmon sperm DNA, etc.).

"Consensus sequence" refers to a nucleic acid sequence which has been subjected to repeated DNA sequence analysis to resolve uncalled bases, extended using the XL-PCR kit (Applied Biosystems,

Foster City CA) in the 5' and/or the 3' direction, and resequenced, or which has been assembled from one or more overlapping cDNA, EST, or genomic DNA fragments using a computer program for fragment assembly, such as the GELVIEW fragment assembly system (GCG, Madison WI) or Phrap (University of Washington, Seattle WA). Some sequences have been both extended and assembled to produce the consensus sequence.

"Conservative amino acid substitutions" are those substitutions that are predicted to least interfere with the properties of the original protein, i.e., the structure and especially the function of the protein is conserved and not significantly changed by such substitutions. The table below shows amino acids which may be substituted for an original amino acid in a protein and which are regarded as conservative amino acid substitutions.

	Original Residue	Conservative Substitution
	Ala	Gly, Ser
	Arg	His, Lys
	Asn	Asp, Gln, His
15	Asp	Asn, Glu
	Cys	Ala, Ser
	Gln	Asn, Glu, His
	Glu	Asp, Gln, His
	Gly	Ala
20	His	Asn, Arg, Gln, Glu
	Ile	Leu, Val
	Leu	Ile, Val
	Lys	Arg, Gln, Glu
	Met	Leu, Ile
25	Phe	His, Met, Leu, Trp, Tyr
	Ser	Cys, Thr
	Thr	Ser, Val
	Trp	Phe, Tyr
	Tyr	His, Phe, Trp
30	Val	Ile, Leu, Thr

Conservative amino acid substitutions generally maintain (a) the structure of the polypeptide backbone in the area of the substitution, for example, as a beta sheet or alpha helical conformation, (b) the charge or hydrophobicity of the molecule at the site of the substitution, and/or (c) the bulk of the side chain.

A "deletion" refers to a change in the amino acid or nucleotide sequence that results in the absence of one or more amino acid residues or nucleotides.

The term "derivative" refers to a chemically modified polynucleotide or polypeptide. Chemical modifications of a polynucleotide can include, for example, replacement of hydrogen by an alkyl, acyl, hydroxyl, or amino group. A derivative polynucleotide encodes a polypeptide which retains at least one biological or immunological function of the natural molecule. A derivative polypeptide is one modified

by glycosylation, pegylation, or any similar process that retains at least one biological or immunological function of the polypeptide from which it was derived.

A "detectable label" refers to a reporter molecule or enzyme that is capable of generating a measurable signal and is covalently or noncovalently joined to a polynucleotide or polypeptide.

5 A "fragment" is a unique portion of GCREC or the polynucleotide encoding GCREC which is identical in sequence to but shorter in length than the parent sequence. A fragment may comprise up to the entire length of the defined sequence, minus one nucleotide/amino acid residue. For example, a fragment may comprise from 5 to 1000 contiguous nucleotides or amino acid residues. A fragment used as a probe, primer, antigen, therapeutic molecule, or for other purposes, may be at least  
10 5, 10, 15, 16, 20, 25, 30, 40, 50, 60, 75, 100, 150, 250 or at least 500 contiguous nucleotides or amino acid residues in length. Fragments may be preferentially selected from certain regions of a molecule. For example, a polypeptide fragment may comprise a certain length of contiguous amino acids selected from the first 250 or 500 amino acids (or first 25% or 50%) of a polypeptide as shown in a certain defined sequence. Clearly these lengths are exemplary, and any length that is supported  
15 by the specification, including the Sequence Listing, tables, and figures, may be encompassed by the present embodiments.

A fragment of SEQ ID NO:40-78 comprises a region of unique polynucleotide sequence that specifically identifies SEQ ID NO:40-78, for example, as distinct from any other sequence in the genome from which the fragment was obtained. A fragment of SEQ ID NO:40-78 is useful, for  
20 example, in hybridization and amplification technologies and in analogous methods that distinguish SEQ ID NO:40-78 from related polynucleotide sequences. The precise length of a fragment of SEQ ID NO:40-78 and the region of SEQ ID NO:40-78 to which the fragment corresponds are routinely determinable by one of ordinary skill in the art based on the intended purpose for the fragment.

A fragment of SEQ ID NO:1-39 is encoded by a fragment of SEQ ID NO:40-78. A fragment  
25 of SEQ ID NO:1-39 comprises a region of unique amino acid sequence that specifically identifies SEQ ID NO:1-39. For example, a fragment of SEQ ID NO:1-39 is useful as an immunogenic peptide

The terms "percent identity" and "% identity," as applied to polynucleotide sequences, refer to the percentage of residue matches between at least two polynucleotide sequences aligned using a standardized algorithm. Such an algorithm may insert, in a standardized and reproducible way, gaps in the sequences being compared in order to optimize alignment between two sequences, and therefore achieve a more meaningful comparison of the two sequences.

Percent identity between polynucleotide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program. This program is part of the LASERGENE software package, a suite of molecular biological analysis programs (DNASTAR, Madison WI). CLUSTAL V is described in Higgins, D.G. and P.M. Sharp (1989) CABIOS 5:151-153 and in Higgins, D.G. et al. (1992) CABIOS 8:189-191. For pairwise alignments of polynucleotide sequences, the default parameters are set as follows: Ktuple=2, gap penalty=5, window=4, and "diagonals saved"=4. The "weighted" residue weight table is selected as the default. Percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polynucleotide sequences.

Alternatively, a suite of commonly used and freely available sequence comparison algorithms is provided by the National Center for Biotechnology Information (NCBI) Basic Local Alignment Search Tool (BLAST) (Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410), which is available from several sources, including the NCBI, Bethesda, MD, and on the Internet at <http://www.ncbi.nlm.nih.gov/BLAST/>. The BLAST software suite includes various sequence analysis programs including "blastn," that is used to align a known polynucleotide sequence with other polynucleotide sequences from a variety of databases. Also available is a tool called "BLAST 2 Sequences" that is used for direct pairwise comparison of two nucleotide sequences. "BLAST 2 Sequences" can be accessed and used interactively at <http://www.ncbi.nlm.nih.gov/gorf/bl2.html>. The "BLAST 2 Sequences" tool can be used for both blastn and blastp (discussed below). BLAST programs are commonly used with gap and other parameters set to default settings. For example, to compare two nucleotide sequences, one may use blastn with the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) set at default parameters. Such default parameters may be, for example:

*Matrix: BLOSUM62*

*Reward for match: 1*

*Penalty for mismatch: -2*

*Open Gap: 5 and Extension Gap: 2 penalties*

*Gap x drop-off: 50*

*Expect: 10*

*Word Size: 11*

*Filter: on*

Percent identity may be measured over the length of an entire defined sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined sequence, for instance, a fragment of at least 20, at least 30, at least 40, at least 50, at least 70, at least 100, or at least 200 contiguous nucleotides. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures, or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

Nucleic acid sequences that do not show a high degree of identity may nevertheless encode similar amino acid sequences due to the degeneracy of the genetic code. It is understood that changes in a nucleic acid sequence can be made using this degeneracy to produce multiple nucleic acid sequences that all encode substantially the same protein.

The phrases "percent identity" and "% identity," as applied to polypeptide sequences, refer to the percentage of residue matches between at least two polypeptide sequences aligned using a standardized algorithm. Methods of polypeptide sequence alignment are well-known. Some alignment methods take into account conservative amino acid substitutions. Such conservative substitutions, explained in more detail above, generally preserve the charge and hydrophobicity at the site of substitution, thus preserving the structure (and therefore function) of the polypeptide.

Percent identity between polypeptide sequences may be determined using the default parameters of the CLUSTAL V algorithm as incorporated into the MEGALIGN version 3.12e sequence alignment program (described and referenced above). For pairwise alignments of polypeptide sequences using CLUSTAL V, the default parameters are set as follows: Ktuple=1, gap penalty=3, window=5, and "diagonals saved"=5. The PAM250 matrix is selected as the default residue weight table. As with polynucleotide alignments, the percent identity is reported by CLUSTAL V as the "percent similarity" between aligned polypeptide sequence pairs.

Alternatively the NCBI BLAST software suite may be used. For example, for a pairwise comparison of two polypeptide sequences, one may use the "BLAST 2 Sequences" tool Version 2.0.12 (April-21-2000) with blastp set at default parameters. Such default parameters may be, for example:

*Matrix: BLOSUM62*

*Open Gap: 11 and Extension Gap: 1 penalties*

*Gap x drop-off: 50*

*Expect: 10*

*Word Size: 3*

*Filter: on*



Percent identity may be measured over the length of an entire defined polypeptide sequence, for example, as defined by a particular SEQ ID number, or may be measured over a shorter length, for example, over the length of a fragment taken from a larger, defined polypeptide sequence, for instance, a fragment of at least 15, at least 20, at least 30, at least 40, at least 50, at least 70 or at least 150  
5 contiguous residues. Such lengths are exemplary only, and it is understood that any fragment length supported by the sequences shown herein, in the tables, figures or Sequence Listing, may be used to describe a length over which percentage identity may be measured.

“Human artificial chromosomes” (HACs) are linear microchromosomes which may contain DNA sequences of about 6 kb to 10 Mb in size and which contain all of the elements required for  
10 chromosome replication, segregation and maintenance.

The term “humanized antibody” refers to an antibody molecule in which the amino acid sequence in the non-antigen binding regions has been altered so that the antibody more closely resembles a human antibody, and still retains its original binding ability.

“Hybridization” refers to the process by which a polynucleotide strand anneals with a  
15 complementary strand through base pairing under defined hybridization conditions. Specific hybridization is an indication that two nucleic acid sequences share a high degree of complementarity. Specific hybridization complexes form under permissive annealing conditions and remain hybridized after the “washing” step(s). The washing step(s) is particularly important in determining the stringency of the hybridization process, with more stringent conditions allowing less non-specific binding, i.e.,  
20 binding between pairs of nucleic acid strands that are not perfectly matched. Permissive conditions for annealing of nucleic acid sequences are routinely determinable by one of ordinary skill in the art and may be consistent among hybridization experiments, whereas wash conditions may be varied among experiments to achieve the desired stringency, and therefore hybridization specificity. Permissive annealing conditions occur, for example, at 68°C in the presence of about 6 x SSC, about 1% (w/v)  
25 SDS, and about 100 µg/ml sheared, denatured salmon sperm DNA.

Generally, stringency of hybridization is expressed, in part, with reference to the temperature under which the wash step is carried out. Such wash temperatures are typically selected to be about 5°C to 20°C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength and pH. The  $T_m$  is the temperature (under defined ionic strength and pH) at which 50% of the  
30 target sequence hybridizes to a perfectly matched probe. An equation for calculating  $T_m$  and conditions for nucleic acid hybridization are well known and can be found in Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; specifically see volume 2, chapter 9.

High stringency conditions for hybridization between polynucleotides of the present invention

include wash conditions of 68°C in the presence of about 0.2 x SSC and about 0.1% SDS, for 1 hour. Alternatively, temperatures of about 65°C, 60°C, 55°C, or 42°C may be used. SSC concentration may be varied from about 0.1 to 2 x SSC, with SDS being present at about 0.1%. Typically, blocking reagents are used to block non-specific hybridization. Such blocking reagents include, for instance, sheared and denatured salmon sperm DNA at about 100-200 µg/ml. Organic solvent, such as formamide at a concentration of about 35-50% v/v, may also be used under particular circumstances, such as for RNA:DNA hybridizations. Useful variations on these wash conditions will be readily apparent to those of ordinary skill in the art. Hybridization, particularly under high stringency conditions, may be suggestive of evolutionary similarity between the nucleotides. Such similarity is strongly indicative of a similar role for the nucleotides and their encoded polypeptides.

The term "hybridization complex" refers to a complex formed between two nucleic acid sequences by virtue of the formation of hydrogen bonds between complementary bases. A hybridization complex may be formed in solution (e.g., C<sub>0</sub>t or R<sub>0</sub>t analysis) or formed between one nucleic acid sequence present in solution and another nucleic acid sequence immobilized on a solid support (e.g., paper, membranes, filters, chips, pins or glass slides, or any other appropriate substrate to which cells or their nucleic acids have been fixed).

The words "insertion" and "addition" refer to changes in an amino acid or nucleotide sequence resulting in the addition of one or more amino acid residues or nucleotides, respectively.

"Immune response" can refer to conditions associated with inflammation, trauma, immune disorders, or infectious or genetic disease, etc. These conditions can be characterized by expression of various factors, e.g., cytokines, chemokines, and other signaling molecules, which may affect cellular and systemic defense systems.

An "immunogenic fragment" is a polypeptide or oligopeptide fragment of GCREC which is capable of eliciting an immune response when introduced into a living organism, for example, a mammal. The term "immunogenic fragment" also includes any polypeptide or oligopeptide fragment of GCREC which is useful in any of the antibody production methods disclosed herein or known in the art.

The term "microarray" refers to an arrangement of a plurality of polynucleotides, polypeptides, or other chemical compounds on a substrate.

The terms "element" and "array element" refer to a polynucleotide, polypeptide, or other chemical compound having a unique and defined position on a microarray.

The term "modulate" refers to a change in the activity of GCREC. For example, modulation may cause an increase or a decrease in protein activity, binding characteristics, or any other biological, functional, or immunological properties of GCREC.

The phrases "nucleic acid" and "nucleic acid sequence" refer to a nucleotide, oligonucleotide,

polynucleotide, or any fragment thereof. These phrases also refer to DNA or RNA of genomic or synthetic origin which may be single-stranded or double-stranded and may represent the sense or the antisense strand, to peptide nucleic acid (PNA), or to any DNA-like or RNA-like material.

"Operably linked" refers to the situation in which a first nucleic acid sequence is placed in a functional relationship with a second nucleic acid sequence. For instance, a promoter is operably linked to a coding sequence if the promoter affects the transcription or expression of the coding sequence. Operably linked DNA sequences may be in close proximity or contiguous and, where necessary to join two protein coding regions, in the same reading frame.

"Peptide nucleic acid" (PNA) refers to an antisense molecule or anti-gene agent which comprises an oligonucleotide of at least about 5 nucleotides in length linked to a peptide backbone of amino acid residues ending in lysine. The terminal lysine confers solubility to the composition. PNAs preferentially bind complementary single stranded DNA or RNA and stop transcript elongation, and may be pegylated to extend their lifespan in the cell.

"Post-translational modification" of an GCREC may involve lipidation, glycosylation, phosphorylation, acetylation, racemization, proteolytic cleavage, and other modifications known in the art. These processes may occur synthetically or biochemically. Biochemical modifications will vary by cell type depending on the enzymatic milieu of GCREC.

"Probe" refers to nucleic acid sequences encoding GCREC, their complements, or fragments thereof, which are used to detect identical, allelic or related nucleic acid sequences. Probes are isolated oligonucleotides or polynucleotides attached to a detectable label or reporter molecule. Typical labels include radioactive isotopes, ligands, chemiluminescent agents, and enzymes. "Primers" are short nucleic acids, usually DNA oligonucleotides, which may be annealed to a target polynucleotide by complementary base-pairing. The primer may then be extended along the target DNA strand by a DNA polymerase enzyme. Primer pairs can be used for amplification (and identification) of a nucleic acid sequence, e.g., by the polymerase chain reaction (PCR).

Probes and primers as used in the present invention typically comprise at least 15 contiguous nucleotides of a known sequence. In order to enhance specificity, longer probes and primers may also be employed, such as probes and primers that comprise at least 20, 25, 30, 40, 50, 60, 70, 80, 90, 100, or at least 150 consecutive nucleotides of the disclosed nucleic acid sequences. Probes and primers may be considerably longer than these examples, and it is understood that any length supported by the specification, including the tables, figures, and Sequence Listing, may be used.

Methods for preparing and using probes and primers are described in the references, for example Sambrook, J. et al. (1989) Molecular Cloning: A Laboratory Manual, 2<sup>nd</sup> ed., vol. 1-3, Cold Spring Harbor Press, Plainview NY; Ausubel, F.M. et al. (1987) Current Protocols in Molecular Biology, Greene Publ. Assoc. & Wiley-Intersciences, New York NY; Innis, M. et al. (1990) PCR

Protocols, A Guide to Methods and Applications, Academic Press, San Diego CA. PCR primer pairs can be derived from a known sequence, for example, by using computer programs intended for that purpose such as Primer (Version 0.5, 1991, Whitehead Institute for Biomedical Research, Cambridge MA).

5 Oligonucleotides for use as primers are selected using software known in the art for such purpose. For example, OLIGO 4.06 software is useful for the selection of PCR primer pairs of up to 100 nucleotides each, and for the analysis of oligonucleotides and larger polynucleotides of up to 5,000 nucleotides from an input polynucleotide sequence of up to 32 kilobases. Similar primer selection programs have incorporated additional features for expanded capabilities. For example, the PrimOU  
10 primer selection program (available to the public from the Genome Center at University of Texas South West Medical Center, Dallas TX) is capable of choosing specific primers from megabase sequences and is thus useful for designing primers on a genome-wide scope. The Primer3 primer selection program (available to the public from the Whitehead Institute/MIT Center for Genome Research, Cambridge MA) allows the user to input a "mispriming library," in which sequences to avoid as primer  
15 binding sites are user-specified. Primer3 is useful, in particular, for the selection of oligonucleotides for microarrays. (The source code for the latter two primer selection programs may also be obtained from their respective sources and modified to meet the user's specific needs.) The PrimeGen program (available to the public from the UK Human Genome Mapping Project Resource Centre, Cambridge UK) designs primers based on multiple sequence alignments, thereby allowing selection of primers that  
20 hybridize to either the most conserved or least conserved regions of aligned nucleic acid sequences. Hence, this program is useful for identification of both unique and conserved oligonucleotides and polynucleotide fragments. The oligonucleotides and polynucleotide fragments identified by any of the above selection methods are useful in hybridization technologies, for example, as PCR or sequencing primers, microarray elements, or specific probes to identify fully or partially complementary  
25 polynucleotides in a sample of nucleic acids. Methods of oligonucleotide selection are not limited to those described above.

A "recombinant nucleic acid" is a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two or more otherwise separated segments of sequence. This artificial combination is often accomplished by chemical synthesis or, more commonly, by the  
30 artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques such as those described in Sambrook, supra. The term recombinant includes nucleic acids that have been altered solely by addition, substitution, or deletion of a portion of the nucleic acid. Frequently, a recombinant nucleic acid may include a nucleic acid sequence operably linked to a promoter sequence. Such a recombinant nucleic acid may be part of a vector that is used, for example, to transform a cell.

Alternatively, such recombinant nucleic acids may be part of a viral vector, e.g., based on a vaccinia virus, that could be used to vaccinate a mammal wherein the recombinant nucleic acid is expressed, inducing a protective immunological response in the mammal.

5 A "regulatory element" refers to a nucleic acid sequence usually derived from untranslated regions of a gene and includes enhancers, promoters, introns, and 5' and 3' untranslated regions (UTRs). Regulatory elements interact with host or viral proteins which control transcription, translation, or RNA stability.

"Reporter molecules" are chemical or biochemical moieties used for labeling a nucleic acid, amino acid, or antibody. Reporter molecules include radionuclides; enzymes; fluorescent, 10 chemiluminescent, or chromogenic agents; substrates; cofactors; inhibitors; magnetic particles; and other moieties known in the art.

An "RNA equivalent," in reference to a DNA sequence, is composed of the same linear sequence of nucleotides as the reference DNA sequence with the exception that all occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose 15 instead of deoxyribose.

The term "sample" is used in its broadest sense. A sample suspected of containing GCREC, nucleic acids encoding GCREC, or fragments thereof may comprise a bodily fluid; an extract from a cell, chromosome, organelle, or membrane isolated from a cell; a cell; genomic DNA, RNA, or cDNA, in solution or bound to a substrate; a tissue; a tissue print; etc.

20 The terms "specific binding" and "specifically binding" refer to that interaction between a protein or peptide and an agonist, an antibody, an antagonist, a small molecule, or any natural or synthetic binding composition. The interaction is dependent upon the presence of a particular structure of the protein, e.g., the antigenic determinant or epitope, recognized by the binding molecule. For example, if an antibody is specific for epitope "A," the presence of a polypeptide comprising the epitope 25 A, or the presence of free unlabeled A, in a reaction containing free labeled A and the antibody will reduce the amount of labeled A that binds to the antibody.

The term "substantially purified" refers to nucleic acid or amino acid sequences that are removed from their natural environment and are isolated or separated, and are at least 60% free, preferably at least 75% free, and most preferably at least 90% free from other components with which 30 they are naturally associated.

A "substitution" refers to the replacement of one or more amino acid residues or nucleotides by different amino acid residues or nucleotides, respectively.

"Substrate" refers to any suitable rigid or semi-rigid support including membranes, filters, chips, slides, wafers, fibers, magnetic or nonmagnetic beads, gels, tubing, plates, polymers,

microparticles and capillaries. The substrate can have a variety of surface forms, such as wells, trenches, pins, channels and pores, to which polynucleotides or polypeptides are bound.

A "transcript image" refers to the collective pattern of gene expression by a particular cell type or tissue under given conditions at a given time.

5 "Transformation" describes a process by which exogenous DNA is introduced into a recipient cell. Transformation may occur under natural or artificial conditions according to various methods well known in the art, and may rely on any known method for the insertion of foreign nucleic acid sequences into a prokaryotic or eukaryotic host cell. The method for transformation is selected based on the type of host cell being transformed and may include, but is not limited to, bacteriophage or viral infection, 10 electroporation, heat shock, lipofection, and particle bombardment. The term "transformed cells" includes stably transformed cells in which the inserted DNA is capable of replication either as an autonomously replicating plasmid or as part of the host chromosome, as well as transiently transformed cells which express the inserted DNA or RNA for limited periods of time.

A "transgenic organism," as used herein, is any organism, including but not limited to 15 animals and plants, in which one or more of the cells of the organism contains heterologous nucleic acid introduced by way of human intervention, such as by transgenic techniques well known in the art. The nucleic acid is introduced into the cell, directly or indirectly by introduction into a precursor of the cell, by way of deliberate genetic manipulation, such as by microinjection or by infection with a recombinant virus. The term genetic manipulation does not include classical cross-breeding, or in 20 vitro fertilization, but rather is directed to the introduction of a recombinant DNA molecule. The transgenic organisms contemplated in accordance with the present invention include bacteria, cyanobacteria, fungi, plants and animals. The isolated DNA of the present invention can be introduced into the host by methods known in the art, for example infection, transfection, transformation or transconjugation. Techniques for transferring the DNA of the present invention 25 into such organisms are widely known and provided in references such as Sambrook et al. (1989), supra.

A "variant" of a particular nucleic acid sequence is defined as a nucleic acid sequence having at least 40% sequence identity to the particular nucleic acid sequence over a certain length of one of the nucleic acid sequences using blastn with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) 30 set at default parameters. Such a pair of nucleic acids may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, at least 95% or at least 98% or greater sequence identity over a certain defined length. A variant may be described as, for example, an "allelic" (as defined above), "splice," "species," or "polymorphic" variant. A splice variant may have significant identity to a reference molecule, but will generally have a greater or lesser number of polynucleotides 35 due to alternative splicing of exons during mRNA processing. The corresponding polypeptide may

possess additional functional domains or lack domains that are present in the reference molecule. Species variants are polynucleotide sequences that vary from one species to another. The resulting polypeptides will generally have significant amino acid identity relative to each other. A polymorphic variant is a variation in the polynucleotide sequence of a particular gene between individuals of a given species. Polymorphic variants also may encompass "single nucleotide polymorphisms" (SNPs) in which the polynucleotide sequence varies by one nucleotide base. The presence of SNPs may be indicative of, for example, a certain population, a disease state, or a propensity for a disease state.

A "variant" of a particular polypeptide sequence is defined as a polypeptide sequence having at least 40% sequence identity to the particular polypeptide sequence over a certain length of one of the polypeptide sequences using blastp with the "BLAST 2 Sequences" tool Version 2.0.9 (May-07-1999) set at default parameters. Such a pair of polypeptides may show, for example, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 98% or greater sequence identity over a certain defined length of one of the polypeptides.

## 15 THE INVENTION

The invention is based on the discovery of new human G-protein coupled receptors (GCREC), the polynucleotides encoding GCREC, and the use of these compositions for the diagnosis, treatment, or prevention of cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections.

Table 1 summarizes the nomenclature for the polynucleotide and polypeptide sequences of the invention. Each polynucleotide and its corresponding polypeptide are correlated to a single Incyte project identification number (Incyte Project ID). Each polypeptide sequence is denoted by both a polypeptide sequence identification number (Polypeptide SEQ ID NO:) and an Incyte polypeptide sequence number (Incyte Polypeptide ID) as shown. Each polynucleotide sequence is denoted by both a polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and an Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) as shown.

Table 2 shows sequences with homology to the polypeptides of the invention as identified by BLAST analysis against the GenBank protein (genpept) database. Columns 1 and 2 show the polypeptide sequence identification number (Polypeptide SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for each polypeptide of the invention. Column 3 shows the GenBank identification number (Genbank ID NO:) of the nearest GenBank homolog. Column 4 shows the probability score for the match between each polypeptide and its GenBank homolog. Column 5 shows the annotation of the GenBank homolog along with relevant citations where applicable, all of which are expressly incorporated by reference herein.

Table 3 shows various structural features of each of the polypeptides of the invention. Columns

1 and 2 show the polypeptide sequence identification number (SEQ ID NO:) and the corresponding Incyte polypeptide sequence number (Incyte Polypeptide ID) for each polypeptide of the invention. Column 3 shows the number of amino acid residues in each polypeptide. Column 4 shows potential phosphorylation sites, and column 5 shows potential glycosylation sites, as determined by the MOTIFS program of the GCG sequence analysis software package (Genetics Computer Group, Madison WI). Column 6 shows amino acid residues comprising signature sequences, domains, and motifs. Column 7 shows analytical methods for protein structure/function analysis and in some cases, searchable databases to which the analytical methods were applied.

As shown in Table 4, the polynucleotide sequences of the present invention were assembled using cDNA sequences or coding (exon) sequences derived from genomic DNA, or any combination of these two types of sequences. Columns 1 and 2 list the polynucleotide sequence identification number (Polynucleotide SEQ ID NO:) and the corresponding Incyte polynucleotide consensus sequence number (Incyte Polynucleotide ID) for each polynucleotide of the invention. Column 3 shows the length of each polynucleotide sequence in basepairs. Column 4 lists fragments of the polynucleotide sequences which are useful, for example, in hybridization or amplification technologies that identify SEQ ID NO:40-78 or that distinguish between SEQ ID NO:40-78 and related polynucleotide sequences. Column 5 shows identification numbers corresponding to cDNA sequences, coding sequences (exons) predicted from genomic DNA, and/or sequence assemblages comprised of both cDNA and genomic DNA. These sequences were used to assemble the polynucleotide sequences of the invention. Columns 6 and 7 of Table 4 show the nucleotide start (5') and stop (3') positions of the cDNA and genomic sequences in column 5 relative to their respective sequences.

The identification numbers in Column 5 of Table 4 may refer specifically, for example, to Incyte cDNAs along with their corresponding cDNA libraries. For example, 927003T6 is the identification number of an Incyte cDNA sequence, and BRAINOT04 is the cDNA library from which it is derived. Incyte cDNAs for which cDNA libraries are not indicated were derived from pooled cDNA libraries (e.g., 70489898V1). Alternatively, the identification numbers in column 5 may refer to GenBank cDNAs or ESTs (e.g., g835247) which contributed to the assembly of the polynucleotide sequences. Alternatively, the identification numbers in column 5 may refer to coding regions predicted by Genscan analysis of genomic DNA. For example, g4190944.v113.gs\_10.edit is the identification number of a Genscan-predicted coding sequence, with g4190944 being the GenBank identification number of the sequence to which Genscan was applied. The Genscan-predicted coding sequences may have been edited prior to assembly. (See Example IV.) Alternatively, the identification numbers in column 5 may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon stitching" algorithm. (See Example V.) Alternatively, the identification numbers in column 5



may refer to assemblages of both cDNA and Genscan-predicted exons brought together by an "exon-stretching" algorithm. (See Example V.) In some cases, Incyte cDNA coverage redundant with the sequence coverage shown in column 5 was obtained to confirm the final consensus polynucleotide sequence, but the relevant Incyte cDNA identification numbers are not shown.

5        Table 5 shows the representative cDNA libraries for those polynucleotide sequences which were assembled using Incyte cDNA sequences. The representative cDNA library is the Incyte cDNA library which is most frequently represented by the Incyte cDNA sequences which were used to assemble and confirm the above polynucleotide sequences. The tissues and vectors which were used to construct the cDNA libraries shown in Table 5 are described in Table 6.

10        The invention also encompasses GCREC variants. A preferred GCREC variant is one which has at least about 80%, or alternatively at least about 90%, or even at least about 95% amino acid sequence identity to the GCREC amino acid sequence, and which contains at least one functional or structural characteristic of GCREC.

15        The invention also encompasses polynucleotides which encode GCREC. In a particular embodiment, the invention encompasses a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:40-78, which encodes GCREC. The polynucleotide sequences of SEQ ID NO:40-78, as presented in the Sequence Listing, embrace the equivalent RNA sequences, wherein occurrences of the nitrogenous base thymine are replaced with uracil, and the sugar backbone is composed of ribose instead of deoxyribose.

20        The invention also encompasses a variant of a polynucleotide sequence encoding GCREC. In particular, such a variant polynucleotide sequence will have at least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to the polynucleotide sequence encoding GCREC. A particular aspect of the invention encompasses a variant of a polynucleotide sequence comprising a sequence selected from the group consisting of SEQ ID NO:40-78 which has at  
25        least about 70%, or alternatively at least about 85%, or even at least about 95% polynucleotide sequence identity to a nucleic acid sequence selected from the group consisting of SEQ ID NO:40-78. Any one of the polynucleotide variants described above can encode an amino acid sequence which contains at least one functional or structural characteristic of GCREC.

30        It will be appreciated by those skilled in the art that as a result of the degeneracy of the genetic code, a multitude of polynucleotide sequences encoding GCREC, some bearing minimal similarity to the polynucleotide sequences of any known and naturally occurring gene, may be produced. Thus, the invention contemplates each and every possible variation of polynucleotide sequence that could be made by selecting combinations based on possible codon choices. These combinations are made in accordance with the standard triplet genetic code as applied to the polynucleotide sequence of naturally

occurring GCREC, and all such variations are to be considered as being specifically disclosed.

Although nucleotide sequences which encode GCREC and its variants are generally capable of hybridizing to the nucleotide sequence of the naturally occurring GCREC under appropriately selected conditions of stringency, it may be advantageous to produce nucleotide sequences encoding GCREC or its derivatives possessing a substantially different codon usage, e.g., inclusion of non-naturally occurring codons. Codons may be selected to increase the rate at which expression of the peptide occurs in a particular prokaryotic or eukaryotic host in accordance with the frequency with which particular codons are utilized by the host. Other reasons for substantially altering the nucleotide sequence encoding GCREC and its derivatives without altering the encoded amino acid sequences include the production of RNA transcripts having more desirable properties, such as a greater half-life, than transcripts produced from the naturally occurring sequence.

The invention also encompasses production of DNA sequences which encode GCREC and GCREC derivatives, or fragments thereof, entirely by synthetic chemistry. After production, the synthetic sequence may be inserted into any of the many available expression vectors and cell systems using reagents well known in the art. Moreover, synthetic chemistry may be used to introduce mutations into a sequence encoding GCREC or any fragment thereof.

Also encompassed by the invention are polynucleotide sequences that are capable of hybridizing to the claimed polynucleotide sequences, and, in particular, to those shown in SEQ ID NO:40-78 and fragments thereof under various conditions of stringency. (See, e.g., Wahl, G.M. and S.L. Berger (1987) *Methods Enzymol.* 152:399-407; Kimmel, A.R. (1987) *Methods Enzymol.* 152:507-511.) Hybridization conditions, including annealing and wash conditions, are described in "Definitions."

Methods for DNA sequencing are well known in the art and may be used to practice any of the embodiments of the invention. The methods may employ such enzymes as the Klenow fragment of DNA polymerase I, SEQUENASE (US Biochemical, Cleveland OH), Taq polymerase (Applied Biosystems), thermostable T7 polymerase (Amersham Pharmacia Biotech, Piscataway NJ), or combinations of polymerases and proofreading exonucleases such as those found in the ELONGASE amplification system (Life Technologies, Gaithersburg MD). Preferably, sequence preparation is automated with machines such as the MICROLAB 2200 liquid transfer system (Hamilton, Reno NV), PTC200 thermal cycler (MJ Research, Watertown MA) and ABI CATALYST 800 thermal cycler (Applied Biosystems). Sequencing is then carried out using either the ABI 373 or 377 DNA sequencing system (Applied Biosystems), the MEGABACE 1000 DNA sequencing system (Molecular Dynamics, Sunnyvale CA), or other systems known in the art. The resulting sequences are analyzed using a variety of algorithms which are well known in the art. (See, e.g., Ausubel, F.M. (1997) Short Protocols

in Molecular Biology, John Wiley & Sons, New York NY, unit 7.7; Meyers, R.A. (1995) Molecular Biology and Biotechnology, Wiley VCH, New York NY, pp. 856-853.)

The nucleic acid sequences encoding GCREC may be extended utilizing a partial nucleotide sequence and employing various PCR-based methods known in the art to detect upstream sequences, such as promoters and regulatory elements. For example, one method which may be employed, restriction-site PCR, uses universal and nested primers to amplify unknown sequence from genomic DNA within a cloning vector. (See, e.g., Sarkar, G. (1993) PCR Methods Applic. 2:318-322.) Another method, inverse PCR, uses primers that extend in divergent directions to amplify unknown sequence from a circularized template. The template is derived from restriction fragments comprising a known genomic locus and surrounding sequences. (See, e.g., Triglia, T. et al. (1988) Nucleic Acids Res. 16:8186.) A third method, capture PCR, involves PCR amplification of DNA fragments adjacent to known sequences in human and yeast artificial chromosome DNA. (See, e.g., Lagerstrom, M. et al. (1991) PCR Methods Applic. 1:111-119.) In this method, multiple restriction enzyme digestions and ligations may be used to insert an engineered double-stranded sequence into a region of unknown sequence before performing PCR. Other methods which may be used to retrieve unknown sequences are known in the art. (See, e.g., Parker, J.D. et al. (1991) Nucleic Acids Res. 19:3055-3060). Additionally, one may use PCR, nested primers, and PROMOTERFINDER libraries (Clontech, Palo Alto CA) to walk genomic DNA. This procedure avoids the need to screen libraries and is useful in finding intron/exon junctions. For all PCR-based methods, primers may be designed using commercially available software, such as OLIGO 4.06 primer analysis software (National Biosciences, Plymouth MN) or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the template at temperatures of about 68°C to 72°C.

When screening for full length cDNAs, it is preferable to use libraries that have been size-selected to include larger cDNAs. In addition, random-primed libraries, which often include sequences containing the 5' regions of genes, are preferable for situations in which an oligo d(T) library does not yield a full-length cDNA. Genomic libraries may be useful for extension of sequence into 5' non-transcribed regulatory regions.

Capillary electrophoresis systems which are commercially available may be used to analyze the size or confirm the nucleotide sequence of sequencing or PCR products. In particular, capillary sequencing may employ flowable polymers for electrophoretic separation, four different nucleotide-specific, laser-stimulated fluorescent dyes, and a charge coupled device camera for detection of the emitted wavelengths. Output/light intensity may be converted to electrical signal using appropriate software (e.g., GENOTYPER and SEQUENCE NAVIGATOR, Applied Biosystems), and the entire

process from loading of samples to computer analysis and electronic data display may be computer controlled. Capillary electrophoresis is especially preferable for sequencing small DNA fragments which may be present in limited amounts in a particular sample.

5 In another embodiment of the invention, polynucleotide sequences or fragments thereof which encode GCREC may be cloned in recombinant DNA molecules that direct expression of GCREC, or fragments or functional equivalents thereof, in appropriate host cells. Due to the inherent degeneracy of the genetic code, other DNA sequences which encode substantially the same or a functionally equivalent amino acid sequence may be produced and used to express GCREC.

10 The nucleotide sequences of the present invention can be engineered using methods generally known in the art in order to alter GCREC-encoding sequences for a variety of purposes including, but not limited to, modification of the cloning, processing, and/or expression of the gene product. DNA shuffling by random fragmentation and PCR reassembly of gene fragments and synthetic oligonucleotides may be used to engineer the nucleotide sequences. For example, oligonucleotide-mediated site-directed mutagenesis may be used to introduce mutations that create new restriction sites, 15 alter glycosylation patterns, change codon preference, produce splice variants, and so forth.

The nucleotides of the present invention may be subjected to DNA shuffling techniques such as MOLECULARBREEDING (Maxygen Inc., Santa Clara CA; described in U.S. Patent Number 5,837,458; Chang, C.-C. et al. (1999) Nat. Biotechnol. 17:793-797; Christians, F.C. et al. (1999) Nat. Biotechnol. 17:259-264; and Cramer, A. et al. (1996) Nat. Biotechnol. 14:315-319) to alter or 20 improve the biological properties of GCREC, such as its biological or enzymatic activity or its ability to bind to other molecules or compounds. DNA shuffling is a process by which a library of gene variants is produced using PCR-mediated recombination of gene fragments. The library is then subjected to selection or screening procedures that identify those gene variants with the desired properties. These preferred variants may then be pooled and further subjected to recursive rounds of 25 DNA shuffling and selection/screening. Thus, genetic diversity is created through "artificial" breeding and rapid molecular evolution. For example, fragments of a single gene containing random point mutations may be recombined, screened, and then reshuffled until the desired properties are optimized. Alternatively, fragments of a given gene may be recombined with fragments of homologous genes in the same gene family, either from the same or different species, thereby 30 maximizing the genetic diversity of multiple naturally occurring genes in a directed and controllable manner.

In another embodiment, sequences encoding GCREC may be synthesized, in whole or in part, using chemical methods well known in the art. (See, e.g., Caruthers, M.H. et al. (1980) Nucleic Acids Symp. Ser. 7:215-223; and Horn, T. et al. (1980) Nucleic Acids Symp. Ser. 7:225-232.) Alternatively, 35 GCREC itself or a fragment thereof may be synthesized using chemical methods. For example, peptide

synthesis can be performed using various solution-phase or solid-phase techniques. (See, e.g., Creighton, T. (1984) Proteins, Structures and Molecular Properties, WH Freeman, New York NY, pp.55-60; and Roberge, J.Y. et al. (1995) *Science* 269:202-204.) Automated synthesis may be achieved using the ABI 431A peptide synthesizer (Applied Biosystems). Additionally, the amino acid sequence of GCREC, or any part thereof, may be altered during direct synthesis and/or combined with sequences from other proteins, or any part thereof, to produce a variant polypeptide or a polypeptide having a sequence of a naturally occurring polypeptide.

The peptide may be substantially purified by preparative high performance liquid chromatography. (See, e.g., Chiez, R.M. and F.Z. Regnier (1990) *Methods Enzymol.* 182:392-421.)

- 10 The composition of the synthetic peptides may be confirmed by amino acid analysis or by sequencing. (See, e.g., Creighton, supra, pp. 28-53.)

In order to express a biologically active GCREC, the nucleotide sequences encoding GCREC or derivatives thereof may be inserted into an appropriate expression vector, i.e., a vector which contains the necessary elements for transcriptional and translational control of the inserted coding sequence in a suitable host. These elements include regulatory sequences, such as enhancers, constitutive and inducible promoters, and 5' and 3' untranslated regions in the vector and in polynucleotide sequences encoding GCREC. Such elements may vary in their strength and specificity. Specific initiation signals may also be used to achieve more efficient translation of sequences encoding GCREC. Such signals include the ATG initiation codon and adjacent sequences, e.g. the Kozak sequence. In cases where sequences encoding GCREC and its initiation codon and upstream regulatory sequences are inserted into the appropriate expression vector, no additional transcriptional or translational control signals may be needed. However, in cases where only coding sequence, or a fragment thereof, is inserted, exogenous translational control signals including an in-frame ATG initiation codon should be provided by the vector. Exogenous translational elements and initiation codons may be of various origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of enhancers appropriate for the particular host cell system used. (See, e.g., Scharf, D. et al. (1994) *Results Probl. Cell Differ.* 20:125-162.)

- 25 Methods which are well known to those skilled in the art may be used to construct expression vectors containing sequences encoding GCREC and appropriate transcriptional and translational control elements. These methods include in vitro recombinant DNA techniques, synthetic techniques, and in vivo genetic recombination. (See, e.g., Sambrook, J. et al. (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Press, Plainview NY, ch. 4, 8, and 16-17; Ausubel, F.M. et al. (1995) Current Protocols in Molecular Biology, John Wiley & Sons, New York NY, ch. 9, 13, and 16.)

A variety of expression vector/host systems may be utilized to contain and express sequences encoding GCREC. These include, but are not limited to, microorganisms such as bacteria transformed with recombinant bacteriophage, plasmid, or cosmid DNA expression vectors; yeast transformed with yeast expression vectors; insect cell systems infected with viral expression vectors (e.g., baculovirus);  
5 plant cell systems transformed with viral expression vectors (e.g., cauliflower mosaic virus, CaMV, or tobacco mosaic virus, TMV) or with bacterial expression vectors (e.g., Ti or pBR322 plasmids); or animal cell systems. (See, e.g., Sambrook, supra; Ausubel, supra; Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509; Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945; Takamatsu, N. (1987) EMBO J. 6:307-311; The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196; Logan, J. and T. Shenk (1984) Proc. Natl. Acad. Sci. USA 81:3655-3659; and Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355.) Expression vectors derived from retroviruses, adenoviruses, or herpes or vaccinia viruses, or from various bacterial plasmids, may be used for delivery of nucleotide sequences to the targeted organ, tissue, or cell population. (See, e.g., Di  
10 Nicola, M. et al. (1998) Cancer Gen. Ther. 5(6):350-356; Yu, M. et al. (1993) Proc. Natl. Acad. Sci. USA 90(13):6340-6344; Buller, R.M. et al. (1985) Nature 317(6040):813-815; McGregor, D.P. et al. (1994) Mol. Immunol. 31(3):219-226; and Verma, I.M. and N. Somia (1997) Nature 389:239-242.) The invention is not limited by the host cell employed.

In bacterial systems, a number of cloning and expression vectors may be selected depending upon the use intended for polynucleotide sequences encoding GCREC. For example, routine cloning,  
20 subcloning, and propagation of polynucleotide sequences encoding GCREC can be achieved using a multifunctional *E. coli* vector such as PBLUESCRIPT (Stratagene, La Jolla CA) or PSFORT1 plasmid (Life Technologies). Ligation of sequences encoding GCREC into the vector's multiple cloning site disrupts the *lacZ* gene, allowing a colorimetric screening procedure for identification of transformed  
25 bacteria containing recombinant molecules. In addition, these vectors may be useful for in vitro transcription, dideoxy sequencing, single strand rescue with helper phage, and creation of nested deletions in the cloned sequence. (See, e.g., Van Heeke, G. and S.M. Schuster (1989) J. Biol. Chem. 264:5503-5509.) When large quantities of GCREC are needed, e.g. for the production of antibodies, vectors which direct high level expression of GCREC may be used. For example, vectors containing  
30 the strong, inducible SP6 or T7 bacteriophage promoter may be used.

Yeast expression systems may be used for production of GCREC. A number of vectors containing constitutive or inducible promoters, such as alpha factor, alcohol oxidase, and PGH promoters, may be used in the yeast *Saccharomyces cerevisiae* or *Pichia pastoris*. In addition, such vectors direct either the secretion or intracellular retention of expressed proteins and enable integration  
35 of foreign sequences into the host genome for stable propagation. (See, e.g., Ausubel, 1995, supra;

Bitter, G.A. et al. (1987) *Methods Enzymol.* 153:516-544; and Scorer, C.A. et al. (1994) *Bio/Technology* 12:181-184.)

Plant systems may also be used for expression of GCREC. Transcription of sequences encoding GCREC may be driven by viral promoters, e.g., the 35S and 19S promoters of CaMV used alone or in combination with the omega leader sequence from TMV (Takamatsu, N. (1987) *EMBO J.* 6:307-311). Alternatively, plant promoters such as the small subunit of RUBISCO or heat shock promoters may be used. (See, e.g., Coruzzi, G. et al. (1984) *EMBO J.* 3:1671-1680; Broglie, R. et al. (1984) *Science* 224:838-843; and Winter, J. et al. (1991) *Results Probl. Cell Differ.* 17:85-105.) These constructs can be introduced into plant cells by direct DNA transformation or pathogen-mediated transfection. (See, e.g., The McGraw Hill Yearbook of Science and Technology (1992) McGraw Hill, New York NY, pp. 191-196.)

In mammalian cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, sequences encoding GCREC may be ligated into an adenovirus transcription/translation complex consisting of the late promoter and tripartite leader sequence. Insertion in a non-essential E1 or E3 region of the viral genome may be used to obtain infective virus which expresses GCREC in host cells. (See, e.g., Logan, J. and T. Shenk (1984) *Proc. Natl. Acad. Sci. USA* 81:3655-3659.) In addition, transcription enhancers, such as the Rous sarcoma virus (RSV) enhancer, may be used to increase expression in mammalian host cells. SV40 or EBV-based vectors may also be used for high-level protein expression.

Human artificial chromosomes (HACs) may also be employed to deliver larger fragments of DNA than can be contained in and expressed from a plasmid. HACs of about 6 kb to 10 Mb are constructed and delivered via conventional delivery methods (liposomes, polycationic amino polymers, or vesicles) for therapeutic purposes. (See, e.g., Harrington, J.J. et al. (1997) *Nat. Genet.* 15:345-355.)

For long term production of recombinant proteins in mammalian systems, stable expression of GCREC in cell lines is preferred. For example, sequences encoding GCREC can be transformed into cell lines using expression vectors which may contain viral origins of replication and/or endogenous expression elements and a selectable marker gene on the same or on a separate vector. Following the introduction of the vector, cells may be allowed to grow for about 1 to 2 days in enriched media before being switched to selective media. The purpose of the selectable marker is to confer resistance to a selective agent, and its presence allows growth and recovery of cells which successfully express the introduced sequences. Resistant clones of stably transformed cells may be propagated using tissue culture techniques appropriate to the cell type.

Any number of selection systems may be used to recover transformed cell lines. These include, but are not limited to, the herpes simplex virus thymidine kinase and adenine phosphoribosyltransferase

genes, for use in *tk* and *ap<sup>r</sup>* cells, respectively. (See, e.g., Wigler, M. et al. (1977) Cell 11:223-232; Lowy, I. et al. (1980) Cell 22:817-823.) Also, antimetabolite, antibiotic, or herbicide resistance can be used as the basis for selection. For example, *dhfr* confers resistance to methotrexate; *neo* confers resistance to the aminoglycosides neomycin and G-418; and *als* and *pat* confer resistance to

5 chlorsulfuron and phosphinotricin acetyltransferase, respectively. (See, e.g., Wigler, M. et al. (1980) Proc. Natl. Acad. Sci. USA 77:3567-3570; Colbere-Garapin, F. et al. (1981) J. Mol. Biol. 150:1-14.) Additional selectable genes have been described, e.g., *trpB* and *hisD*, which alter cellular requirements for metabolites. (See, e.g., Hartman, S.C. and R.C. Mulligan (1988) Proc. Natl. Acad. Sci. USA 85:8047-8051.) Visible markers, e.g., anthocyanins, green fluorescent proteins (GFP; Clontech),  $\beta$

10 glucuronidase and its substrate  $\beta$ -glucuronide, or luciferase and its substrate luciferin may be used. These markers can be used not only to identify transformants, but also to quantify the amount of transient or stable protein expression attributable to a specific vector system. (See, e.g., Rhodes, C.A. (1995) Methods Mol. Biol. 55:121-131.)

Although the presence/absence of marker gene expression suggests that the gene of interest is

15 also present, the presence and expression of the gene may need to be confirmed. For example, if the sequence encoding GCREC is inserted within a marker gene sequence, transformed cells containing sequences encoding GCREC can be identified by the absence of marker gene function. Alternatively, a marker gene can be placed in tandem with a sequence encoding GCREC under the control of a single promoter. Expression of the marker gene in response to induction or selection usually indicates

20 expression of the tandem gene as well.

In general, host cells that contain the nucleic acid sequence encoding GCREC and that express GCREC may be identified by a variety of procedures known to those of skill in the art. These procedures include, but are not limited to, DNA-DNA or DNA-RNA hybridizations, PCR amplification, and protein bioassay or immunoassay techniques which include membrane, solution, or

25 chip based technologies for the detection and/or quantification of nucleic acid or protein sequences.

Immunological methods for detecting and measuring the expression of GCREC using either specific polyclonal or monoclonal antibodies are known in the art. Examples of such techniques include enzyme-linked immunosorbent assays (ELISAs), radioimmunoassays (RIAs), and fluorescence activated cell sorting (FACS). A two-site, monoclonal-based immunoassay utilizing monoclonal

30 antibodies reactive to two non-interfering epitopes on GCREC is preferred, but a competitive binding assay may be employed. These and other assays are well known in the art. (See, e.g., Hampton, R. et al. (1990) Serological Methods, a Laboratory Manual, APS Press, St. Paul MN, Sect. IV; Coligan, J.E. et al. (1997) Current Protocols in Immunology, Greene Pub. Associates and Wiley-Interscience, New York NY; and Pound, J.D. (1998) Immunochemical Protocols, Humana Press, Totowa NJ.)



A wide variety of labels and conjugation techniques are known by those skilled in the art and may be used in various nucleic acid and amino acid assays. Means for producing labeled hybridization or PCR probes for detecting sequences related to polynucleotides encoding GCREC include oligolabeling, nick translation, end-labeling, or PCR amplification using a labeled nucleotide.

- 5 Alternatively, the sequences encoding GCREC, or any fragments thereof, may be cloned into a vector for the production of an mRNA probe. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes in vitro by addition of an appropriate RNA polymerase such as T7, T3, or SP6 and labeled nucleotides. These procedures may be conducted using a variety of commercially available kits, such as those provided by Amersham Pharmacia Biotech, Promega  
10 (Madison WI), and US Biochemical. Suitable reporter molecules or labels which may be used for ease of detection include radionuclides, enzymes, fluorescent, chemiluminescent, or chromogenic agents, as well as substrates, cofactors, inhibitors, magnetic particles, and the like.

- Host cells transformed with nucleotide sequences encoding GCREC may be cultured under conditions suitable for the expression and recovery of the protein from cell culture. The protein  
15 produced by a transformed cell may be secreted or retained intracellularly depending on the sequence and/or the vector used. As will be understood by those of skill in the art, expression vectors containing polynucleotides which encode GCREC may be designed to contain signal sequences which direct secretion of GCREC through a prokaryotic or eukaryotic cell membrane.

- In addition, a host cell strain may be chosen for its ability to modulate expression of the  
20 inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the polypeptide include, but are not limited to, acetylation, carboxylation, glycosylation, phosphorylation, lipidation, and acylation. Post-translational processing which cleaves a "prepro" or "pro" form of the protein may also be used to specify protein targeting, folding, and/or activity. Different host cells which have specific cellular machinery and characteristic mechanisms for post-translational activities  
25 (e.g., CHO, HeLa, MDCK, HEK293, and WI38) are available from the American Type Culture Collection (ATCC, Manassas VA) and may be chosen to ensure the correct modification and processing of the foreign protein.

- In another embodiment of the invention, natural, modified, or recombinant nucleic acid sequences encoding GCREC may be ligated to a heterologous sequence resulting in translation of a  
30 fusion protein in any of the aforementioned host systems. For example, a chimeric GCREC protein containing a heterologous moiety that can be recognized by a commercially available antibody may facilitate the screening of peptide libraries for inhibitors of GCREC activity. Heterologous protein and peptide moieties may also facilitate purification of fusion proteins using commercially available affinity matrices. Such moieties include, but are not limited to, glutathione S-transferase (GST), maltose

binding protein (MBP), thioredoxin (Trx), calmodulin binding peptide (CBP), 6-His, FLAG, *c-myc*, and hemagglutinin (HA). GST, MBP, Trx, CBP, and 6-His enable purification of their cognate fusion proteins on immobilized glutathione, maltose, phenylarsine oxide, calmodulin, and metal-chelate resins, respectively. FLAG, *c-myc*, and hemagglutinin (HA) enable immunoaffinity purification of fusion proteins using commercially available monoclonal and polyclonal antibodies that specifically recognize these epitope tags. A fusion protein may also be engineered to contain a proteolytic cleavage site located between the GCREC encoding sequence and the heterologous protein sequence, so that GCREC may be cleaved away from the heterologous moiety following purification. Methods for fusion protein expression and purification are discussed in Ausubel (1995, supra, ch. 10). A variety of commercially available kits may also be used to facilitate expression and purification of fusion proteins.

In a further embodiment of the invention, synthesis of radiolabeled GCREC may be achieved in vitro using the TNT rabbit reticulocyte lysate or wheat germ extract system (Promega). These systems couple transcription and translation of protein-coding sequences operably associated with the T7, T3, or SP6 promoters. Translation takes place in the presence of a radiolabeled amino acid precursor, for example, <sup>35</sup>S-methionine.

GCREC of the present invention or fragments thereof may be used to screen for compounds that specifically bind to GCREC. At least one and up to a plurality of test compounds may be screened for specific binding to GCREC. Examples of test compounds include antibodies, oligonucleotides, proteins (e.g., receptors), or small molecules.

In one embodiment, the compound thus identified is closely related to the natural ligand of GCREC, e.g., a ligand or fragment thereof, a natural substrate, a structural or functional mimetic, or a natural binding partner. (See, e.g., Coligan, J.E. et al. (1991) Current Protocols in Immunology 1(2): Chapter 5.) Similarly, the compound can be closely related to the natural receptor to which GCREC binds, or to at least a fragment of the receptor, e.g., the ligand binding site. In either case, the compound can be rationally designed using known techniques. In one embodiment, screening for these compounds involves producing appropriate cells which express GCREC, either as a secreted protein or on the cell membrane. Preferred cells include cells from mammals, yeast, Drosophila, or E. coli. Cells expressing GCREC or cell membrane fractions which contain GCREC are then contacted with a test compound and binding, stimulation, or inhibition of activity of either GCREC or the compound is analyzed.

An assay may simply test binding of a test compound to the polypeptide, wherein binding is detected by a fluorophore, radioisotope, enzyme conjugate, or other detectable label. For example, the assay may comprise the steps of combining at least one test compound with GCREC, either in solution or affixed to a solid support, and detecting the binding of GCREC to the compound. Alternatively, the assay may detect or measure binding of a test compound in the presence of a

labeled competitor. Additionally, the assay may be carried out using cell-free preparations, chemical libraries, or natural product mixtures, and the test compound(s) may be free in solution or affixed to a solid support.

GCREC of the present invention or fragments thereof may be used to screen for compounds that modulate the activity of GCREC. Such compounds may include agonists, antagonists, or partial or inverse agonists. In one embodiment, an assay is performed under conditions permissive for GCREC activity, wherein GCREC is combined with at least one test compound, and the activity of GCREC in the presence of a test compound is compared with the activity of GCREC in the absence of the test compound. A change in the activity of GCREC in the presence of the test compound is indicative of a compound that modulates the activity of GCREC. Alternatively, a test compound is combined with an in vitro or cell-free system comprising GCREC under conditions suitable for GCREC activity, and the assay is performed. In either of these assays, a test compound which modulates the activity of GCREC may do so indirectly and need not come in direct contact with the test compound. At least one and up to a plurality of test compounds may be screened.

In another embodiment, polynucleotides encoding GCREC or their mammalian homologs may be "knocked out" in an animal model system using homologous recombination in embryonic stem (ES) cells. Such techniques are well known in the art and are useful for the generation of animal models of human disease. (See, e.g., U.S. Patent Number 5,175,383 and U.S. Patent Number 5,767,337.) For example, mouse ES cells, such as the mouse 129/SvJ cell line, are derived from the early mouse embryo and grown in culture. The ES cells are transformed with a vector containing the gene of interest disrupted by a marker gene, e.g., the neomycin phosphotransferase gene (neo; Capecchi, M.R. (1989) Science 244:1288-1292). The vector integrates into the corresponding region of the host genome by homologous recombination. Alternatively, homologous recombination takes place using the Cre-loxP system to knockout a gene of interest in a tissue- or developmental stage-specific manner (Marth, J.D. (1996) Clin. Invest. 97:1999-2002; Wagner, K.U. et al. (1997) Nucleic Acids Res. 25:4323-4330). Transformed ES cells are identified and microinjected into mouse cell blastocysts such as those from the C57BL/6 mouse strain. The blastocysts are surgically transferred to pseudopregnant dams, and the resulting chimeric progeny are genotyped and bred to produce heterozygous or homozygous strains. Transgenic animals thus generated may be tested with potential therapeutic or toxic agents.

Polynucleotides encoding GCREC may also be manipulated in vitro in ES cells derived from human blastocysts. Human ES cells have the potential to differentiate into at least eight separate cell lineages including endoderm, mesoderm, and ectodermal cell types. These cell lineages differentiate into, for example, neural cells, hematopoietic lineages, and cardiomyocytes (Thomson, J.A. et al. (1998) Science 282:1145-1147).

Polynucleotides encoding GCREC can also be used to create "knockin" humanized animals

(pigs) or transgenic animals (mice or rats) to model human disease. With knockin technology, a region of a polynucleotide encoding GCREC is injected into animal ES cells, and the injected sequence integrates into the animal cell genome. Transformed cells are injected into blastulae, and the blastulae are implanted as described above. Transgenic progeny or inbred lines are studied and treated with potential pharmaceutical agents to obtain information on treatment of a human disease. Alternatively, a mammal inbred to overexpress GCREC, e.g., by secreting GCREC in its milk, may also serve as a convenient source of that protein (Janne, J. et al. (1998) *Biotechnol. Annu. Rev.* 4:55-74).

### THERAPEUTICS

Chemical and structural similarity, e.g., in the context of sequences and motifs, exists between regions of GCREC and G-protein coupled receptors. In addition, the expression of GCREC is closely associated with cancerous, neurological, gastrointestinal, and lung tissue. Therefore, GCREC appears to play a role in cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections. In the treatment of disorders associated with increased GCREC expression or activity, it is desirable to decrease the expression or activity of GCREC. In the treatment of disorders associated with decreased GCREC expression or activity, it is desirable to increase the expression or activity of GCREC.

Therefore, in one embodiment, GCREC or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GCREC. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental

retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders, peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia

5 gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathisia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial frontotemporal dementia; a cardiovascular

10 disorder such as arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothrombosis, vascular tumors, complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary artery bypass graft surgery, congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease, degenerative valvular heart disease, calcific aortic

15 valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, and complications of cardiac transplantation; a gastrointestinal disorder such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric

20 carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, cirrhosis, passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome,

25 colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis, Wilson's disease, alpha<sub>1</sub>-antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, centrilobular necrosis, peliosis hepatis,

30 hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas; an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia, asthma, atherosclerosis, autoimmune

35 hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal

dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a metabolic disorder such as diabetes, obesity, and osteoporosis; and an infection by a viral agent classified as adenovirus, arenavirus, bunyavirus, calicivirus, coronavirus, filovirus, hepadnavirus, herpesvirus, flavivirus, orthomyxovirus, parvovirus, papovavirus, paramyxovirus, picornavirus, poxvirus, reovirus, retrovirus, rhabdovirus, and togavirus:

In another embodiment, a vector capable of expressing GCREC or a fragment or derivative thereof may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GCREC including, but not limited to, those described above.

In a further embodiment, a composition comprising a substantially purified GCREC in conjunction with a suitable pharmaceutical carrier may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GCREC including, but not limited to, those provided above.

In still another embodiment, an agonist which modulates the activity of GCREC may be administered to a subject to treat or prevent a disorder associated with decreased expression or activity of GCREC including, but not limited to, those listed above.

In a further embodiment, an antagonist of GCREC may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of GCREC. Examples of such disorders include, but are not limited to, those cell proliferative, neurological, cardiovascular, gastrointestinal, autoimmune/inflammatory, and metabolic disorders, and viral infections, described above. In one aspect, an antibody which specifically binds GCREC may be used directly as an antagonist or indirectly as a targeting or delivery mechanism for bringing a pharmaceutical agent to cells or tissues which express GCREC.

In an additional embodiment, a vector expressing the complement of the polynucleotide encoding GCREC may be administered to a subject to treat or prevent a disorder associated with increased expression or activity of GCREC including, but not limited to, those described above.

In other embodiments, any of the proteins, antagonists, antibodies, agonists, complementary

sequences, or vectors of the invention may be administered in combination with other appropriate therapeutic agents. Selection of the appropriate agents for use in combination therapy may be made by one of ordinary skill in the art, according to conventional pharmaceutical principles. The combination of therapeutic agents may act synergistically to effect the treatment or prevention of the various disorders described above. Using this approach, one may be able to achieve therapeutic efficacy with lower dosages of each agent, thus reducing the potential for adverse side effects.

An antagonist of GCREC may be produced using methods which are generally known in the art. In particular, purified GCREC may be used to produce antibodies or to screen libraries of pharmaceutical agents to identify those which specifically bind GCREC. Antibodies to GCREC may also be generated using methods that are well known in the art. Such antibodies may include, but are not limited to, polyclonal, monoclonal, chimeric, and single chain antibodies, Fab fragments, and fragments produced by a Fab expression library. Neutralizing antibodies (i.e., those which inhibit dimer formation) are generally preferred for therapeutic use.

For the production of antibodies, various hosts including goats, rabbits, rats, mice, humans, and others may be immunized by injection with GCREC or with any fragment or oligopeptide thereof which has immunogenic properties. Depending on the host species, various adjuvants may be used to increase immunological response. Such adjuvants include, but are not limited to, Freund's, mineral gels such as aluminum hydroxide, and surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, KLH, and dinitrophenol. Among adjuvants used in humans, BCG (bacilli Calmette-Guerin) and *Corynebacterium parvum* are especially preferable.

It is preferred that the oligopeptides, peptides, or fragments used to induce antibodies to GCREC have an amino acid sequence consisting of at least about 5 amino acids, and generally will consist of at least about 10 amino acids. It is also preferable that these oligopeptides, peptides, or fragments are identical to a portion of the amino acid sequence of the natural protein. Short stretches of GCREC amino acids may be fused with those of another protein, such as KLH, and antibodies to the chimeric molecule may be produced.

Monoclonal antibodies to GCREC may be prepared using any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique, the human B-cell hybridoma technique, and the EBV-hybridoma technique. (See, e.g., Kohler, G. et al. (1975) Nature 256:495-497; Kozbor, D. et al. (1985) J. Immunol. Methods 81:31-42; Cote, R.J. et al. (1983) Proc. Natl. Acad. Sci. USA 80:2026-2030; and Cole, S.P. et al. (1984) Mol. Cell Biol. 62:109-120.)

In addition, techniques developed for the production of "chimeric antibodies," such as the splicing of mouse antibody genes to human antibody genes to obtain a molecule with appropriate

antigen specificity and biological activity, can be used. (See, e.g., Morrison, S.L. et al. (1984) Proc. Natl. Acad. Sci. USA 81:6851-6855; Neuberger, M.S. et al. (1984) Nature 312:604-608; and Takeda, S. et al. (1985) Nature 314:452-454.) Alternatively, techniques described for the production of single chain antibodies may be adapted, using methods known in the art, to produce GCREC-specific single chain antibodies. Antibodies with related specificity, but of distinct idiotypic composition, may be generated by chain shuffling from random combinatorial immunoglobulin libraries. (See, e.g., Burton, D.R. (1991) Proc. Natl. Acad. Sci. USA 88:10134-10137.)

Antibodies may also be produced by inducing *in vivo* production in the lymphocyte population or by screening immunoglobulin libraries or panels of highly specific binding reagents as disclosed in the literature. (See, e.g., Orlandi, R. et al. (1989) Proc. Natl. Acad. Sci. USA 86:3833-3837; Winter, G. et al. (1991) Nature 349:293-299.)

Antibody fragments which contain specific binding sites for GCREC may also be generated. For example, such fragments include, but are not limited to,  $F(ab')_2$  fragments produced by pepsin digestion of the antibody molecule and Fab fragments generated by reducing the disulfide bridges of the  $F(ab)_2$  fragments. Alternatively, Fab expression libraries may be constructed to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity. (See, e.g., Huse, W.D. et al. (1989) Science 246:1275-1281.)

Various immunoassays may be used for screening to identify antibodies having the desired specificity. Numerous protocols for competitive binding or immunoradiometric assays using either polyclonal or monoclonal antibodies with established specificities are well known in the art. Such immunoassays typically involve the measurement of complex formation between GCREC and its specific antibody. A two-site, monoclonal-based immunoassay utilizing monoclonal antibodies reactive to two non-interfering GCREC epitopes is generally used, but a competitive binding assay may also be employed (Pound, *supra*).

Various methods such as Scatchard analysis in conjunction with radioimmunoassay techniques may be used to assess the affinity of antibodies for GCREC. Affinity is expressed as an association constant,  $K_a$ , which is defined as the molar concentration of GCREC-antibody complex divided by the molar concentrations of free antigen and free antibody under equilibrium conditions. The  $K_a$  determined for a preparation of polyclonal antibodies, which are heterogeneous in their affinities for multiple GCREC epitopes, represents the average affinity, or avidity, of the antibodies for GCREC. The  $K_a$  determined for a preparation of monoclonal antibodies, which are monospecific for a particular GCREC epitope, represents a true measure of affinity. High-affinity antibody preparations with  $K_a$  ranging from about  $10^9$  to  $10^{12}$  L/mole are preferred for use in immunoassays in which the GCREC-antibody complex must withstand rigorous manipulations. Low-affinity antibody preparations with  $K_a$



ranging from about  $10^6$  to  $10^7$  L/mole are preferred for use in immunopurification and similar procedures which ultimately require dissociation of GCREC, preferably in active form, from the antibody (Catty, D. (1988) Antibodies, Volume I: A Practical Approach, IRL Press, Washington DC; Liddell, J.E. and A. Cryer (1991) A Practical Guide to Monoclonal Antibodies, John Wiley & Sons, New York NY).

The titer and avidity of polyclonal antibody preparations may be further evaluated to determine the quality and suitability of such preparations for certain downstream applications. For example, a polyclonal antibody preparation containing at least 1-2 mg specific antibody/ml, preferably 5-10 mg specific antibody/ml, is generally employed in procedures requiring precipitation of GCREC-antibody complexes. Procedures for evaluating antibody specificity, titer, and avidity, and guidelines for antibody quality and usage in various applications, are generally available. (See, e.g., Catty, supra, and Coligan et al. supra.)

In another embodiment of the invention, the polynucleotides encoding GCREC, or any fragment or complement thereof, may be used for therapeutic purposes. In one aspect, modifications of gene expression can be achieved by designing complementary sequences or antisense molecules (DNA, RNA, PNA, or modified oligonucleotides) to the coding or regulatory regions of the gene encoding GCREC. Such technology is well known in the art, and antisense oligonucleotides or larger fragments can be designed from various locations along the coding or control regions of sequences encoding GCREC. (See, e.g., Agrawal, S., ed. (1996) Antisense Therapeutics, Humana Press Inc., Totawa NJ.)

In therapeutic use, any gene delivery system suitable for introduction of the antisense sequences into appropriate target cells can be used. Antisense sequences can be delivered intracellularly in the form of an expression plasmid which, upon transcription, produces a sequence complementary to at least a portion of the cellular sequence encoding the target protein. (See, e.g., Slater, J.E. et al. (1998) *J. Allergy Clin. Immunol.* 102(3):469-475; and Scanlon, K.J. et al. (1995) 9(13):1288-1296.) Antisense sequences can also be introduced intracellularly through the use of viral vectors, such as retrovirus and adeno-associated virus vectors. (See, e.g., Miller, A.D. (1990) *Blood* 76:271; Ausubel, supra; Uckert, W. and W. Walther (1994) *Pharmacol. Ther.* 63(3):323-347.) Other gene delivery mechanisms include liposome-derived systems, artificial viral envelopes, and other systems known in the art. (See, e.g., Rossi, J.J. (1995) *Br. Med. Bull.* 51(1):217-225; Boado, R.J. et al. (1998) *J. Pharm. Sci.* 87(11):1308-1315; and Morris, M.C. et al. (1997) *Nucleic Acids Res.* 25(14):2730-2736.)

In another embodiment of the invention, polynucleotides encoding GCREC may be used for somatic or germline gene therapy. Gene therapy may be performed to (i) correct a genetic deficiency (e.g., in the cases of severe combined immunodeficiency (SCID)-X1 disease characterized by X-linked inheritance (Cavazzana-Calvo, M. et al. (2000) *Science* 288:669-672), severe combined

immunodeficiency syndrome associated with an inherited adenosine deaminase (ADA) deficiency (Blaese, R.M. et al. (1995) Science 270:475-480; Bordignon, C. et al. (1995) Science 270:470-475), cystic fibrosis (Zabner, J. et al. (1993) Cell 75:207-216; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:643-666; Crystal, R.G. et al. (1995) Hum. Gene Therapy 6:667-703), thalassemias, familial hypercholesterolemia, and hemophilia resulting from Factor VIII or Factor IX deficiencies (Crystal, R.G. (1995) Science 270:404-410; Verma, I.M. and N. Somia (1997) Nature 389:239-242), (ii) express a conditionally lethal gene product (e.g., in the case of cancers which result from unregulated cell proliferation), or (iii) express a protein which affords protection against intracellular parasites (e.g., against human retroviruses, such as human immunodeficiency virus (HIV) (Baltimore, D. (1988) Nature 335:395-396; Poeschla, E. et al. (1996) Proc. Natl. Acad. Sci. USA. 93:11395-11399), hepatitis B or C virus (HBV, HCV); fungal parasites, such as Candida albicans and Paracoccidioides brasiliensis; and protozoan parasites such as Plasmodium falciparum and Trypanosoma cruzi). In the case where a genetic deficiency in GCREC expression or regulation causes disease, the expression of GCREC from an appropriate population of transduced cells may alleviate the clinical manifestations caused by the genetic deficiency.

In a further embodiment of the invention, diseases or disorders caused by deficiencies in GCREC are treated by constructing mammalian expression vectors encoding GCREC and introducing these vectors by mechanical means into GCREC-deficient cells. Mechanical transfer technologies for use with cells in vivo or ex vitro include (i) direct DNA microinjection into individual cells, (ii) ballistic gold particle delivery, (iii) liposome-mediated transfection, (iv) receptor-mediated gene transfer, and (v) the use of DNA transposons (Morgan, R.A. and W.F. Anderson (1993) Annu. Rev. Biochem. 62:191-217; Ivics, Z. (1997) Cell 91:501-510; Boulay, J-L. and H. Récipon (1998) Curr. Opin. Biotechnol. 9:445-450).

Expression vectors that may be effective for the expression of GCREC include, but are not limited to, the PCDNA 3.1, EPITAG, PRCCMV2, PREP, PVAX vectors (Invitrogen, Carlsbad CA), PCMV-SCRIPT, PCMV-TAG, PEGSH/PERV (Stratagene, La Jolla CA), and PTET-OFF, PTET-ON, PTRE2, PTRE2-LUC, PTK-HYG (Clontech, Palo Alto CA). GCREC may be expressed using (i) a constitutively active promoter, (e.g., from cytomegalovirus (CMV), Rous sarcoma virus (RSV), SV40 virus, thymidine kinase (TK), or  $\beta$ -actin genes), (ii) an inducible promoter (e.g., the tetracycline-regulated promoter (Gossen, M. and H. Bujard (1992) Proc. Natl. Acad. Sci. U.S.A. 89:5547-5551; Gossen, M. et al. (1995) Science 268:1766-1769; Rossi, F.M.V. and H.M. Blau (1998) Curr. Opin. Biotechnol. 9:451-456), commercially available in the T-REX plasmid (Invitrogen)); the ecdysone-inducible promoter (available in the plasmids PVGRXR and PIND; Invitrogen); the FK506/rapamycin inducible promoter; or the RU486/mifepristone inducible promoter (Rossi, F.M.V.

and Blau, H.M. supra), or (iii) a tissue-specific promoter or the native promoter of the endogenous gene encoding GCRC from a normal individual.

Commercially available liposome transformation kits (e.g., the PERFECT LIPID TRANSFECTION KIT, available from Invitrogen) allow one with ordinary skill in the art to deliver polynucleotides to target cells in culture and require minimal effort to optimize experimental parameters. In the alternative, transformation is performed using the calcium phosphate method (Graham, F.L. and A.J. Eb (1973) *Virology* 52:456-467), or by electroporation (Neumann, E. et al. (1982) *EMBO J.* 1:841-845). The introduction of DNA to primary cells requires modification of these standardized mammalian transfection protocols.

In another embodiment of the invention, diseases or disorders caused by genetic defects with respect to GCRC expression are treated by constructing a retrovirus vector consisting of (i) the polynucleotide encoding GCRC under the control of an independent promoter or the retrovirus long terminal repeat (LTR) promoter, (ii) appropriate RNA packaging signals, and (iii) a Rev-responsive element (RRE) along with additional retrovirus *cis*-acting RNA sequences and coding sequences required for efficient vector propagation. Retrovirus vectors (e.g., PFB and PFBNEO) are commercially available (Stratagene) and are based on published data (Riviere, I. et al. (1995) *Proc. Natl. Acad. Sci. U.S.A.* 92:6733-6737), incorporated by reference herein. The vector is propagated in an appropriate vector producing cell line (VPCL) that expresses an envelope gene with a tropism for receptors on the target cells or a promiscuous envelope protein such as VSVg (Armentano, D. et al. (1987) *J. Virol.* 61:1647-1650; Bender, M.A. et al. (1987) *J. Virol.* 61:1639-1646; Adam, M.A. and A.D. Miller (1988) *J. Virol.* 62:3802-3806; Dull, T. et al. (1998) *J. Virol.* 72:8463-8471; Zufferey, R. et al. (1998) *J. Virol.* 72:9873-9880). U.S. Patent Number 5,910,434 to Rigg ("Method for obtaining retrovirus packaging cell lines producing high transducing efficiency retroviral supernatant") discloses a method for obtaining retrovirus packaging cell lines and is hereby incorporated by reference.

Propagation of retrovirus vectors, transduction of a population of cells (e.g., CD4<sup>+</sup> T-cells), and the return of transduced cells to a patient are procedures well known to persons skilled in the art of gene therapy and have been well documented (Ranga, U. et al. (1997) *J. Virol.* 71:7020-7029; Bauer, G. et al. (1997) *Blood* 89:2259-2267; Bonyhadi, M.L. (1997) *J. Virol.* 71:4707-4716; Ranga, U. et al. (1998) *Proc. Natl. Acad. Sci. U.S.A.* 95:1201-1206; Su, L. (1997) *Blood* 89:2283-2290).

In the alternative, an adenovirus-based gene therapy delivery system is used to deliver polynucleotides encoding GCRC to cells which have one or more genetic abnormalities with respect to the expression of GCRC. The construction and packaging of adenovirus-based vectors are well known to those with ordinary skill in the art. Replication defective adenovirus vectors have proven to be versatile for importing genes encoding immunoregulatory proteins into intact islets in the pancreas

(Csete, M.E. et al. (1995) Transplantation 27:263-268). Potentially useful adenoviral vectors are described in U.S. Patent Number 5,707,618 to Armentano ("Adenovirus vectors for gene therapy"), hereby incorporated by reference. For adenoviral vectors, see also Antinozzi, P.A. et al. (1999) Annu. Rev. Nutr. 19:511-544 and Verma, I.M. and N. Somia (1997) Nature 18:389:239-242, both  
5 incorporated by reference herein.

In another alternative, a herpes-based, gene therapy delivery system is used to deliver polynucleotides encoding GCREC to target cells which have one or more genetic abnormalities with respect to the expression of GCREC. The use of herpes simplex virus (HSV)-based vectors may be especially valuable for introducing GCREC to cells of the central nervous system, for which HSV has a  
10 tropism. The construction and packaging of herpes-based vectors are well known to those with ordinary skill in the art. A replication-competent herpes simplex virus (HSV) type 1-based vector has been used to deliver a reporter gene to the eyes of primates (Liu, X. et al. (1999) Exp. Eye Res. 169:385-395). The construction of a HSV-1 virus vector has also been disclosed in detail in U.S. Patent Number 5,804,413 to DeLuca ("Herpes simplex virus strains for gene transfer"), which is  
15 hereby incorporated by reference. U.S. Patent Number 5,804,413 teaches the use of recombinant HSV d92 which consists of a genome containing at least one exogenous gene to be transferred to a cell under the control of the appropriate promoter for purposes including human gene therapy. Also taught by this patent are the construction and use of recombinant HSV strains deleted for ICP4, ICP27 and ICP22. For HSV vectors, see also Goins, W.F. et al. (1999) J. Virol. 73:519-532 and Xu, H. et al. (1994) Dev.  
20 Biol. 163:152-161, hereby incorporated by reference. The manipulation of cloned herpesvirus sequences, the generation of recombinant virus following the transfection of multiple plasmids containing different segments of the large herpesvirus genomes, the growth and propagation of herpesvirus, and the infection of cells with herpesvirus are techniques well known to those of ordinary skill in the art.

25 In another alternative, an alphavirus (positive, single-stranded RNA virus) vector is used to deliver polynucleotides encoding GCREC to target cells. The biology of the prototypic alphavirus, Semliki Forest Virus (SFV), has been studied extensively and gene transfer vectors have been based on the SFV genome (Garoff, H. and K.-J. Li (1998) Curr. Opin. Biotechnol. 9:464-469). During alphavirus RNA replication, a subgenomic RNA is generated that normally encodes the viral capsid  
30 proteins. This subgenomic RNA replicates to higher levels than the full length genomic RNA, resulting in the overproduction of capsid proteins relative to the viral proteins with enzymatic activity (e.g., protease and polymerase). Similarly, inserting the coding sequence for GCREC into the alphavirus genome in place of the capsid-coding region results in the production of a large number of GCREC-coding RNAs and the synthesis of high levels of GCREC in vector transduced cells. While alphavirus

infection is typically associated with cell lysis within a few days, the ability to establish a persistent infection in hamster normal kidney cells (BHK-21) with a variant of Sindbis virus (SIN) indicates that the lytic replication of alphaviruses can be altered to suit the needs of the gene therapy application (Dryga, S.A. et al. (1997) Virology 228:74-83). The wide host range of alphaviruses will allow the introduction of GCREC into a variety of cell types. The specific transduction of a subset of cells in a population may require the sorting of cells prior to transduction. The methods of manipulating infectious cDNA clones of alphaviruses, performing alphavirus cDNA and RNA transfections, and performing alphavirus infections, are well known to those with ordinary skill in the art.

Oligonucleotides derived from the transcription initiation site, e.g., between about positions -10 and +10 from the start site, may also be employed to inhibit gene expression. Similarly, inhibition can be achieved using triple helix base-pairing methodology. Triple helix pairing is useful because it causes inhibition of the ability of the double helix to open sufficiently for the binding of polymerases, transcription factors, or regulatory molecules. Recent therapeutic advances using triplex DNA have been described in the literature. (See, e.g., Gee, J.E. et al. (1994) in Huber, B.E. and B.I. Carr, Molecular and Immunologic Approaches, Futura Publishing, Mt. Kisco NY, pp. 163-177.) A complementary sequence or antisense molecule may also be designed to block translation of mRNA by preventing the transcript from binding to ribosomes.

Ribozymes, enzymatic RNA molecules, may also be used to catalyze the specific cleavage of RNA. The mechanism of ribozyme action involves sequence-specific hybridization of the ribozyme molecule to complementary target RNA, followed by endonucleolytic cleavage. For example, engineered hammerhead motif ribozyme molecules may specifically and efficiently catalyze endonucleolytic cleavage of sequences encoding GCREC.

Specific ribozyme cleavage sites within any potential RNA target are initially identified by scanning the target molecule for ribozyme cleavage sites, including the following sequences: GUA, GUU, and GUC. Once identified, short RNA sequences of between 15 and 20 ribonucleotides, corresponding to the region of the target gene containing the cleavage site, may be evaluated for secondary structural features which may render the oligonucleotide inoperable. The suitability of candidate targets may also be evaluated by testing accessibility to hybridization with complementary oligonucleotides using ribonuclease protection assays.

Complementary ribonucleic acid molecules and ribozymes of the invention may be prepared by any method known in the art for the synthesis of nucleic acid molecules. These include techniques for chemically synthesizing oligonucleotides such as solid phase phosphoramidite chemical synthesis. Alternatively, RNA molecules may be generated by *in vitro* and *in vivo* transcription of DNA sequences encoding GCREC. Such DNA sequences may be incorporated into a wide variety of vectors with

suitable RNA polymerase promoters such as T7 or SP6. Alternatively, these cDNA constructs that synthesize complementary RNA, constitutively or inducibly, can be introduced into cell lines, cells, or tissues.

RNA molecules may be modified to increase intracellular stability and half-life. Possible modifications include, but are not limited to, the addition of flanking sequences at the 5' and/or 3' ends of the molecule, or the use of phosphorothioate or 2' O-methyl rather than phosphodiesterase linkages within the backbone of the molecule. This concept is inherent in the production of PNAs and can be extended in all of these molecules by the inclusion of nontraditional bases such as inosine, queosine, and wybutosine, as well as acetyl-, methyl-, thio-, and similarly modified forms of adenine, cytidine, guanine, thymine, and uridine which are not as easily recognized by endogenous endonucleases.

An additional embodiment of the invention encompasses a method for screening for a compound which is effective in altering expression of a polynucleotide encoding GCRC. Compounds which may be effective in altering expression of a specific polynucleotide may include, but are not limited to, oligonucleotides, antisense oligonucleotides, triple helix-forming oligonucleotides, transcription factors and other polypeptide transcriptional regulators, and non-macromolecular chemical entities which are capable of interacting with specific polynucleotide sequences. Effective compounds may alter polynucleotide expression by acting as either inhibitors or promoters of polynucleotide expression. Thus, in the treatment of disorders associated with increased GCRC expression or activity, a compound which specifically inhibits expression of the polynucleotide encoding GCRC may be therapeutically useful, and in the treatment of disorders associated with decreased GCRC expression or activity, a compound which specifically promotes expression of the polynucleotide encoding GCRC may be therapeutically useful.

At least one, and up to a plurality, of test compounds may be screened for effectiveness in altering expression of a specific polynucleotide. A test compound may be obtained by any method commonly known in the art, including chemical modification of a compound known to be effective in altering polynucleotide expression; selection from an existing, commercially-available or proprietary library of naturally-occurring or non-natural chemical compounds; rational design of a compound based on chemical and/or structural properties of the target polynucleotide; and selection from a library of chemical compounds created combinatorially or randomly. A sample comprising a polynucleotide encoding GCRC is exposed to at least one test compound thus obtained. The sample may comprise, for example, an intact or permeabilized cell, or an *in vitro* cell-free or reconstituted biochemical system. Alterations in the expression of a polynucleotide encoding GCRC are assayed by any method commonly known in the art. Typically, the expression of a specific nucleotide is detected by hybridization with a probe having a nucleotide sequence complementary to the sequence of the polynucleotide encoding GCRC. The amount of hybridization may be quantified, thus

forming the basis for a comparison of the expression of the polynucleotide both with and without exposure to one or more test compounds. Detection of a change in the expression of a polynucleotide exposed to a test compound indicates that the test compound is effective in altering the expression of the polynucleotide. A screen for a compound effective in altering expression of a specific  
5 polynucleotide can be carried out, for example, using a Schizosaccharomyces pombe gene expression system (Atkins, D. et al. (1999) U.S. Patent No. 5,932,435; Arndt, G.M. et al. (2000) Nucleic Acids Res. 28:E15) or a human cell line such as HeLa cell (Clarke, M.L. et al. (2000) Biochem. Biophys. Res. Commun. 268:8-13). A particular embodiment of the present invention involves screening a combinatorial library of oligonucleotides (such as deoxyribonucleotides, ribonucleotides, peptide  
10 nucleic acids, and modified oligonucleotides) for antisense activity against a specific polynucleotide sequence (Bruce, T.W. et al. (1997) U.S. Patent No. 5,686,242; Bruce, T.W. et al. (2000) U.S. Patent No. 6,022,691).

Many methods for introducing vectors into cells or tissues are available and equally suitable for use in vivo, in vitro, and ex vivo. For ex vivo therapy, vectors may be introduced into stem cells taken  
15 from the patient and clonally propagated for autologous transplant back into that same patient. Delivery by transfection, by liposome injections, or by polycationic amino polymers may be achieved using methods which are well known in the art. (See, e.g., Goldman, C.K. et al. (1997) Nat. Biotechnol. 15:462-466.)

Any of the therapeutic methods described above may be applied to any subject in need of such  
20 therapy, including, for example, mammals such as humans, dogs, cats, cows, horses, rabbits, and monkeys.

An additional embodiment of the invention relates to the administration of a composition which generally comprises an active ingredient formulated with a pharmaceutically acceptable excipient. Excipients may include, for example, sugars, starches, celluloses, gums, and proteins. Various  
25 formulations are commonly known and are thoroughly discussed in the latest edition of Remington's Pharmaceutical Sciences (Maack Publishing, Easton PA). Such compositions may consist of GCREC, antibodies to GCREC, and mimetics, agonists, antagonists, or inhibitors of GCREC.

The compositions utilized in this invention may be administered by any number of routes including, but not limited to, oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal,  
30 intraventricular, pulmonary, transdermal, subcutaneous, intraperitoneal, intranasal, enteral, topical, sublingual, or rectal means.

Compositions for pulmonary administration may be prepared in liquid or dry powder form. These compositions are generally aerosolized immediately prior to inhalation by the patient. In the case of small molecules (e.g. traditional low molecular weight organic drugs), aerosol delivery of fast-acting  
35 formulations is well-known in the art. In the case of macromolecules (e.g. larger peptides and proteins),

recent developments in the field of pulmonary delivery via the alveolar region of the lung have enabled the practical delivery of drugs such as insulin to blood circulation (see, e.g., Patton, J.S. et al., U.S. Patent No. 5,997,848). Pulmonary delivery has the advantage of administration without needle injection, and obviates the need for potentially toxic penetration enhancers.

5       Compositions suitable for use in the invention include compositions wherein the active ingredients are contained in an effective amount to achieve the intended purpose. The determination of an effective dose is well within the capability of those skilled in the art.

      Specialized forms of compositions may be prepared for direct intracellular delivery of macromolecules comprising GCREC or fragments thereof. For example, liposome preparations  
10       containing a cell-impermeable macromolecule may promote cell fusion and intracellular delivery of the macromolecule. Alternatively, GCREC or a fragment thereof may be joined to a short cationic N-terminal portion from the HIV Tat-1 protein. Fusion proteins thus generated have been found to transduce into the cells of all tissues, including the brain, in a mouse model system (Schwarze, S.R. et al. (1999) Science 285:1569-1572).

15       For any compound, the therapeutically effective dose can be estimated initially either in cell culture assays, e.g., of neoplastic cells, or in animal models such as mice, rats, rabbits, dogs, monkeys, or pigs. An animal model may also be used to determine the appropriate concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.

20       A therapeutically effective dose refers to that amount of active ingredient, for example GCREC or fragments thereof, antibodies of GCREC, and agonists, antagonists or inhibitors of GCREC, which ameliorates the symptoms or condition. Therapeutic efficacy and toxicity may be determined by standard pharmaceutical procedures in cell cultures or with experimental animals, such as by calculating the  $ED_{50}$  (the dose therapeutically effective in 50% of the population) or  $LD_{50}$  (the dose  
25       lethal to 50% of the population) statistics. The dose ratio of toxic to therapeutic effects is the therapeutic index, which can be expressed as the  $LD_{50}/ED_{50}$  ratio. Compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies are used to formulate a range of dosage for human use. The dosage contained in such compositions is preferably within a range of circulating concentrations that includes the  $ED_{50}$  with little or no toxicity.  
30       The dosage varies within this range depending upon the dosage form employed, the sensitivity of the patient, and the route of administration.

      The exact dosage will be determined by the practitioner, in light of factors related to the subject requiring treatment. Dosage and administration are adjusted to provide sufficient levels of the active moiety or to maintain the desired effect. Factors which may be taken into account include the severity



of the disease state, the general health of the subject, the age, weight, and gender of the subject, time and frequency of administration, drug combination(s), reaction sensitivities, and response to therapy. Long-acting compositions may be administered every 3 to 4 days, every week, or biweekly depending on the half-life and clearance rate of the particular formulation.

5 Normal dosage amounts may vary from about 0.1  $\mu\text{g}$  to 100,000  $\mu\text{g}$ , up to a total dose of about 1 gram, depending upon the route of administration. Guidance as to particular dosages and methods of delivery is provided in the literature and generally available to practitioners in the art. Those skilled in the art will employ different formulations for nucleotides than for proteins or their inhibitors. Similarly, delivery of polynucleotides or polypeptides will be specific to particular cells,  
10 conditions, locations, etc.

#### DIAGNOSTICS

In another embodiment, antibodies which specifically bind GCREC may be used for the diagnosis of disorders characterized by expression of GCREC, or in assays to monitor patients being treated with GCREC or agonists, antagonists, or inhibitors of GCREC. Antibodies useful for  
15 diagnostic purposes may be prepared in the same manner as described above for therapeutics. Diagnostic assays for GCREC include methods which utilize the antibody and a label to detect GCREC in human body fluids or in extracts of cells or tissues. The antibodies may be used with or without modification, and may be labeled by covalent or non-covalent attachment of a reporter molecule. A wide variety of reporter molecules, several of which are described above, are known in the art and may  
20 be used.

A variety of protocols for measuring GCREC, including ELISAs, RIAs, and FACS, are known in the art and provide a basis for diagnosing altered or abnormal levels of GCREC expression. Normal or standard values for GCREC expression are established by combining body fluids or cell extracts taken from normal mammalian subjects, for example, human subjects, with antibodies to GCREC  
25 under conditions suitable for complex formation. The amount of standard complex formation may be quantitated by various methods, such as photometric means. Quantities of GCREC expressed in subject, control, and disease samples from biopsied tissues are compared with the standard values. Deviation between standard and subject values establishes the parameters for diagnosing disease.

In another embodiment of the invention, the polynucleotides encoding GCREC may be used for  
30 diagnostic purposes. The polynucleotides which may be used include oligonucleotide sequences, complementary RNA and DNA molecules, and PNAs. The polynucleotides may be used to detect and quantify gene expression in biopsied tissues in which expression of GCREC may be correlated with disease. The diagnostic assay may be used to determine absence, presence, and excess expression of GCREC, and to monitor regulation of GCREC levels during therapeutic intervention.

In one aspect, hybridization with PCR probes which are capable of detecting polynucleotide sequences, including genomic sequences, encoding GCREC or closely related molecules may be used to identify nucleic acid sequences which encode GCREC. The specificity of the probe, whether it is made from a highly specific region, e.g., the 5' regulatory region, or from a less specific region, e.g., a conserved motif, and the stringency of the hybridization or amplification will determine whether the probe identifies only naturally occurring sequences encoding GCREC, allelic variants, or related sequences.

Probes may also be used for the detection of related sequences, and may have at least 50% sequence identity to any of the GCREC encoding sequences. The hybridization probes of the subject invention may be DNA or RNA and may be derived from the sequence of SEQ ID NO:40-78 or from genomic sequences including promoters, enhancers, and introns of the GCREC gene.

Means for producing specific hybridization probes for DNAs encoding GCREC include the cloning of polynucleotide sequences encoding GCREC or GCREC derivatives into vectors for the production of mRNA probes. Such vectors are known in the art, are commercially available, and may be used to synthesize RNA probes *in vitro* by means of the addition of the appropriate RNA polymerases and the appropriate labeled nucleotides. Hybridization probes may be labeled by a variety of reporter groups, for example, by radionuclides such as  $^{32}\text{P}$  or  $^{35}\text{S}$ , or by enzymatic labels, such as alkaline phosphatase coupled to the probe via avidin/biotin coupling systems, and the like.

Polynucleotide sequences encoding GCREC may be used for the diagnosis of disorders associated with expression of GCREC. Examples of such disorders include, but are not limited to, a cell proliferative disorder such as actinic keratosis, arteriosclerosis, atherosclerosis, bursitis, cirrhosis, hepatitis, mixed connective tissue disease (MCTD), myelofibrosis, paroxysmal nocturnal hemoglobinuria, polycythemia vera, psoriasis, primary thrombocythemia, and cancers including adenocarcinoma, leukemia, lymphoma, melanoma, myeloma, sarcoma, teratocarcinoma, and, in particular, cancers of the adrenal gland, bladder, bone, bone marrow, brain, breast, cervix, gall bladder, ganglia, gastrointestinal tract, heart, kidney, liver, lung, muscle, ovary, pancreas, parathyroid, penis, prostate, salivary glands, skin, spleen, testis, thymus, thyroid, and uterus; a neurological disorder such as epilepsy, ischemic cerebrovascular disease, stroke, cerebral neoplasms, Alzheimer's disease, Pick's disease, Huntington's disease, dementia, Parkinson's disease and other extrapyramidal disorders, amyotrophic lateral sclerosis and other motor neuron disorders, progressive neural muscular atrophy, retinitis pigmentosa, hereditary ataxias, multiple sclerosis and other demyelinating diseases, bacterial and viral meningitis, brain abscess, subdural empyema, epidural abscess, suppurative intracranial thrombophlebitis, myelitis and radiculitis, viral central nervous system disease, prion diseases including kuru, Creutzfeldt-Jakob disease, and Gerstmann-Straussler-Scheinker syndrome, fatal familial insomnia, nutritional and metabolic diseases of the

nervous system, neurofibromatosis, tuberous sclerosis, cerebelloretinal hemangioblastomatosis, encephalotrigeminal syndrome, mental retardation and other developmental disorders of the central nervous system, cerebral palsy, neuroskeletal disorders, autonomic nervous system disorders, cranial nerve disorders, spinal cord diseases, muscular dystrophy and other neuromuscular disorders,

5 peripheral nervous system disorders, dermatomyositis and polymyositis, inherited, metabolic, endocrine, and toxic myopathies, myasthenia gravis, periodic paralysis, mental disorders including mood, anxiety, and schizophrenic disorders, seasonal affective disorder (SAD), akathisia, amnesia, catatonia, diabetic neuropathy, tardive dyskinesia, dystonias, paranoid psychoses, postherpetic neuralgia, Tourette's disorder, progressive supranuclear palsy, corticobasal degeneration, and familial

10 frontotemporal dementia; a cardiovascular disorder such as arteriovenous fistula, atherosclerosis, hypertension, vasculitis, Raynaud's disease, aneurysms, arterial dissections, varicose veins, thrombophlebitis and phlebothrombosis, vascular tumors, complications of thrombolysis, balloon angioplasty, vascular replacement, and coronary artery bypass graft surgery, congestive heart failure, ischemic heart disease, angina pectoris, myocardial infarction, hypertensive heart disease,

15 degenerative valvular heart disease, calcific aortic valve stenosis, congenitally bicuspid aortic valve, mitral annular calcification, mitral valve prolapse, rheumatic fever and rheumatic heart disease, infective endocarditis, nonbacterial thrombotic endocarditis, endocarditis of systemic lupus erythematosus, carcinoid heart disease, cardiomyopathy, myocarditis, pericarditis, neoplastic heart disease, congenital heart disease, and complications of cardiac transplantation; a gastrointestinal

20 disorder such as dysphagia, peptic esophagitis, esophageal spasm, esophageal stricture, esophageal carcinoma, dyspepsia, indigestion, gastritis, gastric carcinoma, anorexia, nausea, emesis, gastroparesis, antral or pyloric edema, abdominal angina, pyrosis, gastroenteritis, intestinal obstruction, infections of the intestinal tract, peptic ulcer, cholelithiasis, cholecystitis, cholestasis, pancreatitis, pancreatic carcinoma, biliary tract disease, hepatitis, hyperbilirubinemia, cirrhosis,

25 passive congestion of the liver, hepatoma, infectious colitis, ulcerative colitis, ulcerative proctitis, Crohn's disease, Whipple's disease, Mallory-Weiss syndrome, colonic carcinoma, colonic obstruction, irritable bowel syndrome, short bowel syndrome, diarrhea, constipation, gastrointestinal hemorrhage, acquired immunodeficiency syndrome (AIDS) enteropathy, jaundice, hepatic encephalopathy, hepatorenal syndrome, hepatic steatosis, hemochromatosis, Wilson's disease, alpha-

30 antitrypsin deficiency, Reye's syndrome, primary sclerosing cholangitis, liver infarction, portal vein obstruction and thrombosis, centrilobular necrosis, peliosis hepatis, hepatic vein thrombosis, veno-occlusive disease, preeclampsia, eclampsia, acute fatty liver of pregnancy, intrahepatic cholestasis of pregnancy, and hepatic tumors including nodular hyperplasias, adenomas, and carcinomas; an autoimmune/inflammatory disorder such as acquired immunodeficiency syndrome (AIDS), Addison's

35 disease, adult respiratory distress syndrome, allergies, ankylosing spondylitis, amyloidosis, anemia,

asthma, atherosclerosis, autoimmune hemolytic anemia, autoimmune thyroiditis, autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED), bronchitis, cholecystitis, contact dermatitis, Crohn's disease, atopic dermatitis, dermatomyositis, diabetes mellitus, emphysema, episodic lymphopenia with lymphocytotoxins, erythroblastosis fetalis, erythema nodosum, atrophic gastritis, glomerulonephritis, Goodpasture's syndrome, gout, Graves' disease, Hashimoto's thyroiditis, hypereosinophilia, irritable bowel syndrome, multiple sclerosis, myasthenia gravis, myocardial or pericardial inflammation, osteoarthritis, osteoporosis, pancreatitis, polymyositis, psoriasis, Reiter's syndrome, rheumatoid arthritis, scleroderma, Sjögren's syndrome, systemic anaphylaxis, systemic lupus erythematosus, systemic sclerosis, thrombocytopenic purpura, ulcerative colitis, uveitis, Werner syndrome, complications of cancer, hemodialysis, and extracorporeal circulation, viral, bacterial, fungal, parasitic, protozoal, and helminthic infections, and trauma; a metabolic disorder such as diabetes, obesity, and osteoporosis; and an infection by a viral agent classified as adenovirus, arenavirus, bunyavirus, calicivirus, coronavirus, filovirus, hepadnavirus, herpesvirus, flavivirus, orthomyxovirus, parvovirus, papovavirus, paramyxovirus, picornavirus, poxvirus, reovirus, retrovirus, rhabdovirus, and togavirus. The polynucleotide sequences encoding GCREC may be used in Southern or northern analysis, dot blot, or other membrane-based technologies; in PCR technologies; in dipstick, pin, and multiformat ELISA-like assays; and in microarrays utilizing fluids or tissues from patients to detect altered GCREC expression. Such qualitative or quantitative methods are well known in the art.

In a particular aspect, the nucleotide sequences encoding GCREC may be useful in assays that detect the presence of associated disorders, particularly those mentioned above. The nucleotide sequences encoding GCREC may be labeled by standard methods and added to a fluid or tissue sample from a patient under conditions suitable for the formation of hybridization complexes. After a suitable incubation period, the sample is washed and the signal is quantified and compared with a standard value. If the amount of signal in the patient sample is significantly altered in comparison to a control sample then the presence of altered levels of nucleotide sequences encoding GCREC in the sample indicates the presence of the associated disorder. Such assays may also be used to evaluate the efficacy of a particular therapeutic treatment regimen in animal studies, in clinical trials, or to monitor the treatment of an individual patient.

In order to provide a basis for the diagnosis of a disorder associated with expression of GCREC, a normal or standard profile for expression is established. This may be accomplished by combining body fluids or cell extracts taken from normal subjects, either animal or human, with a sequence, or a fragment thereof, encoding GCREC, under conditions suitable for hybridization or amplification. Standard hybridization may be quantified by comparing the values obtained from normal subjects with values from an experiment in which a known amount of a substantially purified

polynucleotide is used. Standard values obtained in this manner may be compared with values obtained from samples from patients who are symptomatic for a disorder. Deviation from standard values is used to establish the presence of a disorder.

Once the presence of a disorder is established and a treatment protocol is initiated,  
5 hybridization assays may be repeated on a regular basis to determine if the level of expression in the patient begins to approximate that which is observed in the normal subject. The results obtained from successive assays may be used to show the efficacy of treatment over a period ranging from several days to months.

With respect to cancer, the presence of an abnormal amount of transcript (either under- or  
10 overexpressed) in biopsied tissue from an individual may indicate a predisposition for the development of the disease, or may provide a means for detecting the disease prior to the appearance of actual clinical symptoms. A more definitive diagnosis of this type may allow health professionals to employ preventative measures or aggressive treatment earlier thereby preventing the development or further progression of the cancer.

15 Additional diagnostic uses for oligonucleotides designed from the sequences encoding GCREC may involve the use of PCR. These oligomers may be chemically synthesized, generated enzymatically, or produced *in vitro*. Oligomers will preferably contain a fragment of a polynucleotide encoding GCREC, or a fragment of a polynucleotide complementary to the polynucleotide encoding GCREC, and will be employed under optimized conditions for identification of a specific gene or condition.  
20 Oligomers may also be employed under less stringent conditions for detection or quantification of closely related DNA or RNA sequences.

In a particular aspect, oligonucleotide primers derived from the polynucleotide sequences encoding GCREC may be used to detect single nucleotide polymorphisms (SNPs). SNPs are substitutions, insertions and deletions that are a frequent cause of inherited or acquired genetic disease  
25 in humans. Methods of SNP detection include, but are not limited to, single-stranded conformation polymorphism (SSCP) and fluorescent SSCP (fSSCP) methods. In SSCP, oligonucleotide primers derived from the polynucleotide sequences encoding GCREC are used to amplify DNA using the polymerase chain reaction (PCR). The DNA may be derived, for example, from diseased or normal tissue, biopsy samples, bodily fluids, and the like. SNPs in the DNA cause differences in the secondary  
30 and tertiary structures of PCR products in single-stranded form, and these differences are detectable using gel electrophoresis in non-denaturing gels. In fSSCP, the oligonucleotide primers are fluorescently labeled, which allows detection of the amplimers in high-throughput equipment such as DNA sequencing machines. Additionally, sequence database analysis methods, termed *in silico* SNP (isSNP), are capable of identifying polymorphisms by comparing the sequence of individual

overlapping DNA fragments which assemble into a common consensus sequence. These computer-based methods filter out sequence variations due to laboratory preparation of DNA and sequencing errors using statistical models and automated analyses of DNA sequence chromatograms. In the alternative, SNPs may be detected and characterized by mass spectrometry using, for example, the high throughput MASSARRAY system (Sequenom, Inc., San Diego CA).

Methods which may also be used to quantify the expression of GCREC include radiolabeling or biotinylating nucleotides, coamplification of a control nucleic acid, and interpolating results from standard curves. (See, e.g., Melby, P.C. et al. (1993) J. Immunol. Methods 159:235-244; Duplaa, C. et al. (1993) Anal. Biochem. 212:229-236.) The speed of quantitation of multiple samples may be accelerated by running the assay in a high-throughput format where the oligomer or polynucleotide of interest is presented in various dilutions and a spectrophotometric or colorimetric response gives rapid quantitation.

In further embodiments, oligonucleotides or longer fragments derived from any of the polynucleotide sequences described herein may be used as elements on a microarray. The microarray can be used in transcript imaging techniques which monitor the relative expression levels of large numbers of genes simultaneously as described below. The microarray may also be used to identify genetic variants, mutations, and polymorphisms. This information may be used to determine gene function, to understand the genetic basis of a disorder, to diagnose a disorder, to monitor progression/regression of disease as a function of gene expression, and to develop and monitor the activities of therapeutic agents in the treatment of disease. In particular, this information may be used to develop a pharmacogenomic profile of a patient in order to select the most appropriate and effective treatment regimen for that patient. For example, therapeutic agents which are highly effective and display the fewest side effects may be selected for a patient based on his/her pharmacogenomic profile.

In another embodiment, GCREC, fragments of GCREC, or antibodies specific for GCREC may be used as elements on a microarray. The microarray may be used to monitor or measure protein-protein interactions, drug-target interactions, and gene expression profiles, as described above.

A particular embodiment relates to the use of the polynucleotides of the present invention to generate a transcript image of a tissue or cell type. A transcript image represents the global pattern of gene expression by a particular tissue or cell type. Global gene expression patterns are analyzed by quantifying the number of expressed genes and their relative abundance under given conditions and at a given time. (See Seilhamer et al., "Comparative Gene Transcript Analysis," U.S. Patent Number 5,840,484, expressly incorporated by reference herein.) Thus a transcript image may be generated by hybridizing the polynucleotides of the present invention or their complements to the totality of transcripts or reverse transcripts of a particular tissue or cell type. In one embodiment, the

hybridization takes place in high-throughput format, wherein the polynucleotides of the present invention or their complements comprise a subset of a plurality of elements on a microarray. The resultant transcript image would provide a profile of gene activity.

Transcript images may be generated using transcripts isolated from tissues, cell lines, biopsies, or other biological samples. The transcript image may thus reflect gene expression in vivo, as in the case of a tissue or biopsy sample, or in vitro, as in the case of a cell line.

Transcript images which profile the expression of the polynucleotides of the present invention may also be used in conjunction with in vitro model systems and preclinical evaluation of pharmaceuticals, as well as toxicological testing of industrial and naturally-occurring environmental compounds. All compounds induce characteristic gene expression patterns, frequently termed molecular fingerprints or toxicant signatures, which are indicative of mechanisms of action and toxicity (Nuwaysir, E.F. et al. (1999) Mol. Carcinog. 24:153-159; Steiner, S. and N.L. Anderson (2000) Toxicol. Lett. 112-113:467-471, expressly incorporated by reference herein). If a test compound has a signature similar to that of a compound with known toxicity, it is likely to share those toxic properties. These fingerprints or signatures are most useful and refined when they contain expression information from a large number of genes and gene families. Ideally, a genome-wide measurement of expression provides the highest quality signature. Even genes whose expression is not altered by any tested compounds are important as well, as the levels of expression of these genes are used to normalize the rest of the expression data. The normalization procedure is useful for comparison of expression data after treatment with different compounds. While the assignment of gene function to elements of a toxicant signature aids in interpretation of toxicity mechanisms, knowledge of gene function is not necessary for the statistical matching of signatures which leads to prediction of toxicity. (See, for example, Press Release 00-02 from the National Institute of Environmental Health Sciences, released February 29, 2000, available at <http://www.niehs.nih.gov/oc/news/toxchip.htm>.) Therefore, it is important and desirable in toxicological screening using toxicant signatures to include all expressed gene sequences.

In one embodiment, the toxicity of a test compound is assessed by treating a biological sample containing nucleic acids with the test compound. Nucleic acids that are expressed in the treated biological sample are hybridized with one or more probes specific to the polynucleotides of the present invention, so that transcript levels corresponding to the polynucleotides of the present invention may be quantified. The transcript levels in the treated biological sample are compared with levels in an untreated biological sample. Differences in the transcript levels between the two samples are indicative of a toxic response caused by the test compound in the treated sample.

Another particular embodiment relates to the use of the polypeptide sequences of the present invention to analyze the proteome of a tissue or cell type. The term proteome refers to the global

pattern of protein expression in a particular tissue or cell type. Each protein component of a proteome can be subjected individually to further analysis. Proteome expression patterns, or profiles, are analyzed by quantifying the number of expressed proteins and their relative abundance under given conditions and at a given time. A profile of a cell's proteome may thus be generated by separating and  
5 analyzing the polypeptides of a particular tissue or cell type. In one embodiment, the separation is achieved using two-dimensional gel electrophoresis, in which proteins from a sample are separated by isoelectric focusing in the first dimension, and then according to molecular weight by sodium dodecyl sulfate slab gel electrophoresis in the second dimension (Steiner and Anderson, *supra*). The proteins are visualized in the gel as discrete and uniquely positioned spots, typically by staining the gel with an agent  
10 such as Coomassie Blue or silver or fluorescent stains. The optical density of each protein spot is generally proportional to the level of the protein in the sample. The optical densities of equivalently positioned protein spots from different samples, for example, from biological samples either treated or untreated with a test compound or therapeutic agent, are compared to identify any changes in protein spot density related to the treatment. The proteins in the spots are partially sequenced using, for  
15 example, standard methods employing chemical or enzymatic cleavage followed by mass spectrometry. The identity of the protein in a spot may be determined by comparing its partial sequence, preferably of at least 5 contiguous amino acid residues, to the polypeptide sequences of the present invention. In some cases, further sequence data may be obtained for definitive protein identification.

A proteomic profile may also be generated using antibodies specific for GCREC to quantify the  
20 levels of GCREC expression. In one embodiment, the antibodies are used as elements on a microarray, and protein expression levels are quantified by exposing the microarray to the sample and detecting the levels of protein bound to each array element (Lueking, A. et al. (1999) *Anal. Biochem.* 270:103-111; Mendoz, L.G. et al. (1999) *Biotechniques* 27:778-788). Detection may be performed by a variety of methods known in the art, for example, by reacting the proteins in the sample with a thiol- or amino-  
25 reactive fluorescent compound and detecting the amount of fluorescence bound at each array element.

Toxicant signatures at the proteome level are also useful for toxicological screening, and should be analyzed in parallel with toxicant signatures at the transcript level. There is a poor correlation between transcript and protein abundances for some proteins in some tissues (Anderson, N.L. and J. Seilhamer (1997) *Electrophoresis* 18:533-537), so proteome toxicant signatures may be useful in the  
30 analysis of compounds which do not significantly affect the transcript image, but which alter the proteomic profile. In addition, the analysis of transcripts in body fluids is difficult, due to rapid degradation of mRNA, so proteomic profiling may be more reliable and informative in such cases.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins that are expressed in the treated biological



sample are separated so that the amount of each protein can be quantified. The amount of each protein is compared to the amount of the corresponding protein in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample. Individual proteins are identified by sequencing the amino acid residues of the individual proteins and comparing these partial sequences to the polypeptides of the present invention.

In another embodiment, the toxicity of a test compound is assessed by treating a biological sample containing proteins with the test compound. Proteins from the biological sample are incubated with antibodies specific to the polypeptides of the present invention. The amount of protein recognized by the antibodies is quantified. The amount of protein in the treated biological sample is compared with the amount in an untreated biological sample. A difference in the amount of protein between the two samples is indicative of a toxic response to the test compound in the treated sample.

Microarrays may be prepared, used, and analyzed using methods known in the art. (See, e.g., Brennan, T.M. et al. (1995) U.S. Patent No. 5,474,796; Schena, M. et al. (1996) Proc. Natl. Acad. Sci. USA 93:10614-10619; Baldeschweiler et al. (1995) PCT application WO95/251116; Shalon, D. et al. (1995) PCT application WO95/35505; Heller, R.A. et al. (1997) Proc. Natl. Acad. Sci. USA 94:2150-2155; and Heller, M.J. et al. (1997) U.S. Patent No. 5,605,662.) Various types of microarrays are well known and thoroughly described in DNA Microarrays: A Practical Approach, M. Schena, ed. (1999) Oxford University Press, London, hereby expressly incorporated by reference.

In another embodiment of the invention, nucleic acid sequences encoding GCRC may be used to generate hybridization probes useful in mapping the naturally occurring genomic sequence. Either coding or noncoding sequences may be used, and in some instances, noncoding sequences may be preferable over coding sequences. For example, conservation of a coding sequence among members of a multi-gene family may potentially cause undesired cross hybridization during chromosomal mapping. The sequences may be mapped to a particular chromosome, to a specific region of a chromosome, or to artificial chromosome constructions, e.g., human artificial chromosomes (HACs), yeast artificial chromosomes (YACs), bacterial artificial chromosomes (BACs), bacterial P1 constructions, or single chromosome cDNA libraries. (See, e.g., Harrington, J.J. et al. (1997) Nat. Genet. 15:345-355; Price, C.M. (1993) Blood Rev. 7:127-134; and Trask, B.J. (1991) Trends Genet. 7:149-154.) Once mapped, the nucleic acid sequences of the invention may be used to develop genetic linkage maps, for example, which correlate the inheritance of a disease state with the inheritance of a particular chromosome region or restriction fragment length polymorphism (RFLP). (See, for example, Lander, E.S. and D. Botstein (1986) Proc. Natl. Acad. Sci. USA 83:7353-7357.)

Fluorescent in situ hybridization (FISH) may be correlated with other physical and genetic map data. (See, e.g., Heinz-Ulrich, et al. (1995) in Meyers, *supra*, pp. 965-968.) Examples of genetic map data can be found in various scientific journals or at the Online Mendelian Inheritance in Man (OMIM)

World Wide Web site. Correlation between the location of the gene encoding GCREC on a physical map and a specific disorder, or a predisposition to a specific disorder, may help define the region of DNA associated with that disorder and thus may further positional cloning efforts.

In situ hybridization of chromosomal preparations and physical mapping techniques, such as linkage analysis using established chromosomal markers, may be used for extending genetic maps. Often the placement of a gene on the chromosome of another mammalian species, such as mouse, may reveal associated markers even if the exact chromosomal locus is not known. This information is valuable to investigators searching for disease genes using positional cloning or other gene discovery techniques. Once the gene or genes responsible for a disease or syndrome have been crudely localized by genetic linkage to a particular genomic region, e.g., ataxia-telangiectasia to 11q22-23, any sequences mapping to that area may represent associated or regulatory genes for further investigation. (See, e.g., Gatti, R.A. et al. (1988) *Nature* 336:577-580.) The nucleotide sequence of the instant invention may also be used to detect differences in the chromosomal location due to translocation, inversion, etc., among normal, carrier, or affected individuals.

In another embodiment of the invention, GCREC, its catalytic or immunogenic fragments, or oligopeptides thereof can be used for screening libraries of compounds in any of a variety of drug screening techniques. The fragment employed in such screening may be free in solution, affixed to a solid support, borne on a cell surface, or located intracellularly. The formation of binding complexes between GCREC and the agent being tested may be measured.

Another technique for drug screening provides for high throughput screening of compounds having suitable binding affinity to the protein of interest. (See, e.g., Geysen, et al. (1984) PCT application WO84/03564.) In this method, large numbers of different small test compounds are synthesized on a solid substrate. The test compounds are reacted with GCREC, or fragments thereof, and washed. Bound GCREC is then detected by methods well known in the art. Purified GCREC can also be coated directly onto plates for use in the aforementioned drug screening techniques. Alternatively, non-neutralizing antibodies can be used to capture the peptide and immobilize it on a solid support.

In another embodiment, one may use competitive drug screening assays in which neutralizing antibodies capable of binding GCREC specifically compete with a test compound for binding GCREC. In this manner, antibodies can be used to detect the presence of any peptide which shares one or more antigenic determinants with GCREC.

In additional embodiments, the nucleotide sequences which encode GCREC may be used in any molecular biology techniques that have yet to be developed, provided the new techniques rely on properties of nucleotide sequences that are currently known, including, but not limited to, such

properties as the triplet genetic code and specific base pair interactions.

Without further elaboration, it is believed that one skilled in the art can, using the preceding description, utilize the present invention to its fullest extent. The following embodiments are, therefore, to be construed as merely illustrative, and not limitative of the remainder of the disclosure in any way whatsoever.

The disclosures of all patents, applications and publications, mentioned above and below, in particular U.S. Ser. No. 60/172,852, U.S. Ser. No. 60/171,732, U.S. Ser. No. 60/176,148, and U.S. Ser. No. 60/177,331, are expressly incorporated by reference herein.

## EXAMPLES

### I. Construction of cDNA Libraries

Incyte cDNAs were derived from cDNA libraries described in the LIFESEQ GOLD database (Incyte Genomics, Palo Alto CA) and shown in Table 4, column 5. The Incyte cDNA shown for SEQ ID NO:40 was derived from a cDNA library constructed from bone marrow tissue. The Incyte cDNAs shown for SEQ ID NO:41 were derived from cDNA libraries constructed from small intestine, including tissues associated with Crohn's disease, from large intestine, and from brain tissues. The Incyte cDNAs shown for SEQ ID NO:42 were derived from cDNA libraries constructed from prostate tumor, small intestine, breast, and epidermal tissues. The Incyte cDNAs shown for SEQ ID NO:43 were derived cDNA libraries constructed from soft tissue tumor, fetal rib, and brain tissue associated with Huntington's disease. The Incyte cDNAs shown for SEQ ID NO:57 were derived from cDNA libraries constructed from lymphocytes and mast cells, and from breast, uterine, prostate, adrenal gland, spinal cord, tibial muscle, lung, esophagus, small intestine, and colon tissues. The Incyte cDNAs shown for SEQ ID NO:58 were derived from cDNA libraries constructed from a fallopian tube tumor, uterine endometrium, and bronchial tissue. The Incyte cDNAs shown for SEQ ID NO:59 were derived from cDNA libraries constructed from colon tissues, including cecal tumor tissue, as well as from pancreatic tumor, pituitary gland, and brain tissues. The Incyte cDNAs shown for SEQ ID NO:60 were derived from cDNA libraries constructed from brain, including brain tumor tissue and tissues associated with Huntington's disease, and from prostate tumor, cervical adenocarcinoma, breast, small intestine, and bladder tissues. Some tissues were homogenized and lysed in guanidinium isothiocyanate, while others were homogenized and lysed in phenol or in a suitable mixture of denaturants, such as TRIZOL (Life Technologies), a monophasic solution of phenol and guanidine isothiocyanate. The resulting lysates were centrifuged over CsCl cushions or extracted with chloroform. RNA was precipitated from the lysates with either isopropanol or sodium acetate and ethanol, or by other routine methods.

Phenol extraction and precipitation of RNA were repeated as necessary to increase RNA

purity. In some cases, RNA was treated with DNase. For most libraries, poly(A)+ RNA was isolated using oligo d(T)-coupled paramagnetic particles (Promega), OLIGOTEX latex particles (QIAGEN, Chatsworth CA), or an OLIGOTEX mRNA purification kit (QIAGEN). Alternatively, RNA was isolated directly from tissue lysates using other RNA isolation kits, e.g., the POLY(A)PURE mRNA purification kit (Ambion, Austin TX).

In some cases, Stratagene was provided with RNA and constructed the corresponding cDNA libraries. Otherwise, cDNA was synthesized and cDNA libraries were constructed with the UNIZAP vector system (Stratagene) or SUPERScript plasmid system (Life Technologies), using the recommended procedures or similar methods known in the art. (See, e.g., Ausubel, 1997, supra, units 5.1-6.6.) Reverse transcription was initiated using oligo d(T) or random primers. Synthetic oligonucleotide adapters were ligated to double stranded cDNA, and the cDNA was digested with the appropriate restriction enzyme or enzymes. For most libraries, the cDNA was size-selected (300-1000 bp) using SEPHACRYL S1000, SEPHAROSE CL2B, or SEPHAROSE CL4B column chromatography (Amersham Pharmacia Biotech) or preparative agarose gel electrophoresis. cDNAs were ligated into compatible restriction-enzyme sites of the polylinker of a suitable plasmid, e.g., PBLUESCRIPT plasmid (Stratagene), PSPORT1 plasmid (Life Technologies), PCDNA2.1 plasmid (Invitrogen, Carlsbad CA), or pINCY (Incyte Genomics, Palo Alto CA). Recombinant plasmids were transformed into competent *E. coli* cells including XL1-Blue, XL1-BlueMRF, or SOLR from Stratagene or DH5 $\alpha$ , DH10B, or ElectroMAX DH10B from Life Technologies.

## II. Isolation of cDNA Clones

Plasmids obtained as described in Example I were recovered from host cells by in vivo excision using the UNIZAP vector system (Stratagene) or by cell lysis. Plasmids were purified using at least one of the following: a Magic or WIZARD Minipreps DNA purification system (Promega); an AGTC Miniprep purification kit (Edge Biosystems, Gaithersburg MD); and QIAWELL 8 Plasmid, QIAWELL 8 Plus Plasmid, QIAWELL 8 Ultra Plasmid purification systems or the R.E.A.L. PREP 96 plasmid purification kit from QIAGEN. Following precipitation, plasmids were resuspended in 0.1 ml of distilled water and stored, with or without lyophilization, at 4°C.

Alternatively, plasmid DNA was amplified from host cell lysates using direct link PCR in a high-throughput format (Rao, V.B. (1994) Anal. Biochem. 216:1-14). Host cell lysis and thermal cycling steps were carried out in a single reaction mixture. Samples were processed and stored in 384-well plates, and the concentration of amplified plasmid DNA was quantified fluorometrically using PICOGREEN dye (Molecular Probes, Eugene OR) and a FLUOROSKAN II fluorescence scanner (Labsystems Oy, Helsinki, Finland).

## III. Sequencing and Analysis

Incyte cDNA recovered in plasmids as described in Example II were sequenced as follows. Sequencing reactions were processed using standard methods or high-throughput instrumentation such as the ABI CATALYST 800 (Applied Biosystems) thermal cycler or the PTC-200 thermal cycler (MJ Research) in conjunction with the HYDRA microdispenser (Robbins Scientific) or the  
5 MICROLAB 2200 (Hamilton) liquid transfer system. cDNA sequencing reactions were prepared using reagents provided by Amersham Pharmacia Biotech or supplied in ABI sequencing kits such as the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems). Electrophoretic separation of cDNA sequencing reactions and detection of labeled polynucleotides were carried out using the MEGABACE 1000 DNA sequencing system (Molecular Dynamics); the ABI  
10 PRISM 373 or 377 sequencing system (Applied Biosystems) in conjunction with standard ABI protocols and base calling software; or other sequence analysis systems known in the art. Reading frames within the cDNA sequences were identified using standard methods (reviewed in Ausubel, 1997, supra, unit 7.7). Some of the cDNA sequences were selected for extension using the techniques disclosed in Example VIII.

15 The polynucleotide sequences derived from Incyte cDNAs were validated by removing vector, linker, and poly(A) sequences and by masking ambiguous bases, using algorithms and programs based on BLAST, dynamic programming, and dinucleotide nearest neighbor analysis. The Incyte cDNA sequences or translations thereof were then queried against a selection of public databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases, and BLOCKS, PRINTS,  
20 DOMO, PRODOM, and hidden Markov model (HMM)-based protein family databases such as PFAM. (HMM is a probabilistic approach which analyzes consensus primary structures of gene families. See, for example, Eddy, S.R. (1996) Curr. Opin. Struct. Biol. 6:361-365.) The queries were performed using programs based on BLAST, FASTA, BLIMPS, and HMMR. The Incyte cDNA sequences were assembled to produce polynucleotide sequences. Alternatively, GenBank cDNAs,  
25 GenBank ESTs, stitched sequences, stretched sequences, or Genscan-predicted coding sequences (see Examples IV and V) were used to extend Incyte cDNA assemblages to full length. Assembly was performed using programs based on Phred, Phrap, and Consed, and cDNA assemblages were screened for open reading frames using programs based on GeneMark, BLAST, and FASTA. The polynucleotide sequences were translated to derive the corresponding polypeptide sequences which were  
30 subsequently analyzed by querying against databases such as the GenBank protein databases (genpept), SwissProt, BLOCKS, PRINTS, DOMO, PRODOM, Prosite, and hidden Markov model (HMM)-based protein family databases such as PFAM. Full length polynucleotide sequences are also analyzed using MACDNASIS PRO software (Hitachi Software Engineering, South San Francisco CA) and LASERGENE software (DNASTAR). Polynucleotide and polypeptide sequence alignments are  
35 generated using default parameters specified by the CLUSTAL algorithm as incorporated into the

MEGALIGN multisequence alignment program (DNASTAR), which also calculates the percent identity between aligned sequences.

Table 7 summarizes the tools, programs, and algorithms used for the analysis and assembly of Incyte cDNA and assembled polynucleotide sequences and provides applicable descriptions, references, and threshold parameters. The first column of Table 7 shows the tools, programs, and algorithms used, the second column provides brief descriptions thereof, the third column presents appropriate references, all of which are incorporated by reference herein in their entirety, and the fourth column presents, where applicable, the scores, probability values, and other parameters used to evaluate the strength of a match between two sequences (the higher the score or the lower the probability value, the greater the identity between two sequences).

The programs described above for the assembly and analysis of polynucleotide and polypeptide sequences were also used to identify polynucleotide sequence fragments from SEQ ID NO:40-78. Fragments from about 20 to about 4000 nucleotides which are useful in hybridization and amplification technologies are described in Table 4, column 4.

#### IV. Identification and Editing of Coding Sequences from Genomic DNA

Putative G-protein coupled receptors were initially identified by running the Genscan gene identification program against public genomic sequence databases (e.g., gbpri and gbhtg). Genscan is a general-purpose gene identification program which analyzes genomic DNA sequences from a variety of organisms (See Burge, C. and S. Karlin (1997) J. Mol. Biol. 268:78-94, and Burge, C. and S. Karlin (1998) Curr. Opin. Struct. Biol. 8:346-354). The program concatenates predicted exons to form an assembled cDNA sequence extending from a methionine to a stop codon. The output of Genscan is a FASTA database of polynucleotide and polypeptide sequences. The maximum range of sequence for Genscan to analyze at once was set to 30 kb. To determine which of these Genscan predicted cDNA sequences encode G-protein coupled receptors, the encoded polypeptides were analyzed by querying against PFAM models for G-protein coupled receptors (7tm\_1, 7tm\_2, 7tm\_3, and 7tm\_4). Potential G-protein coupled receptors were also identified by homology to Incyte cDNA sequences that had been annotated as G-protein coupled receptors. These selected Genscan-predicted sequences were then compared by BLAST analysis to the genpept and gbpri public databases. Where necessary, the Genscan-predicted sequences were then edited by comparison to the top BLAST hit from genpept to correct errors in the sequence predicted by Genscan, such as extra or omitted exons. BLAST analysis was also used to find any Incyte cDNA or public cDNA coverage of the Genscan-predicted sequences, thus providing evidence for transcription. When Incyte cDNA coverage was available, this information was used to correct or confirm the Genscan predicted sequence. Polynucleotide sequences, including SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:61, SEQ ID NO:62,

and SEQ ID NO:63, were obtained by assembling Genscan-predicted coding sequences with Incyte cDNA sequences and/or public cDNA sequences using the assembly process described in Example III. Alternatively, polynucleotide sequences, including SEQ ID NO:44, SEQ ID NO:45, SEQ ID NO:46, SEQ ID NO:64, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:73, SEQ ID NO:74, SEQ ID NO:75, SEQ ID NO:76, SEQ ID NO:77, and SEQ ID NO:78, are full length coding regions derived entirely from edited or unedited Genscan-predicted coding sequences. Alternatively, polynucleotide sequences, including SEQ ID NO:47, SEQ ID NO:48, SEQ ID NO:49, SEQ ID NO:50, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, and SEQ ID NO:56, are partial genes derived from the assembly and editing of Genscan-predicted sequences only.

#### V. Assembly of Genomic Sequence Data with cDNA Sequence Data

##### "Stitched" Sequences

Partial cDNA sequences were extended with exons predicted by the Genscan gene identification program described in Example IV. Partial cDNAs assembled as described in Example III were mapped to genomic DNA and parsed into clusters containing related cDNAs and Genscan exon predictions from one or more genomic sequences. Each cluster was analyzed using an algorithm based on graph theory and dynamic programming to integrate cDNA and genomic information, generating possible splice variants that were subsequently confirmed, edited, or extended to create a full length sequence. Sequence intervals in which the entire length of the interval was present on more than one sequence in the cluster were identified, and intervals thus identified were considered to be equivalent by transitivity. For example, if an interval was present on a cDNA and two genomic sequences, then all three intervals were considered to be equivalent. This process allows unrelated but consecutive genomic sequences to be brought together, bridged by cDNA sequence. Intervals thus identified were then "stitched" together by the stitching algorithm in the order that they appear along their parent sequences to generate the longest possible sequence, as well as sequence variants. Linkages between intervals which proceed along one type of parent sequence (cDNA to cDNA or genomic sequence to genomic sequence) were given preference over linkages which change parent type (cDNA to genomic sequence). The resultant stitched sequences were translated and compared by BLAST analysis to the genpept and gbpr public databases. Incorrect exons predicted by Genscan were corrected by comparison to the top BLAST hit from genpept. Sequences were further extended with additional cDNA sequences, or by inspection of genomic DNA, when necessary.

##### "Stretched" Sequences

Partial DNA sequences were extended to full length with an algorithm based on BLAST analysis. First, partial cDNAs assembled as described in Example III were queried against public

databases such as the GenBank primate, rodent, mammalian, vertebrate, and eukaryote databases using the BLAST program. The nearest GenBank protein homolog was then compared by BLAST analysis to either Incyte cDNA sequences or GenScan exon predicted sequences described in Example IV. A chimeric protein was generated by using the resultant high-scoring segment pairs (HSPs) to map the translated sequences onto the GenBank protein homolog. Insertions or deletions may occur in the chimeric protein with respect to the original GenBank protein homolog. The GenBank protein homolog, the chimeric protein, or both were used as probes to search for homologous genomic sequences from the public human genome databases. Partial DNA sequences were therefore "stretched" or extended by the addition of homologous genomic sequences. The resultant stretched sequences were examined to determine whether it contained a complete gene.

#### VI. Chromosomal Mapping of GCREC Encoding Polynucleotides

The sequences which were used to assemble SEQ ID NO:40-78 were compared with sequences from the Incyte LIFESEQ database and public domain databases using BLAST and other implementations of the Smith-Waterman algorithm. Sequences from these databases that matched SEQ ID NO:40-78 were assembled into clusters of contiguous and overlapping sequences using assembly algorithms such as Phrap (Table 7). Radiation hybrid and genetic mapping data available from public resources such as the Stanford Human Genome Center (SHGC), Whitehead Institute for Genome Research (WIGR), and Généthon were used to determine if any of the clustered sequences had been previously mapped. Inclusion of a mapped sequence in a cluster resulted in the assignment of all sequences of that cluster, including its particular SEQ ID NO., to that map location.

Map locations are represented by ranges, or intervals, or human chromosomes. The map position of an interval, in centiMorgans, is measured relative to the terminus of the chromosome's p-arm. (The centiMorgan (cM) is a unit of measurement based on recombination frequencies between chromosomal markers. On average, 1 cM is roughly equivalent to 1 megabase (Mb) of DNA in humans, although this can vary widely due to hot and cold spots of recombination.) The cM distances are based on genetic markers mapped by Généthon which provide boundaries for radiation hybrid markers whose sequences were included in each of the clusters. Human genome maps and other resources available to the public, such as the NCBI "GeneMap'99" World Wide Web site (<http://www.ncbi.nlm.nih.gov/genemap/>), can be employed to determine if previously identified disease genes map within or in proximity to the intervals indicated above.

#### VII. Analysis of Polynucleotide Expression

Northern analysis is a laboratory technique used to detect the presence of a transcript of a gene and involves the hybridization of a labeled nucleotide sequence to a membrane on which RNAs from a particular cell type or tissue have been bound. (See, e.g., Sambrook, *supra*, ch. 7; Ausubel (1995) *supra*, ch. 4 and 16.)



Analogous computer techniques applying BLAST were used to search for identical or related molecules in cDNA databases such as GenBank or LIFESEQ (Incyte Genomics). This analysis is much faster than multiple membrane-based hybridizations. In addition, the sensitivity of the computer search can be modified to determine whether any particular match is categorized as exact or similar.

- 5 The basis of the search is the product score, which is defined as:

$$\frac{\text{BLAST Score} \times \text{Percent Identity}}{5 \times \text{minimum \{length(Seq. 1), length(Seq. 2)\}}}$$

- 10 The product score takes into account both the degree of similarity between two sequences and the length of the sequence match. The product score is a normalized value between 0 and 100, and is calculated as follows: the BLAST score is multiplied by the percent nucleotide identity and the product is divided by (5 times the length of the shorter of the two sequences). The BLAST score is calculated by assigning a score of +5 for every base that matches in a high-scoring segment pair (HSP), and -4 for  
 15 every mismatch. Two sequences may share more than one HSP (separated by gaps). If there is more than one HSP, then the pair with the highest BLAST score is used to calculate the product score. The product score represents a balance between fractional overlap and quality in a BLAST alignment. For example, a product score of 100 is produced only for 100% identity over the entire length of the shorter of the two sequences being compared. A product score of 70 is produced either by 100% identity and  
 20 70% overlap at one end, or by 88% identity and 100% overlap at the other. A product score of 50 is produced either by 100% identity and 50% overlap at one end, or 79% identity and 100% overlap.

- Alternatively, polynucleotide sequences encoding GCREC are analyzed with respect to the tissue sources from which they were derived. For example, some full length sequences are assembled, at least in part, with overlapping Incyte cDNA sequences (see Example III). Each cDNA sequence is  
 25 derived from a cDNA library constructed from a human tissue. Each human tissue is classified into one of the following organ/tissue categories: cardiovascular system; connective tissue; digestive system; embryonic structures; endocrine system; exocrine glands; genitalia, female; genitalia, male; germ cells; hemic and immune system; liver; musculoskeletal system; nervous system; pancreas; respiratory system; sense organs; skin; stomatognathic system; unclassified/mixed; or urinary tract. The number of  
 30 libraries in each category is counted and divided by the total number of libraries across all categories. Similarly, each human tissue is classified into one of the following disease/condition categories: cancer, cell line, developmental, inflammation, neurological, trauma, cardiovascular, pooled, and other, and the number of libraries in each category is counted and divided by the total number of libraries across all categories. The resulting percentages reflect the tissue- and disease-specific expression of cDNA  
 35 encoding GCREC. cDNA sequences and cDNA library/tissue information are found in the LIFESEQ

GOLD database (Incyte Genomics, Palo Alto CA).

#### VIII. Extension of GCREC Encoding Polynucleotides

Full length polynucleotide sequences were also produced by extension of an appropriate fragment of the full length molecule using oligonucleotide primers designed from this fragment. One primer was synthesized to initiate 5' extension of the known fragment, and the other primer was synthesized to initiate 3' extension of the known fragment. The initial primers were designed using OLIGO 4.06 software (National Biosciences), or another appropriate program, to be about 22 to 30 nucleotides in length, to have a GC content of about 50% or more, and to anneal to the target sequence at temperatures of about 68°C to about 72°C. Any stretch of nucleotides which would result in hairpin structures and primer-primer dimerizations was avoided.

Selected human cDNA libraries were used to extend the sequence. If more than one extension was necessary or desired, additional or nested sets of primers were designed.

High fidelity amplification was obtained by PCR using methods well known in the art. PCR was performed in 96-well plates using the PTC-200 thermal cycler (MJ Research, Inc.). The reaction mix contained DNA template, 200 nmol of each primer, reaction buffer containing  $Mg^{2+}$ ,  $(NH_4)_2SO_4$ , and 2-mercaptoethanol, Taq DNA polymerase (Amersham Pharmacia Biotech), ELONGASE enzyme (Life Technologies), and Pfu DNA polymerase (Stratagene), with the following parameters for primer pair PCI A and PCI B: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C. In the alternative, the parameters for primer pair T7 and SK+ were as follows: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 57°C, 1 min; Step 4: 68°C, 2 min; Step 5: Steps 2, 3, and 4 repeated 20 times; Step 6: 68°C, 5 min; Step 7: storage at 4°C.

The concentration of DNA in each well was determined by dispensing 100  $\mu$ l PICOGREEN quantitation reagent (0.25% (v/v) PICOGREEN; Molecular Probes, Eugene OR) dissolved in 1X TE and 0.5  $\mu$ l of undiluted PCR product into each well of an opaque fluorimeter plate (Corning Costar, Acton MA), allowing the DNA to bind to the reagent. The plate was scanned in a Fluoroskan II (Labsystems Oy, Helsinki, Finland) to measure the fluorescence of the sample and to quantify the concentration of DNA. A 5  $\mu$ l to 10  $\mu$ l aliquot of the reaction mixture was analyzed by electrophoresis on a 1 % agarose gel to determine which reactions were successful in extending the sequence.

The extended nucleotides were desalted and concentrated, transferred to 384-well plates, digested with CviJI cholera virus endonuclease (Molecular Biology Research, Madison WI), and sonicated or sheared prior to religation into pUC 18 vector (Amersham Pharmacia Biotech). For shotgun sequencing, the digested nucleotides were separated on low concentration (0.6 to 0.8%) agarose gels, fragments were excised, and agar digested with Agar ACE (Promega). Extended clones were

religated using T4 ligase (New England Biolabs, Beverly MA) into pUC 18 vector (Amersham Pharmacia Biotech), treated with Pfu DNA polymerase (Stratagene) to fill-in restriction site overhangs, and transfected into competent *E. coli* cells. Transformed cells were selected on antibiotic-containing media, and individual colonies were picked and cultured overnight at 37°C in 384-well plates in LB/2x carb liquid media.

The cells were lysed, and DNA was amplified by PCR using Taq DNA polymerase (Amersham Pharmacia Biotech) and Pfu DNA polymerase (Stratagene) with the following parameters: Step 1: 94°C, 3 min; Step 2: 94°C, 15 sec; Step 3: 60°C, 1 min; Step 4: 72°C, 2 min; Step 5: steps 2, 3, and 4 repeated 29 times; Step 6: 72°C, 5 min; Step 7: storage at 4°C. DNA was quantified by PICOGREEN reagent (Molecular Probes) as described above. Samples with low DNA recoveries were reamplified using the same conditions as described above. Samples were diluted with 20% dimethylsulfoxide (1:2, v/v), and sequenced using DYENAMIC energy transfer sequencing primers and the DYENAMIC DIRECT kit (Amersham Pharmacia Biotech) or the ABI PRISM BIGDYE Terminator cycle sequencing ready reaction kit (Applied Biosystems).

In like manner, full length polynucleotide sequences are verified using the above procedure or are used to obtain 5' regulatory sequences using the above procedure along with oligonucleotides designed for such extension, and an appropriate genomic library.

#### IX. Labeling and Use of Individual Hybridization Probes

Hybridization probes derived from SEQ ID NO:40-78 are employed to screen cDNAs, genomic DNAs, or mRNAs. Although the labeling of oligonucleotides, consisting of about 20 base pairs, is specifically described, essentially the same procedure is used with larger nucleotide fragments. Oligonucleotides are designed using state-of-the-art software such as OLIGO 4.06 software (National Biosciences) and labeled by combining 50 pmol of each oligomer, 250  $\mu$ Ci of [ $\gamma$ -<sup>32</sup>P] adenosine triphosphate (Amersham Pharmacia Biotech), and T4 polynucleotide kinase (DuPont NEN, Boston MA). The labeled oligonucleotides are substantially purified using a SEPHADEX G-25 superfine size exclusion dextran bead column (Amersham Pharmacia Biotech). An aliquot containing 10<sup>7</sup> counts per minute of the labeled probe is used in a typical membrane-based hybridization analysis of human genomic DNA digested with one of the following endonucleases: Ase I, Bgl II, Eco RI, Pst I, Xba I, or Pvu II (DuPont NEN).

The DNA from each digest is fractionated on a 0.7% agarose gel and transferred to nylon membranes (Nytran Plus, Schleicher & Schuell, Durham NH). Hybridization is carried out for 16 hours at 40°C. To remove nonspecific signals, blots are sequentially washed at room temperature under conditions of up to, for example, 0.1 x saline sodium citrate and 0.5% sodium dodecyl sulfate. Hybridization patterns are visualized using autoradiography or an alternative imaging means and

compared.

#### X. Microarrays

The linkage or synthesis of array elements upon a microarray can be achieved utilizing photolithography, piezoelectric printing (ink-jet printing, See, e.g., Baldeschweiler, supra), mechanical microspotting technologies, and derivatives thereof. The substrate in each of the aforementioned technologies should be uniform and solid with a non-porous surface (Schena (1999), supra). Suggested substrates include silicon, silica, glass slides, glass chips, and silicon wafers. Alternatively, a procedure analogous to a dot or slot blot may also be used to arrange and link elements to the surface of a substrate using thermal, UV, chemical, or mechanical bonding procedures. A typical array may be produced using available methods and machines well known to those of ordinary skill in the art and may contain any appropriate number of elements. (See, e.g., Schena, M. et al. (1995) Science 270:467-470; Shalon, D. et al. (1996) Genome Res. 6:639-645; Marshall, A. and J. Hodgson (1998) Nat. Biotechnol. 16:27-31.)

Full length cDNAs, Expressed Sequence Tags (ESTs), or fragments or oligomers thereof may comprise the elements of the microarray. Fragments or oligomers suitable for hybridization can be selected using software well known in the art such as LASERGENE software (DNASTAR). The array elements are hybridized with polynucleotides in a biological sample. The polynucleotides in the biological sample are conjugated to a fluorescent label or other molecular tag for ease of detection. After hybridization, nonhybridized nucleotides from the biological sample are removed, and a fluorescence scanner is used to detect hybridization at each array element. Alternatively, laser desorption and mass spectrometry may be used for detection of hybridization. The degree of complementarity and the relative abundance of each polynucleotide which hybridizes to an element on the microarray may be assessed. In one embodiment, microarray preparation and usage is described in detail below.

#### 25 Tissue or Cell Sample Preparation

Total RNA is isolated from tissue samples using the guanidinium thiocyanate method and poly(A)<sup>+</sup> RNA is purified using the oligo-(dT) cellulose method. Each poly(A)<sup>+</sup> RNA sample is reverse transcribed using MMLV reverse-transcriptase, 0.05 pg/μl oligo-(dT) primer (21mer), 1X first strand buffer, 0.03 units/μl RNase inhibitor, 500 μM dATP, 500 μM dGTP, 500 μM dTTP, 40 μM dCTP, 40 μM dCTP-Cy3 (BDS) or dCTP-Cy5 (Amersham Pharmacia Biotech). The reverse transcription reaction is performed in a 25 ml volume containing 200 ng poly(A)<sup>+</sup> RNA with GEMBRIGHT kits (Incyte). Specific control poly(A)<sup>+</sup> RNAs are synthesized by in vitro transcription from non-coding yeast genomic DNA. After incubation at 37° C for 2 hr, each reaction sample (one with Cy3 and another with Cy5 labeling) is treated with 2.5 ml of 0.5M sodium hydroxide and incubated for 20 minutes at 85° C to stop the reaction and degrade the RNA. Samples are purified

using two successive CHROMA SPIN 30 gel filtration spin columns (CLONTECH Laboratories, Inc. (CLONTECH), Palo Alto CA) and after combining, both reaction samples are ethanol precipitated using 1 ml of glycogen (1 mg/ml), 60 ml sodium acetate, and 300 ml of 100% ethanol. The sample is then dried to completion using a SpeedVAC (Savant Instruments Inc., Holbrook NY) and  
5 resuspended in 14  $\mu$ l 5X SSC/0.2% SDS.

#### Microarray Preparation

Sequences of the present invention are used to generate array elements. Each array element is amplified from bacterial cells containing vectors with cloned cDNA inserts. PCR amplification uses primers complementary to the vector sequences flanking the cDNA insert. Array elements are  
10 amplified in thirty cycles of PCR from an initial quantity of 1-2 ng to a final quantity greater than 5  $\mu$ g. Amplified array elements are then purified using SEPHACRYL-400 (Amersham Pharmacia Biotech).

Purified array elements are immobilized on polymer-coated glass slides. Glass microscope slides (Corning) are cleaned by ultrasound in 0.1% SDS and acetone, with extensive distilled water  
15 washes between and after treatments. Glass slides are etched in 4% hydrofluoric acid (VWR Scientific Products Corporation (VWR), West Chester PA), washed extensively in distilled water, and coated with 0.05% aminopropyl silane (Sigma) in 95% ethanol. Coated slides are cured in a 110°C oven.

Array elements are applied to the coated glass substrate using a procedure described in US  
20 Patent No. 5,807,522, incorporated herein by reference. 1  $\mu$ l of the array element DNA, at an average concentration of 100 ng/ $\mu$ l, is loaded into the open capillary printing element by a high-speed robotic apparatus. The apparatus then deposits about 5 nl of array element sample per slide.

Microarrays are UV-crosslinked using a STRATALINKER UV-crosslinker (Stratagene). Microarrays are washed at room temperature once in 0.2% SDS and three times in distilled water.  
25 Non-specific binding sites are blocked by incubation of microarrays in 0.2% casein in phosphate buffered saline (PBS) (Tropix, Inc., Bedford MA) for 30 minutes at 60°C followed by washes in 0.2% SDS and distilled water as before.

#### Hybridization

Hybridization reactions contain 9  $\mu$ l of sample mixture consisting of 0.2  $\mu$ g each of Cy3 and  
30 Cy5 labeled cDNA synthesis products in 5X SSC, 0.2% SDS hybridization buffer. The sample mixture is heated to 65°C for 5 minutes and is aliquoted onto the microarray surface and covered with an 1.8 cm<sup>2</sup> coverslip. The arrays are transferred to a waterproof chamber having a cavity just slightly larger than a microscope slide. The chamber is kept at 100% humidity internally by the addition of 140  $\mu$ l of 5X SSC in a corner of the chamber. The chamber containing the arrays is incubated for  
35 about 6.5 hours at 60°C. The arrays are washed for 10 min at 45°C in a first wash buffer (1X SSC,

0.1% SDS), three times for 10 minutes each at 45°C in a second wash buffer (0.1X SSC), and dried.

#### Detection

Reporter-labeled hybridization complexes are detected with a microscope equipped with an Innova 70 mixed gas 10 W laser (Coherent, Inc., Santa Clara CA) capable of generating spectral lines at 488 nm for excitation of Cy3 and at 632 nm for excitation of Cy5. The excitation laser light is focused on the array using a 20X microscope objective (Nikon, Inc., Melville NY). The slide containing the array is placed on a computer-controlled X-Y stage on the microscope and raster-scanned past the objective. The 1.8 cm x 1.8 cm array used in the present example is scanned with a resolution of 20 micrometers.

In two separate scans, a mixed gas multiline laser excites the two fluorophores sequentially. Emitted light is split, based on wavelength, into two photomultiplier tube detectors (PMT R1477, Hamamatsu Photonics Systems, Bridgewater NJ) corresponding to the two fluorophores. Appropriate filters positioned between the array and the photomultiplier tubes are used to filter the signals. The emission maxima of the fluorophores used are 565 nm for Cy3 and 650 nm for Cy5. Each array is typically scanned twice, one scan per fluorophore using the appropriate filters at the laser source, although the apparatus is capable of recording the spectra from both fluorophores simultaneously.

The sensitivity of the scans is typically calibrated using the signal intensity generated by a cDNA control species added to the sample mixture at a known concentration. A specific location on the array contains a complementary DNA sequence, allowing the intensity of the signal at that location to be correlated with a weight ratio of hybridizing species of 1:100,000. When two samples from different sources (e.g., representing test and control cells), each labeled with a different fluorophore, are hybridized to a single array for the purpose of identifying genes that are differentially expressed, the calibration is done by labeling samples of the calibrating cDNA with the two fluorophores and adding identical amounts of each to the hybridization mixture.

The output of the photomultiplier tube is digitized using a 12-bit RTI-835H analog-to-digital (A/D) conversion board (Analog Devices, Inc., Norwood MA) installed in an IBM-compatible PC computer. The digitized data are displayed as an image where the signal intensity is mapped using a linear 20-color transformation to a pseudocolor scale ranging from blue (low signal) to red (high signal). The data is also analyzed quantitatively. Where two different fluorophores are excited and measured simultaneously, the data are first corrected for optical crosstalk (due to overlapping emission spectra) between the fluorophores using each fluorophore's emission spectrum.

A grid is superimposed over the fluorescence signal image such that the signal from each spot is centered in each element of the grid. The fluorescence signal within each element is then integrated to obtain a numerical value corresponding to the average intensity of the signal. The software used for signal analysis is the GEMTOOLS gene expression analysis program (Incyte).

## XI. Complementary Polynucleotides

Sequences complementary to the GCREC-encoding sequences, or any parts thereof, are used to detect, decrease, or inhibit expression of naturally occurring GCREC. Although use of oligonucleotides comprising from about 15 to 30 base pairs is described, essentially the same procedure is used with smaller or with larger sequence fragments. Appropriate oligonucleotides are designed using OLIGO 4.06 software (National Biosciences) and the coding sequence of GCREC. To inhibit transcription, a complementary oligonucleotide is designed from the most unique 5' sequence and used to prevent promoter binding to the coding sequence. To inhibit translation, a complementary oligonucleotide is designed to prevent ribosomal binding to the GCREC-encoding transcript.

## XII. Expression of GCREC

Expression and purification of GCREC is achieved using bacterial or virus-based expression systems. For expression of GCREC in bacteria, cDNA is subcloned into an appropriate vector containing an antibiotic resistance gene and an inducible promoter that directs high levels of cDNA transcription. Examples of such promoters include, but are not limited to, the *trp-lac* (*tac*) hybrid promoter and the T5 or T7 bacteriophage promoter in conjunction with the *lac* operator regulatory element. Recombinant vectors are transformed into suitable bacterial hosts, e.g., BL21(DE3). Antibiotic resistant bacteria express GCREC upon induction with isopropyl beta-D-thiogalactopyranoside (IPTG). Expression of GCREC in eukaryotic cells is achieved by infecting insect or mammalian cell lines with recombinant Autographica californica nuclear polyhedrosis virus (AcMNPV), commonly known as baculovirus. The nonessential polyhedrin gene of baculovirus is replaced with cDNA encoding GCREC by either homologous recombination or bacterial-mediated transposition involving transfer plasmid intermediates. Viral infectivity is maintained and the strong polyhedrin promoter drives high levels of cDNA transcription. Recombinant baculovirus is used to infect Spodoptera frugiperda (Sf9) insect cells in most cases, or human hepatocytes, in some cases. Infection of the latter requires additional genetic modifications to baculovirus. (See Engelhard, E.K. et al. (1994) Proc. Natl. Acad. Sci. USA 91:3224-3227; Sandig, V. et al. (1996) Hum. Gene Ther. 7:1937-1945.)

In most expression systems, GCREC is synthesized as a fusion protein with, e.g., glutathione S-transferase (GST) or a peptide epitope tag, such as FLAG or 6-His, permitting rapid, single-step, affinity-based purification of recombinant fusion protein from crude cell lysates. GST, a 26-kilodalton enzyme from Schistosoma japonicum, enables the purification of fusion proteins on immobilized glutathione under conditions that maintain protein activity and antigenicity (Amersham Pharmacia Biotech). Following purification, the GST moiety can be proteolytically cleaved from GCREC at specifically engineered sites. FLAG, an 8-amino acid peptide, enables immunoaffinity purification

using commercially available monoclonal and polyclonal anti-FLAG antibodies (Eastman Kodak). 6-His, a stretch of six consecutive histidine residues, enables purification on metal-chelate resins (QIAGEN). Methods for protein expression and purification are discussed in Ausubel (1995, *supra*, ch. 10 and 16). Purified GCREC obtained by these methods can be used directly in the assays shown in Examples XVI, XVII, and XVIII, where applicable.

### XIII. Functional Assays

GCREC function is assessed by expressing the sequences encoding GCREC at physiologically elevated levels in mammalian cell culture systems. cDNA is subcloned into a mammalian expression vector containing a strong promoter that drives high levels of cDNA expression. Vectors of choice include PCMV SPORT (Life Technologies) and PCR3.1 (Invitrogen, Carlsbad CA), both of which contain the cytomegalovirus promoter. 5-10  $\mu$ g of recombinant vector are transiently transfected into a human cell line, for example, an endothelial or hematopoietic cell line, using either liposome formulations or electroporation. 1-2  $\mu$ g of an additional plasmid containing sequences encoding a marker protein are co-transfected. Expression of a marker protein provides a means to distinguish transfected cells from nontransfected cells and is a reliable predictor of cDNA expression from the recombinant vector. Marker proteins of choice include, e.g., Green Fluorescent Protein (GFP; Clontech), CD64, or a CD64-GFP fusion protein. Flow cytometry (FCM), an automated, laser optics-based technique, is used to identify transfected cells expressing GFP or CD64-GFP and to evaluate the apoptotic state of the cells and other cellular properties. FCM detects and quantifies the uptake of fluorescent molecules that diagnose events preceding or coincident with cell death. These events include changes in nuclear DNA content as measured by staining of DNA with propidium iodide; changes in cell size and granularity as measured by forward light scatter and 90 degree side light scatter; down-regulation of DNA synthesis as measured by decrease in bromodeoxyuridine uptake; alterations in expression of cell surface and intracellular proteins as measured by reactivity with specific antibodies; and alterations in plasma membrane composition as measured by the binding of fluorescein-conjugated Annexin V protein to the cell surface. Methods in flow cytometry are discussed in Ormerod, M.G. (1994) *Flow Cytometry*, Oxford, New York NY.

The influence of GCREC on gene expression can be assessed using highly purified populations of cells transfected with sequences encoding GCREC and either CD64 or CD64-GFP. CD64 and CD64-GFP are expressed on the surface of transfected cells and bind to conserved regions of human immunoglobulin G (IgG). Transfected cells are efficiently separated from nontransfected cells using magnetic beads coated with either human IgG or antibody against CD64 (DYNAL, Lake Success NY). mRNA can be purified from the cells using methods well known by those of skill in the art. Expression of mRNA encoding GCREC and other genes of interest can be analyzed by northern analysis or



microarray techniques.

#### **XIV. Production of GCREC Specific Antibodies**

GCREC substantially purified using polyacrylamide gel electrophoresis (PAGE; see, e.g., Harrington, M.G. (1990) *Methods Enzymol.* 182:488-495), or other purification techniques, is used to immunize rabbits and to produce antibodies using standard protocols.

Alternatively, the GCREC amino acid sequence is analyzed using LASERGENE software (DNASTAR) to determine regions of high immunogenicity, and a corresponding oligopeptide is synthesized and used to raise antibodies by means known to those of skill in the art. Methods for selection of appropriate epitopes, such as those near the C-terminus or in hydrophilic regions are well described in the art. (See, e.g., Ausubel, 1995, *supra*, ch. 11.)

Typically, oligopeptides of about 15 residues in length are synthesized using an ABI 431A peptide synthesizer (Applied Biosystems) using Fmoc chemistry and coupled to KLH (Sigma-Aldrich, St. Louis MO) by reaction with N-maleimidobenzoyl-N-hydroxysuccinimide ester (MBS) to increase immunogenicity. (See, e.g., Ausubel, 1995, *supra*.) Rabbits are immunized with the oligopeptide-KLH complex in complete Freund's adjuvant. Resulting antisera are tested for antipeptide and anti-GCREC activity by, for example, binding the peptide or GCREC to a substrate, blocking with 1% BSA, reacting with rabbit antisera, washing, and reacting with radio-iodinated goat anti-rabbit IgG.

#### **XV. Purification of Naturally Occurring GCREC Using Specific Antibodies**

Naturally occurring or recombinant GCREC is substantially purified by immunoaffinity chromatography using antibodies specific for GCREC. An immunoaffinity column is constructed by covalently coupling anti-GCREC antibody to an activated chromatographic resin, such as CNBr-activated SEPHAROSE (Amersham Pharmacia Biotech). After the coupling, the resin is blocked and washed according to the manufacturer's instructions.

Media containing GCREC are passed over the immunoaffinity column, and the column is washed under conditions that allow the preferential absorbance of GCREC (e.g., high ionic strength buffers in the presence of detergent). The column is eluted under conditions that disrupt antibody/GCREC binding (e.g., a buffer of pH 2 to pH 3, or a high concentration of a chaotrope, such as urea or thiocyanate ion), and GCREC is collected.

#### **XVI. Identification of Molecules Which Interact with GCREC**

Molecules which interact with GCREC may include agonists and antagonists, as well as molecules involved in signal transduction, such as G proteins. GCREC, or a fragment thereof, is labeled with <sup>125</sup>I Bolton-Hunter reagent. (See, e.g., Bolton A.E. and W.M. Hunter (1973) *Biochem. J.* 133:529-539.) A fragment of GCREC includes, for example, a fragment comprising one or more of the three extracellular loops, the extracellular N-terminal region, or the third intracellular loop. Candidate

molecules previously arrayed in the wells of a multi-well plate are incubated with the labeled GCREC, washed, and any wells with labeled GCREC complex are assayed. Data obtained using different concentrations of GCREC are used to calculate values for the number, affinity, and association of GCREC with the candidate ligand molecules.

5           Alternatively, molecules interacting with GCREC are analyzed using the yeast two-hybrid system as described in Fields, S. and O. Song (1989) Nature 340:245-246, or using commercially available kits based on the two-hybrid system, such as the MATCHMAKER system (Clontech). GCREC may also be used in the PATHCALLING process (CuraGen Corp., New Haven CT) which employs the yeast two-hybrid system in a high-throughput manner to determine all interactions between  
10 the proteins encoded by two large libraries of genes (Nandabalan, K. et al. (2000) U.S. Patent No. 6,057,101).

Potential GCREC agonists or antagonists may be tested for activation or inhibition of GCREC receptor activity using the assays described in sections XVII and XVIII. Candidate molecules may be selected from known GPCR agonists or antagonists, peptide libraries, or combinatorial chemical  
15 libraries.

Methods for detecting interactions of GCREC with intracellular signal transduction molecules such as G proteins are based on the premise that internal segments or cytoplasmic domains from an orphan G protein-coupled seven transmembrane receptor may be exchanged with the analogous domains of a known G protein-coupled seven transmembrane receptor and used to identify the G-  
20 proteins and downstream signaling pathways activated by the orphan receptor domains (Kobilka, B.K. et al. (1988) Science 240:1310-1316). In an analogous fashion, domains of the orphan receptor may be cloned as a portion of a fusion protein and used in binding assays to demonstrate interactions with specific G proteins. Studies have shown that the third intracellular loop of G protein-coupled seven transmembrane receptors is important for G protein interaction and signal transduction  
25 (Conklin, B.R. et al. (1993) Cell 73:631-641). For example, the DNA fragment corresponding to the third intracellular loop of GCREC may be amplified by the polymerase chain reaction (PCR) and subcloned into a fusion vector such as nGEX (Pharmacia Biotech). The construct is transformed into

saline. Bound G subunits are detected by [<sup>32</sup>P]ADP-ribosylation with pertussis or cholera toxins. The reactions are terminated by the addition of SDS sample buffer (4.6% (w/v) SDS, 10% (v/v) β-mercaptoethanol, 20% (w/v) glycerol, 95.2 mM Tris-HCl, pH 6.8, 0.01% (w/v) bromphenol blue). The [<sup>32</sup>P]ADP-labeled proteins are separated on 10% SDS-PAGE gels, and autoradiographed. These gels are transferred to nitrocellulose paper, blocked with blotto (5% nonfat dried milk, 50 mM Tris-HCl (pH 8.0), 2 mM CaCl<sub>2</sub>, 80 mM NaCl, 0.02% NaN<sub>3</sub>, and 0.2% Nonidet P-40) for 1 hour at room temperature, followed by incubation for 1.5 hours with Gα subtype selective antibodies (1:500; Calbiochem-Novabiochem). After three washes, blots are incubated with horseradish peroxidase (HRP)-conjugated goat anti-rabbit immunoglobulin (1:2000, Cappel, Westchester PA) and visualized by the chemiluminescence-based ECL method (Amersham Corp.).

#### XVII. Demonstration of GCREC Activity

An assay for GCREC activity measures the expression of GCREC on the cell surface. cDNA encoding GCREC is transfected into an appropriate mammalian cell line. Cell surface proteins are labeled with biotin as described (de la Fuente, M.A. et al. (1997) Blood 90:2398-2405).

Immunoprecipitations are performed using GCREC-specific antibodies, and immunoprecipitated samples are analyzed using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and immunoblotting techniques. The ratio of labeled immunoprecipitant to unlabeled immunoprecipitant is proportional to the amount of GCREC expressed on the cell surface.

In the alternative, an assay for GCREC activity is based on a prototypical assay for ligand/receptor-mediated modulation of cell proliferation. This assay measures the rate of DNA synthesis in Swiss mouse 3T3 cells. A plasmid containing polynucleotides encoding GCREC is added to quiescent 3T3 cultured cells using transfection methods well known in the art. The transiently transfected cells are then incubated in the presence of [<sup>3</sup>H]thymidine, a radioactive DNA precursor molecule. Varying amounts of GCREC ligand are then added to the cultured cells. Incorporation of [<sup>3</sup>H]thymidine into acid-precipitable DNA is measured over an appropriate time interval using a radioisotope counter, and the amount incorporated is directly proportional to the amount of newly synthesized DNA. A linear dose-response curve over at least a hundred-fold GCREC ligand concentration range is indicative of receptor activity. One unit of activity per milliliter is defined as the concentration of GCREC producing a 50% response level, where 100% represents maximal incorporation of [<sup>3</sup>H]thymidine into acid-precipitable DNA (McKay, I. and I. Leigh, eds. (1993) Growth Factors: A Practical Approach, Oxford University Press, New York NY, p. 73.)

In a further alternative, the assay for GCREC activity is based upon the ability of GPCR family proteins to modulate G protein-activated second messenger signal transduction pathways (e.g., cAMP; Gaudin, P. et al. (1998) J. Biol. Chem. 273:4990-4996). A plasmid encoding GCREC is transfected into a mammalian cell line (e.g., Chinese hamster ovary (CHO) or human embryonic

kidney (HEK-293) cell lines) using methods well-known in the art. Transfected cells are grown in 12-well trays in culture medium for 48 hours, then the culture medium is discarded, and the attached cells are gently washed with PBS. The cells are then incubated in culture medium with or without ligand for 30 minutes, then the medium is removed and cells lysed by treatment with 1 M perchloric acid. The cAMP levels in the lysate are measured by radioimmunoassay using methods well-known in the art. Changes in the levels of cAMP in the lysate from cells exposed to ligand compared to those without ligand are proportional to the amount of GCREC present in the transfected cells.

To measure changes in inositol phosphate levels, the cells are grown in 24-well plates containing  $1 \times 10^5$  cells/well and incubated with inositol-free media and [ $^3\text{H}$ ]myoinositol, 2  $\mu\text{Ci}$ /well, for 48 hr. The culture medium is removed, and the cells washed with buffer containing 10 mM LiCl followed by addition of ligand. The reaction is stopped by addition of perchloric acid. Inositol phosphates are extracted and separated on Dowex AG1-X8 (Bio-Rad) anion exchange resin, and the total labeled inositol phosphates counted by liquid scintillation. Changes in the levels of labeled inositol phosphate from cells exposed to ligand compared to those without ligand are proportional to the amount of GCREC present in the transfected cells.

#### XVIII. Identification of GCREC Ligands

GCREC is expressed in a eukaryotic cell line such as CHO (Chinese Hamster Ovary) or HEK (Human Embryonic Kidney) 293 which have a good history of GPCR expression and which contain a wide range of G-proteins allowing for functional coupling of the expressed GCREC to downstream effectors. The transformed cells are assayed for activation of the expressed receptors in the presence of candidate ligands. Activity is measured by changes in intracellular second messengers, such as cyclic AMP or  $\text{Ca}^{2+}$ . These may be measured directly using standard methods well known in the art, or by the use of reporter gene assays in which a luminescent protein (e.g. firefly luciferase or green fluorescent protein) is under the transcriptional control of a promoter responsive to the stimulation of protein kinase C by the activated receptor (Milligan, G. et al. (1996) Trends Pharmacol. Sci. 17:235-237). Assay technologies are available for both of these second messenger systems to allow high throughput readout in multi-well plate format, such as the adenylyl cyclase activation FlashPlate Assay (NEN Life Sciences Products), or fluorescent  $\text{Ca}^{2+}$  indicators such as Fluo-4 AM (Molecular Probes) in combination with the FLIPR fluorimetric plate reading system (Molecular Devices). In cases where the physiologically relevant second messenger pathway is not known, GCREC may be coexpressed with the G-proteins  $\text{G}_{\alpha 15/16}$  which have been demonstrated to couple to a wide range of G-proteins (Offermanns, S. and M.I. Simon (1995) J. Biol. Chem. 270:15175-15180), in order to funnel the signal transduction of the GCREC through a pathway involving phospholipase C and  $\text{Ca}^{2+}$  mobilization. Alternatively, GCREC may be expressed in engineered yeast systems which lack endogenous GPCRs, thus providing the advantage of a null background for GCREC activation screening. These yeast systems substitute a

human GPCR and Ga protein for the corresponding components of the endogenous yeast pheromone receptor pathway. Downstream signaling pathways are also modified so that the normal yeast response to the signal is converted to positive growth on selective media or to reporter gene expression (Broach, J.R. and J. Thorner (1996) Nature 384 (supp.):14-16). The receptors are screened against putative  
5 ligands including known GPCR ligands and other naturally occurring bioactive molecules. Biological extracts from tissues, biological fluids and cell supernatants are also screened.

Various modifications and variations of the described methods and systems of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention.

10 Although the invention has been described in connection with certain embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention which are obvious to those skilled in molecular biology or related fields are intended to be within the scope of the following claims.

Table 1

Incyte Project ID	Polypeptide SEQ ID NO:	Incyte Polypeptide ID	Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID
104941	1	104941CD1	40	104941CB1
1499408	2	1499408CD1	41	1499408CB1
3168839	3	3168839CD1	42	3168839CB1
3291235	4	3291235CD1	43	3291235CB1
7472001	5	7472001CD1	44	7472001CB1
7472003	6	7472003CD1	45	7472003CB1
7472004	7	7472004CD1	46	7472004CB1
7475687	8	7475687CD1	47	7475687CB1
7483029	9	7483029CD1	48	7483029CB1
7477933	10	7477933CD1	49	7477933CB1
7475164	11	7475164CD1	50	7475164CB1
7473909	12	7473909CD1	51	7473909CB1
7475252	13	7475252CD1	52	7475252CB1
7927572	14	7927572CD1	53	7927572CB1
7481257	15	7481257CD1	54	7481257CB1
7485790	16	7485790CD1	55	7485790CB1
7482993	17	7482993CD1	56	7482993CB1
2829053	18	2829053CD1	57	2829053CB1
3068234	19	3068234CD1	58	3068234CB1
5029478	20	5029478CD1	59	5029478CB1
5102576	21	5102576CD1	60	5102576CB1
2200534	22	2200534CD1	61	2200534CB1
3275821	23	3275821CD1	62	3275821CB1
3744167	24	3744167CD1	63	3744167CB1
7472007	25	7472007CD1	64	7472007CB1
7472008	26	7472008CD1	65	7472008CB1
7472013	27	7472013CD1	66	7472013CB1
7472015	28	7472015CD1	67	7472015CB1
7472016	29	7472016CD1	68	7472016CB1

Table 1 (cont.)

Incyte Project ID	Polypeptide SEQ ID NO:	Incyte Polypeptide ID	Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID
7472017	30	7472017CD1	69	7472017CB1
7472018	31	7472018CD1	70	7472018CB1
7472019	32	7472019CD1	71	7472019CB1
7472021	33	7472021CD1	72	7472021CB1
7472009	34	7472009CD1	73	7472009CB1
7472010	35	7472010CD1	74	7472010CB1
7472011	36	7472011CD1	75	7472011CB1
7472012	37	7472012CD1	76	7472012CB1
7472014	38	7472014CD1	77	7472014CB1
7472020	39	7472020CD1	78	7472020CB1

Table 2

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO:	Probability Score	GenBank Homolog
1	104941CD1	g7211316	6.9E-146	Olfactory receptor [Callithrix jacchus]
2	1499408CD1	g202806	5.20E-162	Vasopressin receptor [Rattus norvegicus]
3	3168839CD1	g3618229	2.2E-44	G protein-linked P2Y4 receptor [Rattus norvegicus]
4	3291235CD1	g3287369	1.40E-126	A-2 [Mus musculus]
5	• 7472001CD1	g1256393	2.20E-122	Taste bud receptor protein TB 641 [Rattus norvegicus]
6	7472003CD1	g4378765	1.20E-169	Orphan G protein-coupled receptor GPR54 [Rattus norvegicus]
7	7472004CD1	g1698952	6.30E-118	High-affinity lysophosphatidic acid receptor [Xenopus laevis]
8	7475687CP1	g1256393	4.70E-90	Taste bud receptor protein TB 641 [Rattus norvegicus]
9	7483029CP1	g2447219	2.50E-75	OLF4 [Homo sapiens]
10	7477933CP1	g2792016	4.90E-79	Olfactory receptor [Homo sapiens]
11	7475164CP1	g517366	3.00E-111	Olfactory receptor [Rattus norvegicus]
12	7473909CP1	g4680264	1.90E-22	Odorant receptor S25 [Mus musculus]
13	7475252CP1	g2447219	6.50E-61	OLF4 [Homo sapiens]
14	7927572CP1	g8100089	6.7E-54	Putative taste receptor HTR2 [Homo sapiens]
15	7481257CP1	g4826521	4.00E-29	dJ88J8.1 (novel 7 transmembrane receptor (rhodopsin family) [olfactory receptor like protein (hs6M1-15)]) [Homo sapiens]
16	7485790CP1	g2447219	3.00E-40	OLF4 [Homo sapiens]
17	7482993CP1	g1314665	3.10E-54	CfOLF3 [Canis familiaris]
18	2829053CD1			
19	3068234CD1	g5922725	3.1E-190	Lysophosphatidic acid G protein-coupled receptor [Homo sapiens]
20	5029478CD1	g1049072	3.6E-21	Galanin receptor GALR1 [Rattus norvegicus] (Cloning and characterization of the rat GALR1 galanin receptor from Rin14B insulinoma cells. Brain Res. Mol. Brain Res. 1995 Dec 28;34(2):179-189.)



Table 2 (cont.)

Polypeptide SEQ ID NO:	Incyte Polypeptide ID	GenBank ID NO:	Probability Score	GenBank Homolog
21	5102576CD1	g2792016	2.4E-92	Olfactory receptor [Homo sapiens] (Molecular cloning and chromosomal mapping of olfactory receptor genes expressed in the male germ line: evidence for their wide distribution in the human genome. Biochem. Biophys. Res. Commun. 1997 Aug 18;237(2):283-287.)
22	2200534CD1	g5051404	4.6e-131	573K1.15 (mml7M1-6) 7-transmembrane olfactory receptor-like protein (rhodopsin family) [Mus musculus]
23	3275821CD1	g182742	1.5e-29	Formyl peptide receptor [Homo sapiens] (Murphy, P.M. et al. (1992) J. Biol. Chem. 267:7637-7643)
24	3744167CD1	g9186902	1.2E-240	Leukotriene B4 receptor, BLT2 [Mus musculus]
25	7472007CD1	g7638409	1.3E-199	Olfactory receptor P2 [Mus musculus]
26	7472008CD1	g4218182	1.0e-89	dj271M21.2 (hs6M1-12 (7 transmembrane receptor (rhodopsin family) (olfactory receptor like) protein)) [Homo sapiens]
27	7472013CD1	g205846	2.5e-70	Olfactory protein [Rattus norvegicus]
28	7472015CD1	g1204095	2.5e-25	Dopamine receptor [Fugu rubripes]
29	7472016CD1	g6090796	1.1E-215	Olfactory receptor [Gorilla gorilla]
30	7472017CD1	g3757727	2.0e-61	dj80I19.7 (olfactory receptor-like protein (hs6M1-3)) [Homo sapiens]
31	7472018CD1	g6644328	2.3E-112	Orphan G protein-coupled receptor GPR26 [Rattus norvegicus]
32	7472019CD1	g5869916	2.7e-73	Olfactory receptor [Mus musculus]
33	7472021CD1	g6090804	2.6E-94	Olfactory receptor [Gorilla gorilla]
34	7472009CD1	g1016362	1.6e-68	OL1 receptor [Rattus norvegicus]
35	7472010CD1	g2317704	7.3e-80	Olfactory receptor [Rattus norvegicus]
36	7472011CD1	g6178008	4.9E-114	Odorant receptor MOR18 [Mus musculus]
37	7472012CD1	g205816	6.8e-84	Olfactory protein [Rattus norvegicus]
38	7472014CD1	g205816	3.9e-88	Olfactory protein [Rattus norvegicus]
39	7472020CD1	g2792016	1.9e-97	Olfactory receptor [Homo sapiens]

Table 3

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
1	104941CD1	311	S68 S189 S292 Y310	N5 N66	7 transmembrane receptor (rhodopsin family): G42-Y291 GPCR signature: K91-P130, I208-Y219, Y283-K299, Y103-S151 Olfactory receptor signature: M60-K81, F178-D192, F239-G254, A275-L286, S292-Q306 Transmembrane domains: I31-I47, P211-I229	MOTIFS HMMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS ProfileScan
2	1499408CD1	891	T148 S686 S114 S248 S350 S481 S501 T628 T814 S856 T84 S140 T144 T325 T411 T543 S568 S676 T706 T788 Y372 T232 S178 T342 S363 S371 S397 T21 S211 S226 T307 S332 S367	N378	ATP/GTP binding site (P-loop): G202-T209	MOTIFS
3	3168839CD1	422	T232 S178 T342 S363 S371 S397 T21 S211 S226 T307 S332 S367	N4 N9 N251 N323	7 transmembrane receptor (rhodopsin family): L39-Y297 Rhodopsin-like GPCR superfamily: L24-L48, V57-R78, F101-I123, V137-R158, V192-F215, T232-V256, L279-R305 Transmembrane domains: V275-L295	MOTIFS HMMER-PFAM BLIMPS-BLOCKS ProfileScan BLIMPS-PRINTS HMMER
4	3291235CD1	609	S228 S229 S396 S456 S324 S328 S364 S417 S466 T506 S568 S590 S153 S268 T392 S462 S482 S560 Y348		7 transmembrane receptor (rhodopsin family): E80-E154 GPCR signatures: F76-P115, F395-A405,, A442-E458, E509-P526 Transmembrane domain: V174-L199	MOTIFS HMMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS HMMER

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
5	7472001CD1	313	S68 T194 T200 S267 T309 T138 T164 T290 S306	N5 N85	7 transmembrane receptor (rhodopsin family): G41-I259 GPCR signature: K91-P130, T281-K297, Y103-A147 Olfactory receptor signature: M60-R81, F178-D192, F239-V254, A273-L284, T290-L304 Signal peptide: M1-T38	MOTIFS HMME-PFAM BLIMPS- BLOCKS BLIMPS- PRINTS ProfileScan
6	7472003CD1	398	S36 T155	N10 N18 N28	Transmembrane domains: F30-T48, F63-M83 7 transmembrane receptor (rhodopsin family): G59-Y323 GPCR signature: W108-P147, Y213-Y224, A256-F282, N315-R331, N119-I166 Neuropeptide Y receptor signature: R69-I81, L321-F334	MOTIFS HMME-PFAM BLIMPS- BLOCKS BLIMPS- PRINTS ProfileScan
7	7472004CD1	369	S228 T94 T218 S339 T350	N12	Transmembrane domain: A42-Y65 7 transmembrane receptor (rhodopsin family): G48-Y321 Rhodopsin-like GPCR signature: T33-Y57, I66-F87, F111-I133, R144-V165, V193-L216, A262-V286, S303-H329 Transmembrane domains: T33-V51, M109-I125, Y189-M213, M256-V275	HMMER MOTIFS HMME-PFAM BLIMPS- BLOCKS BLIMPS- PRINTS
8	7475687CF1	194	T186 T76 T82 T46 T172		7 transmembrane receptor (rhodopsin family): M1-Y171 Opsins retinal binding site: Y142-N194 Olfactory receptor signature: F60-D74, F121-V136, A155-L166, T172-T186	MOTIFS HMME-PFAM BLIMPS- BLOCKS BLIMPS- PRINTS ProfileScan

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
9	7483029CP1	173	T16 S34 T60	N32 N167	7 transmembrane receptor (rhodopsin family): G8-C146 Rhodopsin-like GPCR signature: M26-K47, F71-I93, L107-I128	MOTIFS HMMER-PFAM BLIMPS- BLOCKS ProfileScan BLIMPS- PRINTS
					Signal peptide: M1-L22	SPScan HMMER
					Transmembrane domains: M68-A86, M103-L121	HMMER
10	7477933CP1	220	S172		7 transmembrane receptor (rhodopsin family): P1-C192 Olfactory receptor signature: M2-K23, F120-D134, F181-G196 Rhodopsin-like GPCR signature: L47-I69, I142-V165	MOTIFS HMMER-PFAM BLIMPS- BLOCKS BLIMPS- PRINTS
					Transmembrane domains: M44-A62, V85-T110	HMMER
11	7475164CP1	302	T296 S58 S84 T107 T257 T9 T69 S128 T151 S282		7 transmembrane receptor (rhodopsin family): G32-I193 GPCR signature: N81-P120, I273-K289, S93-L142 Olfactory receptor signature: V50-K71, Y168-S182, F229-G244, S265-L276, S282-T296	MOTIFS HMMER-PFAM BLIMPS- BLOCKS ProfileScan BLIMPS- PRINTS
					Transmembrane domains: F19-L39, I188-I207	HMMER
12	7473909CP1	110	S70 S36 T66 S94		GPCR signature: I85-K101 Olfactory receptor signature: F41-G56, A77-L88, S94-Y108	MOTIFS BLIMPS- BLOCKS BLIMPS- PRINTS

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
13	7475252CP1	178	S66 S151 S136	N4 N64	7 transmembrane receptor (rhodopsin family): G40-L153 Rhodopsin-like GPCR signature: V25-S49, M58-K79, L103-I125, S102-S151  Transmembrane domains: L29-I45, M100-M117  Olfactory receptor signature: F25-D39	MOTIFS HMMER-PFAM BLIMPS- BLOCKS ProfileScan BLIMPS- PRINTS HMMER
14	7927572CP1	92				MOTIFS BLIMPS- PRINTS
15	7481257CP1	97			7 transmembrane receptor (rhodopsin family): M1-Y96 GPCR signature: V13-Y24, Q41-Q67 Olfactory receptor signature: F44-G59, L80-L91  Signal peptide: M1-G27	MOTIFS HMMER-PFAM BLIMPS- BLOCKS BLIMPS- PRINTS  SPScan HMMER
16	7485790CP1	133	S74		Transmembrane domain: M8-Y24 7 transmembrane receptor (rhodopsin family): R22-V128 GPCR signature: G71-P110	MOTIFS HMMER-PFAM BLIMPS- BLOCKS BLIMPS- PRINTS HMMER
17	7482993CP1	213	S85 S205 S159 T183	N83	Transmembrane domain: M82-A100 7 transmembrane receptor (rhodopsin family): S2-Y182 GPCR signature: R127-R153, S2-A38 Olfactory receptor signature: F69-N83, F130-G145, V166-L177, T183-G197  Transmembrane domains: P102-I120, F130-V152	MOTIFS HMMER-PFAM BLIMPS- BLOCKS ProfileScan BLIMPS- PRINTS HMMER

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
18	2829053CD1	180	S30 S41 S109 S125 S140 S35 S36 S149		Beta-1 adrenergic receptor signature: I148-S166 Signal peptide: M1-S67	MOTIFS BLIMPS-PRINTS SPScan
19	3068234GD1	353	T146 T217 T233 S321 S17 T21 S294 S329 T141 S229 T303 Y14	N15 N139 N172 N349	7 transmembrane receptor (rhodopsin family): S47-Y293 Rhodopsin-like GPCR superfamily signature: I32-I56, F65-L86, L109-I131, R144-L165, Y187-Y210, L237-L261, K275-Y301 Transmembrane domains: V36-I56, T146-G166, Y187-L207, T240-V258	MOTIFS HMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS HMER
20	5029478CD1	361	T242 S256 S237 S350	N21 N322	7 transmembrane receptor (rhodopsin family): G57-Y321 Rhodopsin-like GPCR superfamily signature: V42-A66, T74-V95, M118-I140, A154-V175, D208-L231, L262-L286, F303-E329 Transmembrane domains: T45-V65, V124-Q144, V209-I233, L266-N291	MOTIFS HMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS HMER
21	5102576CD1	251	S119 S196		7 transmembrane receptor (rhodopsin family): R8-C251 GPCR signature: R57-P96 Olfactory receptor signature: M26-K47, L144-D158, F205-G220, A241-C252 Transmembrane domains: T66-D88, V109-T134	MOTIFS HMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS HMER

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
22	2200534CD1	315	S6 S136 T291	N4 N154	G-protein coupled receptor: DM00013(P232750)17-306: S17-L305 DM00013(A570690)15-304: F16-L305 DM00013(P47881)20-309: P20-L305 PD149621: T246-L305 PD000921: C168-L245 PD002495: N4-L47 BL00237: L89-P128, L207-Y218, T282-K298 Olfactory receptor PR00245: M58-P79, F176-G190, V238-G253, V274-L285, T291-L305 G-protein coupled receptors	HMER BLIMPS- PRINTS- BLIMPS- BLOCKS HMER-PFAM MOTIFS
23	3275821CD1	470	T3 T18 T326 T332 T340 S350 S424 S451 T459 S192	N47	Transmembrane domains: V204-M228, G40-Y290 G-protein coupled receptor: DM00013(P21462)20-317: V34-L306 PD000009: L68-F169 BL00237: W97-P136, G201-H212, A230-A256, N287-R303 GPCR profile: F109-V155 Rhodopsin GPCR family PR00237: W31-G55, L66-Q87, W111-A133, L147-V168, L193-Q216, F235-L259, L277-R303 G-protein coupled receptors Transmembrane domains: T33-A51, L68-L259	BLAST- PRODOM BLAST-DOMO HMER HMER-PFAM BLIMPS- BLOCKS BLIMPS- PRINTS ProfileScan MOTIFS BLAST- PRODOM BLAST-DOMO HMER

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
24	3744167CD1	358	T291 S15 T18 S215	N10 N38 N342	G-protein coupled receptor: DM00013(P46092)/27-318: S19-F290 DM00013(P31391)/41-326: L29-L304 DM00013(P35414)/22-324: W16-F290 BL00237: W87-P126, F190-Y201, R217-V243, S280-L296 GPCR profile: Y99-V145 Rhodopsin GPCR family PR00237: T22-A46, A57-F78, C101-V123, L137-V158, L182-L205, V222-L246, R270-L296	HMMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS ProfileScan MOTIFS
					G-protein coupled receptors	BLAST- PRODOM BLAST-DOMO
					Transmembrane domains: A138-Y159, G37-Y288	HMMER



Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
25	7472007CD1	314	S270 S291 S311 T49 S67 S193	N4 N65	Signal peptide: M1-Q56 Transmembrane domains: L29-V48, L208-W228 7 transmembrane receptor (rhodopsin family) signature: G41-Y290 G-protein coupled receptor signatures: T90-P129, I207-Y218, T282-K298 G-protein coupled receptor signature: Y102-A147 G-protein coupled receptor signature: A110-A125 Olfactory receptor signatures: M59-K80, F177-D191, F238-S253, I274-L285, S291-I305 Melanocortin receptor family: A5-L63 Rhodopsin-like GPCR superfamily: L26-I50, M59-K80, F104-I126, F153-V174, A199-L222, A237-R261, K272-K298 G-protein coupled receptor: DM00013 P23270 18-311: L23-H306 G-protein coupled receptor: DM00013 P23267 20-309: L27-I305 G-protein coupled receptor: DM00013 P23275 17-306: L23-I305 G-protein coupled receptor: DM00013 P30953 18-306: L19-H306 Olfactory receptor PD000921: F168-L246 Olfactory receptor PD149621: V247-R307	SPScan HMMER HMMER-PFAM BLIMPS-BLOCKS ProfileScan MOTIFS BLIMPS-PRINTS BLIMPS-PRINTS BLAST-DOMO BLAST-DOMO BLAST-DOMO BLAST-DOMO BLAST-PRODOR BLAST-PRODOR

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
26	7472008CD1	365	S78 T192 S199 T320 S343 S47 S66 S78 S96 S217 T222 T337 T361	N94	Transmembrane domain: I226-L244 7 transmembrane receptor (rhodopsin family) signature: G70-Y319 G-protein coupled receptor signatures: K119-P158, L236-S247, K264-Q290, T311-H327 Olfactory receptor signatures: M88-Q109, V206-D220, F267-G282, L303-L314, T320-K334 Melanocortin receptor family: V73-L84, K80-L92 Rhodopsin-like GPCR superfamily: L55-L79, M88-Q109, F133-V155, M228-A251, A266-Q290, K301-H327 Olfactory receptor PD000921: L195-L275 Olfactory receptor PD149621: V276-K331 G-protein coupled receptor: DM00013 P30955 18-305: L61-L326 G-protein coupled receptor: DM00013 P23269 15-304: L61-L326 G-protein coupled receptor: DM00013 A57069 15-304: D59-L326 G-protein coupled receptor: DM00013 P23275 17-306: T67-L326	HMER HMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS BLIMPS-PRINTS BLAST-PRODOM BLAST-PRODOM BLAST-DOMO BLAST-DOMO BLAST-DOMO BLAST-DOMO

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
27	7472013CD1	317	S68 S193	N6 N22 N43	Signal peptide: M1-G42 Transmembrane domain: I23-L41 7 transmembrane receptor (rhodopsin family) signatures: G42-L155, A279-Y295 G-protein coupled receptor signatures: P91-P130, M212-Y223, T287-K303 G-protein coupled receptor signature: F103-L148 G-protein coupled receptor signature: T111-A126 Olfactory receptor signatures: M60-Q81, F182-D196, V243-G258, A279-A290, S296-L310 Melanocortin receptor family: W52-L64 Rhodopsin-like GPCR superfamily: L27-S51, M60-Q81, F105-I127, R141-G162, I204-G227, A242-Q266, M277-K303 GPR3 orphan receptor signature: V161-N178 G-protein coupled receptor: DM00013 P23274 18-306: L27-L310 G-protein coupled receptor: DM00013 P23272 18-306: Y25-L310 G-protein coupled receptor: DM00013 P30953 18-306: L27-L310 G-protein coupled receptor: DM00013 P30955 18-305: L27-L310 Olfactory receptor PD000921: G174-L250 Olfactory receptor PD149621: T251-L310	SPScan HMMER HMMER-PFAM BLIMPS-BLOCKS ProfileScan MOTIFS BLIMPS-PRINTS BLIMPS-PRINTS BLIMPS-PRINTS BLIMPS-PRINTS BLAST-DOMO BLAST-DOMO BLAST-DOMO BLAST-DOMO BLAST-PRODOR BLAST-PRODOR

Table 3 (cont.)

SEQ ID NO.	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
28	7472015CD1	335	T73 S79 S214 S309 T217 S329 S331		Signal peptide: M1-A20 Signal peptide: M1-A20 Transmembrane domains: F5-V27, L45-T63, M117-I136 7 transmembrane receptor (rhodopsin family) signatures: T21-Y279 G-protein coupled receptor signatures: R71-P110, F174-Y185, P218-T244, N271-R287 G-protein coupled receptor signature: F84-L129 G-protein coupled receptor signature: A91-I106 Rhodopsin-like GPCR superfamily: S6-L30, S40-L61, V85-I107, V121-G142, V166-L189, A223-V247, E261-R287 G-protein coupled receptor: DM00013 P41596 137-461: G8-D220 G-protein coupled receptor: DM00013 P47800 29-338: G8-Y281 G-protein coupled receptor: DM00013 P31388 20-336: G8-P218 G-protein coupled receptor: DM00013 JN0591 20-336: G8-P218	HMMER SPScan HMMER HMMER-PPFAM BLIMPS-BLOCKS ProfileScan MOTIFS BLIMPS-PRINTS BLAST-DOMO BLAST-DOMO BLAST-DOMO BLAST-DOMO

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
29	7472016CD1	309	S8 S67 S188 S266 S137 S229 S266 S289	N5 N55 N264	Signal peptide: M1-L55 Transmembrane domains: Y28-A48, M199-I218 7 transmembrane receptor (rhodopsin family) signatures: G41-Y288 G-protein coupled receptor signatures: K90-P129, F206-Y217, L234-R260, T280-K296 G-protein coupled receptor signature: Y102-A146 Olfactory receptor signatures: M59-K80, F177-D191, F237-G252, I272-L283, S289-F303 Rhodopsin-like GPCR superfamily: F26-C50, M59-K80, M104-I126 S140-L161, M198-F219, A270-K296 G-protein coupled receptor: DM00013 P23266 17-306: Q20-L302 G-protein coupled receptor: DM00013 P23274 18-306: E22-L299 G-protein coupled receptor: DM00013 P23269 15-304: Q21-L299 G-protein coupled receptor: DM00013 P30955 18-305: E22-L302 Olfactory receptor PD149621: T245-S309 Olfactory receptor PD000921: L166-L244	SPScan HMMER HMMER-PFAM BLIMPS-BLOCKS ProfileScan BLIMPS-PRINTS BLIMPS-PRINTS BLAST-DOMO BLAST-DOMO BLAST-DOMO BLAST-DOMO BLAST-PRODOM BLAST-PRODOM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID:	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
30	7472017CD1	236	S7 T217	N5 N189	Signal peptide: M1-G42 Transmembrane domains: C31-M52, V123-L141 7 transmembrane receptor (rhodopsin family) signatures: F12-Y216 G-protein coupled receptor signatures: K24-P63, L133-Y144, C161-Q187, T208-K224 G-protein coupled receptor signature: Y36-V81 G-protein coupled receptor signature: T44-A59 Olfactory receptor signatures: L164-G179, I200-L211, T217-N231 Rhodopsin-like GPCR superfamily: S38-V60, L125-A148, G163-Q187, K198-K224 Olfactory receptor PD149621: V173-T236 Olfactory receptor PD000921: C103-I172 G-protein coupled receptor: DM00013 P23269 15-304: L15-L227 G-protein coupled receptor: DM00013 P30953 18-306: L15-L227 G-protein coupled receptor: DM00013 A57069 15-304: L15-R228 G-protein coupled receptor: DM00013 P23275 17-306: M1-L227	SPScan HMME HMME-PFAM BLIMPS-BLOCKS ProfilesScan MOTIFS BLIMPS-PRINTS BLIMPS-PRINTS BLAST-PRODOM BLAST-PRODOM BLAST-DOMO BLAST-DOMO BLAST-DOMO BLAST-DOMO

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
31	7472018CD1	363	Y294 S321 S325 T353 S157 T210 S223 T240 T316 T340	N47 N348 N355	Signal peptide: M1-A24 Signal peptide: M1-A24 7 transmembrane receptor (rhodopsin family) signatures: S22-Y294 G-protein coupled receptor signatures: T72-P111, F181-S192, R234-T260, K286-R302 Rhodopsin-like GPCR superfamily: L7-A31, S41-F62, D86-V108, Y122-G143, T173-H196, A239-A263, G276-R302 P2Y4 purinoceptor signatures: Y32-L48, P11-L126 G-protein coupled receptor: DM00013 JN0591 20-336: P3-L305 G-protein coupled receptor: DM00013 P53452 17-344: L7-F268 G-protein coupled receptor: DM00013 P50406 20-335: G4-L305 G-protein coupled receptor: DM00013 P31388 20-336: P3-L305	HMER SPScan HMER-PFAM BLIMPS-BLOCKS BLIMPS-PRINTS BLIMPS-PRINTS BLAST-DOMO BLAST-DOMO BLAST-DOMO BLAST-DOMO

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
32	7472019CD1	308	S162 S290 S67 T187 S192 S265	N5 N65	Transmembrane domains: L30-I49, M197-I215 7 transmembrane receptor (rhodopsin family) signatures: G41-Y289 G-protein coupled receptor signatures: P90-P129, L206-Y217, L234-K260, T281-K297 G-protein coupled receptor signature: S102-T147 Olfactory receptor signatures: I59-Q80, F176-D190, F237-G252, I273-L284, S290-M304 Melanocortin receptor family: F51-L63 Rhodopsin-like GPCR superfamily: T26-H50, I59-Q80, S104-I126, V140-L161, I198-A221, K271-K297 G-protein coupled receptor: DM00013 P23275 17-306; I17-M304 G-protein coupled receptor: DM00013 P23269 15-304; F27-M304 G-protein coupled receptor: DM00013 P23266 17-306; I17-M304 G-protein coupled receptor: DM00013 S29707 18-306; P21-I300 Olfactory receptor PD000921: L165-L244 Olfactory receptor PD149621: T245-M304	HMMER HMMER-PFAM BLIMPS-BLOCKS ProfileScan BLIMPS-PRINTS BLIMPS-PRINTS BLAST-DOMO BLAST-DOMO BLAST-DOMO BLAST-DOMO BLAST-PRODOM BLAST-PRODOM



Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
33	7472021CD1	343	S87 T154 S288 S326 S311 S316	N25 N183 N314	Transmembrane domains: Y55-L75, I214-I234 7 transmembrane receptor (rhodopsin family) signatures: G61-Y310 G-protein coupled receptor signatures: S38-L64, G110-P149, P302-K318 G-protein coupled receptor signature: F122-V168 G-protein coupled receptor signature: S130-A145 Olfactory receptor signatures: M79-Q100, F197-Y211, F258-S273, F297-L305, S311-L325 Melanocortin receptor family: V71-L83 Vasopressin receptor signature: L75-L86 Olfactory receptor PD000921: I186-L265 Olfactory receptor PD149621: V267-E328 G-protein coupled receptor: DM00013   P23269   I5-304: E40-L325 G-protein coupled receptor: DM00013   P23275   I7-306: S38-L325 G-protein coupled receptor: DM00013   P23273   I8-306: I45-L325 G-protein coupled receptor: DM00013   P23266   I7-306: S38-S326	HMER HMER-PFAM BLIMPS-BLOCKS ProfileScan MOTIFS BLIMPS-PRINTS BLIMPS-PRINTS BLAST-PRODOR BLAST-PRODOR BLAST-DOMO BLAST-DOMO BLAST-DOMO BLAST-DOMO

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
34	7472009CD1	323	S87 S232 T290 S8 S67 T193	N5	Transmembrane domains: L30-L47, I201-L221 7 transmembrane receptor (rhodopsin family) signatures: G41-Y289 G-protein coupled receptor signatures: K90-P129, L206-Y217, R234-R260, T281-A297 G-protein coupled receptor signature: F102-M147 G-protein coupled receptor signature: A110-A125 Olfactory receptor signatures: M59-K80, F177-D191, F237-G252, G273-L284, T290-L304 Rhodopsin-like GPCR superfamily: F26-C50, Y104-Y126, V140-A161, T198-L221, K271-A297 Melanocortin receptor family: I51-L63, I126-N137 Vasopressin receptor signature: L55-L66 G-protein coupled receptor: DM00013 P23275 17-306: L25-L304 G-protein coupled receptor: DM00013 A57069 15-304: L27-L304 G-protein coupled receptor: DM00013 P23270 18-311: L25-L304 G-protein coupled receptor: DM00013 P23266 17-306: L27-L304 Olfactory receptor PD149621: T245-T310 Olfactory receptor PD000921: F168-L244	HMMER HMMER-PFAM BLIMPS-BLOCKS ProfileScan MOTIFS BLIMPS-PRINTS BLIMPS-PRINTS BLAST-DOMO BLAST-DOMO BLAST-DOMO BLAST-DOMO BLAST-PRODOM BLAST-PRODOM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
35	7472010CD1	299	T68 S126 S280 T293 S10 S57 T156	N55	Transmembrane domain: L186-I205 7 transmembrane receptor (rhodopsin family) signatures: G31-Y279 G-protein coupled receptor signatures: S79-P118, F188-S199, S224-T250, V271-K287 G-protein coupled receptor signature: F91-F135 G-protein coupled receptor signature: S99-A114 Olfactory receptor signatures: M49-K70, Y166-S180, F227-G242, A263-L274, S280-L294 Melanocortin receptor family: I41-L53 Rhodopsin-like GPCR superfamily: Q16-G40, M49-K70, F93-I115, T181-V204, A226-T250, R261-K287 G-protein coupled receptor: DM00013 S29709 11-299: G23-L294 G-protein coupled receptor: DM00013 S51356 18-307: I24-K292 G-protein coupled receptor: DM00013 P23274 18-306: I24-L294 G-protein coupled receptor: DM00013 P30955 18-305: I24-L294 Olfactory receptor PD149621: V237-R296 Olfactory receptor PD000921: L155-I235	HMER HMER-PFAM BLIMPS-BLOCKS ProfileScan MOTIFS BLIMPS-PRINTS BLIMPS-PRINTS BLAST-DOMO BLAST-DOMO BLAST-DOMO BLAST-DOMO BLAST-PRODROM BLAST-PRODROM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
36	7472011CD1	307	S87 T288 S193	N5	Transmembrane domains: L23-I43, M98-M118, G204-H228 7 transmembrane receptor (rhodopsin family) signatures: G41-Y287 G-protein coupled receptor signatures: K90-P129, R234-R260, T279-Q295 G-protein coupled receptor signature: F102-T148 Olfactory receptor signatures: M59-K80, F177-D191, A237-V252, V271-L282, T288-G302 Melanocortin receptor family: S51-L63 Rhodopsin-like GPCR superfamily: F26-T50, M59-K80, F104-T126, L140-A161, K199-L222, A236-R260, K269-Q295 Olfactory receptor PD000921: L166-I245 Olfactory receptor PD149621: V246-R303 G-protein coupled receptor: DM00013 S29710 15-301: L17-L301 G-protein coupled receptor: DM00013 P23275 17-306: L17-L301 G-protein coupled receptor: DM00013 P23266 17-306: L17-L301 G-protein coupled receptor: DM00013 P47881 20-309: L23-L301	HMER HMER-PFAM BLIMPS-BLOCKS ProfileScan BLIMPS-PRINTS BLIMPS-PRINTS BLAST-PRODOM BLAST-PRODOM BLAST-DOMO BLAST-DOMO BLAST-DOMO BLAST-DOMO

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
37	7472012CD1	314	T19 S230 S291	N5 N38	7 transmembrane receptor (rhodopsin family) signatures: G41-Y290 G-protein coupled receptor signatures: K90-P129, T282-K298 G-protein coupled receptor signature: Y102-M147 G-protein coupled receptor signature: M110-A125 Olfactory receptor signatures: M59-K80, F177-S191, F238-G253, I274-L285, S291-M305 Rhodopsin-like GPCR superfamily: P26-L50, M59-K80, F104-I126, I199-I222, T237-R261, R272-K298 G-protein coupled receptor: DM00013 P23266 17-306; I17-K303 G-protein coupled receptor: DM00013 P23274 18-306; E22-K303 G-protein coupled receptor: DM00013 S29707 18-306; P21-G299 G-protein coupled receptor: DM00013 P30955 18-305; P21-K303 Olfactory receptor PD149621: T246-T310 Olfactory receptor PD000921: L166-L245	HMMER-PFAM  BLIMPS-BLOCKS ProfileScan  MOTIFS  BLIMPS-PRINTS BLIMPS-PRINTS BLAST-DOMO BLAST-DOMO BLAST-DOMO BLAST-DOMO BLAST-PRODOM BLAST-PRODOM

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
38	7472014CD1	310	S19 S67 S93 T267 S18 S137 S290	N5 N265	Transmembrane domains: V30-I46, M59-I78 7 transmembrane receptor (rhodopsin family) signatures: G41-Y289 G-protein coupled receptor signatures: K90-P129, T207-Y218, R235-Q261, T281-K297 G-protein coupled receptor signature: Y102-I151 G-protein coupled receptor signature: T110-A125 Olfactory receptor signatures: M59-K80, F177-S191, F238-G253, A273-L284, S290-M304 Melanocortin receptor family: S51-L63 Rhodopsin-like GPCR superfamily: P26-R50, M59-K80, F104-I126, V199-L222, Q271-K297 Olfactory receptor PD000921: L166-L245 Olfactory receptor PD149621: T246-R306 G-protein coupled receptor: DM00013 P23266 17-306: L17-M304 G-protein coupled receptor: DM00013 P23274 18-306: E22-M304 G-protein coupled receptor: DM00013 P30955 18-305: D23-M304 G-protein coupled receptor: DM00013 P30953 18-306: R20-H305	HMMER HMMER-PFAM BLIMPS-BLOCKS ProfileScan MOTIFS BLIMPS-PRINTS BLIMPS-PRINTS BLAST-PRODOM BLAST-PRODOM BLAST-DOMO BLAST-DOMO BLAST-DOMO BLAST-DOMO

Table 3 (cont.)

SEQ ID NO:	Incyte Polypeptide ID	Amino Acid Residues	Potential Phosphorylation Sites	Potential Glycosylation Sites	Signature Sequences, Domains and Motifs	Analytical Methods and Databases
39	7472020CD1	359	S257 S317 S178 S255	N31	Transmembrane domains: M127-A145, V168-T193 7 transmembrane receptor (rhodopsin family) signatures: R67-Y316 G-protein coupled receptor signatures: R116-P155, G233-Y244, S261-T287, T308-Q324 G-protein coupled receptor signature: F129-V173 Olfactory receptor signatures: M85-K106, F203-D217, F264-G279, A300-L311, S317-R331 GPR orphan receptor signature: S317-W328 Cannabinoid receptor signatures: M60-L73, Y316-A326 G-protein coupled receptor: DM00013 P23265 17-306; E45-L327 G-protein coupled receptor: DM00013 P23268 18-307; S44-L330 G-protein coupled receptor: DM00013 S29707 18-306; P47-L327 G-protein coupled receptor: DM00013 P30953 18-306; P47-L330 Olfactory receptor PD000921: N197-L271 Olfactory receptor PD149621: V273-R333	HMER HMER-PFAM BLIMPS-BLOCKS ProfileScan BLIMPS-PRINTS BLIMPS-PRINTS BLAST-DOMO BLAST-DOMO BLAST-DOMO BLAST-DOMO BLAST-PRODOR BLAST-PRODOR

Table 4

[illegible]



Table 4 (cont.)

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragments	Sequence Fragments	5' Position	3' Position
57	2829053CB1	1370		170756F1 (BMARNOR02)	1	534
				2829053F6 (TLYMNOT03)	428	989
				6098294H1 (UTRENOT09)	849	1143
				5279076H1 (MUSLANOT01)	1071	1308
				4588915H1 (MASTTXX01)	1132	1370
58	30682334CB1	1567		70489898V1	1	459
				70488597V1	353	883
				5837294H1 (FTUBTUT01)	730	983
				70490272V1	955	1567
59	5029478CB1	1321		6035153H1 (PITUNOT06)	1	582
				6558521H1 (BRAFNON02)	504	1190
				5076961F6 (COLCTTUT03)	742	1321
				5496406H1 (BRABDIR01)	1	250
				1720010F6 (BLADNOT06)	151	708
60	5102576CB1	1110		6969401U1	602	710
				5102576F6 (PROSTUS20)	673	1110
				g2905881.v113.gs_2	1	948
				2200534F6 (SPLNFT02)	534	1095
				576308R6 (BRAVXT04)	490	1051
62	3275821CB1	1665	1431-1665, 765-1294, 240-597	3275821F6 (PROSBPT06)	1	548
				g3779013.v113.gs_9	265	1665
63	3744167CB1	1609	1184-1238, 249-522	2762536H1 (BRSTNOT12)	745	994
				g5578767.v113.gs_4	262	1338
				3744167H1 (THYMNOT08)	693	977
				g835247	1212	1609
				3474586H1 (LUNGNOT27)	1	309
64	7472007CB1	945		g2431610.v113.gs_4.nt	1	945
65	7472008CB1	1098		g3093312.v113.gs_10.nt	1	1098
66	7472013CB1	954		g4190944.v113.gs_3.nt	1	954
67	7472015CB1	1008		g4467309.v113.gs_2.nt	1	1008
68	7472016CB1	930		g4567182.v113.gs_19.nt	1	930
69	7472017CB1	711		g5262456.v113.gs_7.nt	1	711
70	7472018CB1	1092		g5523795.v113.gs_12.nt	1	1092

Table 4 (cont.)

Polynucleotide SEQ ID NO:	Incyte Polynucleotide ID	Sequence Length	Selected Fragments	Sequence Fragments	5' Position	3' Position
71	7472019CB1	927		g5566548.v113.gs.7.nt	1	927
72	7472021CB1	1032		g5708153.v113.gs.6.nt	1	1032
73	7472009CB1	972		g3213020.v113.gs.4.nt	1	972
74	7472010CB1	900		g3738097.v113.gs.9.nt	1	900
75	7472011CB1	924		g3924656.v113.gs.5.nt	1	924
76	7472012CB1	945		g4190944.v113.gs.1.nt	1	945
77	7472014CB1	933		g4190944.v113.gs.4.nt	1	933
78	7472020CB1	1080		g5706779.v113.gs.3.nt	1	1080

Table 5

Polynucleotide SEQ ID NO:	Incyte Project ID	Representative Library
61	2200534CB1	BRVVTXT04
62	3275821CB1	PROSBPT06
63	3744167CB1	LUNGNOT27

Table 6

Library	Vector	Library Description
BRAVXT04	PSPORT1	Library was constructed using RNA isolated from separate populations of human astrocytes stimulated for 4 to 6 hours with a combination of cytokines including IL-1. The RNA was pooled for polyA RNA isolation and library construction.
LUNGNOT27	pINCY	Library was constructed using RNA isolated from lung tissue removed from a 17-year-old Hispanic female.
PROSBPT06	pINCY	Library was constructed using RNA isolated from diseased prostate tissue removed from a 66-year-old Caucasian male during a radical prostatectomy and lymph node excision. Pathology indicated adenofibromatous hyperplasia. Pathology for the associated tumor tissue indicated grade 2 (of 4) adenocarcinoma, Gleason grade 3+3. The patient presented with elevated prostate specific antigen (PSA), proteinuria, decreased renal function, and urinary frequency. Patient history included hemiparesis, depressive disorder, sleep apnea, psoriasis, mitral valve prolapse, cerebrovascular disease, benign hypertension, and impotence. Family history included benign hypertension, cerebrovascular disease, and colon cancer.

Table 7

Program	Description	Reference	Parameter Threshold
ABI FACTURA	A program that removes vector sequences and masks ambiguous bases in nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
ABI/PARACEL FDF	A Fast Data Finder useful in comparing and annotating amino acid or nucleic acid sequences.	Applied Biosystems, Foster City, CA; Paracel Inc., Pasadena, CA.	Mismatch <50%
ABI AutoAssembler	A program that assembles nucleic acid sequences.	Applied Biosystems, Foster City, CA.	
BLAST	A Basic Local Alignment Search Tool useful in sequence similarity search for amino acid and nucleic acid sequences. BLAST includes five functions: blastp, blastn, blastx, tblastn, and tblastx.	Altschul, S.F. et al. (1990) J. Mol. Biol. 215:403-410; Altschul, S.F. et al. (1997) Nucleic Acids Res. 25:3389-3402.	ESTs: Probability value= 1.0E-8 or less Full Length sequences: Probability value= 1.0E-10 or less
FASTA	A Pearson and Lipman algorithm that searches for similarity between a query sequence and a group of sequences of the same type. FASTA comprises at least five functions: fasta, tfasta, fastx, tfastx, and ssearch.	Pearson, W.R. and D.J. Lipman (1988) Proc. Natl. Acad. Sci. USA 85:2444-2448; Pearson, W.R. (1990) Methods Enzymol. 183:63-98; and Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489.	ESTs: fasta E value=1.06E-6 Assembled ESTs: fasta Identity= 95% or greater and Match length=200 bases or greater; fastx E value=1.0E-8 or less Full Length sequences: fastx score=100 or greater
BLIMPS	A BLOCKS IMPROVED Searcher that matches a sequence against those in BLOCKS, PRINTS, DOMO, PRODOM, and PFAM databases to search for gene families, sequence homology, and structural fingerprint regions.	Henikoff, S. and J.G. Henikoff (1991) Nucleic Acids Res. 19:6565-6572; Henikoff, J.G. and S. Henikoff (1996) Methods Enzymol. 266:88-105; and Attwood, T.K. et al. (1997) J. Chem. Inf. Comput. Sci. 37:417-424.	Probability value= 1.0E-3 or less
HMMER	An algorithm for searching a query sequence against hidden Markov model (HMM)-based databases of protein family consensus sequences, such as PFAM.	Krogh, A. et al. (1994) J. Mol. Biol. 235:1501-1531; Sonnhammer, E.L.L. et al. (1988) Nucleic Acids Res. 26:320-322; Durbin, R. et al. (1998) Our World View, in a Nutshell, Cambridge Univ. Press, pp. 1-350.	PFAM hits: Probability value= 1.0E-3 or less Signal peptide hits: Score= 0 or greater

Table 7 (cont.)

Program	Description	Reference	Parameter Threshold
ProfileScan	An algorithm that searches for structural and sequence motifs in protein sequences that match sequence patterns defined in Prosite.	Gribskov, M. et al. (1988) CABIOS 4:61-66; Gribskov, M. et al. (1989) Methods Enzymol. 183:146-159; Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221.	Normalized quality score $\geq$ GCG-specified "HIGH" value for that particular Prosite motif. Generally, score=1.4-2.1.
Phred	A base-calling algorithm that examines automated sequencer traces with high sensitivity and probability.	Ewing, B. et al. (1998) Genome Res. 8:175-185; Ewing, B. and P. Green (1998) Genome Res. 8:186-194.	
Phrap	A Phils Revised Assembly Program including SWAT and CrossMatch, programs based on efficient implementation of the Smith-Waterman algorithm, useful in searching sequence homology and assembling DNA sequences.	Smith, T.F. and M.S. Waterman (1981) Adv. Appl. Math. 2:482-489; Smith, T.F. and M.S. Waterman (1981) J. Mol. Biol. 147:195-197; and Green, P., University of Washington, Seattle, WA.	Score= 120 or greater; Match length= 56 or greater
Consed	A graphical tool for viewing and editing Phrap assemblies.	Gordon, D. et al. (1998) Genome Res. 8:195-202.	
SPScan	A weight matrix analysis program that scans protein sequences for the presence of secretory signal peptides.	Nielson, H. et al. (1997) Protein Engineering 10:1-6; Claverie, J.M. and S. Audic (1997) CABIOS 12:431-439.	Score=3.5 or greater
TMAP	A program that uses weight matrices to delineate transmembrane segments on protein sequences and determine orientation.	Persson, B. and P. Argos (1994) J. Mol. Biol. 237:182-192; Persson, B. and P. Argos (1996) Protein Sci. 5:363-371.	
TMHMMER	A program that uses a hidden Markov model (HMM) to delineate transmembrane segments on protein sequences and determine orientation.	Sonnhammer, E.L. et al. (1998) Proc. Sixth Intl. Conf. on Intelligent Systems for Mol. Biol., Glasgow et al., eds., The Am. Assoc. for Artificial Intelligence Press, Menlo Park, CA, pp. 175-182.	
Motifs	A program that searches amino acid sequences for patterns that matched those defined in Prosite.	Bairoch, A. et al. (1997) Nucleic Acids Res. 25:217-221; Wisconsin Package Program Manual, version 9, page M51-59, Genetics Computer Group, Madison, WI.	

What is claimed is:

1. An isolated polypeptide comprising an amino acid sequence selected from the group consisting of:
  - 5 a) an amino acid sequence selected from the group consisting of SEQ ID NO:1-39,
  - b) a naturally occurring amino acid sequence having at least 90% sequence identity to an amino acid sequence selected from the group consisting of SEQ ID NO:1-39,
  - c) a biologically active fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-39, and
  - 10 d) an immunogenic fragment of an amino acid sequence selected from the group consisting of SEQ ID NO:1-39.
2. An isolated polypeptide of claim 1 selected from the group consisting of SEQ ID NO:1-39.
- 15 3. An isolated polynucleotide encoding a polypeptide of claim 1.
4. An isolated polynucleotide encoding a polypeptide of claim 2.
- 20 5. An isolated polynucleotide of claim 4 selected from the group consisting of SEQ ID NO:40-78.
6. A recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide of claim 3.
- 25 7. A cell transformed with a recombinant polynucleotide of claim 6.
8. A transgenic organism comprising a recombinant polynucleotide of claim 6.
- 30 9. A method for producing a polypeptide of claim 1, the method comprising:
  - a) culturing a cell under conditions suitable for expression of the polypeptide, wherein said cell is transformed with a recombinant polynucleotide, and said recombinant polynucleotide comprises a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1, and
  - 35 b) recovering the polypeptide so expressed.

10. An isolated antibody which specifically binds to a polypeptide of claim 1.

11. An isolated polynucleotide comprising a polynucleotide sequence selected from the group consisting of:

- 5 a) a polynucleotide sequence selected from the group consisting of SEQ ID NO:40-78,
- b) a naturally occurring polynucleotide sequence having at least 90% sequence identity to a polynucleotide sequence selected from the group consisting of SEQ ID NO:40-78,
- c) a polynucleotide sequence complementary to a),
- d) a polynucleotide sequence complementary to b), and
- 10 e) an RNA equivalent of a)-d).

12. An isolated polynucleotide comprising at least 60 contiguous nucleotides of a polynucleotide of claim 11.

13. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:

- a) hybridizing the sample with a probe comprising at least 20 contiguous nucleotides comprising a sequence complementary to said target polynucleotide in the sample, and which probe specifically hybridizes to said target polynucleotide, under conditions whereby a hybridization
- 20 complex is formed between said probe and said target polynucleotide or fragments thereof, and
- b) detecting the presence or absence of said hybridization complex, and, optionally, if present, the amount thereof.

14. A method of claim 13, wherein the probe comprises at least 60 contiguous nucleotides.

15. A method for detecting a target polynucleotide in a sample, said target polynucleotide having a sequence of a polynucleotide of claim 11, the method comprising:

- a) amplifying said target polynucleotide or fragment thereof using polymerase chain reaction amplification, and
- 30 b) detecting the presence or absence of said amplified target polynucleotide or fragment thereof, and, optionally, if present, the amount thereof.

16. A composition comprising an effective amount of a polypeptide of claim 1 and a pharmaceutically acceptable excipient.



17. A composition of claim 16, wherein the polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1-39.

18. A method for treating a disease or condition associated with decreased expression of functional GCREC, comprising administering to a patient in need of such treatment the composition of claim 16.

19. A method for screening a compound for effectiveness as an agonist of a polypeptide of claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting agonist activity in the sample.

20. A composition comprising an agonist compound identified by a method of claim 19 and a pharmaceutically acceptable excipient.

21. A method for treating a disease or condition associated with decreased expression of functional GCREC, comprising administering to a patient in need of such treatment a composition of claim 20.

22. A method for screening a compound for effectiveness as an antagonist of a polypeptide of claim 1, the method comprising:

- a) exposing a sample comprising a polypeptide of claim 1 to a compound, and
- b) detecting antagonist activity in the sample.

23. A composition comprising an antagonist compound identified by a method of claim 22 and a pharmaceutically acceptable excipient.

24. A method for treating a disease or condition associated with overexpression of functional GCREC, comprising administering to a patient in need of such treatment a composition of claim 23.

25. A method of screening for a compound that specifically binds to the polypeptide of claim 1, said method comprising the steps of:

- a) combining the polypeptide of claim 1 with at least one test compound under suitable conditions, and
- b) detecting binding of the polypeptide of claim 1 to the test compound, thereby identifying a

compound that specifically binds to the polypeptide of claim 1.

26. A method of screening for a compound that modulates the activity of the polypeptide of claim 1, said method comprising:

- 5 a) combining the polypeptide of claim 1 with at least one test compound under conditions permissive for the activity of the polypeptide of claim 1,
- b) assessing the activity of the polypeptide of claim 1 in the presence of the test compound, and
- c) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound, wherein a change in
- 10 the activity of the polypeptide of claim 1 in the presence of the test compound is indicative of a compound that modulates the activity of the polypeptide of claim 1.

27. A method for screening a compound for effectiveness in altering expression of a target polynucleotide, wherein said target polynucleotide comprises a sequence of claim 5, the method


15 comprising:

- a) exposing a sample comprising the target polynucleotide to a compound, under conditions suitable for the expression of the target polynucleotide,
- b) detecting altered expression of the target polynucleotide, and
- c) comparing the expression of the target polynucleotide in the presence of varying amounts of
- 20 the compound and in the absence of the compound.

28. A method for assessing toxicity of a test compound, said method comprising:

- a) treating a biological sample containing nucleic acids with the test compound;
- b) hybridizing the nucleic acids of the treated biological sample with a probe comprising at
- 25 least 20 contiguous nucleotides of a polynucleotide of claim 11 under conditions whereby a specific hybridization complex is formed between said probe and a target polynucleotide in the biological sample, said target polynucleotide comprising a polynucleotide sequence of a polynucleotide of claim 11 or fragment thereof;
- c) quantifying the amount of hybridization complex; and
- 30 d) comparing the amount of hybridization complex in the treated biological sample with the amount of hybridization complex in an untreated biological sample, wherein a difference in the amount of hybridization complex in the treated biological sample is indicative of toxicity of the test compound.


1/9



SEQ ID NO:1  
(Incyte ID No. 104941CD1)

FIGURE 1


2/9



SEQ ID NO:3  
(Incyte ID No. 3168839CD1)

FIGURE 2


3/9



SEQ ID NO:4  
(Incyte ID No. 3291235CD1)

FIGURE 3


4/9



SEQ ID NO:5  
(Incyte ID No. 7472001CD1)

FIGURE 4


5/9



SEQ ID NO:6  
(Incyte ID No. 7472003CD1)

FIGURE 5

6/9




SEQ ID NO:7  
(Incyte ID No. 7472004CD1)

FIGURE 6




7/9



SEQ ID NO:19  
(Incyte ID No. 3068234CD1)

FIGURE 7


8/9



SEQ ID NO:20  
(Incyte ID No. 5029478CD1)

FIGURE 8

9/9



SEQ ID NO:21  
(Incyte ID No. 5102576CD1)

FIGURE 9

<110> INCYTE GENOMICS, INC.  
 BURFORD, Neil  
 BAUGHN, Mariah R.  
 AU-YOUNG, Janice  
 YANG, Junming  
 LU, Dyung Aina M.  
 REDDY, Roopa

<120> G-PROTEIN COUPLED RECEPTORS

<130> PI-0001 PCT

<140> To Be Assigned

<141> Herewith

<150> 60/172,852; 60/171,732; 60/176,148; 60/177,331

<151> 1999-12-10; 1999-12-22; 2000-01-14; 2000-01-21

<160> 78

<170> PERL Program

<210> 1

<211> 311

<212> PRT

<213> Homo sapiens

<220>

<221> misc\_feature

<223> Incyte ID No: 104941CD1

<400> 1

Met	Glu	Ile	Lys	Asn	Tyr	Ser	Ser	Ser	Thr	Ser	Gly	Phe	Ile	Leu	1	5	10	15
Leu	Gly	Leu	Ser	Ser	Asn	Pro	Gln	Leu	Gln	Lys	Pro	Leu	Phe	Ala	20	25	30	35
Ile	Phe	Leu	Ile	Met	Tyr	Leu	Leu	Ala	Ala	Val	Gly	Asn	Val	Leu	40	45	50	55
Ile	Ile	Pro	Ala	Ile	Tyr	Ser	Asp	Pro	Arg	Leu	His	Thr	Pro	Met	60	65	70	75
Tyr	Phe	Phe	Leu	Ser	Asn	Leu	Ser	Phe	Met	Asp	Ile	Cys	Phe	Thr	80	85	90	95
Thr	Val	Ile	Val	Pro	Lys	Met	Leu	Val	Asn	Phe	Leu	Ser	Glu	Thr	100	105	110	115
Lys	Val	Ile	Ser	Tyr	Val	Gly	Cys	Leu	Ala	Gln	Met	Tyr	Phe	Phe	120	125	130	135
Met	Ala	Phe	Gly	Asn	Thr	Asp	Ser	Tyr	Leu	Leu	Ala	Ser	Met	Ala	140	145	150	155
Ile	Asp	Arg	Leu	Val	Ala	Ile	Cys	Asn	Pro	Leu	His	Tyr	Asp	Val	160	165	170	175
Val	Met	Lys	Pro	Arg	His	Cys	Leu	Leu	Met	Leu	Leu	Gly	Ser	Cys	180	185	190	195
Ser	Ile	Ser	His	Leu	His	Ser	Leu	Phe	Arg	Val	Leu	Leu	Met	Ser	200	205	210	215
Arg	Leu	Ser	Phe	Cys	Ala	Ser	His	Ile	Ile	Lys	His	Phe	Phe	Cys	220	225	230	235
Asp	Thr	Gln	Pro	Val	Leu	Lys	Leu	Ser	Cys	Ser	Asp	Thr	Ser	Ser	240	245	250	255
Ser	Gln	Met	Val	Val	Met	Thr	Glu	Thr	Leu	Ala	Val	Ile	Val	Thr	260	265	270	
Pro	Phe	Leu	Cys	Ile	Ile	Phe	Ser	Tyr	Leu	Arg	Ile	Met	Val	Thr				
Val	Leu	Arg	Ile	Pro	Ser	Ala	Ala	Gly	Lys	Trp	Lys	Ala	Phe	Ser				
Thr	Cys	Gly	Ser	His	Leu	Thr	Ala	Val	Ala	Leu	Phe	Tyr	Gly	Ser				
Ile	Ile	Tyr	Val	Tyr	Phe	Arg	Pro	Leu	Ser	Met	Tyr	Ser	Val	Val				

Arg	Asp	Arg	Val	Ala	Thr	Val	Met	Tyr	Thr	Val	Val	Thr	Pro	Met
				275					280					285
Leu	Asn	Pro	Phe	Ile	Tyr	Ser	Leu	Arg	Asn	Lys	Asp	Met	Lys	Arg
				290					295					300
Gly	Leu	Lys	Lys	Leu	Gln	Asp	Arg	Ile	Tyr	Arg				
				305					310					

&lt;210&gt; 2.

&lt;211&gt; 891

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 1499408CD1

&lt;400&gt; 2

Met	Asp	Gln	Pro	Glu	Ala	Pro	Cys	Ser	Ser	Thr	Gly	Pro	Arg	Leu
1				5					10					15
Ala	Val	Ala	Arg	Glu	Leu	Leu	Leu	Ala	Ala	Leu	Glu	Glu	Leu	Ser
				20					25					30
Gln	Glu	Gln	Leu	Lys	Arg	Phe	Arg	His	Lys	Leu	Arg	Asp	Val	Gly
				35					40					45
Pro	Asp	Gly	Arg	Ser	Ile	Pro	Trp	Gly	Arg	Leu	Glu	Arg	Ala	Asp
				50					55					60
Ala	Val	Asp	Leu	Ala	Glu	Gln	Leu	Ala	Gln	Phe	Tyr	Gly	Pro	Glu
				65					70					75
Pro	Ala	Leu	Glu	Val	Ala	Arg	Lys	Thr	Leu	Lys	Arg	Ala	Asp	Ala
				80					85					90
Arg	Asp	Val	Ala	Ala	Gln	Leu	Gln	Glu	Arg	Arg	Leu	Gln	Arg	Leu
				95					100					105
Gly	Leu	Gly	Ser	Gly	Thr	Leu	Leu	Ser	Val	Ser	Glu	Tyr	Lys	Lys
				110					115					120
Lys	Tyr	Arg	Glu	His	Val	Leu	Gln	Leu	His	Ala	Arg	Val	Lys	Glu
				125					130					135
Arg	Asn	Ala	Arg	Ser	Val	Lys	Ile	Thr	Lys	Arg	Phe	Thr	Lys	Leu
				140					145					150
Leu	Ile	Ala	Pro	Glu	Ser	Ala	Ala	Pro	Glu	Glu	Ala	Leu	Gly	Pro
				155					160					165
Ala	Glu	Glu	Pro	Glu	Pro	Gly	Arg	Ala	Arg	Arg	Ser	Asp	Thr	His
				170					175					180
Thr	Phe	Asn	Arg	Leu	Phe	Arg	Arg	Asp	Glu	Glu	Gly	Arg	Arg	Pro
				185					190					195
Leu	Thr	Val	Val	Leu	Gln	Gly	Pro	Ala	Gly	Ile	Gly	Lys	Thr	Met
				200					205					210
Ala	Ala	Lys	Lys	Ile	Leu	Tyr	Asp	Trp	Ala	Ala	Gly	Lys	Leu	Tyr
				215					220					225
Gln	Gly	Gln	Val	Asp	Phe	Ala	Phe	Phe	Met	Pro	Cys	Gly	Glu	Leu
				230					235					240
Leu	Glu	Arg	Pro	Gly	Thr	Arg	Ser	Leu	Ala	Asp	Leu	Ile	Leu	Asp
				245					250					255
Gln	Cys	Pro	Asp	Arg	Gly	Ala	Pro	Val	Pro	Gln	Met	Leu	Ala	Gln
				260					265					270
Pro	Gln	Arg	Leu	Leu	Phe	Ile	Leu	Asp	Gly	Ala	Asp	Glu	Leu	Pro
				275					280					285
Ala	Leu	Gly	Gly	Pro	Glu	Ala	Ala	Pro	Cys	Thr	Asp	Pro	Phe	Glu
				290					295					300
Ala	Ala	Ser	Gly	Ala	Arg	Val	Leu	Gly	Gly	Leu	Leu	Ser	Lys	Ala
				305					310					315
Leu	Leu	Pro	Thr	Ala	Leu	Leu	Leu	Val	Thr	Thr	Arg	Ala	Ala	Ala
				320					325					330
Pro	Gly	Arg	Leu	Gln	Gly	Arg	Leu	Cys	Ser	Pro	Gln	Cys	Ala	Glu
				335					340					345
Val	Arg	Gly	Phe	Ser	Asp	Lys	Asp	Lys	Lys	Lys	Tyr	Phe	Tyr	Lys
				350					355					360
Phe	Phe	Arg	Asp	Glu	Arg	Arg	Ala	Glu	Arg	Ala	Tyr	Arg	Phe	Val
				365					370					375

Lys	Glu	Asn	Glu	Thr	Leu	Phe	Ala	Leu	Cys	Phe	Val	Pro	Phe	Val
				380					385					390
Cys	Trp	Ile	Val	Cys	Thr	Val	Leu	Arg	Gln	Gln	Leu	Glu	Leu	Gly
				395					400					405
Arg	Asp	Leu	Ser	Arg	Thr	Ser	Lys	Thr	Thr	Thr	Ser	Val	Tyr	Leu
				410					415					420
Leu	Phe	Ile	Thr	Ser	Val	Leu	Ser	Ser	Ala	Pro	Val	Ala	Asp	Gly
				425					430					435
Pro	Arg	Leu	Gln	Gly	Asp	Leu	Arg	Asn	Leu	Cys	Arg	Leu	Ala	Arg
				440					445					450
Glu	Gly	Val	Leu	Gly	Arg	Arg	Ala	Gln	Phe	Ala	Glu	Lys	Glu	Leu
				455					460					465
Glu	Gln	Leu	Glu	Leu	Arg	Gly	Ser	Lys	Val	Gln	Thr	Leu	Phe	Leu
				470					475					480
Ser	Lys	Lys	Glu	Leu	Pro	Gly	Val	Leu	Glu	Thr	Glu	Val	Thr	Tyr
				485					490					495
Gln	Phe	Ile	Asp	Gln	Ser	Phe	Gln	Glu	Phe	Leu	Ala	Ala	Leu	Ser
				500					505					510
Tyr	Leu	Leu	Glu	Asp	Gly	Gly	Val	Pro	Arg	Thr	Ala	Ala	Gly	Gly
				515					520					525
Val	Gly	Thr	Leu	Leu	Arg	Gly	Asp	Ala	Gln	Pro	His	Ser	His	Leu
				530					535					540
Val	Leu	Thr	Thr	Arg	Phe	Leu	Phe	Gly	Leu	Leu	Ser	Ala	Glu	Arg
				545					550					555
Met	Arg	Asp	Ile	Glu	Arg	His	Phe	Gly	Cys	Met	Val	Ser	Glu	Arg
				560					565					570
Val	Lys	Gln	Glu	Ala	Leu	Arg	Trp	Val	Gln	Gly	Gln	Gly	Gln	Gly
				575					580					585
Cys	Pro	Gly	Val	Ala	Pro	Glu	Val	Thr	Glu	Gly	Ala	Lys	Gly	Leu
				590					595					600
Glu	Asp	Thr	Glu	Glu	Pro	Glu	Glu	Glu	Glu	Gly	Glu	Glu	Glu	Pro
				605					610					615
Asn	Tyr	Pro	Leu	Glu	Leu	Leu	Tyr	Cys	Leu	Tyr	Glu	Thr	Gln	Glu
				620					625					630
Asp	Ala	Phe	Val	Arg	Gln	Ala	Leu	Cys	Arg	Phe	Pro	Glu	Leu	Ala
				635					640					645
Leu	Gln	Arg	Val	Arg	Phe	Cys	Arg	Met	Asp	Val	Ala	Val	Leu	Ser
				650					655					660
Tyr	Cys	Val	Arg	Cys	Cys	Pro	Ala	Gly	Gln	Ala	Leu	Arg	Leu	Ile
				665					670					675
Ser	Cys	Arg	Leu	Val	Ala	Ala	Gln	Glu	Lys	Lys	Lys	Lys	Ser	Leu
				680					685					690
Gly	Lys	Arg	Leu	Gln	Ala	Ser	Leu	Gly	Gly	Gly	Ser	Ser	Gln	Gly
				695					700					705
Thr	Thr	Lys	Gln	Leu	Pro	Ala	Ser	Leu	Leu	His	Pro	Leu	Phe	Gln
				710					715					720
Ala	Met	Thr	Asp	Pro	Leu	Cys	His	Leu	Ser	Ser	Leu	Thr	Leu	Ser
				725					730					735
His	Cys	Lys	Leu	Pro	Asp	Ala	Val	Cys	Arg	Asp	Leu	Ser	Glu	Ala
				740					745					750
Leu	Arg	Ala	Ala	Pro	Ala	Leu	Thr	Glu	Leu	Gly	Leu	Leu	His	Asn
				755					760					765
Arg	Leu	Ser	Glu	Ala	Gly	Leu	Arg	Met	Leu	Ser	Glu	Gly	Leu	Ala
				770					775					780
Trp	Pro	Gln	Cys	Arg	Val	Gln	Thr	Val	Arg	Val	Gln	Leu	Pro	Asp
				785					790					795
Pro	Gln	Arg	Gly	Leu	Gln	Tyr	Leu	Val	Gly	Met	Leu	Arg	Gln	Ser
				800					805					810
Pro	Ala	Leu	Thr	Thr	Leu	Asp	Leu	Ser	Gly	Cys	Gln	Leu	Pro	Ala
				815					820					825
Pro	Met	Val	Thr	Tyr	Leu	Cys	Ala	Val	Leu	Gln	His	Gln	Gly	Cys
				830					835					840
Gly	Leu	Gln	Thr	Leu	Ser	Leu	Ala	Ser	Val	Glu	Leu	Ser	Glu	Gln
				845					850					855
Ser	Leu	Gln	Glu	Leu	Gln	Ala	Val	Lys	Arg	Ala	Lys	Pro	Asp	Leu
				860					865					870
Val	Ile	Thr	His	Pro	Ala	Leu	Asp	Gly	His	Pro	Gln	Pro	Pro	Lys

Glu Leu Ile Ser Thr Phe  
875  
890

880

885

<210> 3  
<211> 422  
<212> PRT  
<213> Homo sapiens

<220> .  
<221> misc\_feature  
<223> Incyte ID No: 3168839CD1

&lt;400&gt; 3

Met	Leu	Ala	Asn	Ser	Ser	Ser	Thr	Asn	Ser	Ser	Val	Leu	Pro	Cys	
1				5				10						15	
Pro	Asp	Tyr	Arg	Pro	Thr	His	Arg	Leu	His	Leu	Val	Val	Tyr	Ser	
				20				25						30	
Leu	Val	Leu	Ala	Ala	Gly	Leu	Pro	Leu	Asn	Ala	Leu	Ala	Leu	Trp	
				35				40						45	
Val	Phe	Leu	Arg	Ala	Leu	Arg	Val	His	Ser	Val	Val	Ser	Val	Tyr	
				50				55						60	
Met	Cys	Asn	Leu	Ala	Ala	Ser	Asp	Leu	Leu	Phe	Thr	Leu	Ser	Leu	
				65				70						75	
Pro	Val	Arg	Leu	Ser	Tyr	Tyr	Ala	Leu	His	His	Trp	Pro	Phe	Pro	
				80				85						90	
Asp	Leu	Leu	Cys	Gln	Thr	Thr	Gly	Ala	Ile	Phe	Gln	Met	Asn	Met	
				95				100						105	
Tyr	Gly	Ser	Cys	Ile	Phe	Leu	Met	Leu	Ile	Asn	Val	Asp	Arg	Tyr	
				110				115						120	
Ala	Ala	Ile	Val	His	Pro	Leu	Arg	Leu	Arg	His	Leu	Arg	Arg	Pro	
				125				130						135	
Arg	Val	Ala	Arg	Leu	Leu	Cys	Leu	Gly	Val	Trp	Ala	Leu	Ile	Leu	
				140				145						150	
Val	Phe	Ala	Val	Pro	Ala	Ala	Arg	Val	His	Arg	Pro	Ser	Arg	Cys	
				155				160						165	
Arg	Tyr	Arg	Asp	Leu	Glu	Val	Arg	Leu	Cys	Phe	Glu	Ser	Phe	Ser	
				170				175						180	
Asp	Glu	Leu	Trp	Lys	Gly	Arg	Leu	Leu	Pro	Leu	Val	Leu	Leu	Ala	
				185				190						195	
Glu	Ala	Leu	Gly	Phe	Leu	Leu	Pro	Leu	Ala	Ala	Val	Val	Tyr	Ser	
				200				205						210	
Ser	Gly	Arg	Val	Phe	Trp	Thr	Leu	Ala	Arg	Pro	Asp	Ala	Thr	Gln	
				215				220						225	
Ser	Gln	Arg	Arg	Arg	Lys	Thr	Val	Arg	Leu	Leu	Leu	Ala	Asn	Leu	
				230				235						240	
Val	Ile	Phe	Leu	Leu	Cys	Phe	Val	Pro	Tyr	Asn	Ser	Thr	Leu	Ala	
				245				250						255	
Val	Tyr	Gly	Leu	Leu	Arg	Ser	Lys	Leu	Val	Ala	Ala	Ser	Val	Pro	
				260				265						270	
Ala	Arg	Asp	Arg	Val	Arg	Gly	Val	Leu	Met	Val	Met	Val	Leu	Leu	
				275				280						285	
Ala	Gly	Ala	Asn	Cys	Val	Leu	Asp	Pro	Leu	Val	Tyr	Tyr	Phe	Ser	
				290				295						300	
Ala	Glu	Gly	Phe	Arg	Asn	Thr	Leu	Arg	Gly	Leu	Gly	Thr	Pro	His	
				305				310						315	
Arg	Ala	Arg	Thr	Ser	Ala	Thr	Asn	Gly	Thr	Arg	Ala	Ala	Leu	Ala	
				320				325						330	
Gln	Ser	Glu	Arg	Ser	Ala	Val	Thr	Thr	Asp	Ala	Thr	Arg	Pro	Asp	
				335				340						345	
Ala	Ala	Met	Ser	Pro	Gly	Phe	Arg	Pro	Leu	Asn	Thr	His	Ala	Ile	
				350				355						360	
Ala	Leu	Ser	Val	Pro	Asp	Ser	Gln	Arg	Leu	Ser	Phe	Trp	Glu	Ala	
				365				370						375	
Tyr	Arg	Val	Tyr	Thr	Gln	Glu	Gly	Gly	Leu	Gly	Thr	Trp	Thr	Phe	
				380				385						390	
Gly	Trp	Gln	Phe	Gln	Leu	Ser	Asn	Ala	Glu	Glu	Tyr	Lys	Val	Trp	

395  
 Lys Pro Gly Pro Arg Glu Gly Ser Ala Ala Gly Asn Gly Phe Phe  
 410 415 420  
 Lys Leu

<210> 4  
 <211> 609  
 <212> PRT  
 <213> Homo sapiens  
 <220>  
 <221> misc\_feature  
 <223> Incyte ID No: 3291235CD1

<400> 4  
 Met Ser Asp Glu Arg Arg Leu Pro Gly Ser Ala Val Gly Trp Leu  
 1 5 10 15  
 Val Cys Gly Gly Leu Ser Leu Leu Ala Asn Ala Trp Gly Ile Leu  
 20 25 30  
 Ser Val Gly Ala Lys Gln Lys Lys Trp Lys Pro Leu Glu Phe Leu  
 35 40 45  
 Leu Cys Thr Leu Ala Ala Thr His Met Leu Asn Val Ala Val Pro  
 50 55 60  
 Ile Ala Thr Tyr Ser Val Val Gln Leu Arg Arg Gln Arg Pro Asp  
 65 70 75  
 Phe Glu Trp Asn Glu Gly Leu Cys Lys Val Phe Val Ser Thr Phe  
 80 85 90  
 Tyr Thr Leu Thr Leu Ala Thr Cys Phe Ser Val Thr Ser Leu Ser  
 95 100 105  
 Tyr His Arg Met Trp Met Val Cys Trp Pro Val Asn Tyr Arg Leu  
 110 115 120  
 Ser Asn Ala Lys Lys Gln Ala Val His Thr Val Met Gly Ile Trp  
 125 130 135  
 Met Val Ser Phe Ile Leu Ser Ala Leu Pro Ala Val Gly Trp His  
 140 145 150  
 Asp Thr Ser Glu Arg Phe Tyr Thr His Gly Cys Arg Phe Ile Val  
 155 160 165  
 Ala Glu Ile Gly Leu Gly Phe Gly Val Cys Phe Leu Leu Leu Val  
 170 175 180  
 Gly Gly Ser Val Ala Met Gly Val Ile Cys Thr Ala Ile Ala Leu  
 185 190 195  
 Phe Gln Thr Leu Ala Val Gln Val Gly Arg Gln Ala Asp His Arg  
 200 205 210  
 Ala Phe Thr Val Pro Thr Ile Val Val Glu Asp Ala Gln Gly Lys  
 215 220 225  
 Arg Arg Ser Ser Ile Asp Gly Ser Glu Pro Ala Lys Thr Ser Leu  
 230 235 240  
 Gln Thr Thr Gly Leu Val Thr Thr Ile Val Phe Ile Tyr Asp Cys  
 245 250 255  
 Leu Met Gly Phe Pro Val Leu Val Val Ser Phe Ser Ser Leu Arg  
 260 265 270  
 Ala Asp Ala Ser Ala Pro Trp Met Ala Leu Cys Val Leu Trp Cys  
 275 280 285  
 Ser Val Ala Gln Ala Leu Leu Leu Pro Val Phe Leu Trp Ala Cys  
 290 295 300  
 Asp Arg Tyr Arg Ala Asp Leu Lys Ala Val Arg Glu Lys Cys Met  
 305 310 315  
 Ala Leu Met Ala Asn Asp Glu Glu Ser Asp Asp Glu Thr Ser Leu  
 320 325 330  
 Glu Gly Gly Ile Ser Pro Asp Leu Val Leu Glu Arg Ser Leu Asp  
 335 340 345  
 Tyr Gly Tyr Gly Gly Asp Phe Val Ala Leu Asp Arg Met Ala Lys  
 350 355 360  
 Tyr Glu Ile Ser Ala Leu Glu Gly Gly Leu Pro Gln Leu Tyr Pro  
 365 370 375  
 Leu Arg Pro Leu Gln Glu Asp Lys Met Gln Tyr Leu Gln Val Pro



Pro Thr Arg Arg	380	Phe Ser His Asp Asp	385	Ala Asp Val Trp Ala	390
Val Pro Leu Pro	395	Ala Phe Leu Pro Arg	400	Trp Gly Ser Gly Lys	405
Leu Ser Ala Leu	410	Ala His Leu Val Leu	415	Pro Ala Gly Pro Glu	420
Pro Arg Ala Ser	425	Leu Leu Ala Phe Ala	430	Glu Asp Ala Pro Leu	435
Arg Ala Arg Arg	440	Arg Ser Ala Glu Ser	445	Leu Leu Ser Leu Arg	450
Ser Ala Val Asp	455	Ser Gly Pro Arg Gly	460	Ala Arg Asp Ser Pro	465
Gly Ser Pro Arg	470	Arg Arg Pro Gly Pro	475	Gly Pro Arg Ser Ala	480
Ala Ser Leu Leu	485	Pro Asp Ala Phe Ala	490	Leu Thr Ala Phe Glu	495
Glu Pro Gln Ala	500	Leu Arg Arg Pro Pro	505	Gly Pro Phe Pro Ala	510
Pro Ala Ala Pro	515	Asp Gly Ala Asp Pro	520	Gly Glu Ala Pro Thr	525
Pro Ser Ser Ala	530	Gln Arg Ser Pro Gly	535	Pro Arg Pro Ser Ala	540
Ser His Ala Gly	545	Ser Leu Arg Pro Gly	550	Leu Ser Ala Ser Trp	555
Glu Pro Gly Gly	560	Leu Arg Ala Ala Gly	565	Gly Gly Gly Ser Thr	570
Ser Phe Leu Ser	575	Pro Ser Glu Ser	580	Ser Gly Tyr Ala Thr	585
His Ser Asp Ser	590	Leu Gly Ser Ala Ser	595		600
	605				

&lt;210&gt; 5

&lt;211&gt; 313

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7472001CD1

&lt;400&gt; 5

Met Glu Arg Ile	1	Asn Ser Thr Leu Leu	10	Thr Ala Phe Ile Leu	15
Gly Ile Pro Tyr	20	Pro Leu Arg Leu Arg	25	Thr Leu Phe Phe Val	30
Phe Phe Leu Ile	35	Tyr Ile Leu Thr Gln	40	Leu Gly Asn Leu Leu	45
Leu Ile Thr Val	50	Trp Ala Asp Pro Arg	55	Leu His Ala Arg Pro	60
Tyr Ile Phe Leu	65	Gly Val Leu Ser Val	70	Ile Asp Met Ser Ile	75
Ser Ile Ile Val	80	Pro Arg Leu Met Met	85	Asn Phe Thr Leu Gly	90
Lys Pro Ile Pro	95	Phe Gly Gly Cys Val	100	Ala Gln Leu Tyr Phe	105
His Phe Leu Gly	110	Ser Thr Gln Cys Phe	115	Leu Tyr Thr Leu Met	120
Tyr Asp Arg Tyr	125	Leu Ala Ile Cys Gln	130	Pro Leu Arg Tyr Pro	135
Leu Met Thr Ala	140	Lys Leu Ser Ala Leu	145	Leu Val Ala Gly Ala	150
Met Ala Gly Ser	155	Ile His Gly Ala Leu	160	Gln Ala Ile Leu Thr	165
Arg Leu Pro Tyr	170	Cys Gly Pro Asn Gln	175	Val Asp Tyr Phe Phe	180
Asp Ile Pro Ala		Val Leu Arg Leu Ala		Cys Ala Asp Thr Thr	Val

Asn	Glu	Leu	Val	Thr	Phe	Val	Asp	Ile	Gly	Val	Val	Val	Ala	Ser	185	190	195
															200	205	210
Cys	Phe	Ser	Leu	Ile	Leu	Leu	Ser	Tyr	Ile	Gln	Ile	Ile	Gln	Ala	215	220	225
Ile	Leu	Arg	Ile	His	Thr	Ala	Asp	Gly	Arg	Arg	Arg	Ala	Phe	Ser	230	235	240
Thr	Cys	Gly	Ala	His	Val	Thr	Val	Val	Thr	Val	Tyr	Tyr	Val	Pro	245	250	255
Cys	Ala	Phe	Ile	Tyr	Leu	Arg	Pro	Glu	Thr	Asn	Ser	Pro	Leu	Asp	260	265	270
Gly	Ala	Ala	Ala	Leu	Val	Pro	Thr	Ala	Ile	Thr	Pro	Phe	Leu	Asn	275	280	285
Pro	Leu	Ile	Tyr	Thr	Leu	Arg	Asn	Gln	Glu	Val	Lys	Leu	Ala	Leu	290	295	300
Lys	Arg	Met	Leu	Arg	Ser	Pro	Arg	Thr	Pro	Ser	Glu	Val			305	310	

&lt;210&gt; 6

&lt;211&gt; 398

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7472003CD1

&lt;400&gt; 6

Met	His	Thr	Val	Ala	Thr	Ser	Gly	Pro	Asn	Ala	Ser	Trp	Gly	Ala	1	5	10	15
Pro	Ala	Asn	Ala	Ser	Gly	Cys	Pro	Gly	Cys	Gly	Ala	Asn	Ala	Ser	20	25	30	35
Asp	Gly	Pro	Val	Pro	Ser	Pro	Arg	Ala	Val	Asp	Ala	Trp	Leu	Val	35	40	45	50
Pro	Leu	Phe	Phe	Ala	Ala	Leu	Met	Leu	Leu	Gly	Leu	Val	Gly	Asn	50	55	60	65
Ser	Leu	Val	Ile	Tyr	Val	Ile	Cys	Arg	His	Lys	Pro	Met	Arg	Thr	65	70	75	80
Val	Thr	Asn	Phe	Tyr	Ile	Ala	Asn	Leu	Ala	Ala	Thr	Asp	Val	Thr	80	85	90	95
Phe	Leu	Leu	Cys	Cys	Val	Pro	Phe	Thr	Ala	Leu	Leu	Tyr	Pro	Leu	95	100	105	110
Pro	Gly	Trp	Val	Leu	Gly	Asp	Phe	Met	Cys	Lys	Phe	Val	Asn	Tyr	110	115	120	125
Ile	Gln	Gln	Val	Ser	Val	Gln	Ala	Thr	Cys	Ala	Thr	Leu	Thr	Ala	125	130	135	140
Met	Ser	Val	Asp	Arg	Trp	Tyr	Val	Thr	Val	Phe	Pro	Leu	Arg	Ala	140	145	150	155
Leu	His	Arg	Arg	Thr	Pro	Arg	Leu	Ala	Leu	Ala	Val	Ser	Leu	Ser	155	160	165	170
Ile	Trp	Thr	Gly	Ser	Ala	Ala	Val	Ser	Ala	Pro	Val	Leu	Ala	Leu	170	175	180	185
His	Arg	Leu	Ser	Pro	Gly	Pro	Arg	Ala	Tyr	Cys	Ser	Glu	Ala	Phe	185	190	195	200
Pro	Ser	Arg	Ala	Leu	Glu	Arg	Ala	Phe	Ala	Leu	Tyr	Asn	Leu	Leu	200	205	210	215
Ala	Leu	Tyr	Leu	Leu	Pro	Leu	Leu	Ala	Thr	Cys	Ala	Cys	Tyr	Ala	215	220	225	230
Ala	Met	Leu	Arg	His	Leu	Gly	Arg	Val	Ala	Val	Arg	Pro	Ala	Pro	230	235	240	245
Ala	Asp	Ser	Ala	Leu	Gln	Gly	Gln	Val	Leu	Ala	Glu	Arg	Ala	Gly	245	250	255	260
Ala	Val	Arg	Ala	Lys	Val	Ser	Arg	Leu	Val	Ala	Ala	Val	Val	Leu	260	265	270	275
Leu	Phe	Ala	Ala	Cys	Trp	Gly	Pro	Ile	Gln	Leu	Phe	Leu	Val	Leu	275	280	285	
Gln	Ala	Leu	Gly	Pro	Ala	Gly	Ser	Trp	His	Pro	Arg	Ser	Tyr	Ala				

Ala Tyr Ala Leu Lys	Thr Trp Ala His	Cys Met Ser Tyr Ser	Asn
305	310	315	315
Ser Ala Leu Asn Pro	Leu Leu Tyr Ala	Phe Leu Gly Ser His	Phe
320	325	330	330
Arg Gln Ala Phe Arg	Arg Val Cys Pro	Cys Ala Pro Arg Arg	Pro
335	340	345	345
Arg Arg Pro Arg Arg	Pro Gly Pro Ser	Asp Pro Ala Ala Pro	His
350	355	360	360
Ala Glu Leu Leu Arg	Leu Gly Ser His	Pro Ala Pro Ala Arg	Ala
365	370	375	375
Gln Lys Pro Gly Ser	Ser Gly Leu Ala	Ala Arg Gly Leu Cys	Val
380	385	390	390
Leu Gly Glu Asp Asn	Ala Pro Leu		
395			

&lt;210&gt; 7

&lt;211&gt; 369

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7472004CD1

&lt;400&gt; 7

Met Ala Pro Thr Gly	Leu Ser Ser Leu Thr	Val Asn Ser Thr Ala
1	5	10
Val Pro Thr Thr Pro	Ala Ala Phe Lys Ser	Leu Asn Leu Pro Leu
20	25	30
Gln Ile Thr Leu Ser	Ala Ile Met Ile Phe	Ile Leu Phe Val Ser
35	40	45
Phe Leu Gly Asn Leu	Val Val Cys Leu Met	Val Tyr Gln Lys Ala
50	55	60
Ala Met Arg Ser Ala	Ile Asn Ile Leu Leu	Ala Ser Leu Ala Phe
65	70	75
Ala Asp Met Leu Leu	Ala Val Leu Asn Met	Pro Phe Ala Leu Val
80	85	90
Thr Ile Leu Thr Thr	Arg Trp Ile Phe Gly	Lys Phe Phe Cys Arg
95	100	105
Val Ser Ala Met Phe	Trp Leu Phe Val Ile	Glu Gly Val Ala
110	115	120
Ile Leu Leu Ile Ile	Ser Ile Asp Arg Phe	Leu Ile Ile Val Gln
125	130	135
Arg Gln Asp Lys Leu	Asn Pro Tyr Arg Ala	Lys Val Leu Ile Ala
140	145	150
Val Ser Trp Ala Thr	Ser Phe Cys Val Ala	Phe Pro Leu Ala Val
155	160	165
Gly Asn Pro Asp Leu	Gln Ile Pro Ser Arg	Ala Pro Gln Cys Val
170	175	180
Phe Gly Tyr Thr Thr	Asn Pro Gly Tyr Gln	Ala Tyr Val Ile Leu
185	190	195
Ile Ser Leu Ile Ser	Phe Phe Ile Pro Phe	Leu Val Ile Leu Tyr
200	205	210
Ser Phe Met Gly Ile	Leu Asn Thr Leu Arg	His Asn Ala Leu Arg
215	220	225
Ile His Ser Tyr Pro	Glu Gly Ile Cys Leu	Ser Gln Ala Ser Lys
230	235	240
Leu Gly Leu Met Ser	Leu Gln Arg Pro Phe	Gln Met Ser Ile Asp
245	250	255
Met Gly Phe Lys Thr	Arg Ala Phe Thr Thr	Ile Leu Ile Leu Phe
260	265	270
Ala Val Phe Ile Val	Cys Trp Ala Pro Phe	Thr Thr Tyr Ser Leu
275	280	285
Val Ala Thr Phe Ser	Lys His Phe Tyr Tyr	Gln His Asn Phe Phe
290	295	300
Glu Ile Ser Thr Trp	Leu Leu Trp Leu Cys	Tyr Leu Lys Ser Ala

WO 01/42288

PCT/US00/33382

Leu	Asn	Pro	Leu	Ile	Tyr	Tyr	Trp	Arg	Ile	Lys	Lys	Phe	His	Asp	305	310	315
Ala	Cys	Leu	Asp	Met	Met	Pro	Lys	Ser	Phe	Lys	Phe	Leu	Pro	Gln	320	325	330
Leu	Pro	Gly	His	Thr	Lys	Arg	Arg	Ile	Arg	Pro	Ser	Ala	Val	Tyr	335	340	345
Val	Cys	Gly	Glu	His	Arg	Thr	Val	Val							350	355	360
															365		

<210> 8  
 <211> 194  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7475687CPI

Met	Ala	Tyr	Asp	Arg	Tyr	Leu	Ala	Ile	Cys	Gln	Pro	Leu	Arg	Tyr	1	5	10
Pro	Val	Leu	Met	Asn	Gly	Arg	Leu	Cys	Thr	Val	Leu	Val	Ala	Gly	20	25	30
Ala	Trp	Val	Ala	Gly	Ser	Met	His	Gly	Ser	Ile	Gln	Ala	Thr	Leu	35	40	45
Thr	Phe	Arg	Leu	Pro	Tyr	Cys	Gly	Pro	Asn	Gln	Val	Asp	Tyr	Phe	50	55	60
Ile	Cys	Asp	Ile	Pro	Ala	Val	Leu	Arg	Leu	Ala	Cys	Ala	Asp	Thr	65	70	75
Thr	Val	Asn	Glu	Leu	Val	Thr	Phe	Val	Asp	Ile	Gly	Val	Val	Ala	80	85	90
Ala	Ser	Cys	Phe	Met	Leu	Ile	Leu	Leu	Ser	Tyr	Ala	Asn	Ile	Val	95	100	105
Asn	Ala	Ile	Leu	Lys	Ile	Arg	Thr	Thr	Asp	Gly	Arg	Arg	Arg	Ala	110	115	120
Phe	Ser	Thr	Cys	Gly	Ser	His	Leu	Ile	Val	Val	Thr	Val	Tyr	Tyr	125	130	135
Val	Pro	Cys	Ile	Phe	Ile	Tyr	Leu	Arg	Ala	Gly	Ser	Lys	Gly	Pro	140	145	150
Leu	Asp	Gly	Ala	Ala	Ala	Val	Phe	Tyr	Thr	Val	Val	Thr	Pro	Leu	155	160	165
Leu	Asn	Pro	Leu	Ile	Tyr	Thr	Leu	Arg	Asn	Gln	Glu	Val	Lys	Ser	170	175	180
Ala	Leu	Lys	Arg	Ile	Thr	Ala	Gly	Gln	Ala	Asp	Val	Asn	Asn		185	190	

<210> 9  
 <211> 173  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7483029CPI

Met	Tyr	Leu	Val	Thr	Val	Leu	Gly	Asn	Leu	Leu	Ile	Ile	Leu	Ala	1	5	10
Thr	Ile	Ser	Asp	Ser	His	Leu	His	Thr	Pro	Met	Tyr	Phe	Phe	Leu	20	25	30
Ser	Asn	Leu	Ser	Phe	Ala	Asp	Ile	Cys	Phe	Val	Ser	Thr	Thr	Val	35	40	45
Pro	Lys	Met	Leu	Val	Asn	Ile	Gln	Thr	Gln	Ser	Arg	Val	Ile	Thr	50	55	60
Tyr	Ala	Asp	Cys	Ile	Thr	Gln	Met	Cys	Phe	Phe	Ile	Leu	Phe	Val	65	70	75

Val	Leu	Asp	Ser	Leu	Leu	Leu	Thr	Val	Met	Ala	Tyr	Asp	Arg	Phe	
				80					85					90	
Val	Ala	Ile	Cys	His	Pro	Leu	His	Tyr	Thr	Val	Ile	Met	Asn	Ser	
				95					100					105	
Trp	Leu	Cys	Gly	Leu	Leu	Val	Leu	Val	Ser	Trp	Ile	Val	Ser	Ile	
				110					115					120	
Leu	Tyr	Ser	Leu	Leu	Gln	Ser	Ile	Met	Ala	Leu	Gln	Leu	Ser	Phe	
				125					130					135	
Cys	Thr	Glu	Leu	Lys	Ile	Pro	His	Phe	Phe	Cys	Glu	Leu	Asn	Gln	
				140					145					150	
Val	Ile	His	Leu	Ala	Cys	Ser	Asp	Thr	Phe	Ile	Asn	Asp	Met	Met	
				155					160					165	
Met	Asn	Phe	Thr	Ser	Val	Leu	Leu								
				170											

<210> 10  
 <211> 220  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7477933CP1

<400>	10														
Pro	Met	Tyr	Phe	Phe	Leu	Ser	Asn	Leu	Cys	Trp	Ala	Asp	Ile	Gly	
1				5					10					15	
Leu	Thr	Ser	Ala	Thr	Val	Pro	Lys	Val	Ile	Leu	Asp	Met	Gln	Ser	
				20					25					30	
His	Ser	Arg	Val	Ile	Ser	His	Val	Gly	Cys	Leu	Thr	Gln	Met	Ser	
				35					40					45	
Phe	Leu	Val	Leu	Phe	Ala	Cys	Ile	Glu	Gly	Met	Leu	Leu	Thr	Val	
				50					55					60	
Met	Ala	Tyr	Gly	Cys	Phe	Val	Ala	Ile	Cys	Arg	Pro	Leu	His	Tyr	
				65					70					75	
Pro	Val	Ile	Val	Asn	Pro	His	Leu	Cys	Val	Phe	Phe	Val	Leu	Val	
				80					85					90	
Ser	Phe	Phe	Leu	Asn	Leu	Leu	Asp	Ser	Gln	Leu	His	Ser	Trp	Ile	
				95					100					105	
Val	Leu	Gln	Phe	Thr	Ile	Ile	Lys	Asn	Val	Glu	Ile	Ser	Asn	Phe	
				110					115					120	
Phe	Cys	Asp	Pro	Ser	Gln	Leu	Leu	Asn	Leu	Ala	Cys	Ser	Asp	Ser	
				125					130					135	
Val	Ile	Asn	Ser	Ile	Phe	Ile	Tyr	Phe	Asp	Ser	Thr	Met	Phe	Gly	
				140					145					150	
Phe	Leu	Pro	Ile	Ser	Gly	Ile	Leu	Leu	Ser	Tyr	Tyr	Lys	Ile	Val	
				155					160					165	
Pro	Ser	Ile	Leu	Arg	Met	Ser	Ser	Ser	Asp	Gly	Lys	Tyr	Lys	Ala	
				170					175					180	
Phe	Ser	Thr	Tyr	Gly	Ser	His	Leu	Gly	Val	Val	Cys	Trp	Phe	Tyr	
				185					190					195	
Gly	Thr	Val	Ile	Gly	Met	Tyr	Leu	Ala	Ser	Ala	Val	Ser	Pro	Pro	
				200					205					210	
Pro	Arg	Asn	Gly	Val	Val	Ala	Ser	Val	Met						
				215					220						

<210> 11  
 <211> 302  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7475164CP1

<400> 11  
 Ala Glu Phe Ile Leu Ala Gly Leu Thr Gln Arg Pro Glu Leu Gln

1	5	10	15
Leu Pro Leu Phe	Leu Leu Phe Leu Gly	Ile Tyr Val Val Thr	Val
20	25	30	
Val Gly Asn Leu	Gly Met Ile Phe Leu	Ile Ala Leu Ser Ser	Gln
35	40	45	
Leu Tyr Pro Pro	Val Tyr Tyr Phe Leu	Ser His Leu Ser Phe	Ile
50	55	60	
Asp Leu Cys Tyr	Ser Ser Val Ile Thr	Pro Lys Met Leu Val	Asn
65	70	75	
Phe Val Pro Glu	Glu Asn Ile Ile Ser	Phe Leu Glu Cys Ile	Thr
80	85	90	
Gln Leu Tyr Phe	Phe Leu Ile Phe Val	Ile Ala Glu Gly Tyr	Leu
95	100	105	
Leu Thr Ala Met	Glu Tyr Asp Arg Tyr	Val Ala Ile Cys Arg	Pro
110	115	120	
Leu Leu Tyr Asn	Ile Val Met Ser His	Arg Val Cys Ser Ile	Met
125	130	135	
Met Ala Val Val	Tyr Ser Leu Gly Phe	Leu Trp Ala Thr Val	His
140	145	150	
Thr Thr Arg Met	Ser Val Leu Ser Phe	Cys Arg Ser His Thr	Val
155	160	165	
Ser His Tyr Phe	Cys Asp Ile Leu Pro	Leu Leu Thr Leu Ser	Cys
170	175	180	
Ser Ser Thr His	Ile Asn Glu Ile Leu	Leu Phe Ile Ile Gly	Gly
185	190	195	
Val Asn Thr Leu	Ala Thr Thr Leu Ala	Val Leu Ile Ser Tyr	Ala
200	205	210	
Phe Ile Phe Ser	Ser Ile Leu Gly Ile	His Ser Thr Glu Gly	Gln
215	220	225	
Ser Lys Ala Phe	Gly Thr Cys Ser Ser	His Leu Leu Ala Val	Gly
230	235	240	
Ile Phe Phe Gly	Ser Ile Thr Phe Met	Tyr Phe Lys Pro Pro	Ser
245	250	255	
Ser Thr Thr Met	Glu Lys Glu Lys Val	Ser Ser Val Phe Tyr	Ile
260	265	270	
Thr Ile Ile Pro	Met Leu Asn Pro Leu	Ile Tyr Ser Leu Arg	Asn
275	280	285	
Lys Asp Val Lys	Asn Ala Leu Lys Lys	Met Thr Arg Gly Arg	Gln
290	295	300	
Ser Ser			

<210> 12  
 <211> 110  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7473909CP1

<400> 12
Gly Pro Arg Thr Ala Ser Gly Cys Val Ile Met Ile Cys Phe Ala
1 5 10 15
Leu Thr Val Leu Ser Tyr Ile Arg Ile Leu Ala Thr Val Val Gln
20 25 30
Ile Arg Ser Ala Ala Ser Arg Arg Lys Ala Phe Ser Thr Cys Ser
35 40 45
Ser His Leu Gly Met Val Leu Leu Phe Tyr Gly Thr Gly Ser Ser
50 55 60
Thr Tyr Met Arg Pro Thr Thr Arg Tyr Ser Pro Leu Glu Gly Arg
65 70 75
Leu Ala Ala Val Phe Tyr Ser Ile Leu Ile Pro Thr Leu Asn Pro
80 85 90
Leu Ile Tyr Ser Leu Arg Asn Gln Asp Met Lys Arg Ala Leu Trp
95 100 105
Lys Leu Tyr Leu Gln

110

<210> 13  
 <211> 178  
 <212> PRT  
 <213> Homo sapiens.

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7475252CP1

<400> 13  
 Glu Pro Glu Asn Leu Thr Gly Val Leu Glu Phe Leu Leu Leu Gly  
 1 5 10 15  
 Leu Pro Asp Asp Pro Glu Leu Gln Pro Val Leu Phe Gly Leu Phe  
 20 25 30  
 Leu Ser Met Tyr Leu Val Met Val Leu Gly Asn Leu Leu Ile Ile  
 35 40 45  
 Leu Ala Val Ser Ser Asp Ser His Leu His Ser Pro Met Tyr Phe  
 50 55 60  
 Phe Leu Ser Asn Leu Ser Leu Ala Asp Ile Gly Phe Ala Ser Thr  
 65 70 75  
 Thr Val Pro Lys Met Ile Val Asp Ile Gln Ala His Ser Arg Leu  
 80 85 90  
 Ile Ser Tyr Val Gly Cys Leu Thr Gln Met Ser Phe Leu Ile Phe  
 95 100 105  
 Phe Ala Cys Met Glu Ser Leu Leu Leu Ile Val Met Ala Tyr Asp  
 110 115 120  
 Arg Phe Val Ala Ile Cys His Pro Leu His Tyr Gln Val Ile Met  
 125 130 135  
 Ser Pro Arg Leu Cys Gly Phe Leu Val Leu Val Ser Phe Phe Leu  
 140 145 150  
 Ser Leu Leu Asp Ser Gln Leu His Asn Leu Ile Val Leu Gln Leu  
 155 160 165  
 Thr Cys Phe Asn Asp Val Glu Ile Ser Asn Phe Phe Leu  
 170 175

<210> 14  
 <211> 92  
 <212> PRT  
 <213> Homo sapiens.

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7927572CP1

<400> 14  
 Leu Leu Asp Ala Gln Leu Tyr Asn Leu Ile Ala Leu Gln Met Thr  
 1 5 10 15  
 Cys Phe Lys Asp Val Glu Ile Pro Asn Phe Phe Cys Asp Pro Ser  
 20 25 30  
 Gln Leu Pro His Leu Ala Cys Cys Asp Thr Phe Asn Asn Asn Ile  
 35 40 45  
 Ile Leu Tyr Phe Pro Asp Ala Ile Phe Gly Phe Leu Pro Ile Ser  
 50 55 60  
 Gly Thr Leu Phe Ser Tyr Asp Lys Ile Val Ser Ser Ile Leu Arg  
 65 70 75  
 Val Ser Ser Ser Gly Gly Lys Tyr Lys Ala Phe Ser Thr Tyr Gly  
 80 85 90  
 Ser His

<210> 15  
 <211> 97  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7481257CP1

<400> 15

Met	Glu	Val	Thr	Thr	Phe	Ala	Met	Cys	Leu	Ile	Ile	Val	Leu	Val	
1				5					10					15	
Pro	Leu	Leu	Leu	Ile	Leu	Val	Ser	Tyr	Gly	Phe	Ile	Ala	Val	Ala	
				20					25					30	
Val	Leu	Lys	Ile	Lys	Ser	Ala	Ala	Gly	Arg	Gln	Lys	Ala	Phe	Gly	
				35					40					45	
Thr	Cys	Ser	Ser	His	Leu	Val	Val	Val	Ser	Ile	Phe	Cys	Gly	Thr	
				50					55					60	
Val	Thr	Tyr	Met	Tyr	Ile	Gln	Pro	Gly	Asn	Ser	Pro	Asn	Gln	Asn	
				65					70					75	
Glu	Gly	Lys	Leu	Leu	Ser	Ile	Phe	Tyr	Ser	Ile	Val	Thr	Pro	Ser	
				80					85					90	
Leu	Asn	Pro	Leu	Ile	Tyr	Thr									
				95											

<210> 16  
 <211> 133  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7485790CP1

<400> 16

Asp	Pro	Glu	Leu	Gln	Pro	Ile	Leu	Ala	Gly	Leu	Ser	Leu	Ser	Met	
1				5					10					15	
Tyr	Leu	Val	Thr	Val	Leu	Arg	Asn	Leu	Leu	Ile	Ser	Leu	Ala	Val	
				20					25					30	
Ser	Ser	Asp	Ser	His	Leu	His	Thr	Pro	Met	Cys	Phe	Phe	Leu	Ser	
				35					40					45	
Asn	Leu	Cys	Trp	Ala	Asp	Ile	Gly	Phe	Thr	Ser	Ala	Thr	Val	Pro	
				50					55					60	
Lys	Met	Ile	Val	Asp	Met	Arg	Ser	His	Ser	Gly	Val	Ile	Ser	Tyr	
				65					70					75	
Ala	Asp	Cys	Leu	Thr	Arg	Met	Ser	Phe	Leu	Val	Leu	Phe	Ala	Cys	
				80					85					90	
Val	Glu	Asp	Met	Leu	Leu	Thr	Val	Met	Ala	Tyr	Asp	Cys	Phe	Val	
				95					100					105	
Ala	Ile	Cys	Arg	Pro	Leu	His	Tyr	Pro	Val	Ile	Val	Asn	Pro	His	
				110					115					120	
Leu	Cys	Val	Phe	Leu	Val	Ser	Val	Ser	Phe	Ser	Leu	Ala			
				125					130						

<210> 17  
 <211> 213  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7482993CP1

<400> 17

Gly	Ser	Glu	Cys	Leu	Leu	Leu	Ala	Ala	Met	Ala	Tyr	Asp	Arg	Tyr	
1				5					10					15	
Ile	Ala	Ile	Cys	Asn	Pro	Leu	Arg	Tyr	Ser	Val	Ile	Leu	Ser	Lys	
				20					25					30	
Val	Leu	Cys	Asn	Gln	Leu	Ala	Ala	Ser	Cys	Trp	Ala	Ala	Gly	Phe	
				35					40					45	
Leu	Asn	Ser	Val	Val	His	Thr	Val	Leu	Thr	Phe	Cys	Leu	Pro	Phe	
				50					55					60	



Cys	Gly	Asn	Asn	Gln	Ile	Asn	Tyr	Phe	Phe	Cys	Asp	Ile	Pro	Pro	
				65					70					75	
Leu	Leu	Ile	Leu	Ser	Cys	Gly	Asn	Thr	Ser	Val	Asn	Glu	Leu	Ala	
				80					85					90	
Leu	Leu	Ser	Thr	Gly	Val	Phe	Ile	Gly	Trp	Thr	Pro	Phe	Leu	Cys	
				95					100					105	
Ile	Val	Leu	Ser	Tyr	Ile	Cys	Ile	Ile	Ser	Thr	Ile	Leu	Arg	Ile	
				110					115					120	
Gln	Ser	Ser	Glu	Gly	Arg	Arg	Lys	Ala	Phe	Ser	Thr	Cys	Ala	Ser	
				125					130					135	
His	Leu	Ala	Ile	Val	Phe	Leu	Phe	Tyr	Gly	Ser	Ala	Ile	Phe	Thr	
				140					145					150	
Tyr	Val	Arg	Pro	Ile	Ser	Thr	Tyr	Ser	Leu	Lys	Lys	Asp	Arg	Leu	
				155					160					165	
Val	Ser	Val	Leu	Tyr	Ser	Val	Val	Thr	Pro	Met	Leu	Asn	Pro	Ile	
				170					175					180	
Ile	Tyr	Thr	Leu	Arg	Asn	Lys	Asp	Ile	Lys	Glu	Ala	Val	Lys	Thr	
				185					190					195	
Ile	Gly	Ser	Lys	Trp	Gln	Pro	Pro	Ile	Ser	Ser	Leu	Asp	Ser	Lys	
				200					205					210	
Leu	Thr	Tyr													

<210> 18  
 <211> 180  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2829053CD1

Met	Ser	Glu	Ala	Ala	Thr	Arg	Trp	Ser	Cys	Gln	Gly	Ser	Cys	Gln	
1				5					10					15	
Lys	Thr	Cys	Phe	Ser	Arg	Val	Arg	Pro	Trp	Arg	Arg	Arg	Cys	Ser	
				20					25					30	
Cys	Gly	Asp	Ser	Ser	Ser	Arg	Arg	Arg	Arg	Ser	Cys	Cys	Thr	Gly	
				35					40					45	
Ser	Leu	Gly	Pro	Met	Pro	Arg	Leu	Pro	Ser	Leu	Trp	Pro	Leu	Ser	
				50					55					60	
Leu	Pro	Leu	Arg	Ser	Leu	Ser	Ser	Pro	His	Arg	Val	Gln	Gly	Leu	
				65					70					75	
Gly	Pro	Pro	Arg	Arg	Leu	Lys	Ser	Gln	Leu	Leu	Pro	Arg	Phe	Phe	
				80					85					90	
Trp	Arg	Arg	Gln	Gln	Glu	Pro	Leu	Ser	Ser	Phe	Pro	Gly	Arg	Asn	
				95					100					105	
Glu	Gly	Gly	Ser	Glu	Met	Glu	Ile	Leu	Gly	Val	Cys	Pro	Val	Ser	
				110					115					120	
Pro	Gly	Ala	Leu	Ser	Tyr	Met	Glu	Ser	Pro	Thr	Gly	Phe	Trp	Arg	
				125					130					135	
Pro	Arg	Glu	Ala	Ser	Ser	Leu	Glu	Leu	Ala	Lys	Gly	Ile	Ser	Lys	
				140					145					150	
Arg	Arg	His	Phe	Leu	Pro	Ala	Pro	Ala	Leu	Cys	Pro	Asn	Pro	Arg	
				155					160					165	
Ser	Ser	Glu	Ala	Phe	Pro	Gly	Ala	Val	Cys	Val	Thr	Leu	Ala	Ile	
				170					175					180	

<210> 19  
 <211> 353  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 3068234CD1

&lt;400&gt; 19

```

Met Asn Glu Cys His Tyr Asp Lys His Met Asp Phe Phe Tyr Asn
 1          5          10          15
Arg Ser Asn Thr Asp Thr Val Asp Asp Trp Thr Gly Thr Lys Leu
 20          25          30
Val Ile Val Leu Cys Val Gly Thr Phe Phe Cys Leu Phe Ile Phe
 35          40          45
Phe Ser Asn Ser Leu Val Ile Ala Ala Val Ile Lys Asn Arg Lys
 50          55          60
Phe His Phe Pro Phe Tyr Tyr Leu Leu Ala Asn Leu Ala Ala Ala
 65          70          75
Asp Phe Phe Ala Gly Ile Ala Tyr Val Phe Leu Met Phe Asn Thr
 80          85          90
Gly Pro Val Ser Lys Thr Leu Thr Val Asn Arg Trp Phe Leu Arg
 95          100          105
Gln Gly Leu Leu Asp Ser Ser Leu Thr Ala Ser Leu Thr Asn Leu
 110          115          120
Leu Val Ile Ala Val Glu Arg His Met Ser Ile Met Arg Met Arg
 125          130          135
Val His Ser Asn Leu Thr Lys Lys Arg Val Thr Leu Leu Ile Leu
 140          145          150
Leu Val Trp Ala Ile Ala Ile Phe Met Gly Ala Val Pro Thr Leu
 155          160          165
Gly Trp Asn Cys Leu Cys Asn Ile Ser Ala Cys Ser Ser Leu Ala
 170          175          180
Pro Ile Tyr Ser Arg Ser Tyr Leu Val Phe Trp Thr Val Ser Asn
 185          190          195
Leu Met Ala Phe Leu Ile Met Val Val Val Tyr Leu Arg Ile Tyr
 200          205          210
Val Tyr Val Lys Arg Lys Thr Asn Val Leu Ser Pro His Thr Ser
 215          220          225
Gly Ser Ile Ser Arg Arg Arg Thr Pro Met Lys Leu Met Lys Thr
 230          235          240
Val Met Thr Val Leu Gly Ala Phe Val Val Cys Trp Thr Pro Gly
 245          250          255
Leu Val Val Leu Leu Leu Asp Gly Leu Asn Cys Arg Gln Cys Gly
 260          265          270
Val Gln His Val Lys Arg Trp Phe Leu Leu Leu Ala Leu Leu Asn
 275          280          285
Ser Val Val Asn Pro Ile Ile Tyr Ser Tyr Lys Asp Glu Asp Met
 290          295          300
Tyr Gly Thr Met Lys Lys Met Ile Cys Cys Phe Ser Gln Glu Asn
 305          310          315
Pro Glu Arg Arg Pro Ser Arg Ile Pro Ser Thr Val Leu Ser Arg
 320          325          330
Ser Asp Thr Gly Ser Gln Tyr Ile Glu Asp Ser Ile Ser Gln Gly
 335          340          345
Ala Val Cys Asn Lys Ser Thr Ser
 350

```

&lt;210&gt; 20

&lt;211&gt; 361

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 5029478CD1

&lt;400&gt; 20

```

Met Ser Pro Glu Cys Ala Arg Ala Ala Gly Asp Ala Pro Leu Arg
 1          5          10          15
Ser Leu Glu Gln Ala Asn Arg Thr Arg Phe Pro Phe Phe Ser Asp
 20          25          30
Val Lys Gly Asp His Arg Leu Val Leu Ala Ala Val Glu Thr Thr
 35          40          45
Val Leu Val Leu Ile Phe Ala Val Ser Leu Leu Gly Asn Val Cys

```

Ala	Leu	Val	Leu	Val	Ala	Arg	Arg	Arg	Arg	Arg	Gly	Ala	Thr	Ala	60
				65						70					75
Cys	Leu	Val	Leu	Asn	Leu	Phe	Cys	Ala	Asp	Leu	Leu	Phe	Ile	Ser	90
				80						85					95
Ala	Ile	Pro	Leu	Val	Leu	Ala	Val	Arg	Trp	Thr	Glu	Ala	Trp	Leu	105
				95						100					105
Leu	Gly	Pro	Val	Ala	Cys	His	Leu	Leu	Phe	Tyr	Val	Met	Thr	Leu	120
				110						115					120
Ser	Gly	Ser	Val	Thr	Ile	Leu	Thr	Leu	Ala	Ala	Val	Ser	Leu	Glu	135
				125						130					135
Arg	Met	Val	Cys	Ile	Val	His	Leu	Gln	Arg	Gly	Val	Arg	Gly	Pro	150
				140						145					150
Gly	Arg	Arg	Ala	Arg	Ala	Val	Leu	Leu	Ala	Leu	Ile	Trp	Gly	Tyr	165
				155						160					165
Ser	Ala	Val	Ala	Ala	Leu	Pro	Leu	Cys	Val	Phe	Phe	Arg	Val	Val	180
				170						175					180
Pro	Gln	Arg	Leu	Pro	Gly	Ala	Asp	Gln	Glu	Ile	Ser	Ile	Cys	Thr	195
				185						190					195
Leu	Ile	Trp	Pro	Thr	Ile	Pro	Gly	Glu	Ile	Ser	Trp	Asp	Val	Ser	210
				200						205					210
Phe	Val	Thr	Leu	Asn	Phe	Leu	Val	Pro	Gly	Leu	Val	Ile	Val	Ile	225
				215						220					225
Ser	Tyr	Ser	Lys	Ile	Leu	Gln	Ile	Thr	Lys	Ala	Ser	Arg	Lys	Arg	240
				230						235					240
Leu	Thr	Val	Ser	Leu	Ala	Tyr	Ser	Glu	Ser	His	Gln	Ile	Arg	Val	255
				245						250					255
Ser	Gln	Gln	Asp	Phe	Arg	Leu	Phe	Arg	Thr	Leu	Phe	Leu	Leu	Met	270
				260						265					270
Val	Ser	Phe	Phe	Ile	Met	Trp	Ser	Pro	Ile	Ile	Ile	Thr	Ile	Leu	285
				275						280					285
Leu	Ile	Leu	Ile	Gln	Asn	Phe	Lys	Gln	Asp	Leu	Val	Ile	Trp	Pro	300
				290						295					300
Ser	Leu	Phe	Phe	Trp	Val	Val	Ala	Phe	Thr	Phe	Ala	Asn	Ser	Ala	315
				305						310					315
Leu	Asn	Pro	Ile	Leu	Tyr	Asn	Met	Thr	Leu	Cys	Arg	Asn	Glu	Trp	330
				320						325					330
Lys	Lys	Ile	Phe	Cys	Cys	Phe	Trp	Phe	Pro	Glu	Lys	Gly	Ala	Ile	345
				335						340					345
Leu	Thr	Asp	Thr	Ser	Val	Lys	Arg	Asn	Asp	Leu	Ser	Ile	Ile	Ser	360
				350						355					360

Gly

<210> 21  
 <211> 251  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 5102576CD1

<400> 21  
 Met Tyr Leu Val Thr Val Leu Arg Asn Leu Phe Ser Ile Leu Ala  
 1 5 10 15  
 Val Ser Ser Asp Cys Pro Leu His Thr Pro Met Tyr Phe Phe Leu  
 20 25 30  
 Ser Asn Leu Cys Trp Pro Asp Ile Gly Phe Thr Ser Ala Met Val  
 35 40 45  
 Pro Lys Met Ile Val Asp Thr Gln Ser His Ser Arg Val Ile Ser  
 50 55 60  
 His Ala Gly Cys Leu Thr Gln Met Ser Phe Leu Leu Leu Val Ala  
 65 70 75  
 Cys Ile Glu Gly Met Leu Leu Thr Val Met Ala Tyr Asp Cys Phe  
 80 85 90  
 Val Ala Ile Cys Arg Pro Leu His Tyr Pro Val Ile Val Asn Pro

	95		100		105
His Leu Cys Val	Phe Phe Val Leu Val	Ser Phe Phe Leu Ser	Leu		
	110		115		120
Leu Asp Ser Gln	Leu His Ser Trp Ile	Val Leu Gln Leu Thr	Ile		
	125		130		135
Ile Lys Asn Val	Glu Ile Ser Asn Leu	Val Cys Asp Pro Ser	Gln		
	140		145		150
Leu Leu Asn Leu	Ala Cys Ser Asp Ser	Val Ile Asn Asn Ile	Phe		
	155		160		165
Ile Tyr Phe Asp	Ser Thr Met Phe Gly	Phe Leu Pro Ile Ser	Gly		
	170		175		180
Ile Phe Leu Ser	Tyr Tyr Lys Ile Val	Pro Ser Ile Leu Arg	Ile		
	185		190		195
Ser Ser Ser Asp	Gly Lys Tyr Lys Ala	Phe Ser Thr Cys Gly	Cys		
	200		205		210
His Leu Ala Val	Val Cys Trp Phe Tyr	Gly Thr Gly Ile Gly	Met		
	215		220		225
Tyr Leu Thr Ser	Ala Val Ser Pro Pro	Pro Arg Asn Gly Val	Val		
	230		235		240
Ala Ser Val Met	Tyr Ala Val Val Thr	Pro Cys			
	245		250		

&lt;210&gt; 22

&lt;211&gt; 315

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2200534CD1

&lt;400&gt; 22

Met Lys Ala Asn Tyr	Ser Ala Glu Glu Arg	Phe Leu Leu Leu Gly
1	5	10
Phe Ser Asp Trp Pro	Ser Leu Gln Pro Val	Leu Phe Ala Leu Val
	20	25
Leu Leu Cys Tyr Leu	Leu Thr Leu Thr Gly	Asn Ser Ala Leu Val
	35	40
Leu Leu Ala Val Arg	Asp Pro Arg Leu His	Thr Pro Met Tyr Tyr
	50	55
Phe Leu Cys His Leu	Ala Leu Val Asp Ala	Gly Phe Thr Thr Ser
	65	70
Val Val Pro Pro Leu	Leu Ala Asn Leu Arg	Gly Pro Ala Leu Trp
	80	85
Leu Pro Arg Ser His	Cys Thr Ala Gln Leu	Cys Ala Ser Leu Ala
	95	100
Leu Gly Ser Ala Glu	Cys Val Leu Leu Ala	Val Met Ala Leu Asp
	110	115
Arg Ala Ala Ala Val	Cys Arg Pro Leu Arg	Tyr Ala Gly Leu Val
	125	130
Ser Pro Arg Leu Cys	Arg Thr Leu Ala Ser	Ala Ser Trp Leu Ser
	140	145
Gly Leu Thr Asn Ser	Val Ala Gln Thr Ala	Leu Leu Ala Glu Arg
	155	160
Pro Leu Cys Ala Pro	Arg Leu Leu Asp His	Phe Ile Cys Glu Leu
	170	175
Pro Ala Leu Leu Lys	Leu Ala Cys Gly Gly	Asp Gly Asp Thr Thr
	185	190
Glu Asn Gln Met Phe	Ala Ala Arg Val Val	Ile Leu Leu Leu Pro
	200	205
Phe Ala Val Ile Leu	Ala Ser Tyr Gly Ala	Val Ala Arg Ala Val
	215	220
Cys Cys Met Arg Phe	Ser Gly Gly Arg Arg	Arg Ala Val Gly Thr
	230	235
Cys Gly Ser His Leu	Thr Ala Val Cys Leu	Phe Tyr Gly Ser Ala
	245	250
Ile Tyr Thr Tyr Leu	Gln Pro Ala Gln Arg	Tyr Asn Gln Ala Arg

Gly Lys Phe Val	260	Leu Phe Tyr Thr	265	Val Val Thr Pro Ala Leu	270
	275		280		285
Asn Pro Leu Ile	290	Tyr Thr Leu Arg Asn	295	Lys Lys Val Lys Gly Ala	300
Ala Arg Arg Leu	305	Leu Arg Ser Leu Gly	310	Arg Gly Gln Ala Gly Gln	315

<210> 23  
 <211> 470  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 3275821CD1

<400> 23

Met Asp Thr Thr Met	1	Glu Ala Asp Leu Gly	10	Ala Thr Gly His Arg	15
Pro Arg Thr Glu Leu	20	Asp Asp Glu Asp Ser	25	Tyr Pro Gln Gly Gly	30
Trp Asp Thr Val Phe	35	Leu Val Ala Leu Leu	40	Leu Leu Gly Leu Pro	45
Ala Asn Gly Leu Met	50	Ala Trp Leu Ala Gly	55	Ser Gln Ala Arg His	60
Gly Ala Gly Thr Arg	65	Leu Ala Leu Leu Leu	70	Leu Ser Leu Ala Leu	75
Ser Asp Phe Leu Phe	80	Leu Ala Ala Ala Ala	85	Phe Gln Ile Leu Glu	90
Ile Arg His Gly Gly	95	His Trp Pro Leu Gly	100	Thr Ala Ala Cys Arg	105
Phe Tyr Tyr Phe Leu	110	Trp Gly Val Ser Tyr	115	Ser Ser Gly Leu Phe	120
Leu Leu Ala Ala Leu	125	Ser Leu Asp Arg Cys	130	Leu Leu Ala Leu Cys	135
Pro His Trp Tyr Pro	140	Gly His Arg Pro Val	145	Arg Leu Pro Leu Trp	150
Val Cys Ala Gly Val	155	Trp Val Leu Ala Thr	160	Leu Phe Ser Val Pro	165
Trp Leu Val Phe Pro	170	Glu Ala Ala Val Trp	175	Trp Tyr Asp Leu Val	180
Ile Cys Leu Asp Phe	185	Trp Asp Ser Glu Glu	190	Leu Ser Leu Arg Met	195
Leu Glu Val Leu Gly	200	Gly Phe Leu Pro Phe	205	Leu Leu Leu Leu Val	210
Cys His Val Leu Thr	215	Gln Ala Thr Ala Cys	220	Arg Thr Cys His Arg	225
Gln Gln Gln Pro Ala	230	Ala Cys Arg Gly Phe	235	Ala Arg Val Ala Arg	240
Thr Ile Leu Ser Ala	245	Tyr Val Val Leu Arg	250	Leu Pro Tyr Gln Leu	255
Ala Gln Leu Leu Tyr	260	Leu Ala Phe Leu Trp	265	Asp Val Tyr Ser Gly	270
Tyr Leu Leu Trp Glu	275	Ala Leu Val Tyr Ser	280	Asp Tyr Leu Ile Leu	285
Leu Asn Ser Cys Leu	290	Ser Pro Phe Leu Cys	295	Leu Met Ala Ser Ala	300
Asp Leu Arg Thr Leu	305	Leu Arg Ser Val Leu	310	Ser Ser Phe Ala Ala	315
Ala Leu Cys Glu Glu	320	Arg Pro Gly Ser Phe	325	Thr Pro Thr Glu Pro	330
Gln Thr Gln Leu Asp	335	Ser Glu Gly Pro Thr	340	Leu Pro Glu Pro Met	345
Ala Glu Ala Gln Ser	350	Gln Met Asp Pro Val	355	Ala Gln Pro Gln Val	360

Asn	Pro	Thr	Leu	Gln	Pro	Arg	Ser	Asp	Pro	Thr	Ala	Gln	Pro	Gln	
				365					370					375	
Leu	Asn	Pro	Thr	Ala	Gln	Pro	Gln	Ser	Asp	Pro	Thr	Ala	Gln	Pro	
				380					385					390	
Gln	Leu	Asn	Leu	Met	Ala	Gln	Pro	Gln	Ser	Asp	Ser	Val	Ala	Gln	
				395					400					405	
Pro	Gln	Ala	Asp	Thr	Asn	Val	Gln	Thr	Pro	Ala	Pro	Ala	Ala	Ser	
				410					415					420	
Ser	Val	Pro	Ser	Pro	Cys	Asp	Glu	Ala	Ser	Pro	Thr	Pro	Ser	Ser	
				425					430					435	
His	Pro	Thr	Pro	Gly	Ala	Leu	Glu	Asp	Pro	Ala	Thr	Pro	Pro	Ala	
				440					445					450	
Ser	Glu	Gly	Glu	Ser	Pro	Ser	Ser	Thr	Pro	Pro	Glu	Ala	Ala	Pro	
				455					460					465	
Gly	Ala	Gly	Pro	Thr											
				470											

&lt;210&gt; 24

&lt;211&gt; 358

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 3744167CD1

&lt;400&gt; 24

Met	Ser	Val	Cys	Tyr	Arg	Pro	Pro	Gly	Asn	Glu	Thr	Leu	Leu	Ser	
1				5					10					15	
Trp	Lys	Thr	Ser	Arg	Ala	Thr	Gly	Thr	Ala	Phe	Leu	Leu	Leu	Ala	
				20					25					30	
Ala	Leu	Leu	Gly	Leu	Pro	Gly	Asn	Gly	Phe	Val	Val	Trp	Ser	Leu	
				35					40					45	
Ala	Gly	Trp	Arg	Pro	Ala	Arg	Gly	Arg	Pro	Leu	Ala	Ala	Thr	Leu	
				50					55					60	
Val	Leu	His	Leu	Ala	Leu	Ala	Asp	Gly	Ala	Val	Leu	Leu	Leu	Thr	
				65					70					75	
Pro	Leu	Phe	Val	Ala	Phe	Leu	Thr	Arg	Gln	Ala	Trp	Pro	Leu	Gly	
				80					85					90	
Gln	Ala	Gly	Cys	Lys	Ala	Val	Tyr	Tyr	Val	Cys	Ala	Leu	Ser	Met	
				95					100					105	
Tyr	Ala	Ser	Val	Leu	Leu	Thr	Gly	Leu	Leu	Ser	Leu	Gln	Arg	Cys	
				110					115					120	
Leu	Ala	Val	Thr	Arg	Pro	Phe	Leu	Ala	Pro	Arg	Leu	Arg	Ser	Pro	
				125					130					135	
Ala	Leu	Ala	Arg	Arg	Leu	Leu	Leu	Ala	Val	Trp	Leu	Ala	Ala	Leu	
				140					145					150	
Leu	Leu	Ala	Val	Pro	Ala	Ala	Val	Tyr	Arg	His	Leu	Trp	Arg	Asp	
				155					160					165	
Arg	Val	Cys	Gln	Leu	Cys	His	Pro	Ser	Pro	Val	His	Ala	Ala	Ala	
				170					175					180	
His	Leu	Ser	Leu	Glu	Thr	Leu	Thr	Ala	Phe	Val	Leu	Pro	Phe	Gly	
				185					190					195	
Leu	Met	Leu	Gly	Cys	Tyr	Ser	Val	Thr	Leu	Ala	Arg	Leu	Arg	Gly	
				200					205					210	
Ala	Arg	Trp	Gly	Ser	Gly	Arg	His	Gly	Ala	Arg	Val	Gly	Arg	Leu	
				215					220					225	
Val	Ser	Ala	Ile	Val	Leu	Ala	Phe	Gly	Leu	Leu	Trp	Ala	Pro	Tyr	
				230					235					240	
His	Ala	Val	Asn	Leu	Leu	Gln	Ala	Val	Ala	Ala	Leu	Ala	Pro	Pro	
				245					250					255	
Glu	Gly	Ala	Leu	Ala	Lys	Leu	Gly	Gly	Ala	Gly	Gln	Ala	Ala	Arg	
				260					265					270	
Ala	Gly	Thr	Thr	Ala	Leu	Ala	Phe	Phe	Ser	Ser	Ser	Val	Asn	Pro	
				275					280					285	
Val	Leu	Tyr	Val	Phe	Thr	Ala	Gly	Asp	Leu	Leu	Pro	Arg	Ala	Gly	
				290					295					300	

WO 01/42283

PCT/US00/33382

Pro	Arg	Phe	Leu	Thr	Arg	Leu	Phe	Glu	Gly	Ser	Gly	Glu	Ala	Arg	
				305					310					315	
Gly	Gly	Gly	Arg	Ser	Arg	Glu	Gly	Thr	Met	Glu	Leu	Arg	Thr	Thr	
				320					325					330	
Pro	Gln	Leu	Lys	Val	Val	Gly	Gln	Gly	Arg	Gly	Asn	Gly	Asp	Pro	
				335					340					345	
Gly	Gly	Gly	Met	Glu	Lys	Asp	Gly	Pro	Glu	Trp	Asp	Leu			
				350					355						

<210> 25  
 <211> 314  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7472007CD1

<400>	25														
Met	Trp	Glu	Asn	Trp	Thr	Ile	Val	Ser	Glu	Phe	Val	Leu	Val	Ser	
1				5					10					15	
Phe	Ser	Ala	Leu	Ser	Thr	Glu	Leu	Gln	Ala	Leu	Leu	Phe	Leu	Leu	
				20					25					30	
Phe	Leu	Thr	Ile	Tyr	Leu	Val	Thr	Leu	Met	Gly	Asn	Val	Leu	Ile	
				35					40					45	
Ile	Leu	Val	Thr	Ile	Ala	Asp	Ser	Ala	Leu	Gln	Ser	Pro	Met	Tyr	
				50					55					60	
Phe	Phe	Leu	Arg	Asn	Leu	Ser	Phe	Leu	Glu	Ile	Gly	Phe	Asn	Leu	
				65					70					75	
Val	Ile	Val	Pro	Lys	Met	Leu	Gly	Thr	Leu	Ile	Ile	Gln	Asp	Thr	
				80					85					90	
Thr	Ile	Ser	Phe	Leu	Gly	Cys	Ala	Thr	Gln	Met	Tyr	Phe	Phe	Phe	
				95					100					105	
Phe	Phe	Gly	Ala	Ala	Glu	Cys	Cys	Leu	Leu	Ala	Thr	Met	Ala	Tyr	
				110					115					120	
Asp	Arg	Tyr	Val	Ala	Ile	Cys	Asp	Pro	Leu	His	Tyr	Pro	Val	Ile	
				125					130					135	
Met	Gly	His	Ile	Ser	Cys	Ala	Gln	Leu	Ala	Ala	Ala	Ser	Trp	Phe	
				140					145					150	
Ser	Gly	Phe	Ser	Val	Ala	Thr	Val	Gln	Thr	Thr	Trp	Ile	Phe	Ser	
				155					160					165	
Phe	Pro	Phe	Cys	Gly	Pro	Asn	Arg	Val	Asn	His	Phe	Phe	Cys	Asp	
				170					175					180	
Ser	Pro	Pro	Val	Ile	Ala	Leu	Val	Cys	Ala	Asp	Thr	Ser	Val	Phe	
				185					190					195	
Glu	Leu	Glu	Ala	Leu	Thr	Ala	Thr	Val	Pro	Phe	Ile	Leu	Phe	Pro	
				200					205					210	
Phe	Leu	Leu	Ile	Leu	Gly	Ser	Tyr	Val	Arg	Ile	Leu	Ser	Thr	Ile	
				215					220					225	
Phe	Arg	Met	Pro	Ser	Ala	Glu	Gly	Lys	His	Gln	Ala	Phe	Ser	Thr	
				230					235					240	
Cys	Ser	Ala	His	Leu	Leu	Val	Val	Ser	Leu	Phe	Tyr	Ser	Thr	Ala	
				245					250					255	
Ile	Leu	Thr	Tyr	Phe	Arg	Pro	Gln	Ser	Ser	Ala	Ser	Ser	Glu	Ser	
				260					265					270	
Lys	Lys	Leu	Leu	Ser	Leu	Ser	Ser	Thr	Val	Val	Thr	Pro	Met	Leu	
				275					280					285	
Asn	Pro	Ile	Ile	Tyr	Ser	Ser	Arg	Asn	Lys	Glu	Val	Lys	Ala	Ala	
				290					295					300	
Leu	Lys	Arg	Leu	Ile	His	Arg	Thr	Leu	Gly	Ser	Gln	Lys	Leu		
				305					310						

<210> 26  
 <211> 365  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7472008CD1

<400> 26  
 Met Glu Gly Ser Val Glu Ala Thr Pro Glu Ile Pro Ala Gln Met  
 1 5 10 15  
 Lys Cys His Pro Ser Arg Pro Ser Thr Leu Asn Gln Leu Ser Phe  
 20 25 30  
 Tyr Gly Ala Val Ser Ser Leu Gly Arg Met His Gly Leu Glu Thr  
 35 40 45  
 Lys Ser Ser Ala Glu Ile Arg Ala Gly Leu Lys Arg Cys Asp Thr  
 50 55 60  
 Leu Val Leu Glu Ala Ser Thr Leu Glu Gly Asn Met Val Ile Val  
 65 70 75  
 Leu Val Ser Leu Lys Asp Pro Lys Leu His Ile Pro Met Tyr Phe  
 80 85 90  
 Phe Leu Ser Asn Leu Ser Leu Val Asp Leu Cys Leu Thr Ser Ser  
 95 100 105  
 Cys Val Pro Gln Met Leu Ile Asn Phe Trp Gly Pro Glu Lys Thr  
 110 115 120  
 Ile Ser Tyr Ile Gly Cys Ala Ile Gln Leu Tyr Val Phe Leu Trp  
 125 130 135  
 Leu Gly Ala Thr Glu Tyr Val Leu Leu Val Val Met Ala Val Asp  
 140 145 150  
 Cys Tyr Val Ala Val Cys His Pro Leu Gln Asn Thr Met Ile Met  
 155 160 165  
 His Pro Lys Leu Cys Leu Gln Leu Ala Ile Leu Ala Trp Gly Thr  
 170 175 180  
 Gly Leu Ala Gln Ser Leu Ile Gln Ser Pro Ala Thr Leu Arg Leu  
 185 190 195  
 Pro Phe Cys Ser Gln Arg Met Val Asp Asp Val Val Cys Glu Val  
 200 205 210  
 Pro Ala Leu Ile Gln Leu Ser Ser Thr Asp Thr Thr Tyr Ser Glu  
 215 220 225  
 Ile Gln Met Ser Ile Ala Ser Val Val Leu Leu Val Met Pro Leu  
 230 235 240  
 Ile Ile Ile Leu Ser Ser Ser Gly Ala Ile Ala Lys Ala Val Leu  
 245 250 255  
 Arg Ile Lys Ser Thr Ala Gly Gln Lys Lys Ala Phe Gly Thr Cys  
 260 265 270  
 Ile Ser His Leu Leu Val Val Ser Leu Phe Tyr Gly Thr Val Thr  
 275 280 285  
 Gly Val Tyr Leu Gln Pro Lys Asn His Tyr Pro His Glu Trp Gly  
 290 295 300  
 Lys Phe Leu Thr Leu Phe Tyr Thr Val Val Thr Pro Thr Leu Asn  
 305 310 315  
 Pro Leu Ile Tyr Thr Leu Arg Asn Lys Glu Leu His Pro Trp Leu  
 320 325 330  
 Lys Glu Ala Lys Val Gln Thr Ala Ser Glu Ser Ala Ser Pro Lys  
 335 340 345  
 His Trp Gln Leu Pro His Gly Val Gly Pro Val Gly Val Gln Lys  
 350 355 360  
 Thr Arg Thr Glu Leu  
 365

<210> 27  
 <211> 317  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7472013CD1

<400> 27  
 Met Ser Phe Ala Pro Asn Ala Ser His Ser Pro Val Phe Leu Leu



```

1      5      10      15
Leu Gly Phe Ser Arg Ala Asn Ile Ser Tyr Thr Leu Leu Phe Phe
20      25      30
Leu Phe Leu Ala Ile Tyr Leu Thr Thr Ile Leu Gly Asn Val Thr
35      40      45
Leu Val Leu Leu Ile Ser Trp Asp Ser Arg Leu His Ser Pro Met
50      55      60
Tyr Tyr Leu Leu Arg Gly Leu Ser Val Ile Asp Met Gly Leu Ser
65      70      75
Thr Val Thr Leu Pro Gln Leu Leu Ala His Leu Val Ser His Tyr
80      85      90
Pro Thr Ile Pro Ala Ala Arg Cys Leu Ala Gln Phe Phe Phe Phe
95      100      105
Tyr Ala Phe Gly Val Thr Asp Thr Leu Val Ile Ala Val Met Ala
110      115      120
Leu Asp Arg Tyr Val Ala Ile Cys Asp Pro Leu His Tyr Ala Leu
125      130      135
Val Met Asn His Gln Arg Cys Ala Cys Leu Leu Ala Leu Ser Trp
140      145      150
Val Val Ser Ile Leu His Thr Met Leu Arg Val Gly Leu Val Leu
155      160      165
Pro Leu Cys Trp Thr Gly Asp Ala Gly Gly Asn Val Asn Leu Pro
170      175      180
His Phe Phe Cys Asp His Arg Pro Leu Leu Arg Ala Ser Cys Ser
185      190      195
Asp Ile His Ser Asn Glu Leu Ala Ile Phe Phe Glu Gly Gly Phe
200      205      210
Leu Met Leu Gly Pro Cys Ala Leu Ile Val Leu Ser Tyr Val Arg
215      220      225
Ile Gly Ala Ala Ile Leu Arg Leu Pro Ser Ala Ala Gly Arg Arg
230      235      240
Arg Ala Val Ser Thr Cys Gly Ser His Leu Thr Met Val Gly Phe
245      250      255
Leu Tyr Gly Thr Ile Ile Cys Val Tyr Phe Gln Pro Pro Phe Gln
260      265      270
Asn Ser Gln Tyr Gln Asp Met Val Ala Ser Val Met Tyr Thr Ala
275      280      285
Ile Thr Pro Leu Ala Asn Pro Phe Val Tyr Ser Leu His Asn Lys
290      295      300
Asp Val Lys Gly Ala Leu Cys Arg Leu Leu Glu Trp Val Lys Val
305      310      315
Asp Pro

```

```

<210> 28
<211> 335
<212> PRT
<213> Homo sapiens

```

```

<220>
<221> misc_feature
<223> Incyte ID No: 7472015CD1

```

```

<400> 28
Met Glu Ser Ser Phe Ser Phe Gly Val Ile Leu Ala Val Leu Ala
1      5      10      15
Ser Leu Ile Ile Ala Thr Asn Thr Leu Val Ala Val Ala Val Leu
20      25      30
Leu Leu Ile His Lys Asn Asp Gly Val Ser Leu Cys Phe Thr Leu
35      40      45
Asn Leu Ala Val Ala Asp Thr Leu Ile Gly Val Ala Ile Ser Gly
50      55      60
Leu Leu Thr Asp Gln Leu Ser Ser Pro Ser Arg Pro Thr Gln Lys
65      70      75
Thr Leu Cys Ser Leu Arg Met Ala Phe Val Thr Ser Ser Ala Ala
80      85      90
Ala Ser Val Leu Thr Val Met Leu Ile Thr Phe Asp Arg Tyr Leu

```

Ala	Ile	Lys	Gln	Pro	Phe	Arg	Tyr	Leu	Lys	Ile	Met	Ser	Gly	Phe	105
				110					115						120
Val	Ala	Gly	Ala	Cys	Ile	Ala	Gly	Leu	Trp	Leu	Val	Ser	Tyr	Leu	125
				125					130						135
Ile	Gly	Phe	Leu	Pro	Leu	Gly	Ile	Pro	Met	Phe	Gln	Gln	Thr	Ala	140
				140					145						150
Tyr	Lys	Gly	Gln	Cys	Ser	Phe	Phe	Ala	Val	Phe	His	Pro	His	Phe	155
				155					160						165
Val	Leu	Thr	Leu	Ser	Cys	Val	Gly	Phe	Phe	Pro	Ala	Met	Leu	Leu	170
				170					175						180
Phe	Val	Phe	Phe	Tyr	Cys	Asp	Met	Leu	Lys	Ile	Ala	Ser	Met	His	185
				185					190						195
Ser	Gln	Gln	Ile	Arg	Lys	Met	Glu	His	Ala	Gly	Ala	Met	Ala	Gly	200
				200					205						210
Gly	Tyr	Arg	Ser	Pro	Arg	Thr	Pro	Ser	Asp	Phe	Lys	Ala	Leu	Arg	215
				215					220						225
Thr	Val	Ser	Val	Leu	Ile	Gly	Ser	Phe	Ala	Leu	Ser	Trp	Thr	Pro	230
				230					235						240
Phe	Leu	Ile	Thr	Gly	Ile	Val	Gln	Val	Ala	Cys	Gln	Glu	Cys	His	245
				245					250						255
Leu	Tyr	Leu	Val	Leu	Glu	Arg	Tyr	Leu	Trp	Leu	Leu	Gly	Val	Gly	260
				260					265						270
Asn	Ser	Leu	Leu	Asn	Pro	Leu	Ile	Tyr	Ala	Tyr	Trp	Gln	Lys	Glu	275
				275					280						285
Val	Arg	Leu	Gln	Leu	Tyr	His	Met	Ala	Leu	Gly	Val	Lys	Lys	Val	290
				290					295						300
Leu	Thr	Ser	Phe	Leu	Leu	Phe	Leu	Ser	Ala	Arg	Asn	Cys	Gly	Pro	305
				305					310						315
Glu	Arg	Pro	Arg	Glu	Ser	Ser	Cys	His	Ile	Val	Thr	Ile	Ser	Ser	320
				320					325						330
Ser	Glu	Phe	Asp	Gly											335

&lt;210&gt; 29

&lt;211&gt; 309

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No.: 7472016CD1

&lt;400&gt; 29

Met	Arg	Glu	Asn	Asn	Gln	Ser	Ser	Thr	Leu	Glu	Phe	Ile	Leu	Leu	1
				5					10						15
Gly	Val	Thr	Gly	Gln	Gln	Glu	Gln	Glu	Asp	Phe	Phe	Tyr	Ile	Leu	20
				20					25						30
Phe	Leu	Phe	Ile	Tyr	Pro	Ile	Thr	Leu	Ile	Gly	Asn	Leu	Leu	Ile	35
				35					40						45
Val	Leu	Ala	Ile	Cys	Ser	Asp	Val	Arg	Leu	His	Asn	Pro	Met	Tyr	50
				50					55						60
Phe	Leu	Leu	Ala	Asn	Leu	Ser	Leu	Val	Asp	Ile	Phe	Phe	Ser	Ser	65
				65					70						75
Val	Thr	Ile	Pro	Lys	Met	Leu	Ala	Asn	His	Leu	Leu	Gly	Ser	Lys	80
				80					85						90
Ser	Ile	Ser	Phe	Gly	Gly	Cys	Leu	Thr	Gln	Met	Tyr	Phe	Met	Ile	95
				95					100						105
Ala	Leu	Gly	Asn	Thr	Asp	Ser	Tyr	Ile	Leu	Ala	Ala	Met	Ala	Tyr	110
				110					115						120
Asp	Arg	Ala	Val	Ala	Ile	Ser	His	Pro	Leu	His	Tyr	Thr	Thr	Ile	125
				125					130						135
Met	Ser	Pro	Arg	Ser	Cys	Ile	Trp	Leu	Ile	Ala	Gly	Ser	Trp	Val	140
				140					145						150
Ile	Gly	Asn	Ala	Asn	Ala	Leu	Pro	His	Thr	Leu	Leu	Thr	Ala	Ser	155
				155					160						165
Leu	Ser	Phe	Cys	Gly	Asn	Gln	Glu	Val	Ala	Asn	Phe	Tyr	Cys	Asp	160

Ile Thr Pro Leu	170	Lys Leu Ser Cys	175	Ser Asp Ile His Phe	180
Val Lys Met Met	185	Leu Gly Val Gly	190	Ile Phe Ser Val Pro	195
Leu Cys Ile Ile	200	Val Ser Tyr Ile Arg	205	Phe Ser Thr Val Phe	210
Gln Val Pro Ser	215	Thr Lys Gly Val Leu	220	Lys Ala Phe Ser Thr	225
Gly Ser His Leu	230	Thr Val Val Ser Leu	235	Tyr Gly Thr Val Met	240
Gly Thr Tyr Phe	245	Arg Pro Leu Thr Asn	250	Tyr Ser Leu Lys Asp	255
Val Ile Thr Val	260	Met Tyr Thr Ala Val	265	Thr Pro Met Leu Asn	270
Phe Ile Tyr Ser	275	Leu Arg Asn Arg Asp	280	Lys Ala Ala Leu Arg	285
Lys Leu Phe Asn	290	Lys Arg Ile Ser Ser	295		300
	305				

<210> 30  
 <211> 236  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7472017CD1

Met Gly Met Thr Asn	1	Ser Ser Val Lys	5	Gly Asp Phe Ile Leu	10	Leu	15
Leu Trp Asn Leu Lys	20	Gly Pro Asp Lys	25	Thr Ile Thr Phe Leu	30	Gly	35
Cys Val Ile Gln Leu	35	Tyr Ile Ser Leu	40	Ala Leu Gly Ser Thr	45	Glu	50
Cys Val Leu Leu Ala	50	Val Met Ala Phe	55	Asp Arg Tyr Ala Ala	60	Val	65
Cys Lys Pro Leu His	65	Tyr Thr Ala Val	70	Met Asn Pro Gln Leu	75	Cys	80
Gln Ala Leu Ala Gly	80	Val Ala Trp Leu	85	Ser Gly Val Gly Asn	90	Thr	95
Leu Ile Gln Gly Thr	95	Val Thr Leu Trp	100	Leu Pro Arg Cys Gly	105	His	110
Arg Leu Leu Gln His	110	Phe Phe Leu Ala	115	Cys Val Asp Ile His	120	Asp	125
Asn Glu Val Gln Leu	125	Phe Val Ala Ser	130	Leu Val Leu Leu Leu	135	Leu	140
Pro Leu Val Leu Ile	140	Leu Leu Ser Tyr	145	Gly His Ile Ala Lys	150	Val	155
Val Ile Arg Ile Lys	155	Ser Val Gln Ala	160	Trp Cys Lys Gly Leu	165	Gly	170
Thr Cys Gly Ser His	170	Leu Ile Val Val	175	Ser Leu Phe Cys Gly	180	Thr	185
Ile Thr Ala Val Tyr	185	Ile Gln Ser Asn	190	Ser Ser Tyr Ala His	195	Ala	200
His Gly Lys Phe Ile	200	Ser Leu Phe Tyr	205	Thr Val Val Thr Pro	210	Thr	215
Leu Asn Pro Leu Ile	215	Tyr Thr Leu Arg	220	Asn Asn Asp Val Lys	225	Gly	230
Ala Leu Arg Leu Phe	230	Asn Arg Asp Leu	235	Gly Thr			

<210> 31  
 <211> 363  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7472018CD1

<400> 31  
 Met Gly Pro Gly Glu Ala Leu Leu Ala Gly Leu Leu Val Met Val  
 1 5 10 15  
 Leu Ala Val Ala Leu Leu Ser Asn Ala Leu Val Leu Leu Cys Cys  
 20 25 30  
 Ala Tyr Ser Ala Glu Leu Arg Thr Arg Ala Ser Gly Val Leu Leu  
 35 40 45  
 Val Asn Leu Ser Leu Gly His Leu Leu Leu Ala Ala Leu Asp Met  
 50 55 60  
 Pro Phe Thr Leu Leu Gly Val Met Arg Gly Arg Thr Pro Ser Ala  
 65 70 75  
 Pro Gly Ala Cys Gln Val Ile Gly Phe Leu Asp Thr Phe Leu Ala  
 80 85 90  
 Ser Asn Ala Ala Leu Ser Val Ala Ala Leu Ser Ala Asp Gln Trp  
 95 100 105  
 Leu Ala Val Gly Phe Pro Leu Arg Tyr Ala Gly Arg Leu Arg Pro  
 110 115 120  
 Arg Tyr Ala Gly Leu Leu Leu Gly Cys Ala Trp Gly Gln Ser Leu  
 125 130 135  
 Ala Phe Ser Gly Ala Ala Leu Gly Cys Ser Trp Leu Gly Tyr Ser  
 140 145 150  
 Ser Ala Phe Ala Ser Cys Ser Leu Arg Leu Pro Pro Glu Pro Glu  
 155 160 165  
 Arg Pro Arg Phe Ala Ala Phe Thr Ala Thr Leu His Ala Val Gly  
 170 175 180  
 Phe Val Leu Pro Leu Ala Val Leu Cys Leu Thr Ser Leu Gln Val  
 185 190 195  
 His Arg Val Ala Arg Arg His Cys Gln Arg Met Asp Thr Val Thr  
 200 205 210  
 Met Lys Ala Leu Ala Leu Leu Ala Asp Leu His Pro Ser Val Arg  
 215 220 225  
 Gln Arg Cys Leu Ile Gln Gln Lys Arg Arg Arg His Arg Ala Thr  
 230 235 240  
 Arg Lys Ile Gly Ile Ala Ile Ala Thr Phe Leu Ile Cys Phe Ala  
 245 250 255  
 Pro Tyr Val Met Thr Arg Leu Ala Glu Leu Val Pro Phe Val Thr  
 260 265 270  
 Val Asn Ala Gln Trp Gly Ile Leu Ser Lys Cys Leu Thr Tyr Ser  
 275 280 285  
 Lys Ala Val Ala Asp Pro Phe Thr Tyr Ser Leu Leu Arg Arg Pro  
 290 295 300  
 Phe Arg Gln Val Leu Ala Gly Met Val His Arg Leu Leu Lys Arg  
 305 310 315  
 Thr Pro Arg Pro Ala Ser Thr His Asp Ser Ser Leu Asp Val Ala  
 320 325 330  
 Gly Met Val His Gln Leu Leu Lys Arg Thr Pro Arg Pro Ala Ser  
 335 340 345  
 Thr His Asn Gly Ser Val Asp Thr Glu Asn Asp Ser Cys Leu Gln  
 350 355 360  
 Gln Thr His

<210> 32  
 <211> 308  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7472019CD1

<400> 32  
 Met Ala Met Asp Asn Val Thr Ala Val Phe Gln Phe Leu Leu Ile

1	5	10	15
Gly Ile Ser Asn Tyr	Pro Gln Trp Arg Asp	Thr Phe Phe Thr	Leu
20	25	30	
Val Leu Ile Ile Tyr	Leu Ser Thr Leu Leu	Gly Asn Gly Phe	Met
35	40	45	
Ile Phe Leu Ile His	Phe Asp Pro Asn Leu	His Thr Pro Ile	Tyr
50	55	60	
Phe Phe Leu Ser Asn	Leu Ser Phe Leu Asp	Leu Cys Tyr Gly	Thr
65	70	75	
Ala Ser Met Pro Gln	Ala Leu Val His Cys	Phe Ser Thr His	Pro
80	85	90	
Tyr Leu Ser Tyr Pro	Arg Cys Leu Ala Gln	Thr Ser Val Ser	Leu
95	100	105	
Ala Leu Ala Thr Ala	Glu Cys Leu Leu Leu	Ala Ala Met Ala	Tyr
110	115	120	
Asp Arg Val Val Ala	Ile Ser Asn Pro Leu	Arg Tyr Ser Val	Val
125	130	135	
Met Asn Gly Pro Val	Cys Val Cys Leu Val	Ala Thr Ser Trp	Gly
140	145	150	
Thr Ser Leu Val Leu	Thr Ala Met Leu Ile	Leu Ser Leu Arg	Leu
155	160	165	
His Phe Cys Gly Ala	Asn Val Ile Asn His	Phe Ala Cys Glu	Ile
170	175	180	
Leu Ser Leu Ile Lys	Leu Thr Cys Ser Asp	Thr Ser Leu Asn	Glu
185	190	195	
Phe Met Ile Leu Ile	Thr Ser Ile Phe Thr	Leu Leu Leu Pro	Phe
200	205	210	
Gly Phe Val Leu Leu	Ser Tyr Ile Arg Ile	Ala Met Ala Ile	Ile
215	220	225	
Arg Ile Arg Ser Leu	Gln Gly Arg Leu Lys	Ala Phe Thr Thr	Cys
230	235	240	
Gly Ser His Leu Thr	Val Val Thr Ile Phe	Tyr Gly Ser Ala	Ile
245	250	255	
Ser Met Tyr Met Lys	Thr Gln Ser Lys Ser	Tyr Pro Asp Gln	Asp
260	265	270	
Lys Phe Ile Ser Val	Phe Tyr Gly Ala Leu	Thr Pro Met Leu	Asn
275	280	285	
Pro Leu Ile Tyr Ser	Leu Arg Lys Lys Asp	Val Lys Arg Ala	Ile
290	295	300	
Arg Lys Val Met Leu	Lys Arg Thr		
305			

<210> 33  
 <211> 343  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7472021CD1

<400> 33
Met His Phe Leu Pro Thr Val Phe Gly Phe Leu Asn Arg Val Thr
1 5 10 15
Leu Gly Ile Phe Arg Glu Thr Met Val Asn Leu Thr Ser Met Ser
20 25 30
Gly Phe Leu Leu Met Gly Phe Ser Asp Glu Arg Lys Leu Gln Ile
35 40 45
Leu His Ala Leu Val Phe Leu Val Thr Tyr Leu Leu Ala Leu Thr
50 55 60
Gly Asn Leu Leu Ile Ile Thr Ile Ile Thr Val Asp Arg Arg Leu
65 70 75
His Ser Pro Met Tyr Tyr Phe Leu Lys His Leu Ser Leu Leu Asp
80 85 90
Leu Cys Phe Ile Ser Val Thr Val Pro Gln Ser Ile Ala Asn Ser
95 100 105
Leu Met Gly Asn Gly Tyr Ile Ser Leu Val Gln Cys Ile Leu Gln

Val Phe Phe Phe	110	Ala Leu Ala Ser	115	Ser Glu Val Ala Ile	120
Thr Val Met Ser	125	Tyr Asp Arg Tyr Ala	130	Ala Ile Cys Gln Pro	135
His Tyr Glu Thr	140	Ile Met Asp Pro Arg	145	Ala Cys Arg His Ala	150
Ile Ala Val Trp	155	Ile Ala Gly Gly Leu	160	Ser Gly Leu Met His	165
Ala Ile Asn Phe	170	Ser Ile Pro Leu Cys	175	Gly Lys Arg Val Ile	180
Gln Phe Phe Cys	185	Asp Val Pro Gln Met	190	Leu Lys Leu Ala Cys	195
Tyr Glu Phe Ile	200	Asn Glu Ile Ala Leu	205	Ala Ala Phe Thr Thr	210
Ala Ala Phe Ile	215	Cys Leu Ile Ser Ile	220	Val Leu Ser Tyr Ile	225
Ile Phe Ser Thr	230	Val Leu Arg Ile Pro	235	Ser Ala Glu Gly Arg	240
Lys Val Phe Ser	245	Thr Cys Leu Pro His	250	Leu Phe Val Ala Thr	255
Phe Leu Ser Ala	260	Ala Gly Phe Glu Phe	265	Leu Arg Leu Pro Ser	270
Ser Ser Ser Thr	275	Val Asp Leu Val Phe	280	Ser Val Phe Tyr Thr	285
Ile Pro Pro Thr	290	Leu Asn Pro Val Ile	295	Tyr Ser Leu Arg Asn	300
Ser Met Lys Ala	305	Ala Leu Arg Lys Met	310	Leu Ser Lys Glu Glu	315
Pro Gln Arg Lys	320	Met Cys Leu Lys Ala	325	Met Phe Lys Leu	330
	335		340		

&lt;210&gt; 34

&lt;211&gt; 323

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7472009CD1

&lt;400&gt; 34

Met Trp Gln Lys Asn	Gln Thr Ser Leu Ala	Asp Phe Ile Leu Glu
1 5	10	15
Gly Leu Phe Asp Asp	Ser Leu Thr His Leu	Phe Leu Phe Ser Leu
20	25	30
Thr Met Val Val Phe	Leu Ile Ala Val Ser	Gly Asn Thr Leu Thr
35	40	45
Ile Leu Leu Ile Cys	Ile Asp Pro Gln Leu	His Thr Pro Met Tyr
50	55	60
Phe Leu Leu Ser Gln	Leu Ser Leu Met Asp	Leu Met His Val Ser
65	70	75
Thr Thr Ile Leu Lys	Met Ala Thr Asn Tyr	Leu Ser Gly Lys Lys
80	85	90
Ser Ile Ser Phe Val	Gly Cys Ala Thr Gln	His Phe Leu Tyr Leu
95	100	105
Cys Leu Gly Gly Ala	Glu Cys Phe Leu Leu	Ala Val Met Ser Tyr
110	115	120
Asp Arg Tyr Val Ala	Ile Cys His Pro Leu	Arg Tyr Ala Val Leu
125	130	135
Met Asn Lys Lys Val	Gly Leu Met Met Ala	Val Met Ser Trp Leu
140	145	150
Gly Ala Ser Val Asn	Ser Leu Ile His Met	Ala Ile Leu Met His
155	160	165
Phe Pro Phe Cys Gly	Pro Arg Lys Val Tyr	His Phe Tyr Cys Glu
170	175	180
Phe Pro Ala Val Val	Lys Leu Val Cys Gly	Asp Ile Thr Val Tyr

Glu Thr Thr Val	185	Tyr Ile Ser Ser Ile	190	Leu Leu Leu Leu Pro	195
	200		205		210
Phe Leu Ile Ser	215	Thr Ser Tyr Val Phe	220	Ile Leu Gln Ser Val	225
Gln Met Arg Ser	230	Ser Gly Ser Lys Arg	235	Asn Ala Phe Ala Thr	240
Gly Ser His Leu	245	Thr Val Val Ser Leu	250	Trp Phe Gly Ala Cys	255
Phe Ser Tyr Met	260	Arg Pro Arg Ser Gln	265	Cys Thr Leu Leu Gln	270
Lys Val Gly Ser	275	Val Phe Tyr Ser Ile	280	Ile Thr Pro Thr Leu	285
Ser Leu Ile Tyr	290	Thr Leu Arg Asn Lys	295	Asp Val Ala Lys Ala	300
Arg Arg Val Leu	305	Arg Arg Asp Val Ile	310	Thr Gln Cys Ile Gln	315
Leu Gln Leu Trp	320	Leu Pro Arg Val			

<210> 35  
 <211> 299  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7472010CD1

<400> 35	
Met Glu Leu Glu Gly	5
1	10
Gln Val Ile Gln Thr	20
Gly Asn Leu Gly Leu	35
His Thr Pro Met Tyr	50
Leu Cys Tyr Ser Cys	65
Val Ser Glu Ser Ile	80
Phe Phe Phe Cys Phe	95
Ser Met Ala Tyr Asp	110
Tyr Met Val Thr Met	125
Gly Ser Tyr Val Val	140
Ser Met Leu Arg Leu	155
Tyr Leu Cys Asp Val	170
Thr His Val Ser Glu	185
Thr Met Leu Ser Ser	200
Leu Ser Asn Ile Leu	215
Ala Phe Ser Thr Trp	230
Phe Gly Ser Gly Thr	245
Ser Met Asn His Gly	260
Val Pro Met Leu Asn	

Asp Phe Leu Gly Ser	10
Val Gly Glu Leu Gly	15
Cys Ser Gly Ile Tyr	25
Ile Thr Leu Ile Gly	40
Phe Phe Leu Phe Asn	55
Val Phe Thr Pro Lys	70
Ile Ser Tyr Val Gly	85
Phe Val Asn Ser Glu	100
Arg Tyr Val Ala Ile	115
Ser Pro Arg Val Cys	130
Val Gly Phe Ala Gly	145
Thr Phe Cys Asp Ser	160
Leu Pro Leu Leu Gln	175
Leu Val Phe Phe Ile	190
Ile Ser Ile Val Ile	205
Leu Cys Ile Pro Ser	220
Gly Ser His Ile Ile	235
Phe Thr Tyr Leu Thr	250
Arg Phe Ala Ser Val	265
Pro Ser Ile Tyr Ser	

Val Gly Glu Leu Gly	15
Thr Val Val Val	30
Leu Ser Leu	45
Asp Phe	60
Thr Gln Leu	75
Val Leu Val	90
Leu Leu	105
Leu Leu	120
Met Phe	135
Gly Thr	150
His Ser	165
Thr Ser	180
Ile Ile	195
Ile Ile	210
Lys	225
Phe Gly	240
Val	255
Val	270
Asp	

275 280 285  
 Asp Lys Leu Ala Leu Gly Lys Thr Leu Lys Arg Val Leu Phe  
 290 295

<210> 36  
 <211> 307  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7472011CD1

<400> 36  
 Met Glu Thr Gly Asn Leu Thr Trp Val Ser Asp Phe Val Phe Leu  
 1 5 10 15  
 Gly Leu Ser Gln Thr Arg Glu Leu Gln Arg Phe Leu Phe Leu Met  
 20 25 30  
 Phe Leu Phe Val Tyr Ile Thr Thr Val Met Gly Asn Ile Leu Ile  
 35 40 45  
 Ile Ile Thr Val Thr Ser Asp Ser Gln Leu His Thr Pro Met Tyr  
 50 55 60  
 Phe Leu Leu Arg Asn Leu Ala Val Leu Asp Leu Cys Phe Ser Ser  
 65 70 75  
 Val Thr Ala Pro Lys Met Leu Val Asp Leu Leu Ser Glu Lys Lys  
 80 85 90  
 Thr Ile Ser Tyr Gln Gly Cys Met Gly Gln Ile Phe Phe Phe His  
 95 100 105  
 Phe Leu Gly Gly Ala Met Val Phe Phe Leu Ser Val Met Ala Phe  
 110 115 120  
 Asp Arg Leu Ile Ala Ile Ser Arg Pro Leu Arg Tyr Val Thr Val  
 125 130 135  
 Met Asn Thr Gln Leu Trp Val Gly Leu Val Val Ala Thr Trp Val  
 140 145 150  
 Gly Gly Phe Val His Ser Ile Val Gln Leu Ala Leu Met Leu Pro  
 155 160 165  
 Leu Pro Phe Cys Gly Pro Asn Ile Leu Asp Asn Phe Tyr Cys Asp  
 170 175 180  
 Val Pro Gln Val Leu Arg Leu Ala Cys Thr Asp Thr Ser Leu Leu  
 185 190 195  
 Glu Phe Leu Lys Ile Ser Asn Ser Gly Leu Leu Asp Val Val Trp  
 200 205 210  
 Phe Phe Leu Leu Leu Met Ser Tyr Leu Phe Ile Leu Val Met Leu  
 215 220 225  
 Arg Ser His Pro Gly Glu Ala Arg Arg Lys Ala Ala Ser Thr Cys  
 230 235 240  
 Thr Thr His Ile Ile Val Val Ser Met Ile Phe Val Pro Ser Ile  
 245 250 255  
 Tyr Leu Tyr Ala Arg Pro Phe Thr Pro Phe Pro Met Asp Lys Leu  
 260 265 270  
 Val Ser Ile Gly His Thr Val Met Thr Pro Met Leu Asn Pro Met  
 275 280 285  
 Ile Tyr Thr Leu Arg Asn Gln Asp Met Gln Ala Ala Val Arg Arg  
 290 295 300  
 Leu Gly Arg His Arg Leu Val  
 305

<210> 37  
 <211> 314  
 <212> PRT  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7472012CD1

<400> 37



Met	Asp	Asn	Ser	Asn	Trp	Thr	Ser	Val	Ser	His	Phe	Val	Leu	Leu	1	5	10	15
Gly	Ile	Ser	Thr	His	Pro	Glu	Glu	Gln	Ile	Pro	Leu	Phe	Leu	Val	20	25	30	35
Phe	Ser	Leu	Met	Tyr	Ala	Ile	Asn	Ile	Ser	Gly	Asn	Leu	Ala	Ile	40	45	50	55
Ile	Thr	Leu	Ile	Leu	Ser	Ala	Pro	Arg	Leu	His	Ile	Pro	Met	Tyr	60	65	70	75
Ile	Phe	Leu	Ser	Asn	Leu	Ala	Leu	Thr	Asp	Ile	Cys	Phe	Thr	Ser	80	85	90	95
Thr	Thr	Val	Pro	Lys	Met	Leu	Gln	Ile	Ile	Phe	Ser	Pro	Thr	Lys	100	105	110	115
Val	Ile	Ser	Tyr	Thr	Gly	Cys	Leu	Ala	Gln	Thr	Tyr	Phe	Phe	Ile	120	125	130	135
Cys	Phe	Ala	Val	Met	Glu	Asn	Phe	Ile	Leu	Ala	Val	Met	Ala	Tyr	140	145	150	155
Asp	Arg	Tyr	Ile	Ala	Ile	Cys	His	Pro	Phe	His	Tyr	Thr	Met	Ile	160	165	170	175
Leu	Thr	Arg	Met	Leu	Cys	Val	Lys	Met	Val	Val	Met	Cys	His	Ala	180	185	190	195
Leu	Ser	His	Leu	His	Ala	Met	Leu	His	Thr	Phe	Leu	Ile	Gly	Gln	200	205	210	215
Leu	Ile	Phe	Cys	Ala	Asp	Asn	Arg	Ile	Pro	His	Phe	Phe	Cys	Asp	220	225	230	235
Leu	Tyr	Ala	Leu	Met	Lys	Ile	Ser	Cys	Thr	Ser	Thr	Tyr	Leu	Asn	240	245	250	255
Thr	Leu	Met	Ile	His	Thr	Glu	Gly	Ala	Val	Val	Ile	Ser	Gly	Ala	260	265	270	275
Leu	Ala	Phe	Ile	Thr	Ala	Ser	Tyr	Ala	Cys	Ile	Ile	Leu	Val	Val	280	285	290	295
Leu	Arg	Ile	Pro	Ser	Ala	Lys	Gly	Arg	Trp	Lys	Thr	Phe	Ser	Thr	300	305	310	315
Cys	Gly	Ser	His	Leu	Thr	Val	Val	Ala	Ile	Phe	Tyr	Gly	Thr	Leu	320	325	330	335
Ser	Trp	Val	Tyr	Phe	Arg	Pro	Leu	Ser	Ser	Tyr	Ser	Val	Thr	Lys	340	345	350	355
Gly	Arg	Ile	Ile	Thr	Val	Val	Tyr	Thr	Val	Val	Thr	Pro	Met	Leu	360	365	370	375
Asn	Pro	Phe	Ile	Tyr	Ser	Leu	Arg	Asn	Gly	Asp	Val	Lys	Gly	Gly	380	385	390	395
Phe	Met	Lys	Trp	Met	Ser	Arg	Met	Gln	Thr	Phe	Phe	Phe	Arg		400	405	410	415

&lt;210&gt; 38

&lt;211&gt; 310

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7472014CD1

&lt;400&gt; 38

Met	Gly	Arg	Asn	Asn	Leu	Thr	Arg	Pro	Ser	Glu	Phe	Ile	Leu	Leu	1	5	10	15
Gly	Leu	Ser	Ser	Arg	Pro	Glu	Asp	Gln	Lys	Pro	Leu	Phe	Ala	Val	20	25	30	35
Phe	Leu	Pro	Ile	Tyr	Leu	Ile	Thr	Val	Ile	Gly	Asn	Leu	Leu	Ile	40	45	50	55
Ile	Leu	Ala	Ile	Arg	Ser	Asp	Thr	Arg	Leu	Gln	Thr	Pro	Met	Tyr	60	65	70	75
Phe	Phe	Leu	Ser	Ile	Leu	Ser	Phe	Val	Asp	Ile	Cys	Tyr	Val	Thr	80	85	90	95
Val	Ile	Ile	Pro	Lys	Met	Leu	Val	Asn	Phe	Leu	Ser	Glu	Thr	Lys	100	105	110	115
Thr	Ile	Ser	Tyr	Gly	Glu	Cys	Leu	Thr	Gln	Met	Tyr	Phe	Phe	Leu	120	125	130	135

Ala Phe Gly Asn Thr	Asp Ser Tyr Leu	Leu Ala Ala Met Ala	Ile
110	115	120	
Asp Arg Tyr Val Ala	Ile Cys Asn Pro	Phe His Tyr Ile Thr	Ile
125	130	135	
Met Ser His Arg Cys	Cys Val Leu Leu	Leu Val Leu Ser Phe	Cys
140	145	150	
Ile Pro His Phe His	Ser Leu Leu His	Ile Leu Leu Thr Asn	Gln
155	160	165	
Leu Ile Phe Cys Ala	Ser Asn Val Ile	His His Phe Phe Cys	Asp
170	175	180	
Asp Gln Pro Val Leu	Lys Leu Ser Cys	Ser Ser His Phe Val	Lys
185	190	195	
Glu Ile Thr Val Met	Thr Glu Gly Leu	Ala Val Ile Met Thr	Pro
200	205	210	
Phe Ser Cys Ile Ile	Ile Ser Tyr Leu	Arg Ile Leu Ile Thr	Val
215	220	225	
Leu Lys Ile Pro Ser	Ala Ala Gly Lys	Arg Lys Ala Phe Ser	Thr
230	235	240	
Cys Gly Ser His Leu	Thr Val Val Thr	Leu Phe Tyr Gly Ser	Ile
245	250	255	
Ser Tyr Val Tyr Phe	Gln Pro Leu Ser	Asn Tyr Thr Val Lys	Asp
260	265	270	
Gln Ile Ala Thr Ile	Ile Tyr Thr Val	Leu Thr Pro Met Leu	Asn
275	280	285	
Pro Phe Ile Tyr Ser	Leu Arg Asn Lys	Asp Met Lys Gln Gly	Leu
290	295	300	
Ala Lys Leu Met His	Arg Met Lys Cys	Gln	
305	310		

&lt;210&gt; 39

&lt;211&gt; 359

&lt;212&gt; PRT

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7472020CD1

&lt;400&gt; 39

Met Phe Lys Ala Ile	Leu Gly His Val	Trp Pro Lys Asp His	Gly
1	5	10	15
Leu Asp Lys Leu Val	Val Arg Cys Pro	Arg His Thr Glu Pro	Trp
20	25	30	
Asn Leu Thr Gly Ile	Ser Glu Phe Leu	Leu Gly Leu Ser	Glu
35	40	45	
Asp Pro Glu Leu Gln	Pro Val Leu Pro	Gly Leu Ser Leu Ser	Met
50	55	60	
Tyr Leu Val Thr Val	Leu Arg Asn Leu	Leu Ile Ile Leu Ala	Val
65	70	75	
Ser Ser Asp Ser His	Leu His Thr Pro	Met Cys Phe Phe Leu	Ser
80	85	90	
Asn Leu Cys Trp Ala	Asp Ile Gly Phe	Thr Ser Ala Met Val	Pro
95	100	105	
Lys Met Ile Val Asp	Met Gln Ser His	Ser Arg Val Ile Ser	Tyr
110	115	120	
Ala Gly Cys Leu Thr	Gln Met Ser Phe	Phe Val Leu Phe Ala	Cys
125	130	135	
Ile Glu Asp Met Leu	Leu Thr Val Met	Ala Tyr Asp Arg Phe	Val
140	145	150	
Ala Ile Cys His Pro	Leu His Tyr Pro	Val Ile Met Asn Pro	His
155	160	165	
Leu Gly Val Phe Leu	Val Leu Val Ser	Phe Phe Leu Ser Leu	Leu
170	175	180	
Asp Ser Gln Leu His	Ser Trp Ile Val	Leu Gln Phe Thr Phe	Phe
185	190	195	
Lys Asn Val Glu Ile	Ser Asn Phe Val	Cys Asp Pro Ser Gln	Leu
200	205	210	

Leu Asn Leu Ala Cys Ser Asp Ser Val Ile Asn Ser Ile Phe Ile  
 215 220 225  
 Tyr Leu Asp Ser Ile Met Phe Gly Phe Leu Pro Ile Ser Gly Ile  
 230 235 240  
 Leu Leu Ser Tyr Ala Asn Asn Val Pro Ser Ile Leu Arg Ile Ser  
 245 250 255  
 Ser Ser Asp Arg Lys Ser Lys Ala Phe Ser Thr Cys Gly Ser His  
 260 265 270  
 Leu Ala Val Val Cys Leu Phe Tyr Gly Thr Gly Ile Gly Val Tyr  
 275 280 285  
 Leu Thr Ser Ala Val Ser Pro Pro Pro Arg Asn Gly Val Val Ala  
 290 295 300  
 Ser Val Met Tyr Ala Val Val Thr Pro Met Leu Asn Pro Phe Ile  
 305 310 315  
 Tyr Ser Leu Arg Asn Arg Asp Ile Gln Ser Ala Leu Trp Arg Leu  
 320 325 330  
 Arg Ser Arg Thr Val Glu Ser His Asp Leu Leu Ser Gln Asp Leu  
 335 340 345  
 Leu His Pro Phe Ser Cys Val Gly Glu Lys Gly Gln Pro His  
 350 355

<210> 40  
 <211> 936  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 104941CB1

<400> 40  
 atggagataa agaactacag cagcagcacc tcaggcttca tctcctctggg cctctcttcc 60  
 aacctcagc tgcagaaacc tctctttgcc atcttctca tcatgtacct gctcgctgcg 120  
 gtggggaatg tgcctcatcat cccggccatc tactctgacc ccaggctcca caccctatg 180  
 tacttttttc tcagcaactt gtctttcatg gatatactgt tcaaacagct catagtgcct 240  
 aagatgctgg tgaattttct atcagagaca aagggttatct cctatgtggg ctgcctggcc 300  
 cagatgtact tctttatggc atttgggaac actgacagct acctgctggc ctctatggcc 360  
 atcgaccggc tgggtggccat ctgcaacccc ttacactatg atgtgggtat gaaaccacgg 420  
 cattgcctgc tcatgctatt gggttcttgc agcatctccc acctacattc cctgttccgc 480  
 gtgctactta tgtctcgctt gtctttctgt gcctctcaca tcattaagca ctttttctgt 540  
 gacacccagc ctgtgctaaa gctctcctgc tctgacacat cctccagcca gatgggtgtg 600  
 atgactgaga ccttagctgt cattgtgacc cccttctgt gtatcatctt ctctacctg 660  
 cgaatcatgg tcactgtgct cagaatcccc tctgcagccg ggaagtggaa ggccttctct 720  
 acctgtggct cccacctcac tgcagttagc cttttctatg ggagtattat ttatgtctat 780  
 tttagggccc tgtccatgta ctcaagtgtt agggaccggg tagccacagt tatgtacaca 840  
 gtagtgacac ccatgctgaa ccctttcatc tacagcctga ggaacaaaga tatgaagagg 900  
 ggtttgaaga aattacagga cagaatttac cggtaa 936

<210> 41  
 <211> 3365  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 1499408CB1

<400> 41  
 atggaccagc cagaggcccc ctgctccagc acggggccgc gcctcgcggt ggcccgcgag 60  
 ctgctcctgg ctgcgctgga ggaactgagc caagagcagc tgaagcgctt ccgccacaag 120  
 ctgcgcgacg tgggcccgga cggacgcagc atcccggtgg gcggctgga gcgcgcggac 180  
 gccgtggacc tcgcggagca gctggcccag ttctacggcc cggagcctgc cctggagggtg 240  
 gcccgcaaga cctcaagag ggcggacgcg cgcgacgtgg cggcgagct ccaggagcgg 300  
 cggtgcagc ggctcgggct cggctccggg acgctgctct ccgtgtccga gtacaagaag 360  
 aagtaccggg agcacgtgct gcagctgcac gctcgggtga aggagaggaa cgcccgtctc 420  
 gtgaagatca ccaagcgctt caccaagctg ctcatcgccg ccgagagcgc cgcccgcgag 480  
 gaggcgctgg ggcccgcgga agagcctgag ccggggcgcg cgcggcgctc ggacacgcac 540

actttcaacc	gcctcttccg	ccgcgacgag	gagggccggc	ggcgcctgac	cggtggtgctg	600
caggggcccg	cgggcatcgg	caagaccatg	gcggccaaaa	agatcctgta	cgactgggag	660
gcgggcaagc	tgtaccaggg	ccaggtggac	ttcgcttct	tcatgccctg	cggcgagctg	720
ctggagaggg	cgggcacgcg	cagcctggct	gacctgatcc	tggaccagtg	ccccgaccgc	780
ggcgcgccgg	tgccgcagat	gctggcccag	ccgcagcggc	tgctcttcat	cctgggacggc	840
gcggacgagc	tgccggcgct	ggggggcccc	gagggccggc	cctgcacaga	ccccctcgag	900
gcggcgagcg	gcgcgcgggt	gctaggcggg	ctgctgagca	aggcgctgct	gcccacggcc	960
ctcctgctgg	tgaccacgcg	cgccgcgcgc	cccgggaggc	tgaggggccg	cctgtgttcc	1020
ccgcagtgcg	ccgaggtgcg	cggtcttctc	gacaaggaca	agaagaagta	ttcttacaag	1080
ttcttccggg	atgagaggag	ggccgagcgc	gcctaccgct	tcgtgaaggga	gaacgagacg	1140
ctgttcgcgc	tgtgcttcgt	gccttctgtg	tgctggatcg	tggtgcaccgt	gctgcgcag	1200
cagctggagc	tcggctcgga	cctgtgcgcg	acgtccaaga	ccaccacgtc	agtgtacctg	1260
cttttcatca	ccagcgttct	gagctcggct	ccggtagccg	acgggccccg	gttgccagggc	1320
gacctgcgca	atctgtgcgc	cctggccccg	gagggcgctc	tcggacgcag	ggcgagcttt	1380
gccgagaagg	aactggagca	actggagctt	cggtgctcca	aagtgcagac	gctgtttctc	1440
agcaaaaagg	agctgccggg	cgtgctggag	acagaggtca	cctaccagtt	catcgaccag	1500
agcttccagg	agttcctcgc	ggcactgtcc	tacctgctgg	aggacggcgg	ggtgccccag	1560
accgcggctg	gcggcggttg	gacactcctg	cggtgggacg	cccagccgca	cagccacttg	1620
gtgctcacca	cgcgcttctc	cttcggactg	ctgagcgcg	agcggatgcg	cgacatcgag	1680
cgccacttcc	gctgcatggt	ttcagagcgt	gtgaagcagg	aggccctcgc	gtgggtgag	1740
ggacagggag	agggctgccc	cgaggtggca	ccagaggtga	ccgagggggc	caaagggctc	1800
gaggacaccg	aagagggag	ggaggaggag	gagggagagg	agcccaacta	cccactggag	1860
ttgctgtact	gcctgtacga	gacgcaggag	gacgcgtttg	tgccccaagc	cctgtgcccg	1920
ttcccgagc	tgccgctgca	gcgagtgcgc	ttctgccgca	tggaagtgge	tggtctgagc	1980
tactcgtga	ggtgctgccc	tgctggacag	gcactgcggc	tgatcagctg	cagattgggt	2040
gctgcgagc	agaagaagaa	gaagagcctg	gggaagcggc	tccaggccag	cctgggtggc	2100
ggcagttctc	aaggcaccac	aaaacaactg	ccagcctccc	ttcttcatcc	actctttcag	2160
gcaatgactg	ccccactgtg	ccatctgagc	agcctcacgc	tgteccactg	caaactccct	2220
gacgcggtct	gccgagacct	ttctgaggcc	ctgagggcag	ccccgcact	gacggagctg	2280
ggcctcctcc	acaacaggct	cagtgaggcg	ggactgcgta	tgctgagtga	gggcctagcc	2340
tgcccgagc	gcagggtgca	gacggtcagg	gtacagctgc	ctgaccccca	gcgagggtct	2400
cagtacctgg	tggttatgct	tcggcagagc	cccgcctga	ccaccctgga	tctcagcggc	2460
tgccaactgc	ccgcccccat	ggtgacctac	ctgtgtgcag	tcctgcagca	ccagggatgc	2520
ggcctgcaga	ccctcagctc	ggcctctgtg	gagctgagcg	agcagtcact	acaggagctt	2580
caggctgtga	agagagcaaa	gccggatctg	gtcatcacac	accagcgcct	ggacggccac	2640
ccacaacctc	ccaaggaact	catctcgacc	ttctgaggct	ctggtggcca	gagcaggggtg	2700
gaagacccta	gtcaaagtcc	ctgtggagag	aacggcccat	tccaagggca	ggaggatatt	2760
gctctcgcc	tttgggaaac	ttttgagcgc	agaggccgca	gacaggcatg	tgggaggccc	2820
agacacggca	ccctgccccg	tcaggacag	gccaggacc	tgccctctc	tccacacctg	2880
gggtaccctc	tctccccag	ccccaccact	actccacca	ccttctctc	ctgagaccct	2940
ccagccattc	cccttgaaaa	cacccccga	ccccaaagca	caataatgac	agcgagagct	3000
ccaattaact	aagcacctac	ctgggggcag	aataaccctt	cactgectga	tccccatctg	3060
cagtgtggcc	caacagcccc	cagaactatg	cccacataga	ctggaggtag	gcagttcacc	3120
gtccctccct	gttaggaatg	agaccatccc	tgaggctatg	gccaggccc	acaggcgctc	3180
agtgtctgag	atctttggga	agggagacta	gggcaggtgg	agacagcgca	gaacccccgt	3240
gctgggtggg	aagcatgacc	acatgggtgg	tgagcagccc	ccatgcactg	acggtaaatt	3300
ccccgtggga	ctcatttctg	ttggtttcta	ttacacctgg	ccaggcgctg	tacaatacag	3360
gtoga						3365

&lt;210&gt; 42

&lt;211&gt; 1325

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 3168839CB1

&lt;400&gt; 42

catggcatcc	ccagcctagc	tcccaatccc	actttggcac	gatgttagcc	aacagctcct	60
caaccaacag	ttctgttctc	ccgtgtcctg	actaccgacc	taccacccgc	ctgcacttgg	120
tggtctacag	cttgggtgctg	gctgcggggc	tccccctcaa	cgcgctagcc	ctctgggtct	180
tcttgccgcg	gctgcgcgtg	cactcggttg	tgagcgtgta	catgtgtaac	ctggcgggcca	240
ggcagctgct	cttcaccctc	tcgctgcccg	ttcgtctctc	ctactacgca	ctgcaccact	300
ggcccttccc	cgacctcctg	tgccagacga	cggcgcccat	cttcagatg	aacatgtacg	360
gcagctgcat	cttctctgat	ctcatcaacg	tggaccgcta	cgcgcgcac	gtgcacccgc	420
tgcgactgcg	ccacctgcgg	cggccccgcg	tggcgcggtg	gctctgcctg	ggcgtgtggg	480

```
cgtcctacct ggtgttttgc gtgcccgcgc cccgcgtgca caggccctcg cgttgccgct 540
accgggacct cgaggtgctg ctatgcttcg agagcttcag cgacgagctg tggaaaggca 600
ggctgctgcc cctcgtgctg ctggccgagg cgctgggctt cctgctgccc ctggcgccgg 660
tggtctactc gtccggccga gtcttctgga cgctggcgcg ccccgacgcc acgacagacc 720
agcgcgccgg gaagaccgtg gcctcctgct tggctaacct cgtcatcttc ctgctgtgct 780
tcgtgcctta caacagcagc ctggcggtct acgggctgct gcggagcaag ctggtggcgg 840
ccagcgtgcc tgcccgcgat cgcgtgctgc ggggtgctgat ggtgatgggt ctgctggccg 900
gcgccaactg cgtgctggac ccgctgggtg actactttag cgccgagggc ttccgcaaca 960
ccctgcgcgg cctgggcaact ccgcaccggg ccaggacctc ggccaccaac gggacgcggg 1020
cgcgctcgcg gcaatccgaa aggtccgcgc tcaccaccga cgccaccagg ccggtatgcc 1080
ccatgtcccc aggtattccg cctctgaaca cacatgccat tgcgtgtcc gtgcccgaact 1140
cccaacgctt ctgcttctgg gaggtttaca ggggtgtacac acaagaaggt gggctgggca 1200
cttggacctt tgggtggcaa ttccagctta gcaacgcaga agagtacaaa gtgtggaagc 1260
cagggcccag ggaaggcagt gctgctggaa atggcttctt taaactgtga gcacgcagag 1320
cacc
```

<210> 43  
<211> 2124  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 3291235CB1

```
<400> 43
gtcttacctc ttaatatgat tagaatggca attaaatctc gacacgtttt aattaaattt 60
caacatgagt tttgcagggg acattcgaag tgtagegctc gccatctccc atcccaagta 120
cctaagggtc acaacgctgt cgccagagag gaagtcactg agtgcccact gccaccccc 180
cacatatgct cgttgtcccc agcatccttg agccaccagg agtgaggggt gctgctccct 240
gagacctggc tccaaggagg atgccacag cgctgccag ctccggtctg caccatgagt 300
gatgagcggc ggctgcttgg cagtgcagtg ggctggctgg tatgtggggg cctctccctg 360
ctggccaatg cctggggcat cctcagcgtt ggcgccaagc agaagaagtg gaagcccttg 420
gagttcctcg tgtgtacgct cgcggccacc cacatgctaa atgtggcgtg gccatcgcc 480
acctactccg tgggtcagct gcggcgccag cgcccgcact tcgagtggaa tgaggggtct 540
tgcaaggctc tcgtgtccac ctctacacc ctccacctgg ccacctgttt ctctgtcacc 600
tccctctcct accaccgcat gtggatggtc tgctggcctg tcaactaccg gctgagcaat 660
gccaaagaagc aggcggtgca cacagtcatg ggtatctgga tgggtgtoctt catcctgtcg 720
gccctgcctg ccgttggctg gcacgacacc agcgagcgct tctacacca tggtgccgc 780
ttcatcgtgg ctgagatcgg cctgggcttt ggctgtgct tctgtgctgt ggtggggcgg 840
agcgtggcca tgggcgtgat ctgcacagc atcgccctct tccagacgct ggccgtgcag 900
gtggggcgcc aggcgacca ccgcgccttc accgtgcca ccatcggtgt ggagacgcg 960
cagggcaagc ggcgtctctc catcgatggc tcggagcccg ccaaaacctc tctgcagacc 1020
acgggcctcg tgaccaccat agtcttctac taagactgcc tcatgggctt cctgtgtctg 1080
gtgtgtgagt ctacagcct gcgggcccag cctcagcgc cctggatggc actctgcgtg 1140
ctgtgtgctc cgtggccca ggccctgctg ctgcctgtgt tctctgggc ctgcgaccgc 1200
taccgggctg acctcaaagc tgtccgggag aagtgcattg ccctcatggc caacgcagag 1260
gagtcagacg atgagaccag cctggaaggt ggcattctcc cggacctggt gttggagcgc 1320
tccttggaat atggctatgg aggtgatatt gtggccctag ataggatggc caagtatgag 1380
atctccgccc tggagggggg cctgccccag ctctaccac tgccggcctt gcaggaggac 1440
aagatgcaat acctgcaggt cccgccacg cgcgcttct cccacgaaga tgcggacgtg 1500
tgggcgcgcg tcccgtgcc cccttctctg cgcgctggg gctccggcaa ggacctgtcc 1560
gccctggcgc acctgtgct gcctgcggg ccogagcgcc ccccgccag cctcctggcc 1620
ttcgcggagg acgcaccact gtcccgcgcg cgcgcgcgt cgcccgagag cctgctgtcg 1680
ctgcggccct cgccgtgga tagcgcccg cggggagccc gcgactcgcc ccccgccagc 1740
ccgcgcgcgc gccccggggc cggccccgc tccgcctcgg cctcgtgct gcccgaccgc 1800
ttgcctcga ccgccttga gtgcgagcca caggccctgc gccgcccgc cgggcccctc 1860
ccgctgcgc ccgcgcgcc cgacggcgca gatcccggag agggcccag gcccccagc 1920
agcgcgcagc ggaagccagg gccacgcccc tctgcgcact cgcacgcggg ctctctgcgc 1980
ccggcctga gcgcgtcgt gggcgagccc ggggggctgc gcgcggcggg cggcgggcgg 2040
agcaccagca gcttctgag ttccccctcc gagtccctcg gctacgccac gctgcaactc 2100
gactcgtgg gctccgcgtc ctat
```

<210> 44  
<211> 942  
<212> DNA  
<213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7472001CB1

<400> 44  
 atggaagaa tcaacagcac actgttgact gcgtttatcc tgacaggaat tccgtatcca 60  
 ctacagctaa ggacactctt tttgtgttc ttttttctaa tctacatcct gactcagctg 120  
 ggaaacctgc ttattttaat cactgtctgg gcagacccaa ggctccatgc ccgccccatg 180  
 tacatctttc ttggtgttct ctacagtcatt gatatgagca tctcctccat cattgtccct 240  
 cgctcatga tgaacttcac tttaggtgtc aaacccatcc catttggtgg ctgtgttgt 300  
 caactctatt tctatcactt cctgggcagc acccagtgc tctctacac cctaattggc 360  
 tatgacaggt acctggcaat atgtcagccc ctgctgtacc ctgtgtcat gactgctaag 420  
 ctgagcgctt tgcctgtggc tggagcctgg atggcaggat ccatccatgg ggctctccag 480  
 gccatcctaa ccttcgcctt gccctactgt gggcccaatc aggtggatta ctctctctgt 540  
 gacatccctg cagtgttgag actggcctgt gctgacacaa cagtcaacga gctggtgacg 600  
 tttgtagaca ttgggggtgtt ggttgccagt tgcctctccc tgatccctct cctctacata 660  
 cagatcattc aggccatcct gagaatccac acagctgatg ggcggcgccg ggctttttca 720  
 acttgtggag cccatgtaac cgtggtcacc gtgtactatg tgccctgtgc ctcatctac 780  
 ctgaggcctg aaaccaacag cccctggat ggggcagctg cctagtccc caccggccatc 840  
 actccttttc tcaacccctt tatctacact ctgcggaacc aagaggtgaa gctggccctg 900  
 aaaagaatgc tcagaagccc aagaactccg agtgaggttt ga 942

<210> 45  
 <211> 1197  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7472003CB1

<400> 45  
 atgcacaccg tggctacgtc cggacccaac ggcctctggg gggcaccggc caacgcctcc 60  
 ggctgcccgg gctgtggcgc caacgcctcg gacggccag tcccttcgcc gcgggcccgtg 120  
 gacgcctggc tcgtgccgct cttcttcgcg gcgctgatgc tgctgggcct ggtgggggaa 180  
 tcgctgtgca tctacgtcat ctgcccgcac aagccgatgc ggaccgtgac caactttctac 240  
 atcgccaacc tggcggccac ggacgtgacc ttctcctgt gctgcgtccc cttcacggcc 300  
 cgtgtgtacc cgtgcccggg ctgggtgctg ggcgacttca tgtgcaagtt cgtcaactac 360  
 atccagcagg tctcgggtgca ggcacagtgt gccactctga ccgccatgag tgtggaccgc 420  
 tggtagctga cgggtgtccc gttgcgcgcc ctgcaccgcc gcacgccccg cctggcgctg 480  
 gctgtcagcc tcagcatctg gacaggctct cggcggtgt ctgcgcgggt gctcgcctg 540  
 caccgcctgt caccggggcc gcgcgcctac tgcagttagg ccttccccag ccgcgcctg 600  
 gaggcgcctt tcgcatgta caacctgctg gcgctgtacc tgcctgccgt gctcgcacc 660  
 tgcgcctget atgcggccat gctgcgccac ctggcgggg tgcgctgctg ccccgccccc 720  
 gccgatagcg ccttcgaggg gcagggtgct gcagagcgcg caggcgccgt gcggggcgaag 780  
 gtctcgcggc tgggtggcgg cgtggtcctg ctcttcgccc cctgctgggg ccccatccag 840  
 ctgttctctg tgcctgcagg gctgggcccc gcgggctcct ggcacccacg cagctacgcc 900  
 gcctacgcgc ttaagacctg ggctcaactg atgtctaca gcaactccgc gctgaacccg 960  
 ctgctctacg ccttccctgg ctgcacttcc cgacaggcct tccgcgcgt ctgcccctgc 1020  
 gcgcgcgcgc gcccgcgcgc ccccgccggg cccggacct cggacccgc agccccacac 1080  
 gcggagctgc tccgctggg gtcccacccg gcccgcgca gggcgagaa gccagggagc 1140  
 agtgggctgg ccgcgcgcgg gctgtgcgtc ctgggggagg acaacgcccc tctctga 1197

<210> 46  
 <211> 1110  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7472004CB1

<400> 46  
 atggctccca ctggtttgag ttccttgacc gtgaatagta cagctgtgcc cacaacacca 60  
 gcagcattta agagcctaaa cttgcctctt cagatcacc tttctgctat aatgatattc 120  
 attctgtttg tgtcttttct tgggaacttg gttgtttgcc tcatggttta ccaaaaagct 180  
 gccatgaggt ctgcaattaa catcctcctt gccagcctag cttttgcaga catgttgctt 240

```

gcagtgtctga acatgccctt tgccctggta actattctta ctaccgatg gatttttggg 300
aaattcttct gtaggggtatc tgctatgttt ttctgggtat ttgtgtaga aggagtagcc 360
atcctgtctca tcattagcat agatagggttc cttattatag tccagaggca ggataagcta 420
aaccatata gagctaagggt tctgattgca gtttcttggg caacttcctt ttgtgtagct 480
tttctttag ccgtaggaaa ccccgacctg cagatacctt cccgagctcc ccagtgtgtg 540
tttgggtaca caaccaatcc aggctaccag gcttatgtga ttttgatttc tctcatttct 600
ttcttcatac ctttctgggt aatactgtac tcatttatgg gcatactcaa cacccttcgg 660
cacaatgcct tgaggatcca tagctaccct gaaggatatat gcctcagcca ggccagcaaa 720
ctgggtctca tgagtctgca gagacctttc cagatgagca ttgacatggg ctttaaaaca 780
cgtgccttca ccactatttt gattctcttt getgtcttca ttgtctgtg ggccccattc 840
accacttaca ggccttggtg aacattcagt aagcactttt actatcagca caactttttt 900
gagattagca cctggctact gtggctctgc tacctcaagt ctgcattgaa tccgctgatc 960
tactactgga ggattaagaa attccatgat gcttgccctgg acatgatgcc taagtccttc 1020
aagtttttgc cgcgctccc tggtcacaca aagcgacgga tacgtcctag tgctgtctat 1080
gtgtgtgggg aacatcggac ggtggtgtga          1110

```

<210> 47  
 <211> 582  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7475687CT1

```

<400> 47
atggcctatg acaggtacct ggcaatatgt cagccctgc gctaccaggt gctcatgaat 60
gggaggttat gcacagtcct tggggtgga gcttgggtcg ccggtccat gcatgggtct 120
atccaggcca cctgacctt ccgcctgccc tactgtgggc ccaatcagggt agattacttt 180
atctgtgaca tccccgcagt attgagactg gcctgtgtctg acacaactgt caatgagctt 240
gtgacctttg tggacatcgg ggtagtggcc gccagtgtct tcatgttaat tctgtctctg 300
tatgccaaac tagtaaatgc catcctgaag atacgcacca ctgatgggag gcgcggggcc 360
ttctccacct gtggctccca cctaactctg gtacagctct actatgtccc ctgtattttc 420
atctacctta gggctggctc caaaggcccc ctggatgggg cagcggctgt gttttacact 480
gttgtcactc cattactgaa cccctcctc tataactga ggaaccagga agtgaagtct 540
gccctgaaga ggataacagc aggccaggcg gatgtaaata ac          582

```

<210> 48  
 <211> 519  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7483029CT1

```

<400> 48
atgtacctgg tcaccgtgct cgggaacctg ctcatcatcc tggccacaat ctcagactcc 60
cacctccaca ccccatgta cttcttcttc tccaacctgt cctttgcaga catctgtttt 120
gtgtctacca ctgtcccaa gatgtgtgtg aacatccaga cacagagcag agtcatcacc 180
tatgcagact gcatcacca gatgtgcttt ttataactct ttgtagtgtt ggacagctta 240
ctcctgactg tgatggccta tgaccgggtt gtggccatct gtcacccct gcactacaca 300
gtcattatga actcctggct ctgtggactg ctggttctgg tgtcctggat cgtgagcatc 360
ctatattctc tgttaccaaag cataatggca ttgcagctgt ccttctgtac agaattgaaa 420
atccctcatt ttttctgtga acttaatcag gtcatccacc ttgcctgttc cgacactttt 480
attaatgaca tgatgatgaa ttttacaagt gtgctgctg          519

```

<210> 49  
 <211> 663  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7477933CT1

<400> 49

```

cccatgtact tcttctcttc caacctgtgc tgggctgaca tcggtctcac ctgggccacg 60
gttcccaagg tgattctgga tatgcagtcg catagcagag tcattctctca tgtgggctgc 120
ctgacacaga tgtctttctt ggctcctttt gcattgtatag aaggcatgct cctgactgtg 180
atggcctatg gctgctttgt agccatctgt cgccctctgc actaccagct catagtgaat 240
cctcacctct gtgtctttct cgttttgggt tcttttttcc ttaacctgtt ggattcccag 300
ctgcacagtt ggattgtgtt acaattcacc atcatcaaga atgtggaaat ctctaatttt 360
ttctgtgacc cctctcagct tctcaacctt gcctgttctg acagcgtcat caatagcata 420
ttcatatatt tcgatagtac tatgtttggt tttcttccca tttcagggat ccttttgtct 480
tactataaaa ttgtcccctc cattctaagg atgtcatcgt cagatgggaa gtataaagcc 540
ttctccacct atggctctca cctaggagtt gtttgctggt tttatggaac agtcattggc 600
atgtacctgg ctccagccgt gtcaccacc cccaggaatg gtgtggtggc atcagtgatg 660
tag 663

```

<210> 50  
 <211> 911  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7475164CT1

```

<400> 50
gggctgagtt tatcctggca ggcttgacac aacgcccaga acttcaactg ccactcttcc 60
tctgttctct tggaatatat gtggctcacag tgggtgggaa cctgggcatg atcttcttaa 120
ttgtctctcag ttctcaactt taccctccag tgtattattt tctcagtcac ttgtcttcca 180
ttgatctctg ctactctctt gtcattaccg ctaagatgct ggtgaacttt gtccagagg 240
agaacattat ctcccttctg gaatgcatta ctcaacttta tttcttctct atttttgtaa 300
ttgcagaagg ctaccttctg acagccatgg aatatgaccg ttatgttgc atctgtcgc 360
cactgcttta caatatgttc atgtcccaca ggtctgttcc cataatgatg gctgtggtat 420
actcactggg ttttctgtgg gccacagtc atactaccg catgtcagtg ttgtcattct 480
gtagggtctca tacgggtcag cattatcttt gtgatattct ccccttattg actctgtctt 540
gctccagcac ccacatcaat gagattctgc tgttcattat tggaggagtt aataccttag 600
caactacact ggcggtcctt atctcttatg ctttcatttt ctctagtata cttggtattc 660
attccactga ggggcaatcc aaagcctttg gcactttag ctcccatctc ttggctgtgg 720
gcatcttttt tgggtctata acattcatgt atttcaagcc cccttcagc actactatgg 780
aaaaagagaa ggtgtcttct gtgttctaca tcacaataat ccccatgctg aatcctctaa 840
tctatagcct gaggaacaag gatgtgaaaa atgcactgaa gaagatgact aggggaaggc 900
agtcactctg a 911

```

<210> 51  
 <211> 332  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7473909CT1

```

<400> 51
caggccccag gacagccagt ggctgtgtca tcatgatctg ctttgccctc actgtcctct 60
cttacatccg catcttgccc acagtgggtc agatccgttc agcagccagc cgccggaagg 120
ccttctccac ctgttcttcc caccctggga tgggtgctct gttctatggc accggcagct 180
ccacctacat gccaccacc acccgctact ccccgctgga agggcgcttg gctgctgtct 240
tctactccat cctcataccc accctgaatc cgctcatcta cagcctgagg aaccaggaca 300
tgaagagagc cctgtggaag ctctatctcc ag 332

```

<210> 52  
 <211> 538  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7475252CT1

<400> 52



```

agagccagag aatctcacag gtgtcttaga attcctgctc ctgggactcc cagatgatcc 60
agaactgcag cccgtcctct ttgggctgtt cctgtccatg tacctggcca tgggtgctggg 120
gaacctgctc atcattctgg ccgtcagctc tgactcccat ctccacagcc ccatgtactt 180
cttctctctc aacctgtcct tggctgacat cggttttgcc tctactactg tccccaagat 240
gattgtggac atccaggctc atagtagact catctcttac gtgggctgcc tgactcagat 300
gtcttttttg atctttttcg catgtatgga aagtctgctc ctgattgtga tggcctatga 360
ccggttcgtg gccatctgtc accccctgca ctaccaagtc atcatgagcc cagcactctg 420
tggcttctta gttttgggtg ctttttttct tagccttttg gactctcagc tgcacaattt 480
gattgtgtta caacttacct gcttcaacga tgtggaaatc tctaattttt ttctgtga 538

```

<210> 53  
 <211> 279  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7927572CT1

```

<400> 53
tcttttagat gccagctgt acaatttgat tgccttacaa atgacctgct tcaaggatgt 60
ggaaattcct aattttctct gtgaccttcc tcaactcccc catcttgcac gttgtgacac 120
cttcaacaat aacataatcc tgtatttccc tgatgccata tttgggtttc ttcccatctc 180
ggggacactt ttctcttacg ataaaattgt ttctctcatt ctgagggttt catcatcagg 240
tgggaagtat aaagccttct ccacctatgg gtctcacct 279

```

<210> 54  
 <211> 291  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7481257CT1

```

<400> 54
atggaggtaa ccacatttgc catgtgcctg attatagttc ttgttctctt tctttctatt 60
cttgtgtcat atggtttcat tgctgtggct gtactcaaga tcaagtctgc agcaggaaga 120
caaaaagcat ttgggacctg ttctctccat ctggttggtg tatccatctt ctgtgggaca 180
gttacatata tgtatataca gccaggaaac agtccaaatc agaattgagg caaacttctc 240
agtatatatt actccattgt tactcccagc ttgaaccat taatttatac g 291

```

<210> 55  
 <211> 402  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7485790CT1

```

<400> 55
aggatccaga actgcagccc atcctcgctg ggctgtccct gtccatgtat ctggtcacgg 60
tgctgaggaa cctcctcatc agcctggctg tcagctctga ctcccacctc cacaccccaa 120
tgtgtctctt cctctccaac ctgtgctggg ctgacatcgg ttccacctcg gccacggttc 180
ccaagatgat tgtggacatg cggctgcata gcggagtcac ctcttatgcg gactgcctga 240
cacggatgtc tttcttggtc ctttttgcat gtgtagaaga catgctcctg actgtgatgg 300
cctatgactg ttttgtagcc atctgtgcc ctctgcaata cccagtcac gtgaatctc 360
acctctgtgt ctctcttagt tcgggtgctt ttctcttagc ct 402

```

<210> 56  
 <211> 639  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature

&lt;223&gt; Incyte ID No: 7482993CT1

&lt;400&gt; 56

```

ggatcacagt gtctctact ggcagcaatg gcatatgatc gttacattgc aatctgcaat 60
cctttaaggt attcagttat tctgagcaag gttctatgca atcaattagc agcctcatgc 120
tggtgtgctg gtttccttaa ctcagtgggtg catacagtgt tgacattctg cctgcccttc 180
tgtggcaaca atcagattaa ttactttctc tgtgacatcc cccctttgct gatcttgtct 240
tgtggaaaca cttctgtcaa tgagttggca ctgctatcca ctgggggtctt cattgggttg 300
actcctttcc tttgtatcgt actttcttac atttgcataa tctccaccat cttgaggatc 360
cagtcctcag agggaagacg aaaagccttt tctacatgtg cctcccacct ggccattgtc 420
tttctctttt attgacagcg catctttaca tatgtacggc ccatctcaac ttactcatta 480
aagaaagata ggttgggttc agtgttgtac agtgttgtta ccccatgtct aaacctata 540
atttacacat tgaggaataa ggacatcaaa gaagctgtca aaactatagg gagcaagtgg 600
cagccaccaa tttctctttt gtagtagtaa ctcacttat 639

```

&lt;210&gt; 57

&lt;211&gt; 1370

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 2829053CB1

&lt;400&gt; 57

```

cggcaccaga aggatataac cagaattctc cagcaacatg aggaggaaaa gaagaaatgg 60
gcacaacagg tggagaagga aaggaggcta gagctcgaga cagactggat gagcagcaaa 120
gggtccttga aggaagaagt gaagaggccc tgcaagtcc cggggcctca tatgaacagg 180
agaaagaagc gcttaccacac tctttccggg aggccagttc taccacagcag gagaccatag 240
acagactgac ctcacagctg gaggtcttcc agggccaaat gaagagggtg gaggagtcca 300
ttctgagccg aaactataag aacatatcc aggtatttg gagccccagc cagttctggg 360
agcaggagct ggagagctta cactttgtca tcgagatgaa gaatgagcgt attcatgagc 420
tggaacaagc gctgatcctc atggaaacag tgaaagagaa aaatctgata ttggaggaaa 480
aaattacgac cctgcaacag gaaaatgagg acctccatgt ccgaagccgc aaccagggtg 540
tctgtccaag gcagctgtca gaagacctgc ttctcacgg tgaggccctg gagaaggagg 600
tgcagctgcg gcgacagctc cagcaggaga agggaggagt gttgtaccgg gtccttgggg 660
ccaatgcctc gcctgccttc cctctggccc ctgtcactcc cactgaggtc tctttctctg 720
ccacataggg tgcagggcct ggcccaccca cgacgcctga agtcacagct ccttccaagg 780
tttttctgga gaagacagca ggagcctctc agttcttttc caggaaggaa cgagggtggg 840
agcgagatgg agatcctggg tgtgtgcccc gtgagccctg gggccttgag ttacatggaa 900
tcaccacagc ggttttggag gccccgagaa gcgtcttccc ttgagttggc caagggaata 960
agcaagagga gacatttctc ccctgcccc gcaactctgt ccaatccgag aagttccgag 1020
gctttccacg gggcagctct tgctacgctg gccatttgac ataaaggaga cagcccctgg 1080
tcccagcttg tcagctctgc tgccgacttg ctgacttacc aacttctct aggtgtttcc 1140
actccaccct ggctctgtca gagcctcagt ttaccctgc attaaaatgg tggggggact 1200
ggtcaaaagga ctcttatgcc actgcagtgg cccattctag gattgtctga aggccagagt 1260
aggggttggg gggagtgtgg acaaaccccc caaatcagag tggggaaggt gagtgtgtaga 1320
gagggggtct ctgaaggccc ttggggctga cagggccagg cagcctcccc 1370

```

&lt;210&gt; 58

&lt;211&gt; 1567

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 3068234CB1

&lt;400&gt; 58

```

gagggactgc gttctaatac ggagctccga ggatgttcac ttcttctcca caatgaatga 60
gtgtcactat gacaagcaca tggacttttt ttataatagg agcaacactg atactgtcga 120
tgactggaca ggaacaaagc ttgtgattgt tttgtgtgtt gggacgtttt tctgcctgtt 180
tatttttttt tctaattctc tggtcacgac ggcagtgatc aaaaacagaa aatttcattt 240
ccccctctac tacctgtttg ctaatttagc tgetgccgat ttcttcgctg gaattgccta 300
tgtattcctg atgtttaaca caggcccagt ttcaaaaact ttgactgtca accgtgtgtt 360
tctccgtcag gggcttcttg acagtagctt gactgtctcc ctcaccaact tgctggttat 420
cgccgtggag aggcacatgt caatcatgag gatgcgggtc catagcaacc tgacaaaaaa 480

```

```
gaggggtgaca ctgctcattt tgettgtctg ggccatcgcc atttttatgg gggcggtccc 540
cacactgggc tgggaattgcc tctgcaacat ctctgectgc tcttccctgg cccccattta 600
cagcaggagt taccttgttt tctggacagt gtccaacctc atggccttcc tcatcatggt 660
tgtgtgttac ctgcggtatc acgtgtacgt caagaggaaa accaacgtct tgtctccgca 720
tacaagtggg tccatcagcc gccggaggac aqccatgaag ctaatgaaga cgggtgatgac 780
tgtcttaggg gcgtttgtgg tatgctggac cccgggcctg gtggttctgc tcctcgacgg 840
cctgaactgc aggcagtgtg gcgtgcagca tgtgaaaagg tggttcctgc tgctggcgct 900
gctcaactcc gtctgtaacc ccatcatcta ctctacaag gacgaggaca tgtatggcac 960
catgaagaag atgatctgct gcttctctca ggagaacca gagaggcgtc cctctcgcat 1020
ccccccaca gtctcagca ggagtgcacac aggcagccag tacatagagg atagtattag 1080
ccaaggtgca gtctgcaata aaagtacttc ctaaactctg gatgcctctc ggcccacca 1140
ggcctcctct gggaaaagag ctgttaagaa tgattacctg tctctaaca agcccatgta 1200
cagtgttatt tgaggtctcc attaatcact gctagatttc tttaaaaaat ttttttcat 1260
agtttaaaag catgggcagt aaagagagga cctgctgcat ttagagaaag cacagaaacg 1320
ggagagggtc ggcggtccc tgcttgctct atgaactgct cagagctctc gtcagtcacc 1380
ctgggcttcc tgggttctgg caccatttct tagccattct ctttgtattt taaaaggacg 1440
ttatgaagg gcttagacca aaataaatca taatgttact tgagccacct tatatagctg 1500
cttgagagt ctatgtagtt ctttctgcat gcattaaaaa tgtttagaaa tgcttcaaaa 1560
aaaaaaa 1567
```

<210> 59  
<211> 1321  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 5029478CB1

```
<400> 59
cagaccgctg cgggcgcgag gcgcgggaa tgtccctga atgcgcgcgg gcagcggggc 60
acgcgccctt gcgcagcctg gagcaagcca accgcacccg ctttcccttc ttctccgacg 120
tcaaggcgga ccaccggctg gtgctggcgg cgggtggagac aaccgtgctg gtgctcatct 180
ttgcagtgtc gctgctgggc aacgtgtgcg ccctgggtgt ggtggcgcgc cgacgacgcc 240
ggcgcgcgac gctctgctg gtaactcaacc tcttctgccc ggacctgctc ttcatcagcg 300
ctatccctct ggtgctggcc gtgcgctgga ctgaggcctg gctgctgggc cccgttgcc 360
gccacctgct cttctacgtg atgacctgga gcggcagcgt caccatcctc acgctggcgg 420
gggtcagcct ggagcgcatg gtgtgcatcg tgcacctgca gcgcggcggt cggggtcctg 480
ggcgcggggc gcgggcagtg ctgctggcgc tcatctgggg ctattcgggc gtcgcgcgtc 540
tgctctctct cgtcttcttc cgagtcgtcc cgcaacggct ccccgcgccc gaccaggaaa 600
tttctatttg cacactgatt tggcccacca ttctggaga gatctcgtgg gatgtctctt 660
ttgtactttt gaacttcttg gtgccaggac tggtcattgt gatcagttac tccaaaattt 720
tacagatcac aaaggcatca aggaagaggc tcacggtaag cctggcctac tcggagagcc 780
accagatccg cgtgtccag caggacttcc ggctcttccg caccctctc ctctcatgg 840
tctccttctt catcatgtgg agcccacat tcatcaccat cctcctcatc ctgatccaga 900
acttcaagca agacctggtc atctggcgt cctcttctt ctgggtggtg gccttcacat 960
ttgctaattc agccctaaac cccatcctct acaacatgac actgtgcagg aatgagtggg 1020
agaaaatttt ttgtgcttc tggttcccag aaaagggagc cattttaaca gacacatctg 1080
tcaaaagaaa tgacttgctg attatttctg gctaattttt ctttatagca gagtttctca 1140
cacctggcga gctgtggcat gcttttaaac agagttcatt tccagtacc tccatcagtg 1200
gcacctgct ttaagaaaat gaacttatgc aaatagacat ccacagcgtc ggtaaatata 1260
ggggtgatca ccaagtttca taatattttc cctttataaa aggatttgtt ggccagggtg 1320
a 1321
```

<210> 60  
<211> 1110  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 5102576CB1

```
<400> 60
atgttctctg tgagttgctc gcatccagca ttaagggtcg gtttttatct tttatttttc 60
caatcctctt tcttctcaa ggtgtccaag acacacggag ccacggaatc tcacaggtgt 120
ctgagaattc ctctctctgg gactctcaga ggatccagaa ctgcagccgg ccctcgcttt 180
```

```

gctgtccctg tccctgtcca tgtatctggg caccgtgctg aggaacctgt tcagcaccct 240
ggctgtcagc tctgactgcc cctccacac ccccatgtac ttcttctctt ccaacctgtg 300
ctggcctgac atcggtttca cctcggccat gggtcccaag atgattgtgg acacgcagtc 360
gcatagcaga gtcactcttc atgcgggctg cctgacacag atgtctttcc tgctccttgt 420
tgcatgtata gaaggcatgc tctgactgtg gatggcctat gactgctttg tagccatctg 480
tcgcccctct cactaccagc tcactcgtga tctcaccctc tgtgtctttt tcgttttggt 540
gtcctttttc cttagcctgt tggattccca gctgcacagt tggatttgtt tacaattaac 600
catcatcaag aatgtggaaa tctctaattt ggctgtgac cctctcaac ttctcaatct 660
tgctgtttct gacagcgtca tcaataacat attcatatat ttcatagta ctatgtttgg 720
ttttcttccc atttcagggg tctttttgtc ttactataaa attgtcccct ccatttcaag 780
gatttcacgt tcagatggga agtataaagc cttctccacc tgtggctgtc atctagcagt 840
tggtttgctg ttttatggaa caggcattgg catgtacctg acttcagctg tgtcaccacc 900
ccccaggaat ggtgtgggtg catcagtgat gtaacgtgtg gtcaccccat gctgaacctt 960
ttcatctgca gctgagaaa caggacata caaagtgcct tgcggagggt gggcagcaga 1020
gcattcgaat cctcatgctt gttccatcct ttttcttgtg tgggtgagaa agggcaatca 1080
cattaaatct ctttatctgc aaaaaaaaaa 1110

```

<210> 61  
 <211> 1095  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 2200534CB1

```

<400> 61
atgaaggcca actacagcgc agaggagcgc tttctcctgc tgggtttctc cgactggcct 60
tccctgcagc cggctcctct cgcctctgtc ctctctgtgt acctcctgac cttgacgggc 120
aactcggcgc tgggtgtgtt ggccgtgctg gaccgcgcgc tgcacacgcc catgtactac 180
ttcctctgcc acctggcctt ggtagacgcg ggcttacta ctacgttgtt gccgcgcgtg 240
ctggccaacc tgcgcggacc agcgtctctg ctgcccgcga gccactgcac ggcccagctg 300
tgcgcacatc tggctctggg ttccggcga tgcgtcctcc tggcgggtgat ggctctggac 360
cgcgcggcgc cagtgtgcgc cccgtgcgc tatgcggggc tctctcccc gcgcctatgt 420
cgacagctgg ccagcgccctc ctggctaagc ggctcacc aactcgtttg gcaaaccgcg 480
ctcctggctg agcggcgcct gtgcgcgcgc cgcctgtctg accacttcat ctgtgagctg 540
ccggcgtttg tcaagctggc ctgcggaggg gacggagaca ctaccgagaa ccagatgttc 600
gccgcgcgcg tggatcctct gctgtgcgcg tttgcccgtc tcttgccctc ctacgggtgc 660
gtggcccagc ctgtctgttg catgcggttc agcggaggcc ggaggagggc ggtggggcacg 720
tgtgggtccc acctgacagc cgtctgcctg ttctacggct cggccatcta cacctacctg 780
cagcccgcgc agcgtacaaa ccaggcacgg ggcaagtctg tatcgtcttt ctacacgtg 840
gtcacacctg ctctcaacc gctcatctac acctcagga ataagaaagt gaagggggca 900
gcgaggaggg tgcctgggag tctggggaga ggccaggctg ggcagtgagt agttggggag 960
gggagaaagt attaaagcag aaccaagga tggaaatacc ccttagtgag tcagtttaga 1020
cttcaggctg ttcatTTTTG tatgataatc tgcaagattt gtcctaagga gtccaatggg 1080
ggatatgttt tctc 1095

```

<210> 62  
 <211> 1665  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 3275821CB1

```

<400> 62
ttcctacctt cactgattct ctgaaccttc ctgtcctcgc ctgtaaagta gattgtatga 60
ggactccatg aggtcatcca cttcaagtcc ttggcatagg ataattactc aaaaggtgat 120
gacaatggcg cagggaggga tgggtgactt cctggagatg cacagcaccg tctctcccat 180
actcggctcat tcacaccatc attgattcac caggcaccca ctccgtgtcc agcaggactc 240
tggggacccc aaatggacac taccatggaa gctgacctgg gtgccactgg ccacaggccc 300
cgcacagagc ttgatgatga ggactcctac ccccaagggt gctgggacac ggtcttctct 360
gtggccctgc tgctccttgg gctgccagcc aatgggttga tggcgtggct ggccggctcc 420
cagcccgcgc atggagctgg cagcgtcttg gcgtgctcc tgcacagcct ggccctctct 480
gacttcttgt tcttggcagc agcggccttc cagatcctag agatccggca tgggggacac 540
tggcgcgtgg ggacagctgc ctgcgcgttc tactacttcc tatggggcgt gtcctactcc 600

```

```
tccggcctct tccgtctggc cgcctcagc ctcgaccgtt gctgtgctggc gctgtgcccc 660
cactggtacc ctgggcaccg cccagtcgcg ctgccccctt ggggtctgcgc cgggtgtctgg 720
gtgctgcccc cactcttcag cgtgcccctg ctgggtcttcc ccgaggctgc cgtctgtgtg 780
tacgacctgg tcatctgcct ggacttctgg gacagcgagg agctgtcgct gaggatgctg 840
gaggctcctg ggggcttctt gcctttcttc ctgctgtctg tctgcccagt gctcaccag 900
gccacagcct gtgcgacctg ccaccgcccc cagcagcccc cagcctgccg gggcttccgc 960
cgtgtggcca ggaccattct gtcagcctat gtggtcctga ggctgcccct ccagctggcc 1020
cagctgctct acctggcctt cctgtgggac gtctactctg gctacctgct ctgggaggcc 1080
ctgggtctact ccgactacct gatcctactc aacagctgcc tcagccccct cctctgcctc 1140
atggccagtg ccgacctccg gacctgtctg cgtctcctgc tctcgtcctt cggggcagct 1200
ctctgcgagg agcgcccggg cagcttcacg cccactgagc cacagaccca gctagattct 1260
gagggtccaa ctctgccaga gccgatggca gaggccagct cacagatgga tctgtgtggc 1320
cagcctcagg tgaaccccac actccagcca cgtatcggtc ccacagctca gccacagctg 1380
aacctacagg ccagccaca gtgggatccc acagcccagc cacagctgaa cctcatggcc 1440
cagccacagt cagattctgt ggcccagcca caggcagaca ctaacgtcca gaccttgca 1500
cctgtgcca gttctgtgcc cagtccctgt gatgaagctt ccccaacccc atcctcgcat 1560
cctacccag gggcccttga ggacccagcc acacctctg cctctgaagg agaaagcccc 1620
agcagacccc cgccagaggc ggccccgggc gcaggcccca cgtga 1665
```

<210> 63  
<211> 1609  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 3744167CB1

```
<400> 63
tctccttttg ccgattagtg gacgtgacag agatgtgaat ggggcaggga tgtcctttga 60
tggcatcaag actttagctt ctggtgcgct gtgtccagc tctgatttca gttgcagcgc 120
tgatggacag ttgcatggaa gctgagactc tcaactgacag tgaaaccctc aaatgaacac 180
aatccctgct ttccctgcaa ggatccttgt aggggtcccc agcttcccca ctttttttct 240
gtgtcctgta ggcccagaag gatgtcggtc tgctaccgtc cccagggaa cgagacactg 300
ctgagctgga agacttcgag cgtggtgtgg agccttcc ctgctgtggc ggcgtgctg 360
gggctgcctg gcaacggctt cgtggtgtgg agcttggcgg gctggcggcc tgcacggggg 420
cgaccgctgg cgccacagct tgtgtgtcac ctggcgctgg ccgacggcgc ggtgtgtctg 480
ctcacgcgcg tctttgtggc cttcctgacc cggcaggcct ggccgctggg ccaggcgggc 540
tgcaaggcgg tgtactacgt gtgcgcgctc agcatgtacg ccagcgtgct gctcaccggc 600
ctgtcagccc tgcagcgtg cctcgcagtc accgccccct tcctggcgcc tgggtgtcgc 660
agcccgccc cgcgcgcgg cctgctgtct gcggtctggc tggccgccc gttgtcgc 720
gtcccggcgg ccgtctaccg ccacctgtgg agggaccgag tatgccagct gtgccaccg 780
tcgcccgtcc acgcgcggc ccacctgagc ctggagactc tgaccgctt cgtgtctcct 840
ttcgggctga tgcctggctg ctacagcgtg acgctggcac ggctgcgggg cgcccctgg 900
ggctccgggc ggcacggggc cggggtgggc cggctgggtg gcgccatcgt gcttgccctc 960
ggcttgcctt gggcccccta ccacgcagtc aaccttctgc aggcggtcgc agcgtggct 1020
ccaccggaag gggccttggc gaagctgggc ggagccggcc aggcggcgcg agcgggaaact 1080
acggccttgg ccttcttcag ttctagcgtc aaccgggtgc tctacgtctt caccgctgga 1140
gatctgctgc ccggggcagg tccccgtttc ctcacgcggc tcttcgaagg ctctggggag 1200
gccccagggg gcgccgctc tagggaagg accatggagc tccgaactac cctcagctg 1260
aaagtgtgtg ggcaggcccg cggcaatgga gacccgggg gtgggatgga gaaggacgt 1320
ccggaatggg acctttgaca gcagacccta caacctgtg ccttccctg tccctttcca 1380
ccccccacc accctccaga ggtcagtgtt ctgggacatt tggggacct tctttgacta 1440
gagtttgat ctggtgggt aggattacta tacacttggg gcaggcccag gctcctccaa 1500
actgagggat tatgagggtg gtgatggtcc ctgttaagga ctattgtgtg cttgcaagtt 1560
ggcatgtacc catgtgccag cattgcttac ttgttgccaa tagctgtta 1609
```

<210> 64  
<211> 945  
<212> DNA  
<213> Homo sapiens

<220>  
<221> misc\_feature  
<223> Incyte ID No: 7472007CB1

<400> 64

```

atgtgggaaa actggacaat tgtcagtga tttgtttctg tgagcttctc agccctgtcc 60
actgagcttc aggtctctact gtttctcctt ttcttgacca ttactttggt tactttaatg 120
ggcaatgtcc tcatcatcct ggtcactata gctgactctg cactacaaag tcctatgtac 180
ttcttctcga gaaacttgct ctctctggag atagggttca acttgggtcat tgtgccaag 240
atgctgggga cctgatcat tcaagacaca accatctcct tccttggatg tgcactcag 300
atgtatttct tcttcttttt tggggctgct gagtgtgcc tcctggccac catggcatat 360
gaccgctacg tggccatctg tgacccttg cactaccag tcatcatggg ccacatatcc 420
tgtgcccagc tggcagctgc ctcttggttc tcagggtttt cagtggccac tgtgcaaacc 480
acatggattt tcagtttccc tttttgtggc cccaacaggg tgaaccactt cttctgtgac 540
agccctcctg ttattgcact ggtctgtgct gacacctctg tgtttgaact ggaggctctg 600
acagccactg tcccatcctc tctcttctct ttcttctga tcttgggac ctatgtccgc 660
atcctctcca ctatctcag gatgccgtca gctgaggga aacatcaggc attctccacc 720
tgttcgccc acccttgggt tgtctctctc ttctatagca ctgccatcct cactgtatttc 780
cgaccccaat ccagtgcctc ttctgagagc aagaagctgc tgtcactctc ttccacagt 840
gtgactccca ttttgaacce catcatctac agctcaagga ataaagaagt gaaggctgca 900
ctgaagcggc ttatccacag gacctgggc tctcagaac tatga 945

```

&lt;210&gt; 65

&lt;211&gt; 1098

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7472008CB1

&lt;400&gt; 65

```

atggagggat ctgttgaagc tacacctgaa attccagctc agatgaaatg tcatccttca 60
agaccagta ctttaaatac attatctttc tatgggtctg tgctctcact aggaagaatg 120
catgggttag aaaccaaag ctctgctgaa attagagctg ggctgaagag atgtgataca 180
ctggtactag aggcactcac tttagaagga aatattgtca tagttcttgt gtccttgaag 240
gatccaaaac tccacatccc tatgtatttc tttctttcca accttctctt ggtagacctc 300
tgtttgacca gcagctgtgt tccacagatg ttgattaaact tctggggccc agaaaagacc 360
atcagctaca ttggctgtgc cattcaactc tatgtttttt tgtggcttgg ggccacggaa 420
tatgtccttc ttgttgcctt ggctgtggat tgttatgtag cagtgtgtca tccactgcaa 480
aataccatga tcatgcaccc aaaactttgt ctgcagctgg ctatcttggc atgggggact 540
ggcttggccc agtctctgat ccagctccct gccaccctcc gggtaccctt ctgctcccag 600
cggatgggtg atgatgttgt ttgtgaagtc ccagctctga ttcagctctc cagtactgat 660
actacctaca gtgaaattca gatgtctatc gccagtggtg tctctcttgt gatgcccttg 720
atcattatcc tttctctctc ttgtgtctat gctaaggctg tgctgagaat taagtcaact 780
gcaggacaga agaaagcatt tggcacctgc atctctacc ttcttgggtt ttctctctt 840
tatggcactg tcacagggtt ctaccttcaa ccaaaaaatc actatcctca tgaatggggc 900
aaatttctca ctcttttcta cactgtagta accccaactc ttaatcccct catctacact 960
ctaaggaaca aggagctcca tcttgggcta aaagaggcca aggtacagac cgcttcagag 1020
agtgcaagcc ccaagcattg gcagcttcca catgggtgtg gtctgtggg tgtgcagaag 1080
acaagaactg agctttga

```

&lt;210&gt; 66

&lt;211&gt; 954

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7472013CB1

&lt;400&gt; 66

```

atgagctttg ccctaatagc ttcacactct cgggtttttt tgctccttgg gttctcgaga 60
gctaacatct cctacactct cctctctctc ctgttctctg ctatttacct gaccaccata 120
ctgggggaat tgacactggg gctgctcatc tcctgggact ccagactgca ctaccccat 180
tattatctgc ttctgtgctt ctctgtgata gacatggggc tatccacagt tacactgcc 240
cagttgtctg ccatttgggt cctctattac ccaaccattc ctgtgcccg ctgcttggct 300
cagttctttt tctctatgct atttgggggt acagatacac ttgtcattgc tgtcatggct 360
ctggatcgct atgtggccat ctgtgacccc ctgcactatg ctttggtaat gaatcaccaa 420
cgggtgtgct gcttactagc cttgagctgg gtgggtgtcca tactgcacac catgttgcgt 480
gtgggactcg tctgctctct ttgctggact ggggatgctg ggggcaacgt taaccttct 540
cacttctttt gtgaccaccg gccactctct cgagcctctt gttctgacat acattctaat 600

```

gagctggcca	tattctttga	gggtggcttc	cttatgctgg	gcccctgtgc	cctcattgta	660
ctctcttatg	tccgaattgg	ggcgcgtatt	ctacgtttgc	cttcagctgc	tggtcgccgc	720
cgagcagtc	ccacctgtgg	atccccacct	accatggttg	gtttcctcta	cggcaccatc	780
atttggtgtc	acttccagcc	tcccttccag	aactctcagt	atcaggacat	ggtggcttca	840
gtaattgtata	ctgccattac	acctttggcc	aaccctattg	tgtatagcct	ccacaataag	900
gatgtcaagg	gtgcactctg	caggctgctt	gaatgggtga	aggtagaccc	ctga	954

<210> 67  
 <211> 1008  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7472015CB1

<400> 67	atggaatcat	ctttctcatt	tggagtgate	cttgcgtgcc	tggcctccct	catcattgct	60
	actaacacac	tagtggctgt	ggctgtgctg	ctgttgatcc	acaagaatga	tggtgtcagt	120
	ctctgcttca	ccttgaatct	ggctgtgggt	gacaccttga	ttggtgtggc	catctctggc	180
	ctactcacag	accagctctc	cagcccttct	cggccacac	agaagaccct	gtgcagcctg	240
	cggatggcat	ttgtcacttc	ctccgcagct	gcctctgtcc	tcacggtcac	gctgatcacc	300
	tttgacaggt	accttgccat	caagcagccc	ttccgctact	tgaagatcat	gagtgggttc	360
	gtggccgggg	cctgcattgc	cgggctgtgg	ttagtgtctt	acctcattgg	cttctcccca	420
	ctcggaatcc	cagattttcc	gcagactgcc	tacaaagggc	agtgcagctt	ctttgctgta	480
	tttcaccttc	acttcgtgct	gacctctctc	tgcgttggct	tcttcccagc	catgctcctc	540
	tttgtctctt	tctactgcga	catgctcaag	attgcctcca	tgacacagca	gcagattcca	600
	aagatggaac	atgcaggagc	catggctgga	ggttatcgat	ccccacggac	tcccagcgac	660
	ttcaaagctc	tccgtactgt	gtctgttctc	attgggagct	ttgctctatc	ctggaccccc	720
	ttccttatca	ctggcattgt	gcagggtggc	tgccaggagt	gtcacctcta	cctagtgtctg	780
	gaacggtacc	tgtggtgctc	cggcgtgggc	aactccctgc	tcaaccact	catctatgcc	840
	tattggcaga	aggaggtgct	actgcagctc	taccacatgg	ccctaggagt	gaagaagggtg	900
	ctcacctcat	tctctctctt	tctctcggcc	aggaattgtg	gcccagagag	gcccagggaa	960
	agttcctgtc	acatcgtcac	tatctccagc	tcagagtttg	atggctaa		1008

<210> 68  
 <211> 930  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7472016CB1

<400> 68	atgagggaaa	ataaccagtc	ctctacactg	gaattcatcc	tcttgggagt	tactgggtcag	60
	caggaacagg	aagattttct	ctacatcctc	ttctgttcca	tttaccctat	cacattgatt	120
	ggaaacctgc	tcattgtcct	agccatttgc	tctgatgttc	gccttcacaa	ccccatgtat	180
	tttctccttg	ccaacctctc	cttgggtgac	atcttctctt	catcggtaac	catccctaag	240
	atgctggcca	accatctctt	gggcagcaaa	tccatctctt	ttgggggatg	cctaacgcag	300
	atgtatttca	tgatagcctt	gggtaacaca	gacagctata	ttttggctgc	aatggcatat	360
	gatcgagctg	tggccatcag	ccaccacttt	cactacacaa	caattatgag	tccacggtct	420
	tgtatctggc	ttattgctgg	gtcttgggtg	attggaaatg	ccaatgccct	ccccacact	480
	ctgctcacag	ctagtctgtc	cttctgtggc	aaccagggaag	tggccaactt	ctactgtgac	540
	attacccctt	tgctgaagtt	atcctgttct	gacatccact	ttcatgtgaa	gatgatgtac	600
	ctaggggttg	gcattttctc	tgtgccatta	ctatgcatca	ttgtctccta	tattcgagtc	660
	ttctccacag	tcttccaggt	tccttccacc	aagggcgtgc	tcaaggcctt	ctccacctgt	720
	ggttcccacc	tcacggttgt	ctctttgtat	tatggtagag	tcatgggcac	gtatttccgc	780
	cctttgacca	atbatagcct	aaaagacgca	gtgatcactg	taatgtacac	ggcagtgacc	840
	ccaatgttaa	atcctttcat	ctacagttctg	agaaatcggg	acatgaaggc	tgccttgccg	900
	aaactcttca	acaagagaat	ctcctcgtaa				930

<210> 69  
 <211> 711  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7472017CB1

<400> 69  
 atgggcatga ccaacagcag tgtcaagggg gacttcatcc tgcgtgctgtg gaacctaaaa 60  
 ggacctgaca aaacaatcac attcctgggt tgtgtcatcc agctctacat ctccctggca 120  
 ttgggctcca ctgagtgtgt cctcctgggt gtaatggctt ttgatcgcta tgcctgcagt 180  
 tgcaaacctc tccactatac cgccgtaatg aacctcagc tgtgccaggc tctggcaggg 240  
 gttgctgtgc tgagtggagt gggaaacact cttatccagg gcactgtcac cctctggctt 300  
 cctcgctgtg gacaccgatt gctccaacat ttcttccttg catgtgtgga catccatgat 360  
 aatgaggttc agctctttgt tgccttactg gtcttgcctt tcttgccctt agtgctaata 420  
 ctgctgtcct atggacatat agccaagggt gtcataagga tcaagtcagt ccaggcctgg 480  
 tgcaaaaggcc tggggacatg tggatcccat ttgatagtag tgcctctctt ctgtgggacc 540  
 atcacagctg tctacatcca gtccaacagt tcttatgccc atgctcatgg gaagttcatc 600  
 tccctcttct atacagttgt gaccccgacc ctcaatcctc tcatctacac actgaggaat 660  
 aatgacgtga aaggagcact gcgattattt aacagagact taggcacata a 711

<210> 70  
 <211> 1092  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7472018CB1

<400> 70  
 atgggccccg gcgaggcgct gctggcggtt ctcttggtga tggtagctggc cgtggcgctg 60  
 ctatccaacg cactgggtgt gctttgttgc gcctacagcg ctgagctccg cactcgagcc 120  
 tcaggcgctc tcttggtgaa tctgtctctg ggcacactgc tgcctggcggc gctggacatg 180  
 cctttcacgc tgcctgggtg gatgcggggg cggacacgt cggcgccccg cgcattgccaa 240  
 gtcattggct tcttgacac cttcctggcg tccaacggcg cgtgagcgt gccggcgctg 300  
 agcgagacc agtggctggc agtgggcttc cactgcgct acgcccggac cctgcgaccg 360  
 cgctatgccg gctgctgtgc gggctgtgce tgggacagt cgtggcctt ctgaggcgct 420  
 gcacttggct gctcgtggct tggctaagag agcgcttcg cgtcctgttc gctgcgctg 480  
 ccgcccagag ctgagcgctc gcgcttcgca gccttcacgg ccacgctcca tgcctgtggc 540  
 ttgctgtgct cgtggcggt agctgtgctc acctgcctc aggtgcacgg ggtggcagc 600  
 agacactgcc agcgcatgga caccgtcacc atgaaggcgc tgcgctgtct cgcggacctg 660  
 caccacagtg tggggcagcg ctgcctcacc cagcagaagc ggcggccgca ccgcccacc 720  
 aggaagattg gcattgctat tgcgaccttc ctcatctgct ttgccccgta tgcattgacc 780  
 aggtggcgcg agctcgtgct cttcgtcacc gtgaacgccc agtggggcat cctcagcaag 840  
 tgcttgacct acagcaaggc ggtggccgac ccgttcacgt actctctgct ccgcccggcg 900  
 tcccgccaag tcttgccggg catggtgcac cggctgtgta agagaacccc gcgcccagca 960  
 tccacccatg acagctctct ggatgtggcc ggcatggtgc accagctgct gaagagaacc 1020  
 ccgcccagcg cgtccaccca caacggctct gtggacacag agaattgatc ctgcctgcag 1080  
 cagacacact ga 1092

<210> 71  
 <211> 927  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7472019CB1

<400> 71  
 atggccatgg acaatgtcac agcagtgttt cagtttctcc ttattggcat ttctaactat 60  
 cctcaatgga gagacacgtt tttoacatta gtgctgataa tttacctcag cacattgttg 120  
 gggaatggat ttatgatctt tcttattcac tttagaccca acctccacac tccaatctac 180  
 ttcttcctta gtaacctgtc tttcttagac ctttgttatg gaacagcttc catgccccag 240  
 gctttgtgtc attgtttctc taccatcccc taacctctct atccccgatg tttggctcaa 300  
 acgagtgtct ccttggcttt ggccacagca gagtgcctcc tactggctgc catggcctat 360  
 gaccgtgtgg ttgctatcag caatcccctg cgttattcag tggttatgaa tggcccagta 420  
 tgtgtctgct tgggtgtctac ctcatggggg acatcacttg tgcctactgc catgctcatc 480  
 ctatccctga ggcttcactt ctgtgggggt aatgtcatca accattttgc ctgtgagatt 540



```

ctctccctca ttaagctgac ctgttctgat accagcctca atgaatttat gatccctcgc 600
accagtatct tcacctgtct gctaccattt ggggttgttc tctctccta catacgaatt 660
gctatggcta tcataaggat tcgctcactc cagggcaggc tcaaggcctt taccacatgt 720
ggctctcacc tgacctgggt gacaatcttc tatgggtcag ccatctccat gtatatgaaa 780
actcagtgca agtctaccc tgaccaggac aagtttatct cagtgtttta tggagctttg 840
acacccatgt tgaacccctt gatatatagc ctgagaaaaa aagatgttaa acgggcaata 900
aggaaagtta tgttgaaaaa gacatga 927

```

&lt;210&gt; 72

&lt;211&gt; 1032

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7472021CB1

&lt;400&gt; 72

```

atgcattttc ttctactgt ctttggcttc ctaaacagag tcacacttgg tatcttcaga 60
gagactatgg tcaatttgac ttcaatgagt ggattccttc ttatgggggt ttctgatgag 120
cgtaagcttc agattttaca tgcaattgga tttctgggtga catacctgct ggccttgaca 180
ggcaacctcc tcattatcac catcattacc gtggaccgtc gtctccattc ccccatgtat 240
tactttttaa agcacctctc tottctggac ctctgcttca tctctgtcac agtccccag 300
tccattgcaa attcacttat gggcaacgggt tacatttctc ttgttcagtg cattcttcag 360
gttttctctc tcatagctct ggcctcatca gaagtggcca ttctcacagt gatgtcttat 420
gacaggtacg cagcaatctg tcaaccactt cattatgaga ctattatgga tccccgtgcc 480
tgtaggcatg cagtgtatgc tgtgtggatt gctggggggc tctctgggct catgcatgct 540
gccattaaat tctccatacc totctgtggg aagagagtca ttcaccaatt cttctgtgat 600
gttcttcaga tgctgaaact agcctgttct tatgaattca ttaatgagat tgcactggct 660
gcattcacaa cgtctgcagc atttatctgt ttgatctcca ttgtgctctc ctacattcgc 720
atcttctcta cagtgtgag aatcccatca gctgagggcc ggaccaaggt cttctccacc 780
tgcctaccac acctatttgt agccaccttc tttctttcag ctgcaggctt tgagtttctc 840
agactgcctt ctgattcctc atcgactgtg gaccttgat tctccgtatt ctatactgtg 900
atactccaa cactcaatcc agtcatttat agcttacgga atgattccat gaaggcagca 960
ctgaggaaaga tgctgtcaaa ggaagagctt cctcagagaa aaatgtgctt aaaagccatg 1020
tttaaactct ga 1032

```

&lt;210&gt; 73

&lt;211&gt; 972

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7472009CB1

&lt;400&gt; 73

```

atgtggcaga agaatcagac ctctctggca gacttcatcc ttgaggggct cttcgatgac 60
tcccttacct accttttct tttctccttg accatgggtg tcttccttat tgcgggtgagt 120
ggcaacacct tcaccattct cctcatctgc attgatcccc agcttcatac accaatgtat 180
ttctgtctca gccagctctc cctcatggat ctgatgcatg tctccacaac catcctgaag 240
atggctacca actacctatc tggcaagaaa tctatctcct ttgtgggctg tgcaaccag 300
cacttctctt atttgtgtct aggtgggtgt gaatgttttc tcttagctgt catgtcctat 360
gaccgtatg ttgccatctg tcatccactg cgctatgctg tgctcatgaa caagaagggt 420
ggactgatga tggtgtgcat gtcatgggtg ggggcatccg tgaactccct aattcacatg 480
gcatcttga tgcacttccc tttctgtggg cctcggaag tctaccactt ctactgtgag 540
ttcccagctg ttgtgaagtt ggtatgtggc gacatcactg tgtatgagac cacagtgtac 600
atcagcagca ttctcctcct cctccccatc ttcttgatt ctacatccta tgtcttcac 660
cttcaaagtg tctttcagat gcgctcatct gggagcaaga gaaatgcctt tgccacttgt 720
ggctcccacc tcacgggtggt ttctcttttg tttgggtgct gcactctctc ctacatgaga 780
cccaggtccc agtgcactct attgcagaac aaagtgggt ctgtgttcta cagcatcatt 840
acgccacat gatattctct gatttatact cctcggaata aagatgtagc taaggctctg 900
agaagagtgc tgaggagaga tgttatcacc cagtgcatto aacgactgca attgtggtg 960
ccccgagtgt ag 972

```

&lt;210&gt; 74

&lt;211&gt; 900

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7472010CB1

&lt;400&gt; 74

```

atggaactgg aaggagactt ccttggtagt gtgggagaat tgggccaagt gatccagacc 60
tggtctggga tctatgtgtt cactgtggtg ggcaacttgg gcttgatcac ctttaattggg 120
ataaatccca gccctcacac ccccatgtac tttttcctct tcaacttgto ctttatagat 180
ctctgttatt cctgtgtgtt taccccaaaa atgctgaatg actttgtttc agaaagtatc 240
atctcttatg tgggatgtat gactcagcta tttttcctct gtttctttgt caattctgag 300
tgctatgtgt tggatcaat ggctatgat cgctatgtgg ccactgcaa cccctgctc 360
tacctggtca ccattgcccc aagggtctgc ttctgtctga tgtttggttc ctatgtggtg 420
gggtttgctg gggccatggc ccacactgga agcatgctgc gactgacctt ctgtgattcc 480
aacgtcattg accattatct gtgtgacgtt ctccccctct tgcagctctc ctgcaccagc 540
acccatgtca gtgagctggt atttttcatt gttgttggag taatcaccat gctatccagc 600
ataagcatcg tcatctctta cgctttgata ctctccaaca tcctctgtat tccttctgca 660
gagggcagat ccaaagcctt tagcacatgg ggctcccaca taattgctgt tgctctgttt 720
tttgggtcag ggacattcac ctacttaaca acatcttttc ctggctctat gaaccatggc 780
agatttgctt cagtctttta caccaatgtg gttcccatgc ttaacccttc gatctacagt 840
ttgaggaata aggatgataa acttgccctg ggcaaaaacc tgaagagagt gctcttctaa 900

```

&lt;210&gt; 75

&lt;211&gt; 924

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7472011CB1

&lt;400&gt; 75

```

atggaaacag ggaacctcac gtgggtatca gactttgtct tcctggggct ctgcgagact 60
cgggagctcc agcgtttctt gtttctaatt ttctgttttg tctacatcac cactgttatg 120
ggaaacatcc ttatcatcat cacagtgaac tctgattccc agctccacac acccatgtac 180
tttctgtctc gaaacctggc tgctctagaa ctctgtttct cttcagtcac tgctcccaaa 240
atgctagtgg acctcctctc tgagaagaaa accatctctt accagggctg catgggtcag 300
atcttcttct tccacttttt gggagggtgc atggctctct tcctctcagt gatggccttt 360
gaccgcctca ttgccatctc cgggcccttc cgctatgtca ccgtcatgaa cactcagctc 420
tggtgtgggc tgggtggtagc cacctgggtg ggaggctttg tcactctat tgctcagctg 480
gctctgatgc tccactgccc cttctgtggc cccaacattt tggataactt ctactgtgat 540
gttccccaag tactgagact tgctgtctgg ttcttctctc tcctgatgtc ctacttatcc 600
tccaacagtg ggctgtgga tgctgtctgg ttcttctctc tcctgatgtc ctacttatcc 660
atcctgtgta tgctgaggtc acatccaggg gaggcaagaa ggaaggcagc ttccacctgc 720
accaccaca tcatcgtggt ttccatgata ttctgtccaa gcatttacct ctatgcccg 780
cccttcactc cattccctat ggacaagctt gtgtccatcg gccacacagt catgaccccc 840
atgctcaacc ccattgatcta taccctgagg aaccaggaca tgcaggcagc agtgagaaga 900
ttagggagac accggtggtt ttga

```

&lt;210&gt; 76

&lt;211&gt; 945

&lt;212&gt; DNA

&lt;213&gt; Homo sapiens

&lt;220&gt;

&lt;221&gt; misc\_feature

&lt;223&gt; Incyte ID No: 7472012CB1

&lt;400&gt; 76

```

atggacaaca gcaactggac cagtgtgtcc cattttgttc tcttgggcat ttccaccac 60
ccagaagagc aaatcccact ctctcttggt ttctcactca tgtacgcaat caatatttct 120
ggcaacttgg ccattcatcc actgattctc tctgtctcac gctccacat cccatgtac 180
atcttctctc gtaacttggc ctgacagac atctgtctca cctccaccac ggtccccaag 240
atgctgcaga ttattttctc cctacaaag gtaatttctt acacaggctg tttagcccaa 300
acttatttct tcatttgctt cgccgtcatg gaaaacttca tcctggctgt gatggcctat 360

```

```

gacaggtaca ttgccatctg ccacccttcc cactacacta tgatctgac tagaatgctg 420
tgtgtgaaga tgggtggtcat gtgccatgct ctctccacc ttcatgccat gctgcatacc 480
tttctcatag gccaaactaat cttctgtgca gataacagaa tccccactt cttctgtgac 540
ctctacgctc tgatgaagat ctccctgcacc agcacctacc tcaacacct tatgattcac 600
acagaagggtg ctgttgtaat cagtggagct ctggccttca ttactgcctc ctatgcctgc 660
atcatcctgg tggctcctcg gatccctca gccaaaggga ggtggaaaac cttttctacc 720
tggcgctccc acctcactgt ggtggccata ttctatggca cctcagttg ggtctacttc 780
cggccctttt ccagctattc agtgaccaag ggtcgatta taacagtcgt gtacacagt 840
gtgactccca tgctgaaccc cttcatctac agcctgagga atggggatgt caaggaggc 900
ttcatgaaat ggatgagcag aatgcagact tttttctta gataa 945

```

<210> 77  
 <211> 933  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7472014CB1

```

<400> 77
atgggaagaa ataacctaac aagaccctct gaattcatcc tcttggact ctctctcga 60
cctgaggatc agaagccgct ctttgcctgt ttctcccca tctacctat cacagtata 120
ggaaacctgc ttatcatcct ggccatccgc tcagacactc gtctccagac gcccatgtac 180
ttctttctaa gcctcctgtc ttttgttgac atttgcctat tgacagtcac tatccctaag 240
atgctggtga acttcttata agagacaaag accatctctt acggtgagtg tctgaccag 300
atgtactttt tcttagcctt tggaaacaca gacagttacc tgctagcagc catggccatt 360
gaccgctatg tggccatag taatcccttc cactacatca ccattatgag tcacagatgc 420
tgtgtcctgc ttctggttct ctcttctgc attccacatt ttcactccct cctgcacatt 480
cttctgacta atcagctcat cttctgtgcc tccaatgtca tccatcactt tttctgcgat 540
gatcaaccag tgctaaaatt gtcctgttcc tcccattttg tcaaagaaat cacagtaatg 600
acagaaggct tggctgtcat aatgaccccg ttttcatgca tcatcatctc ttattttaaga 660
atcctcatca ctgttctgaa gattccttca gctgctggaa agcgtaaagc attttctacc 720
tgtggtcttc atctcacagt ggtgaccctg ttttatggaa gcattagcta tgtctatttt 780
cagccctgtt ccaactatac tgtcaaggat caaatagcaa caattatcta caccgtactg 840
actcctatgc taaatccatt tatctatagt ctgaggaaca aagacatgaa gcagggtttg 900
gcaaagtga tgacacaggat gaaatgtcag taa 933

```

<210> 78  
 <211> 1080  
 <212> DNA  
 <213> Homo sapiens

<220>  
 <221> misc\_feature  
 <223> Incyte ID No: 7472020CB1

```

<400> 78
atgttcaaaag ccaccccttg ccattgtgtg cccaaagacc atgggttga caagcttgtt 60
gtaagggtgtc caagacacac agagccatgg aatctcacag gtatctcaga attcctctc 120
ctgggactct cagaggatcc agaactgcag cccgtcctcc ctgggtgtc cctgtccatg 180
tacctgggtca cgtgtctgag gaacctgtc atcatcctgg ctgtcagctc tgactccac 240
ctccacaccc ccattgtgct ctctctctcc aacctgtgct gggctgacat cggtttcacc 300
tcggccatgg tccccagat gattgtggac atgcagtcgc atagcagagt catctcttat 360
gcgggctgcc tgacacagat gtctttcttt catgtataga agacatgctc 420
ctgacagtga tggcctatga ccgattttgt gccatctgtc accccctgca ctaccagtc 480
atcatgaatc ctaccccttg tgtcttctta gttttggtgt ccttttctct cagcctgttg 540
gattccagtc tgcacagttg gattgtgtta caattcacct tcttcaagaa tgtggaaatc 600
tccaattttg tctgtgacct atctcaact ctcaacctg cctgttctga cagtgtcatc 660
aatagcatat tcataatatt agatagtatt atgtttggtt ttcttcccat ttcaggatc 720
cttttgtctt acgctaacaa tgtccctccc attctaagaa tttcatcatc agataggaag 780
tctaaagcct tctcacctg ttgctctcac ctggcagttg tttgttatt ttatggaaca 840
ggcattggcg tgaacctgac ttcagctgtg tcaccacccc ccaggaaatgg tgtggtggca 900
tcagtgtatg acgtgtgtgt cacccccatt ctgaacctt tcatctacag cctgagaaat 960
agggacattc aaagtgcctt ctggaggctg cgcagcagaa cagtccaatc tcatgatctg 1020
ttatctcaag atctgtctca tctttttct tgtgtgggtg agaaaggtca accacattaa 1080

```

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
14 June 2001 (14.06.2001)

PCT

(10) International Publication Number  
**WO 01/42288 A3**

(51) International Patent Classification<sup>7</sup>: **C07K 14/705**,  
C12N 15/12

(21) International Application Number: PCT/US00/33382

(22) International Filing Date: 7 December 2000 (07.12.2000)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/172,852 10 December 1999 (10.12.1999) US  
60/171,732 22 December 1999 (22.12.1999) US  
60/176,148 14 January 2000 (14.01.2000) US  
60/177,331 21 January 2000 (21.01.2000) US

(71) Applicant (for all designated States except US): **INCYTE GENOMICS, INC.** [US/US]; 3160 Porter Drive, Palo Alto, CA 94304 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BURFORD, Neil**

[GB/US]; 105 Wildwood Circle, Durham, CT 06422 (US). **BAUGHN, Mariah, R.** [US/US]; 14244 Santiago Road, San Leandro, CA 94577 (US). **AU-YOUNG, Janice** [US/US]; 233 Golden Eagle Lane, Brisbane, CA 94005 (US). **YANG, Junming** [CN/US]; 7125 Bark Lane, San Jose, CA 95129 (US). **LU, Dyung, Aina, M.** [US/US]; 233 Coy Drive, San Jose, CA 95123 (US). **REDDY, Roopa** [IN/US]; 1233 W. McKinley Avenue #3, Sunnyvale, CA 94086 (US).


(74) Agents: **HAMLET-COX, Diana et al.**; Incyte Genomics, Inc., 3160 Porter Drive, Palo Alto, CA 94304 (US).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian

[Continued on next page]

(54) Title: G-PROTEIN COUPLED RECEPTORS



SEQ ID NO:1  
(Incyte ID No. 104941CD1)

(57) Abstract: The invention provides human G-protein coupled receptors (GCREC) and polynucleotides which identify and encode GCREC. The invention also provides expression vectors, host, cells, antibodies, agonists, and antagonists. The invention also provides methods for diagnosing, treating, or preventing disorders associated with aberrant expression of GCREC.

WO 01/42288 A3



patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,  
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,  
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(88) Date of publication of the international search report:

14 February 2002

**Published:**

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

# INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 00/33382

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 7 C07K14/705 C12N15/12

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, WPI Data, STRAND

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 92 17585 A (UNIV COLUMBIA) 15 October 1992 (1992-10-15) claims 37,5; figure 10 ---	1-28
X	BUCK L ET AL: "A NOVEL MULTIGENE FAMILY MAY ENCODE ODORANT RECEPTORS: A MOLECULAR BASIS FOR ODOR RECOGNITION" CELL,US,CELL PRESS, CAMBRIDGE, NA, vol. 65, 5 April 1991 (1991-04-05), pages 175-187, XP002029935 ISSN: 0092-8674 the whole document --- -/--	1-28

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

31 May 2001

Date of mailing of the international search report

23.08.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Meyer, W

# INTERNATIONAL SEARCH REPORT

Internal Application No.  
PCT/US 00/33382

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>MCDONALD TERRY ET AL: "Identification and cloning of an orphan G protein-coupled receptor of the glycoprotein hormone receptor subfamily." BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 247, no. 2, 18 June 1998 (1998-06-18), pages 266-270, XP000999191 ISSN: 0006-291X the whole document</p>	1-28
A	<p>GONG Z ET AL: "Rapid identification and isolation of zebrafish cDNA clones" GENE: AN INTERNATIONAL JOURNAL ON GENES AND GENOMES,GB,ELSEVIER SCIENCE PUBLISHERS, BARKING, vol. 201, no. 1-2, 12 November 1997 (1997-11-12), pages 87-98, XP004126460 ISSN: 0378-1119 abstract</p>	1-28
A	<p>STADEL J M ET AL: "Orphan G protein-coupled receptors: a neglected opportunity for pioneer drug discovery" TRENDS IN PHARMACOLOGICAL SCIENCES,GB,ELSEVIER TRENDS JOURNAL, CAMBRIDGE, vol. 18, no. 11, 1 November 1997 (1997-11-01), pages 430-437, XP004099345 ISSN: 0165-6147 abstract; table 1</p>	1-28
A	<p>O'DOWD B F ET AL: "DISCOVERY OF THREE NOVEL G-PROTEIN-COUPLED RECEPTOR GENES" GENOMICS,ACADEMIC PRESS, SAN DIEGO,US, vol. 47, no. 2, 15 January 1998 (1998-01-15), pages 310-313, XP000863786 ISSN: 0888-7543 abstract</p>	1-28
A	<p>MARCHESE A ET AL: "Novel GPCRs and their endogenous ligands: expanding the boundaries of physiology and pharmacology" TRENDS IN PHARMACOLOGICAL SCIENCES,GB,ELSEVIER TRENDS JOURNAL, CAMBRIDGE, vol. 20, no. 9, 1 September 1999 (1999-09-01), pages 370-375, XP004178194 ISSN: 0165-6147 abstract</p>	1-28

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 00/33382

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	LEE DENNIS K ET AL: "Cloning and characterization of additional members of the G protein-coupled receptor family." BIOCHIMICA ET BIOPHYSICA ACTA., vol. 1490, no. 3, 29 February 2000 (2000-02-29), pages 311-323, XP000999198 ISSN: 0006-3002 the whole document	1-28
P,X	ROUQUIER SYLVIE ET AL: "The olfactory receptor gene repertoire in primates and mouse: Evidence for reduction of the functional fraction in primates." PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES, vol. 97, no. 6, 14 March 2000 (2000-03-14), pages 2870-2874, XP002168634 March 14, 2000 ISSN: 0027-8424 the whole document	1-28



# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/US 00/33382

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 18, 21, 24 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
  
partially 1-28

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.1, its corresponding DNA (SEQ.ID.40) and the use thereof.

2. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.2, its corresponding DNA (SEQ.ID.41) and the use thereof.

3. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.3, its corresponding DNA (SEQ.ID.42) and the use thereof.

4. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.4, its corresponding DNA (SEQ.ID.43) and the use thereof.

5. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.5, its corresponding DNA (SEQ.ID.44) and the use thereof.

6. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.6, its corresponding DNA (SEQ.ID.45) and the use thereof.

7. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.7, its corresponding DNA (SEQ.ID.46) and the use thereof.

8. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.8, its corresponding DNA (SEQ.ID.47) and the use thereof.

9. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.9, its corresponding DNA (SEQ.ID.48) and the use thereof.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

10. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.10,  
its corresponding DNA (SEQ.ID.49) and the use thereof.

11. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.11,  
its corresponding DNA (SEQ.ID.50) and the use thereof.

12. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.12,  
its corresponding DNA (SEQ.ID.51) and the use thereof.

13. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.13,  
its corresponding DNA (SEQ.ID.52) and the use thereof.

14. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.14,  
its corresponding DNA (SEQ.ID.53) and the use thereof.

15. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.15,  
its corresponding DNA (SEQ.ID.54) and the use thereof.

16. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.16,  
its corresponding DNA (SEQ.ID.55) and the use thereof.

17. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.17,  
its corresponding DNA (SEQ.ID.56) and the use thereof.

18. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.18 its  
corresponding DNA (SEQ.ID.57) and the use thereof.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

19. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.19,  
its corresponding DNA (SEQ.ID.58) and the use thereof.

20. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.20,  
its corresponding DNA (SEQ.ID.59) and the use thereof.

21. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.21,  
its corresponding DNA (SEQ.ID.60) and the use thereof.

22. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.22,  
its corresponding DNA (SEQ.ID.61) and the use thereof.

23. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.23,  
its corresponding DNA (SEQ.ID.62) and the use thereof.

24. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.24,  
its corresponding DNA (SEQ.ID.63) and the use thereof.

25. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.25,  
its corresponding DNA (SEQ.ID.64) and the use thereof.

26. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.26,  
its corresponding DNA (SEQ.ID.65) and the use thereof.

27. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.27,  
its corresponding DNA (SEQ.ID.66) and the use thereof.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

28. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.28,  
its corresponding DNA (SEQ.ID.67) and the use thereof.

29. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.29,  
its corresponding DNA (SEQ.ID.68) and the use thereof.

30. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.30,  
its corresponding DNA (SEQ.ID.69) and the use thereof.

31. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.31,  
its corresponding DNA (SEQ.ID.70) and the use thereof.

32. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.32,  
its corresponding DNA (SEQ.ID.71) and the use thereof.

33. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.33,  
its corresponding DNA (SEQ.ID.72) and the use thereof.

34. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.34,  
its corresponding DNA (SEQ.ID.73) and the use thereof.

35. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.35,  
its corresponding DNA (SEQ.ID.74) and the use thereof.

36. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.36,  
its corresponding DNA (SEQ.ID.75) and the use thereof.

37. Claims: partially 1-28

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

G protein-coupled receptor as characterized by SEQ.ID.37,  
its corresponding DNA (SEQ.ID.76) and the use thereof.

38. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.38,  
its corresponding DNA (SEQ.ID.77) and the use thereof.

39. Claims: partially 1-28

G protein-coupled receptor as characterized by SEQ.ID.39,  
its corresponding DNA (SEQ.ID.78) and the use thereof.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 00/33382

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9217585 A	15-10-1992	AU 669107 B	30-05-1996
		AU 1796192 A	02-11-1992
		CA 2106847 A	06-10-1992
		EP 0578784 A	19-01-1994
		JP 6509702 T	02-11-1994
-----			